In February 2013, GlaxoSmithKline (GSK) announced a commitment to further clinical transparency through the public disclosure of GSK Clinical Study Reports (CSRs) on the GSK Clinical Study Register.

The following guiding principles have been applied to the disclosure:

- Information will be excluded in order to protect the privacy of patients and all named persons associated with the study
- Patient data listings will be completely removed* to protect patient privacy. Anonymized data from each patient may be made available subject to an approved research proposal. For further information please see the Patient Level Data section of the GSK Clinical Study Register.
- Aggregate data will be included; with any direct reference to individual patients excluded

*Complete removal of patient data listings may mean that page numbers are no longer consecutively numbered

This study includes documents that were originally reported in a language other than English. All documents that are available in English have been made available via the GSK Clinical Study Register.

Annual report for Post-Marketing Surveillance and Surveillance on particular patients groups (2nd year)

	-	-	0	-	
reporter	Company license No. (importer's number)	89			
reporter	name of manufacturer(business)			GlaxoSmithKline	
reporter	Address of manufacturer (Business)	191, Hangang-ro-2-ga, Yongsan-gu, Seoul, 140-702, Korea			
reporter	name	PPD	PPD resident no.		
manufacturer	name	GlaxoSmithKline country Belgium			Belgium
manufacturer	address	89 Rue	e de 1 In	stitut, 1330, Rixensa	rt, Belgium
produc	t on re-examination	Rotarix™	period	l of re-examination	07March 2008 - 06March 2014
	approval no.	161	:	approval date	07 March 2008
surveillance results	period and no. of survey patients	Period: Total No. of subjects entered in the study: 877 subjects No. of subjects from whom surveillance reports were collected: 87 subjects No. of subjects in the Total Vaccinated cohort safety assessment 876 subjects No. of subjects in efficacy assessment: None			
surveillance results	Result and analysis	Refer to the attached report			
Invoice S	Sales (shipment result)		Refe	r to the attached repo	rt
	rt the annual report of the Notice of New Drug Re-e		-	eillance and speci	al surveillance
	Date:				
	Reporter: PPD nager: Director Clinical R& Telephone: PPD Food & Drug Adminis			PPD (B	io-MD)
Attached Documer		<u>, , , , , , , , , , , , , , , , , , , </u>			fee
 Safety data on Data reported r 	nt n results of domestic PMS. the occurrence of adverse events in do egarding safety such as domestic and in domestic and foreign countries and	foreign literatures and	academic	informations	

Annual Report for Post-Marketing Surveillance and Surveillance on **RotarixTM** (Oral live attenuated human rotavirus vaccine)

GlaxoSmithKline

[Annex 1] Overall of post-marketing surveillance
--

Type of	Type of post-marketing surveillance		No. of patients	Performance status and future protocol
	General drug u surveillance	se	877	Any adverse event was reported for 630 subjects during the 31-day post-vaccination period.
		Surveillanc e on children	876	
		Surveillanc e on elderly people	0	
post-m arketing		Surveillanc e on pregnant women	0	
surveill ance	Special subgroup	Surveillanc e on renal impairment patients	0	
		Surveillanc e on hepatic impairment patients	0	
		Surveillanc e on long-term use	0	
		Surveillanc e on other special patients	0	

Contents

1.	POST MARKETING SURVEILLANCE PROTOCOL	8
2.	INDICATIONS AND USAGE OF PRODUCT	10
3.	GENERAL INFORMATION OF PMS	12 12
4.	 SUMMARY OF PMS RESULTS 4.1 Summary and objective of the drug use investigation 4.2 Demographic data 4.3 Previous medical history 4.4 Pre-rotavirus vaccination history 4.5 Drug administration 4.5.1 Administration of concomitant medication 4.5.2 Administration of concomitant vaccination 4.5.3 Administration of study vaccination 	16 17 21 21 21 21
5.	RESULTS OF THE DRUG USE INVESTIGATION	25 25 30
Α.	ADVERSE EVENTS BY PATIENT BACKGROUND FACTORS	34
A.1	GENDER	34
A.2	AGE	34
A.3	MEDICAL HISTORY	34
A.4	CONCOMITANT MEDICATIONS	41
A.5	CONCOMITANT VACCINATIONS	43
A.6	ADVERSE EVENT BY ADVERSE EVENT DURATION	49
В.	ADVERSE EVENTS IN SPECIAL SUBPOPULATIONS	55
B.1	OLD PEOPLE (65 YEARS OR MORE)	55
B.2	INFANT	55
B.3	PREGNANT OR NURSING MOTHER	55
B.4	PATIENTS WITH RENAL IMPAIRMENT	55
B.5	PATIENTS WITH HEPATIC IMPAIRMENT	55

Second Annual Study Report for 111700 (Rota-070 PMS)

C.	FACTORS CONSIDERED AS AFFECTING THE MANIFESTATION OF ADVERSE EVENTS	55
	5.1.5 Classification of adverse events	
Α.	SEVERITY	55
В.	CAUSAL RELATIONSHIP WITH THE SURVEY VACCINE	60
C.	RESULTS OF ADVERSE EVENTS	65
6.	LINE-LISTING OF ADVERSE EVENTS	71
7.	CONSIDERATIONS OF THE RESULTS AND FUTURE PLAN	86
8.	INVOICE SALES	90
9.	DATA ON FOREIGN ADVERSE EVENTS	92

CONTENTS: REPORT TABLES

	CONTENTS: KEPOKT TABLES
Table 1	Demography data: Age* by Gender (Total Vaccinated cohort) 16
Table 2	Demography data: Race by Gender (Total Vaccinated cohort)
Table 3	Previous medical history - by gender (Total Vaccinated cohort)18
Table 4	Previous medical history - by classification (Total Vaccinated cohort)19
Table 5	Pre-rotavirus vaccination history (Total Vaccinated cohort)
Table 6	Administration of concomitant medication - by gender (Total Vaccinated
cohor	t)21
Table 7	Administration of concomitant medication - by classification (Total
Vacci	nated cohort)
Table 8	Administration of concomitant vaccination - by gender (Total Vaccinated
cohor	t)
Table 9	Administration of study vaccine (Total Vaccinated cohort)
Table 10	Serious adverse events and serious adverse drug reactions (Total Vaccinated
cohor	t)
Table 11	Listing of SAEs (Total Vaccinated cohort)
Table 12	Expected & Unexpected adverse events and adverse drug reactions (Total
Vacci	nated cohort)
Table 13	Adverse events experienced by subjects during the entire study period:
Strati	fied by gender (Total Vaccinated cohort)
Table 14	Adverse events experienced by subjects during the entire study period:
Strati	fied by previous medical history (Total Vaccinated cohort)
Table 15	Adverse events experienced by medical history - by gender and classification
(Tota	l Vaccinated cohort)
Table 16	Adverse events experienced by subjects during the entire study period :
Strati	fied by medication (Total Vaccinated cohort)41
Table 17	Adverse events experienced by subjects - by classification of concomitant
media	cation (Total Vaccinated cohort)
Table 18	Adverse events experienced by subjects during the entire study period:
Strati	fied by concomitant vaccination (Total Vaccinated cohort)
Table 19	Adverse events experienced by subjects - by classification of concomitant
vacci	nation (Total Vaccinated cohort)
Table 20	Expected & Unexpected adverse events by medical history, concomitant
vacci	nation, concomitant medication (Total Vaccinated cohort)
Table 21	Expected & Unexpected adverse events by duration (Total Vaccinated
cohor	t)
Table 22	Expected & Unexpected adverse events by severity (Total Vaccinated
cohor	t)
Table 23	Expected & Unexpected adverse events by causality (Total Vaccinated
	nost-Marketing Surveillance annual report Page 6

Second Annual Study Report for 111700 (Rota-070 PMS)

cohoi	rt)
Table 24	Expected & Unexpected adverse events by outcome (Total Vaccinated
cohoi	rt)

I. Post Marketing Surveillance Protocol

1. Post Marketing Surveillance Protocol

II. Indications and Usage of Product

2. Indications and usage of Product

Second Annual Study Report for 111700 (Rota-070 PMS)


III. General Information of PMS

3. General Information of PMS

3.1 Surveillance period

RotarixTM vaccine was registered in Korea on 07 March 2008 and was launched in the same market in June 2008. This surveillance, in the first and second year after the RotarixTM vaccine was registered in Korea, was conducted between September 2008 to December 2009. A total of 877 subjects were enrolled in the study of which 876 subjects were included in the Total Vaccinated cohort (TVC). One subject was eliminated from the analysis since for this subject the subject number was allocated but the study vaccine dose was not administered.

3.2 Subjects composition table [Appendix 2]



[Annex 2] Table of patient composition

3.3 Summary table of PMS

Name of hospital	Name of doctor	CRF No.	Date of contract	Surveillance period	Collected cases
PPD			25August 2008	August 2008- December 2009	20
			09December 2008	December 2008- December 2009	18
			21November 2008	November 2008 - December 2009	20
			21October 2008	October 2008 - December 2009	30
			01September 2008	September 2008 - December 2009	20
			01 September 2008	September 2008 - December 2009	20
			01September 2008	September 2008- December 2009	30
			01 October 2008	October 2008 - December 2009	30
			16 October 2008	October 2008 - December 2009	11
			08 April 2009	April 2009 - December 2009	20
			18 September 2008	September 2008 - December 2009	20
			18 September 2008	September 2008 - December 2009	20
			26 September 2008	September 2008- December 2009	70
			26 September 2008	September 2008 - December 2009	30
			16 October 2008	October 2008- December 2009	20
			11 September 2008	September 2008 - December 2009	30
			11 September 2008	September 2008- December 2009	12
			18 September 2008	September 2008 - December 2009	13*
				September 2008 - December 2009	20
			11 September 2008	September 2008- December 2009	2
			25September 2008	September 2008- December 2009	20
			17 October 2008	October 2008- December 2009	30
			30 October 2008	October 2008- December 2009	20
			29 September 2008	September 2008- December 2009	10
			06 October 2008	October 2008 - December 2009	4
			12 December 2008	December 2008- December 2009	40

Rotarix[™] Post-Marketing Surveillance annual report Page 13 GlaxoSmithKline Korea

Name of hospital	Name of doctor	CRF No.	Date of contract	Surveillance period	Collected cases
PPD			27 November 2008	November 2008- December 2009	40
			29 September 2008	September 2008- December 2009	10
			29 September 2008	September 2008- December 2009	10
			26 December 2008	December 2008- December 2009	100
			21January 2009	January 2009 - December 2009	16
			21J anuary 2009	January 2009- December 2009	1
			18 November 2008	November 2008- December 2009	20
			29 October 2008	October 2008- December 2009	49
			05 December 2008	December 2008- December 2009	50
total					876

Second Annual Study Report for 111700 (Rota-070 PMS)

Collected cases = The number of subjects enrolled and the safety data was recorded in the CRF. * One subject (subject No. PPD was enrolled in to the study but did not receive any dose of Rotarix[™]. Second Annual Study Report for 111700 (Rota-070 PMS)

IV. Summary of PMS results

4. Summary of PMS results

4.1 Summary and objective of the drug use investigation

GlaxoSmithKline Korea has registered its oral live attenuated human rotavirus (HRV) vaccine, Rotarix[™] in Korea on 07 March 2008, following which, the present post-marketing surveillance (PMS) was conducted to collect reactogenicity and safety data on the use of Rotarix[™] in at least 3000 Korean infants (approximately 500 infants to be enrolled every year for 6 years) as per the regulations of the Korean Food and Drugs Administration (KFDA). This surveillance, in the second year after the vaccine was registered in Korea, was conducted between September 2008 and December 2009 and presents the data from the first and second year of surveillance.

4.2 Demographic data

Table 1 presents the demographic data of subjects by age (weeks) and gender for the Total Vaccinated cohort.

Table 2 presents the demographic data of subjects by race and gender for the Total Vaccinated cohort.

Of the 876 subjects who received at least one dose of Rotarix[™] documentation on age at the time of first dose was available for 875 subjects. The age of one subject (subject No. PPD was unknown. The number of male and female subjects was similar; 440 subjects were male and 436 subjects were female. The mean age of the subjects was 9.6 weeks (range: 4 to 24 weeks) with a standard deviation (SD) of 2.35 weeks (Table 1).

Majority of the subjects (874 subjects) were of Korean heritage. Two subjects were of Non-Korean (Chinese) heritage (Table 2).

Group	Gender	Ν	N with	MEAN	SD	MIN	MAX
			age				
HRV	F	436	435	9.5	2.32	6	24
	Μ	440	440	9.6	2.38	4	24
	Total	876	875	9.6	2.35	4	24

HRV = Human rotavirus vaccine

F = female; M = male

N = number of subjects with documentation on gender

N with age = number of subjects with documentation on gender and age

SD = standard deviation

Min, Max = minimum, maximum age

*For the subjects who have received their Dose 1 of Rotarix™ prior to this study age was derived by considering the date of that vaccination.

 Table 2
 Demography data: Race by Gender (Total Vaccinated cohort)

Group	Race	Male N = 440	Female N = 436	Total N = 876
HRV	Korean	439	435	874
	Non-Korean	1	1	2

HRV = Human rotavirus vaccine

N = Total number of subjects in the mentioned category

4.3 Previous medical history

Table 3 presents the summary of previous medical history by gender, for the Total Vaccinated cohort.

Table 4 presents the previous medical history by classification for the Total Vaccinated cohort.

Overall 118 (13.5%) subjects had a previous medical history.

- A total of 42 (4.8%) subjects had a history of respiratory, thoracic and mediastinal disorders (acute bronchiolitis, acute bronchitis, acute nasopharyngitis, bronchitis, cough (common cold), nasal stuffy, nasopharyngitis, pneumonia, respiratory distress syndrome, streptococcal tonsillitis, upper respiratory infection (URI) and urinary tract infection (UTI)).
- A total of 33 (3.8%) subjects had a history of gastrointestinal disorders (acute gastritis, acute gastroenteritis (AGE), diarrhoea, gastroenteritis (GE), gastroesophageal reflux (GER), infantile colic, inguinal hernia, necrotizing entero-colitis (NEC), neonatal vomiting, non infectious neonatal diarrhea, R/O mild AGE and umbilical Hernia).
- A total of 26 (3.0%) subjects had a history of skin and subcutaneous disorders (allergic urticaria, atopic dermatitis, candidid, diaper rash, melanosis, neonatal omphalitis, non specific eczema, seborrheic dermatitis and unspecific rash).
- A total of 13 (1.5%) subjects had a history of eye disorders (acute conjunctivitis, conjunctivitis, eye discharge, neonatal conjunctivitis, R/O conjunctivitis and R/O nasolacrimal duct obstruction).
- A total of 11 (1.3%) subjects had a history of hepatobiliary disorders (jaundice and neonatal jaundice).
- A total of 11 (1.3%) subjects had a history of other disorders (breast milk jaundice, cleft lip and palate, intrauterine growth retardation and prematurity).
- A total of 7 (0.8%) subjects had a history of blood and lymphatic system disorders (anemia, neutropenia and sepsis).

				ale :440		nale =436		otal =876
Group	Previous medical history	Category	Category n		n	%	n	%
HRV .	ANY MEDICAL HISTORY	YES	60	13.6	58	13.3	118	13.5
		NO	380	86.4	378	86.7	758	86.5
	BLOOD AND LYMPHATIC SYSTEM	YES	2	0.5	5	1.1	7	0.8
		NO	438	99.5	431	98.9	869	99.2
	CARDIAC	YES	2	0.5	1	0.2	3	0.3
		NO	438	99.5	435	99.8	873	99.7
	EAR AND LABYRINTH	YES	3	0.7	1	0.2	4	0.5
		NO	437	99.3	435	99.8	872	99.5
	ENDOCRINE	YES	1	0.2	0	0.0	1	0.1
		NO	439	99.8	436	100	875	99.9
	EYE	YES	7	1.6	6	1.4	13	1.5
		NO	433	98.4	430	98.6	863	98.5
	GASTROINTESTINAL	YES	18	4.1	15	3.4	33	3.8
		NO	422	95.9	421	96.6	843	96.2
	HEPATOBILIARY	YES	5	1.1	6	1.4	11	1.3
		NO	435	98.9	430	98.6	865	98.7
	IMMUNE SYSTEM (INCL ALLERGIES, AUTOIMMUNE DISORDERS)	YES	0	0.0	1	0.2	1	0.1
		NO	440	100	435	99.8	875	99.9
	INFECTIONS AND INFESTATIONS	YES	1	0.2	0	0.0	1	0.1
		NO	439	99.8	436	100	875	99.9
	METABOLISM AND NUTRITION	YES	2	0.5	1	0.2	3	0.3
		NO	438	99.5	435	99.8	873	99.7
	NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS, POLYPS)	YES	1	0.2	0	0.0	1	0.1
	,	NO	439	99.8	436	100	875	99.9
	OTHER	YES	3	0.7	8	1.8	11	1.3
		NO	437	99.3	428	98.2	865	98.7
	RESPIRATORY, THORACIC AND MEDIASTINAL	YES	23	5.2	19	4.4	42	4.8
		NO	417	94.8	417	95.6	834	95.2
	SKIN AND SUBCUTANEOUS TISSUE	YES	15	3.4	11	2.5	26	3.0
		NO	425	96.6	425	97.5	850	97.0

Previous medical history - by gender (Total Vaccinated cohort) Table 3

HRV = Human rotavirus vaccine

N = Total number of subjects in each group (Male/female/Total) n (%) = number (percentage) of subjects with the specified category (Yes/No)

Table 4	Previous medical history – by classification (Total Vaccinated
	cohort)

				HRV		
					95%	% CI
Previous Medical History	Diagnosis Or sign Symptom	N+	n	%	LL	UL
BLOOD AND LYMPHATIC SYSTEM	ANEMIA	7	3	2.5	0.5	7.3
	NEUTROPENIA	7	1	0.8	0.0	4.6
	SEPSIS	7	3	2.5	0.5	7.3
CARDIAC	ASD. TR.	4	1	0.8	0.0	4.6
	ATRIAL SEPTAL DEFECT	4	1	0.8	0.0	4.6
	PUL. HTN	4	1	0.8	0.0	4.6
	TRICUSPID	4	1	0.8	0.0	4.6
	REGURGITATION					
EAR AND LABYRINTH	ACUTE RHINITIS	4	1	0.8	0.0	4.6
	OTITIS EXTERNA	4	2	1.7	0.2	6.0
	OTITIS MEDIA	4	1	0.8	0.0	4.6
ENDOCRINE	HYPOTHYROIDISM	1	1	0.8	0.0	4.6
EYE	ACUTE CONJUNCTIVITIS	14	1	0.8	0.0	4.6
	CONJUNCTIVITIS	14	3	2.5	0.5	7.3
	EYE DISCHARGE	14	1	0.8	0.0	4.6
	NEONATAL CONJUNCTIVITIS	14	6	5.1	1.9	10.7
	R/O CONJUNCTIVITIS	14	1	0.8	0.0	4.6
	R/O NASOLACRIMAL DUCT OBSTRUCTION	14	2	1.7	0.2	6.0
GASTROINTESTINAL	ACUTE GASTRITIS	34	1	0.8	0.0	4.6
	AGE	34	8	6.8	3.0	12.9
	DIARRHEA	34	1	0.8	0.0	4.6
	GASTROENTERITIS	34	10	8.5	4.1	15.0
	GER	34	2	1.7	0.2	6.0
	INFANTILE COLIC	34	2	1.7	0.2	6.0
	INGUINAL HERNIA	34	1	0.8	0.0	4.6
	NEC (NECROTIZING ENTERO - COLITIS)	34	1	0.8	0.0	4.6
	NEONATAL VOMITING	34	1	0.8	0.0	4.6
	NON INFECTIOUS NEONATAL DIARRHEA	34	1	0.8	0.0	4.6
	R/O GASTROESOPHAGEAL REFLUX	34	1	0.8	0.0	4.6
	R/O GERD	34	1	0.8	0.0	4.6
	R/O MILD AGE	34	1	0.8	0.0	4.6
	UMBILICAL HERNIA	34	3	2.5	0.5	7.3
HEPATOBILIARY	JAUNDICE	11	3	2.5	0.5	7.3
	NEONATAL JAUNDICE	11	8	6.8	3.0	12.9
MMUNE SYSTEM (INCL ALLERGIES, AUTOIMMUNE DISORDERS)	ALLERGIC PROCTOCOLITIS	1	1	0.8	0.0	4.6
NFECTIONS AND NFESTATIONS	LYMPHADENITIS	1	1	0.8	0.0	4.6
METABOLISM AND NUTRITION	NEONATAL JAUNDICE	3	3	2.5	0.5	7.3
NEOPLASMS BENIGN, MALIGNANT AND	NECROSIS OF SCROTUM	1	1	0.8	0.0	4.6

Rotarix[™] Post-Marketing Surveillance annual report Page 19 GlaxoSmithKline Korea

				HRV		
					95%	% CI
Previous Medical History	Diagnosis Or sign Symptom	N+	n	%	LL	UL
UNSPECIFIED (INCL CYSTS, POLYPS)						
OTHER	BREAST MILK JAUNDICE	11	1	0.8	0.0	4.6
	CLEFT LIP AND PALATE	11	1	0.8	0.0	4.6
	INTRAUTERINE GROWTH RETARDATION	11	1	0.8	0.0	4.6
	PREMATURITY	11	8	6.8	3.0	12.9
RESPIRATORY, THORACIC AND MEDIASTINAL	ACUTE BRONCHIOLITIS	45	2	1.7	0.2	6.0
	ACUTE BRONCHITIS	45	3	2.5	0.5	7.3
	ACUTE NASOPHARYNGITIS	45	3	2.5	0.5	7.3
	BRONCHITIS	45	1	0.8	0.0	4.6
	COUGH (COMMON COLD)	45	1	0.8	0.0	4.6
	NASAL STUFFY	45	1	0.8	0.0	4.6
	NASOPHARYNGITIS	45	2	1.7	0.2	6.0
	PNEUMONIA	45	2	1.7	0.2	6.0
	RESPIRATORY DISTRESS SYNDROME	45	1	0.8	0.0	4.6
	STREPTOCOCCAL TONSILLITIS	45	1	0.8	0.0	4.6
	URI	45	25	21.2	14.2	29.7
	UTI	45	3	2.5	0.5	7.3
SKIN AND SUBCUTANEOUS TISSUE	ALLERGIC URTICARIA	27	1	0.8	0.0	4.6
	ATOPIC DERMATITIS	27	10	8.5	4.1	15.0
	CANDIDID	27	1	0.8	0.0	4.6
	DIAPER RASH	27	3	2.5	0.5	7.3
	MELANOSIS	27	1	0.8	0.0	4.6
	NEONATAL OMPHALITIS	27	3	2.5	0.5	7.3
	NON SPECIFIC ECZEMA	27	1	0.8	0.0	4.6
	SEBORRHEIC DERMITITIS	27	6	5.1	1.9	10.7
	UNSPECIFIC RASH	27	1	0.8	0.0	4.6

HRV = Human rotavirus vaccine

N+=Total Number of cases in the specified previous medical history category

n (%) = number (percentage) of cases in the specified category of diagnosis OR symptom category

95% CI = exact 95% confidence interval - L.L. = lower limit, U.L. = upper limit

ASD. TR = ATRIAL SEPTAL DEFECT

PUL. HTN = Pulmonary hypertension

R/O = Rule Out

AGE = Acute Gastroenteritis

GER = Gastroesophageal reflux

GERD = Gastroesophageal reflux disease

Note: In the above table, the classification of the diagnosis or sign symptoms to the respective previous medical history categories is presented as classified by the investigator.

4.4 **Pre-rotavirus vaccination history**

Table 5 presents the pre-rotavirus (RV) vaccination history.

• A total of 66 subjects (24 (5.5%) males and 42 (9.6%) females) received a dose of Rotarix[™] prior to the start of this PMS study.

Table 5 Pre-rotavirus vaccination history (Total Vaccinated cohort)

		Fem N = 4		Male N = 440				
	Parameters or	n	%	n	%			
Characteristics	Categories							
Did the subject receive HRV vaccine prior to	Yes	42	9.6	24	5.5			
the PMS study?	No	394	90.4	416	94.5			

HRV = Human rotavirus vaccine

N = total number of subjects

n = number of subjects with the specified category.

% = n / Number of subjects with available results x 100

YES = Subjects with a dose of HRV vaccination prior to the start of the study

No = Subject who did not received any dose of HRV vaccination prior to the start of the PMS.

4.5 Drug administration

4.5.1 Administration of concomitant medication

Table 6 presents the administration of concomitant medication by gender for the Total Vaccinated cohort.

Table 7 presents the administration of concomitant medication by classification for the Total Vaccinated cohort.

- The percentage of subjects who started taking any concomitant medication during the study period was 42.7%. Of these 12.9% received any antibiotic medication.
- Prophylactic antipyretics were taken by 1.3% of the subjects.

Table 6Administration of concomitant medication - by gender (TotalVaccinated cohort)

		Male N=440				nale =436	Total N =876		
	Group	Category	n	%	n	%	n	%	
Administration of	HRV	NO	238	54.1	264	60.6	502	57.3	
concomitant medication		YES	202	45.9	172	39.4	374	42.7	

HRV = Human rotavirus vaccine

N = Total number of subjects in each group (MALE /FEMALE)

n(%) = number (percentage) of subjects with the specified category (YES / NO)

Table 7Administration of concomitant medication - by classification (Total
Vaccinated cohort)

	Group					95%	6 CI
	-	Classification	Ν	n	%	LL	UL
Administration of concomitant medication	HRV	Any	876	374	42.7	39.4	46.0
		Any antipyretic	876	103	11.8	9.7	14.1
		Any antibiotic	876	113	12.9	10.8	15.3
		Prophylactic antipyretic	876	11	1.3	0.6	2.2

HRV = Human rotavirus vaccine

N = Number of subjects

n (%) = number (percentage) of subjects with the specified Classification

95% CI = exact 95% confidence interval - L.L. = lower limit, U.L. = upper limit

4.5.2 Administration of concomitant vaccination

Table 8 presents the administration of concomitant vaccination by gender for the Total Vaccinated cohort.

• Overall at least 97.9% of the subjects received any concomitant vaccination with Rotarix[™].

Table 8Administration of concomitant vaccination – by gender (Total
Vaccinated cohort)

Concomitant vaccination	Male N=440				Female N=436				Total N =876			
	n	%	LL	UL	n	%	LL	UL	n	%	LL	UL
Yes	430	97.7	95.9	98.9	428	98.2	96.4	99.2	858	97.9	96.8	98.8
No	10	2.3	1.1	4.1	8	1.8	0.8	3.6	18	2.1	1.2	3.2

N = Total number of subjects

n(%) = Number(percentage) of subjects with specified category

4.5.3 Administration of study vaccination

Table 9 presents the administration of study vaccine for the Total Vaccinated cohort.

- Overall, 92.5% and 79.8% of the subjects received Dose 1 and Dose 2 of RotarixTM, respectively during the study period.
- The percentage of subjects who received Dose 1 of Rotarix[™] prior to the start of this study was 7.5%.

			HRV C	Group
Gender	Characteristics	Parameters or Categories	n	%
Female (N=436)	Dose 1 in this study	NO	42	9.6
		YES	394	90.4
	Dose 2 in this study	NO	84	19.3
		YES	352	80.7
	Dose 1 prior to this study	NO	394	90.4
		YES	42	9.6
Male (N=440)	Dose 1 in this study	NO	24	5.5
, , , , , , , , , , , , , , , , , , ,		YES	416	94.5
	Dose 2 in this study	NO	93	21.1
		YES	347	78.9
	Dose 1 prior to this study	NO	416	94.5
		YES	24	5.5
Total (N=876)	Dose 1 in this study	NO	66	7.5
(<i>'</i> ,		YES	810	92.5
	Dose 2 in this study	NO	177	20.2
		YES	699	79.8
	Dose 1 prior to this study	NO	810	92.5
		YES	66	7.5

Administration of study vaccine (Total Vaccinated cohort) Table 9

HRV = Human rotavirus vaccine

N = Total number of subjects in each group (Male/Female/Total) n(%)= Number(percentage) of subjects with specified category(YES/NO)

V. Results of the drug use investigation

5. Results of the drug use investigation

5.1 Adverse events

In this study, there was a active collection of few adverse events (AEs) (cough, diarrhoea, irritability, loss of appetite, temperature and vomiting) for 8 days post each dose of RotarixTM & the remaining were passively collected from the subjects for 31 days post each dose. Later all AEs were classified as expected & unexpected using the approved Korean prescribing information and the analysis was performed.

An adverse drug reaction (ADR) is any AE whose causality to the drug cannot be ruled out and is assessed as "definitely related" or "probably related" or "possibly related" or "unknown".

Expected AEs - The presence/occurrence/intensity of an AE that is expected from the subject or an observer during the post-vaccination follow-up period as described in the approved prescribing information.

Unexpected AEs - Any AE that are not reflected in the approved prescribing information and that has been reported.

5.1.1 Serious adverse events, adverse drug reaction

Serious Adverse Event

A serious adverse event (SAE) was any untoward medical occurrence that:

- a. resulted in death,
- b. was life-threatening,

NOTE: The term 'life-threatening' in the definition of 'serious' referred to an event in which the subject was at risk of death at the time of the event. It did not refer to an event, which hypothetically might have caused death, if it were more severe.

c. required hospitalisation or prolongation of existing hospitalisation,

NOTE: In general, hospitalisation signified that the subject was detained (usually involving at least an overnight stay) at the hospital or emergency ward for observation and/or treatment that would not have been appropriate in the physician's office or out-patient setting. Complications that occurred during hospitalisation were AEs. If a complication prolonged hospitalisation or fulfilled any other serious criteria, the event was serious. When in doubt as to whether "hospitalisation" occurred or was necessary, the AE was considered serious.

Hospitalisation for elective treatment of a pre-existing condition that did not worsen from baseline was not considered an AE.

d. resulted in disability/incapacity, or

NOTE: The term disability meant a substantial disruption of a person's ability to conduct normal life functions. This definition was not intended to include experiences of

relatively minor medical significance such as uncomplicated headache, nausea, vomiting, diarrhoea, influenza, and accidental trauma (e.g. sprained ankle) which may have interfered or prevented everyday life functions but did not constitute a substantial disruption.

e. was a congenital anomaly/birth defect in the offspring of a study subject.

Medical or scientific judgement was exercised in deciding whether reporting was appropriate in other situations, such as important medical events that may not have been immediately life-threatening or resulted in death or hospitalisation but may have jeopardised the subject or may have required medical or surgical intervention to prevent one of the other outcomes listed in the above definition. These were also considered serious. Examples of such events were invasive or malignant cancers, intensive treatment in an emergency room or at home for allergic bronchospasm, blood dyscrasias or convulsions that did not result in hospitalisation.

Table 10 presents the serious adverse events (SAEs) and serious adverse drug reactions (ADRs) for the Total Vaccinated cohort.

Table 11 presents the listings of SAEs for the Total Vaccinated cohort.

A total of 11 SAEs were reported for 6 subjects during the study period. No serious ADRs were reported during the study period.

A brief summary of these SAEs are given below.

- **Case ID:** PPD An eleven-week old male subject (subject No. PPD developed sepsis 11 days after receiving Dose 1 of Rotarix[™]. The subject was hospitalised and treated with antibiotics and fluid therapy. The event resolved after 23 days. The investigator concluded that the SAE was probably not related to the study vaccination.
- **Case ID:** PPD A nine-week old male subject (subject No. PPD developed bronchiolitis, otitis media acute and acute GE one day after receiving Dose 1 of Rotarix[™]. The subject was hospitalised and treated with Zaditen and Codenal. The event resolved after 34 days. The investigator concluded that the SAEs were probably not related to the study vaccination.
- **Case ID:** PPD An eleven-week old male subject (subject No. PPD developed acute bronchiolitis, 7 days after receiving Dose 1 of RotarixTM. The subject was hospitalised and treated with nebulizer and mucolytic agent. The event resolved after 14 days. The investigator concluded that the SAE was probably not related to the study vaccination.
- Case ID: PPD An eight-week old female subject (subject No. PPD developed acute GE and paralytic ileus, on the day of vaccination after receiving Dose 1 of RotarixTM. The subject was hospitalised and treated with antibiotics and fluid therapy. The event resolved after 22 days. The investigator concluded that the SAEs were probably not related to the study vaccination.
- **Case ID:** ^{PPD} A ten-week old female subject (subject No. ^{PPD} developed acute bronchiolitis, 17 days after receiving Dose 1 of Rotarix[™]. The subject was

hospitalised and treated with nebulizer and IV injection. The event resolved after 34 days. The investigator concluded that the SAE was probably not related to the study vaccination.

- **Case ID:** PPD A fourteen-week old male subject (subject No. PPD developed acute bronchiolitis, 45 days after receiving Dose 1 of RotarixTM. The subject was hospitalised and treated with nebulizer, antibiotics and fluid therapy. The event resolved after 8 days. The investigator concluded that the SAE was probably not related to the study vaccination.
- **Case ID:** PPD A seventeen-week old male subject (subject No. PPD developed infectious croup, 10 days after receiving Dose 2 of Rotarix[™]. The subject was hospitalised and treated with nebulizer, antibiotics and fluid therapy. The event resolved after 9 days. The investigator concluded the SAE was not probably related to the study vaccination.
- **Case ID:** PPD A seventeen-week old male subject (subject No. PPD developed AOM, 10 days after receiving Dose 2 of RotarixTM. The subject was hospitalised and treated with nebulizer, antibiotics and fluid therapy. The event resolved after 9 days. The investigator concluded that the SAE was not probably related to the study vaccination.

Table 10	Serious adverse events and serious adverse drug reactions (Total
	Vaccinated cohort)

				SAE N=876	5		ADR N=876				
		95%						95%			
System organ class (code)	Prefered Term	n	n*	%	LL	UL	n	n*	%	LL	UL
Gastrointestinal disorders (10017947)	lleus paralytic (10021333)	1	1	0.1	0.0	0.6					
Infections and infestations (10021881)	Bronchiolitis (10006448)	4	4	0.5	0.1	1.2					
	Croup infectious (10011416)	1	1	0.1	0.0	0.6	-				
	Gastroenteritis (10017888)	2	2	0.2	0.0	0.8					
	Otitis media acute (10033079)	2	2	0.2	0.0	0.8	-				
	Sepsis (10040047)	1	1	0.1	0.0	0.6					

N = Number of subjects

n (%) = number (percentage) of subjects with the specified category n* = number of symptoms with the specified category 95% CI = exact 95% confidence interval - L.L. = lower limit, U.L. = upper limit

CONFIDENTIAL Second Annual Study Report for 111700 (Rota-070 PMS)

Group	No.	Case Id	Age at onset (Week)	Gender	Verbatim	Preferred term	System Organ Class	MA type	Dose	Day of onset	Duratio n	Intensity	Causality**	Outcome
HRV	PPD		11	М	1. r/o sepsis, 2. fever, 3. iv antibiotics and fluid therapy	Sepsis	Infections and infestations	HO	1	11	23	1	N	Recovered/resolved
			9	М	Note*	Bronchiolitis	Infections and infestations	HO	1	1	34	3	N	Recovered/resolved
			9		Note*	Gastroenteritis	Infections and infestations	HO	1	1	34	3	N	Recovered/resolved
			9		Note*	Otitis media acute	Infections and infestations	HO	1	1	34	3	N	Recovered/resolved
			11	М	Acute bronchiolitis	Bronchiolitis	Infections and infestations	HO	1	7	14	2	N	Recovered/resolved
			8	F	Acute gastroenteritis	Gastroenteritis	Infections and infestations	HO	1	0	22	2	N	Recovered/resolved
			8		Paralytic ileus	lleus paralytic	Gastrointestina I disorders	HO	1	0	22	2	N	Recovered/resolved
			10	F	Acute bronchiolitis	Bronchiolitis	Infections and infestations	HO	1	17	34	2	N	Recovered/resolved
			14	М	Acute bronchiolitis	Bronchiolitis	Infections and infestations	HO	1	45	8	2	N	Recovered/resolved
			17	М	Croup, acute otitis media	Croup infectious	Infections and infestations	HO	2	10	9	2	N	Recovered/resolved
			17		Croup, acute otitis media	Otitis media acute	Infections and infestations	HO	2	10	9	2	N	Recovered/resolved

Table 11 Listing of SAEs (Total Vaccinated cohort)

HRV = Human rotavirus vaccine

M = Male

F = Female

MA type (Medical Advice type): HO: Hospitalisation

* Bronchiolitis, otitis media acute and acute GE.

** Causality according to KFDA assessment = probably not related to the Rotarix™ vaccine

CONFIDENTIAL

Second Annual Study Report for 111700 (Rota-070 PMS)

5.1.2 Adverse events, adverse drug reaction

Table 12 presents the expected and unexpected AEs and ADRs for the Total Vaccinated cohort.

- Irritability was the most frequently reported expected AE, reported for 405 (46.2%) subjects. Decreased appetite and vomiting were reported for 259 (29.6%) and 200 (22.8%) subjects, respectively.
- Irritability was the most frequently reported expected ADR, reported for 47 (5.4%) subjects. Vomiting and pyrexia were reported for 44 (5.0%) and 27 (3.1%) subjects, respectively.
- Cough was the most frequently reported unexpected AE, reported for 209 (23.9%) subjects. Nasopharyngitis (79 (9.0%) subjects), bronchiolitis (64 (7.3%) subjects), dermatitis atopic (34 (3.9%) subjects) and gastrointestinal disorders (26 (3.0%) subjects) were the other reported unexpected AEs.
- Cough was also the most frequently reported unexpected ADR reported for (10 (1.1%)) subjects. Upper respiratory tract infection and gastrointestinal disorders were reported for 5 (0.6%) subjects and 3 (0.3%) subjects, respectively.

CONFIDENTIAL Second Annual Study Report for 111700 (Rota-070 PMS)

Table 12 Expected & Unexpected adverse events and adverse drug reactions (Total Vaccinated cohort)

			AE N=876					ADR N=876				
						95					95	5%
Group	System organ class (code)	Preferred Term (code)	n	n*	%	LL	UL	n	n*	%	LL	UL
	(0000)	Expected /	dverse	Even	ts*					1		<u> </u>
HRV	Gastrointestinal disorders (10017947)	Constipation (10010774)	5	5	0.6	0.2	1.3					
	, , ,	Diarrhoea (10012735)	55	56	6.3	4.8	8.1	15	16	1.7	1.0	2.8
		Vomiting (10047700)	200	224	22.8	20.1	25.8	44	45	5.0	3.7	6.7
	General disorders and administration site conditions (10018065)	Irritability (10022998)	405	488	46.2	42.9	49.6	47	53	5.4	4.0	7.1
		Pyrexia (10037660)	138	150	15.8	13.4	18.3	27	29	3.1	2.0	4.5
	Infections and infestations (10021881)	Upper respiratory tract infection (10046306)	57	65	6.5	5.0	8.3	•	•			•
	Metabolism and nutrition disorders (10027433)	Decreased appetite (10061428)	259	296	29.6	26.6	32.7	26	26	3.0	1.9	4.3
	Respiratory, thoracic and mediastinal disorders (10038738)	Rhinorrhoea (10039101)	6	6	0.7	0.3	1.5					•
	Skin and subcutaneous tissue disorders (10040785)	Dermatitis (10012431)	12	12	1.4	0.7	2.4					•
	,	Rash (10037844)	2	2	0.2	0.0	0.8					<u> </u>
	- ·· ·	Unexpected		1	1		4.0					1
HRV	Eye disorders (10015919)	Conjunctivitis (10010741)	7	7	0.8	0.3	1.6	•	•		•	•
		Conjunctivitis allergic (10010744)	1	1	0.1	0.0	0.6	•	•		•	•
		Entropion (10061842)	1	1	0.1	0.0	0.6	•	•		•	•
		Eye discharge (10015915)	2	2	0.2	0.0	0.8	•	•		•	•
	Gastrointestinal disorders (10017947)	Colitis (10009887)	2	2	0.2	0.0	0.8	•	•		•	•
		Dyspepsia (10013946)	3	3	0.3	0.1	1.0	•	•		•	•
		Gastritis (10017853)	8	10	0.9	0.4	1.8		•	0.0		
		Gastrointestinal disorder (10017944)	26	27	3.0	1.9	4.3	3	3	0.3	0.1	1.0
		Gastrooesophageal reflux disease (10017885)	2	2	0.2	0.0	0.8					•
		lleus paralytic (10021333)	1	1	0.1	0.0	0.6		•			•
		Regurgitation (10067171)	1	1	0.1	0.0	0.6					
	General disorders and	Úlcer (10045285)	1	1	0.1	0.0	0.6					<u> </u>

Rotarix[™] Post-Marketing Surveillance annual report Page 31 *GlaxoSmithKline Korea*

Group	System organ class (code) administration site		AE N=876					ADR N=876				
						95%					95%	
		Preferred Term (code)	n	n*	%	LL	UL	n	n*	%	LL	U
	conditions (10018065)											
	Immune system disorders (10021428)	Atopy (10003645)	6	6	0.7	0.3	1.5	•	•		•	
		Hypersensitivity (10020751)	2	2	0.2	0.0	0.8	1	1	0.1	0.0	0.
		Milk allergy (10027633)	1	1	0.1	0.0	0.6	•	•		•	
	Infections and infestations (10021881)	Acute sinusitis (10001076)	3	3	0.3	0.1	1.0					
		Acute tonsillitis (10001093)	4	4	0.5	0.1	1.2	•	•		•	
		Bronchiolitis (10006448)	64	78	7.3	5.7	9.2	2	2	0.2	0.0	0
		Bronchitis (10006451)	12	12	1.4	0.7	2.4	•	·		•	
		Cellulitis (10007882)	2	2	0.2	0.0	0.8	•	•		•	
		Croup infectious (10011416)	1	1	0.1	0.0	0.6	•	•		•	
		Cystitis (10011781) Ear infection (10014011)	<u>1</u> 1	1	0.1 0.1	0.0	0.6	•	•		•	
		Empyema (10014568)	3	3	0.3	0.1	1.0		•		•	
		Enteritis infectious (10058839)	1	1	0.1	0.0	0.6		•			
		Fungal infection (10017533)	1	1	0.1	0.0	0.6		•			
		Gastroenteritis (10017888)	24	29	2.7	1.8	4.0	1	1	0.1	0.0	0
		Gastroenteritis viral (10017918)	2	2	0.2	0.0	0.8		•		•	
		Influenza (10022000)	1	1	0.1	0.0	0.6	•	•		•	
		Laryngitis (10023874)	1	1	0.1	0.0	0.6	•	•		•	
		Lower respiratory tract infection (10024968)	2	3	0.2	0.0	0.8	•	•		•	
		Nasopharyngitis (10028810)	79	99	9.0	7.2	11.1		•		•	
		Oral candidiasis (10030963)	4	5	0.5	0.1	1.2	•	•		•	
		Otitis externa (10033072)	2	2	0.2	0.0	0.8			0.4		•
		Otitis media (10033078)	7	7	0.8	0.3	1.6	1	1	0.1	0.0	0
		Otitis media acute (10033079) Pharyngitis (10034835)	10	8	0.8	0.3 0.5	1.6 2.1	•	•		•	

CONFIDENTIAL Second Annual Study Report for 111700 (Rota-070 PMS)

Rotarix[™] Post-Marketing Surveillance annual report Page 32 GlaxoSmithKline Korea

AE ADR N=876 N=876 95% 95% System organ class **Preferred Term** % Group n* % LL UL n* LL UL n n (code) (code) 3 Pneumonia 3 0.3 0.1 1.0 (10035664) Respiratory tract 2 4 0.0 0.2 0.8 infection (10062352) Rhinitis (10039083) 8 12 0.9 0.4 1.8 . Sepsis (10040047) 1 1 0.1 0.0 0.6 Tonsillitis 1 2 0.1 0.0 0.6 (10044008) Upper respiratory 24 25 1.3 2.7 1.8 4.0 5 0.6 0.2 5 tract infection (10046306) 1 1 0.6 Urethritis 0.1 0.0 . . . (10046480)Urinary tract 1 0.0 0.6 1 0.1 infection (10046571) Nervous system Tremor (10044565) 1 1 0.1 0.0 0.6 disorders (10029205) Pregnancy, Jaundice neonatal 1 1 0.1 0.0 0.6 puerperium and (10023138)perinatal conditions (10036585)Renal and urinary Tubulointerstitial 1 0.1 0.0 0.6 1 disorders (10038359) nephritis (10048302) Reproductive system Balanoposthitis 1 1 0.1 0.0 0.6 and breast disorders (10004078) (10038604)Respiratory, thoracic 2 Asthma 2 0.2 0.0 0.8 and mediastinal (10003553)disorders (10038738) Cough (10011224) 209 23.9 26.8 243 21.1 10 11 1.1 0.5 2.1 Nasal congestion 3 3 0.3 0.1 1.0 (10028735) Rhinorrhoea 1 1 0.1 0.0 0.6 (10039101)Skin and Dermatitis atopic 34 37 3.9 2.7 5.4 1 0.1 0.0 0.6 1 subcutaneous tissue (10012438) disorders (10040785) Dermatitis contact 2 2 0.2 0.0 0.8 (10012442) Dermatitis diaper 6 6 0.7 1.5 0.3 (10012444) 2 2 Eczema 0.2 0.0 0.8 (10014184)Rash (10037844) 0.1 0.0 0.6 1 1 Seborrhoeic 4 5 0.5 0.1 1.2 dermatitis (10039793)Skin lesion 1 1 0.1 0.0 0.6 (10040882) Urticaria 4 4 0.5 0.1 1.2 1 1 0.1 0.0 0.6 (10046735)

CONFIDENTIAL Second Annual Study Report for 111700 (Rota-070 PMS)

Rotarix[™] Post-Marketing Surveillance annual report Page 33 GlaxoSmithKline Korea

CONFIDENTIAL

Second Annual Study Report for 111700 (Rota-070 PMS)

HRV = Human rotavirus vaccine
N = Number of subjects
n(%) = number (percentage) of subjects with the specified category
n* = number of symptoms with the specified category
S% CI = exact 95% confidence interval - L.L. = lower limit, U.L. = upper limit
* The classification of adverse events as Expected & Unexpected AEs is done by Low level term code mentioned in the cleaning report of this study

5.1.3 Adverse events by factors

A. Adverse events by patient background factors

A.1 Gender

Table 13 presents the AEs experienced by subjects during the entire study period: Stratified by gender for the Total Vaccinated cohort.

The percentage of male (72.5%) and female (71.3%) subjects reporting AEs were similar during the study period.

Table 13Adverse events experienced by subjects during the entire study
period: Stratified by gender (Total Vaccinated cohort)

				LE 440		FEMALE N = 436				
				95%	6 CI			95%	6 CI	
Group	Did the subject experience any adverse events?	n	%	LL	UL	n	%	LL	UL	
HRV	No	121	27.5	23.4	31.9	125	28.7	24.5	33.2	
	Yes	319	72.5	68.1	76.6	311	71.3	66.8	75.5	

HRV = Human rotavirus vaccine

N = Total number of subjects in the given category

n(%) = number(percentage)of subjects in the given category

A.2 Age

Not applicable.

A.3 Medical history

Table 14 presents the AEs experienced by subjects during the entire study period: stratified by previous medical history for the Total Vaccinated cohort.

Table 15 presents the AEs experienced by previous medical history-by gender and classification for the Total Vaccinated cohort.

- Of the 118 subjects who had a previous medical history a total of 85 (72.0%) subjects experienced AEs.
- Irritability was the most frequently reported AE among subjects who had a previous medical history of blood and lymphatic system (4 subjects), eye disorders (10

CONFIDENTIAL

Second Annual Study Report for 111700 (Rota-070 PMS)

subjects), GI disorders (17 subjects), hepatobiliary disorders (8 subjects), metabolism and nutrition disorders (3 subjects), respiratory, thoracic and mediastinal disorders (26 subjects), skin and subcutaneous tissue disorders (13 subjects) and subjects who had other AEs (5 subjects)

- Cough, irritability, decreased appetite and nasopharyngitis were the reported AEs among subjects who had a previous medical history of cardiac disorders and were reported for two subjects each.
- Cough, irritability and vomiting were the most frequently reported AEs among subjects who had a previous medical history of ear and labyrinth disorders and was reported for three subjects each.
- Cough and irritability were reported for 1 subject each among subjects who had a previous medical history of endocrine disorders and infections and infestations each.
- Irritability, pyrexia and vomiting were reported for 1 subject each among subjects who had a previous medical history of neoplasms benign, malignant and unspecified (including cysts and polyps).
- None of the subjects who had a previous medical history of immune system disorders reported any AE.

Table 14Adverse events experienced by subjects during the entire study
period: Stratified by previous medical history (Total Vaccinated
cohort)

		Did the subject have any previous medical history?										
				ES =118								
	Did the subject experience any adverse event?			95%	6 CI			95% CI				
Group		n	%	LL	UL	n	%	LL	UL			
HRV	No	33	28.0	20.1	37.0	213	28.1	24.9	31.4			
	Yes	85	72.0	63.0	79.9	545	71.9	68.6	75.1			

HRV = Human rotavirus vaccine

N = Total number of subjects in the given category

n(%) = number(percentage) of subjects in the given category

				ale 440				nale 436				tal 876	
		r			6 CI		r		6 CI		1		6 CI
Previous Medical	Preferred Term	n	%	LL	UL	n	%	LL	UL	n	%	LL	UL
history	(code)												
BLOOD AND LYMPHATIC SYSTEM	Bronchitis (10006451)	0	0.0	0.0	0.8	1	0.2	0.0	1.3	1	0.1	0.0	0.6
	Decreased	1	0.2	0.0	1.3	2	0.5	0.1	1.6	3	0.3	0.1	1.0
	appetite		•	0.0		-	0.0	•		•		•••	
	(10061428)												
	Irritability	2	0.5	0.1	1.6	2	0.5	0.1	1.6	4	0.5	0.1	1.2
	(10022998)	•				•		0.4		•			1.0
	NO SYMPTOM	0	0.0	0.0	0.8	3	0.7	0.1	2.0	3	0.3	0.1	1.0
	Vomiting (10047700)	0	0.0	0.0	0.8	1	0.2	0.0	1.3	1	0.1	0.0	0.6
CARDIAC	Cough	1	0.2	0.0	1.3	1	0.2	0.0	1.3	2	0.2	0.0	0.8
CANDIAG	(10011224)	1	0.2	0.0	1.5	I	0.2	0.0	1.5	2	0.2	0.0	0.0
	Decreased	1	0.2	0.0	1.3	1	0.2	0.0	1.3	2	0.2	0.0	0.8
	appetite												
	(10061428)												
	Irritability	1	0.2	0.0	1.3	1	0.2	0.0	1.3	2	0.2	0.0	0.8
	(10022998)	1	0.2	0.0	1.3	1	0.2	0.0	1.3	2	0.2	0.0	0.0
	Nasopharyngitis (10028810)		0.2	0.0		1		0.0		2	0.2	0.0	0.8
	Pyrexia	1	0.2	0.0	1.3	0	0.0	0.0	0.8	1	0.1	0.0	0.6
	(10037660)	4	0.0	0.0	4.0	•	0.0	0.0	0.0	4	0.4	0.0	0.0
	Vomiting (10047700)	1	0.2	0.0	1.3	0	0.0	0.0	0.8	1	0.1	0.0	0.6
EAR AND LABYRINTH	Cough (10011224)	3	0.7	0.1	2.0	0	0.0	0.0	0.8	3	0.3	0.1	1.0
	Decreased	2	0.5	0.1	1.6	0	0.0	0.0	0.8	2	0.2	0.0	0.8
	appetite (10061428)												
	Irritability	3	0.7	0.1	2.0	0	0.0	0.0	0.8	3	0.3	0.1	1.0
	(10022998)												
	Pyrexia (10037660)	1	0.2	0.0	1.3	0	0.0	0.0	0.8	1	0.1	0.0	0.6
	Seborrhoeic	0	0.0	0.0	0.8	1	0.2	0.0	1.3	1	0.1	0.0	0.6
	dermatitis (10039793)												
	Vomiting	2	0.5	0.1	1.6	1	0.2	0.0	1.3	3	0.3	0.1	1.0
	(10047700) Cough	1	0.2	0.0	1.3	0	0.0	0.0	0.8	1	0.1	0.0	0.6
ENDOCRINE	(10011224)	1	0.2	0.0	1.5	0	0.0	0.0	0.0	1	0.1	0.0	0.0
	Irritability	1	0.2	0.0	1.3	0	0.0	0.0	0.8	1	0.1	0.0	0.6
	(10022998)					-							
EYE	Cough (10011224)	2	0.5	0.1	1.6	3	0.7	0.1	2.0	5	0.6	0.2	1.3
	Decreased	0	0.0	0.0	0.8	4	0.9	0.3	2.3	4	0.5	0.1	1.2
	appetite	0	0.0	0.0	0.0	-	0.5	0.0	2.0	-	0.0	0.1	1.2
	(10061428)												
	Diarrhoea	2	0.5	0.1	1.6	0	0.0	0.0	0.8	2	0.2	0.0	0.8
	(10012735)	4	0.0	0.0	10	0	0.0	0.0	0.0	4	0.1	0.0	0.0
	Eye discharge (10015915)	1	0.2	0.0	1.3	0	0.0	0.0	0.8	1	0.1	0.0	0.6

Table 15Adverse events experienced by medical history - by gender and
classification (Total Vaccinated cohort)

Rotarix[™] Post-Marketing Surveillance annual report Page 36 *GlaxoSmithKline Korea*

				ale 440				nale 436				tal 876	
				95%	6 CI			95%	% CI			95%	6 CI
Previous Medical history	Preferred Term (code)	n	%	LL	UL	n	%	LL	UL	n	%	LL	UL
	Irritability (10022998)	6	1.4	0.5	2.9	4	0.9	0.3	2.3	10	1.1	0.5	2.1
	NO SYMPTOM	1	0.2	0.0	1.3	2	0.5	0.1	1.6	3	0.3	0.1	1.0
	Pyrexia (10037660)	0	0.0	0.0	0.8	1	0.2	0.0	1.3	1	0.1	0.0	0.6
	Seborrhoeic dermatitis (10039793)	0	0.0	0.0	0.8	1	0.2	0.0	1.3	1	0.1	0.0	0.6
	Upper respiratory tract infection (10046306)	0	0.0	0.0	0.8	1	0.2	0.0	1.3	1	0.1	0.0	0.6
	Vomiting (10047700)	1	0.2	0.0	1.3	2	0.5	0.1	1.6	3	0.3	0.1	1.0
GASTROINTESTINAL	Cough (10011224)	2	0.5	0.1	1.6	3	0.7	0.1	2.0	5	0.6	0.2	1.3
	Decreased appetite (10061428)	6	1.4	0.5	2.9	6	1.4	0.5	3.0	12	1.4	0.7	2.4
	Dermatitis atopic (10012438)	0	0.0	0.0	0.8	1	0.2	0.0	1.3	1	0.1	0.0	0.6
	Diarrhoea (10012735)	2	0.5	0.1	1.6	0	0.0	0.0	0.8	2	0.2	0.0	0.8
	Gastritis (10017853)	0	0.0	0.0	0.8	1	0.2	0.0	1.3	1	0.1	0.0	0.6
	Gastroenteritis (10017888)	1	0.2	0.0	1.3	0	0.0	0.0	0.8	1	0.1	0.0	0.6
	Gastrointestinal disorder (10017944)	0	0.0	0.0	0.8	1	0.2	0.0	1.3	1	0.1	0.0	0.6
	Irritability (10022998)	11	2.5	1.3	4.4	6	1.4	0.5	3.0	17	1.9	1.1	3.1
	NO SYMPTOM	5	1.1	0.4	2.6	6	1.4	0.5	3.0	11	1.3	0.6	2.2
	Nasopharyngitis (10028810)	1	0.2	0.0	1.3	0	0.0	0.0	0.8	1	0.1	0.0	0.6
	Otitis media acute (10033079)	1	0.2	0.0	1.3	0	0.0	0.0	0.8	1	0.1	0.0	0.6
	Pyrexia (10037660)	7	1.6	0.6	3.3	3	0.7	0.1	2.0	10	1.1	0.5	2.1
	Regurgitation (10067171)	1	0.2	0.0	1.3	0	0.0	0.0	0.8	1	0.1	0.0	0.6
	Rhinorrhoea (10039101)	1	0.2	0.0	1.3	0	0.0	0.0	0.8	1	0.1	0.0	0.6
	Seborrhoeic dermatitis (10039793)	0	0.0	0.0	0.8	1	0.2	0.0	1.3	1	0.1	0.0	0.6
	Upper respiratory tract infection (10046306)	0	0.0	0.0	0.8	2	0.5	0.1	1.6	2	0.2	0.0	0.8
	Vomiting (10047700)	6	1.4	0.5	2.9	2	0.5	0.1	1.6	8	0.9	0.4	1.8
HEPATOBILIARY	Cough (10011224)	1	0.2	0.0	1.3	1	0.2	0.0	1.3	2	0.2	0.0	0.8
	Decreased appetite	0	0.0	0.0	0.8	4	0.9	0.3	2.3	4	0.5	0.1	1.2

Rotarix[™] Post-Marketing Surveillance annual report Page 37 GlaxoSmithKline Korea

				ale 440				nale 436				tal 876	
					6 CI				% CI				6 CI
Previous Medical history	Preferred Term (code)	n	%	LL	UL	n	%	LL	UL	n	%	LL	UL
	(10061428)	_				4			1.0	4	0.1		
	Diarrhoea (10012735)	0	0.0	0.0	0.8	1	0.2	0.0	1.3	1	0.1	0.0	0.6
	Irritability (10022998)	4	0.9	0.2	2.3	4	0.9	0.3	2.3	8	0.9	0.4	1.8
	NO SYMPTOM	1	0.2	0.0	1.3	1	0.2	0.0	1.3	2	0.2	0.0	0.8
	Nasopharyngitis (10028810)	0	0.0	0.0	0.8	1	0.2	0.0	1.3	1	0.1	0.0	0.6
	Pyrexia (10037660)	3	0.7	0.1	2.0	1	0.2	0.0	1.3	4	0.5	0.1	1.2
	Upper respiratory tract infection (10046306)	0	0.0	0.0	0.8	1	0.2	0.0	1.3	1	0.1	0.0	0.6
	Vomiting (10047700)	3	0.7	0.1	2.0	3	0.7	0.1	2.0	6	0.7	0.3	1.5
IMMUNE SYSTEM (INCL ALLERGIES, AUTOIMMUNE DISORDERS)	NO SYMPTOM	0	0.0	0.0	0.8	1	0.2	0.0	1.3	1	0.1	0.0	0.6
INFECTIONS AND INFESTATIONS	Cough (10011224)	1	0.2	0.0	1.3	0	0.0	0.0	0.8	1	0.1	0.0	0.6
	Irritability (10022998)	1	0.2	0.0	1.3	0	0.0	0.0	0.8	1	0.1	0.0	0.6
METABOLISM AND NUTRITION	Decreased appetite (10061428)	1	0.2	0.0	1.3	1	0.2	0.0	1.3	2	0.2	0.0	0.8
	Irritability (10022998)	2	0.5	0.1	1.6	1	0.2	0.0	1.3	3	0.3	0.1	1.0
	Pyrexia (10037660)	2	0.5	0.1	1.6	0	0.0	0.0	0.8	2	0.2	0.0	0.8
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS, POLYPS)	Irritability (10022998)	1	0.2	0.0	1.3	0	0.0	0.0	0.8	1	0.1	0.0	0.6
	Pyrexia (10037660)	1	0.2	0.0	1.3	0	0.0	0.0	0.8	1	0.1	0.0	0.6
	Vomiting (10047700)	1	0.2	0.0	1.3	0	0.0	0.0	0.8	1	0.1	0.0	0.6
OTHER	Cellulitis (10007882)	1	0.2	0.0	1.3	0	0.0	0.0	0.8	1	0.1	0.0	0.6
	Cough (10011224)	1	0.2	0.0	1.3	2	0.5	0.1	1.6	3	0.3	0.1	1.0
	Decreased appetite (10061428)	1	0.2	0.0	1.3	2	0.5	0.1	1.6	3	0.3	0.1	1.0
	Diarrhoea (10012735)	0	0.0	0.0	0.8	1	0.2	0.0	1.3	1	0.1	0.0	0.6
	Dyspepsia (10013946)	1	0.2	0.0	1.3	0	0.0	0.0	0.8	1	0.1	0.0	0.6
	Gastroenteritis (10017888)	0	0.0	0.0	0.8	1	0.2	0.0	1.3	1	0.1	0.0	0.6
	Gastrointestinal disorder (10017944)	0	0.0	0.0	0.8	1	0.2	0.0	1.3	1	0.1	0.0	0.6

Rotarix[™] Post-Marketing Surveillance annual report Page 38 GlaxoSmithKline Korea

Male Female Total N=440 N=436 N=876 95% CI 95% CI 95% CI Previous Medical **Preferred Term** % LL UL % UL % LL UL n n LL n history (code) Irritability 2 0.5 0.1 1.6 3 0.1 2.0 0.6 0.2 1.3 0.7 5 (10022998) NO SYMPTOM 0.2 0.0 0.9 0.3 0.2 1.3 1 1.3 4 2.3 5 0.6 Nasopharyngitis 0.2 0.0 1.3 0 0.0 1 0.0 0.0 0.8 1 0.1 0.6 (10028810)Pyrexia 1 0.2 0.0 1.3 2 0.5 0.1 1.6 3 0.3 0.1 1.0 (10037660) Vomiting 0 0.0 0.0 0.8 2 0.5 0.1 1.6 2 0.2 0.0 0.8 (10047700) RESPIRATORY. Acute sinusitis 0 0.0 0.8 1 0.2 0.0 1.3 1 0.1 0.0 0.6 0.0 THORACIC AND (10001076)MEDIASTINAL Bronchiolitis 2 0.5 1.6 0.0 0.1 0 0.0 0.0 0.8 2 0.2 0.8 (10006448) 0.2 1.3 0.0 0.6 Bronchitis 1 0.0 0 0.0 0.8 1 0.1 0.0 (10006451) Cough 9 2.0 0.9 3.8 6 0.5 3.0 15 1.7 1.0 2.8 1.4 (10011224) 9 Decreased 2.0 0.9 3.8 8 1.8 0.8 3.6 17 1.9 1.1 3.1 appetite (10061428)Dermatitis 0 0.0 0.0 0.8 1 0.2 0.0 1.3 1 0.1 0.0 0.6 (10012431)4 2 Diarrhoea 0.9 0.2 2.3 0.5 0.1 1.6 6 0.7 0.3 1.5 (10012735)Gastroenteritis 0 0.0 0.0 0.8 1 0.2 0.0 1.3 1 0.1 0.0 0.6 (10017888)Irritability 16 3.6 2.1 5.8 10 2.3 1.1 4.2 26 3.0 1.9 4.3 (10022998)NO SYMPTOM 4 0.9 0.2 2.3 4 0.9 0.3 2.3 8 0.9 0.4 1.8 Nasal congestion 0 1 0.2 0.0 1.3 0.0 0.0 0.8 1 0.1 0.0 0.6 (10028735)Nasopharyngitis 0.0 0 0.0 0.8 3 0.7 0.1 2.0 3 0.3 0.1 1.0 (10028810)Oral candidiasis 0 0.0 0.0 0.8 1 0.2 0.0 1.3 1 0.1 0.0 0.6 (10030963)Otitis media acute 1 0.2 0.0 1.3 0 0.0 0.0 0.8 1 0.1 0.0 0.6 (10033079)Pyrexia 7 1.6 0.6 3.3 4 0.9 0.3 2.3 11 1.3 0.6 2.2 (10037660)Regurgitation 1 0.2 0.0 1.3 0 0.0 0.0 0.8 1 0.1 0.0 0.6 (10067171)Rhinorrhoea 1 0.2 0.0 1.3 0 0.0 0.0 0.8 1 0.1 0.0 0.6 (10039101)Seborrhoeic 0 0.8 0.6 0.0 0.0 1 0.2 0.0 1.3 1 0.1 0.0 dermatitis (10039793)Upper respiratory 0 0.0 0.0 0.8 6 0.5 3.0 0.7 0.3 1.5 1.4 6 tract infection (10046306)Vomitina 8 1.8 0.8 3.6 6 1.4 0.5 3.0 14 1.6 0.9 2.7 (10047700)SKIN AND Bronchiolitis 1 0.2 0.0 1.3 0 0.0 0.0 0.8 1 0.1 0.0 0.6

CONFIDENTIAL Second Annual Study Report for 111700 (Rota-070 PMS)

Rotarix[™] Post-Marketing Surveillance annual report Page 39 GlaxoSmithKline Korea

				ale 440				nale 436				otal 876	
				95%	6 CI	-		95%	6 CI			95%	6 CI
Previous Medical history	Preferred Term (code)	n	%	LL	UL	n	%	LL	UL	n	%	LL	UL
SUBCUTANEOUS TISSUE	(10006448)												
	Cough (10011224)	3	0.7	0.1	2.0	2	0.5	0.1	1.6	5	0.6	0.2	1.3
	Decreased appetite (10061428)	4	0.9	0.2	2.3	3	0.7	0.1	2.0	7	0.8	0.3	1.6
	Dermatitis (10012431)	0	0.0	0.0	0.8	1	0.2	0.0	1.3	1	0.1	0.0	0.6
	Dermatitis atopic (10012438)	0	0.0	0.0	0.8	1	0.2	0.0	1.3	1	0.1	0.0	0.6
	Diarrhoea (10012735)	1	0.2	0.0	1.3	0	0.0	0.0	0.8	1	0.1	0.0	0.6
	Irritability (10022998)	9	2.0	0.9	3.8	4	0.9	0.3	2.3	13	1.5	0.8	2.5
	NO SYMPTOM	5	1.1	0.4	2.6	3	0.7	0.1	2.0	8	0.9	0.4	1.8
	Nasopharyngitis (10028810)	0	0.0	0.0	0.8	1	0.2	0.0	1.3	1	0.1	0.0	0.6
	Otitis externa (10033072)	0	0.0	0.0	0.8	1	0.2	0.0	1.3	1	0.1	0.0	0.6
	Otitis media acute (10033079)	1	0.2	0.0	1.3	0	0.0	0.0	0.8	1	0.1	0.0	0.6
	Pyrexia (10037660)	3	0.7	0.1	2.0	2	0.5	0.1	1.6	5	0.6	0.2	1.3
	Regurgitation (10067171)	1	0.2	0.0	1.3	0	0.0	0.0	0.8	1	0.1	0.0	0.6
	Rhinorrhoea (10039101)	1	0.2	0.0	1.3	0	0.0	0.0	0.8	1	0.1	0.0	0.6
	Upper respiratory tract infection (10046306)	0	0.0	0.0	0.8	1	0.2	0.0	1.3	1	0.1	0.0	0.6
	Vomiting (10047700)	8	1.8	0.8	3.6	1	0.2	0.0	1.3	9	1.0	0.5	1.9

Second Annual Study Report for 111700 (Rota-070 PMS)

N = Total number of subjects in the given category n (%) = number (percentage)of subjects in the given category NO SYMPTOM = Subjects who had the corresponding previous medical history, but didn't report **any AE**.

Second Annual Study Report for 111700 (Rota-070 PMS)

A.4 Concomitant medications

Table 16 presents the AEs experienced by subjects during the entire study period: stratified by medication for the Total Vaccinated cohort.

Table 17 presents AEs experienced by subjects - by classification of concomitant medication for the Total Vaccinated cohort.

- Majority (96.5%) of the subjects who experienced an AE during the study period took any medication.
- The percentage of subjects who took any concomitant medication to treat an AE was 89.3%.
- The percentage of subjects who took any antibiotics to treat an AE was 93.8%.
- Of the 11 subjects who took prophylactic antipyretics 90.9% of the subjects reported an AE.

Table 16Adverse events experienced by subjects during the entire study
period : Stratified by medication (Total Vaccinated cohort)

)id the su	bject rece	ive any m	edication	?	
				ES 374			N N =	O 502	
				95%	6 CI			95%	6 CI
Group	Did the subject experience any adverse events?	n	%	LL	UL	n	%	LL	UL
HRV	No	13	3.5	1.9	5.9	233	46.4	42.0	50.9
	Yes	361	96.5	94.1	98.1	269	53.6	49.1	58.0

HRV = Human rotavirus vaccine

N = Total number of subjects in the given category

n(%) = number(percentage)of subjects in the given category

Table 17 Adverse events experienced by subjects - by classification of concomitant medication (Total Vaccinated cohort)

							Adverse	events			
					Y	es			Ν	0	
						95%	6 CI			95%	6 CI
Group		Is drug used for treating an AE?	N	n	%	LL	UL	n	%	LL	UL
HRV	Any Medication	No	374	27	7.2	4.8	10.3	13	3.5	1.9	5.9
	-	Yes	374	334	89.3	85.7	92.2		0.0		1.0
	Any antibiotics	No	113	6	5.3	2.0	11.2	1	0.9	0.0	4.8
	-	Yes	113	106	93.8	87.7	97.5		0.0		3.2
	Any antipyretic	No	103	12	11.7	6.2	19.5	6	5.8	2.2	12.2
		Yes	103	85	82.5	73.8	89.3		0.0		3.5
	Phrophylactic Antipyretics	No	11	10	90.9	58.7	99.8	1	9.1	0.2	41.3

HRV = Human rotavirus vaccine

N = Total number of subjects in the given classification

n(%) = number(percentage)of subjects in the given classification

Second Annual Study Report for 111700 (Rota-070 PMS)

A.5 Concomitant vaccinations

Table 18 presents the AEs experienced by subjects during the entire study period: stratified by concomitant vaccination for the Total Vaccinated cohort.

Table 19 presents the AEs experienced by subjects - by classification of concomitant vaccination for the Total Vaccinated cohort.

- Of the 858 subjects who received any paediatric vaccination other than Rotarix[™] in this study 620 (72.3%) subjects reported an AE.
- Of the 815 subjects who received *Haemophilus influenza* type b (Hib) vaccine in this study 598 (73.4%) subjects reported an AE.
- Of the 776 subjects who received pneumococcal (Pn) vaccine in this study 570 (73.5%) subjects reported an AE.
- Of the 465 subjects who received the diphtheria-tetanus-pertussis (DTP) vaccine in this study 336 (72.3%) subjects reported an AE.

Table 18Adverse events experienced by subjects during the entire study
period: Stratified by concomitant vaccination (Total Vaccinated
cohort)

			Did the	subject re	eceive any	/ concomi	tant vacc	ination?	
				ES 858			N N =	O : 18	
				95%	6 CI			95%	6 CI
Group	Did the subject experience any adverse event?	n	%	LL	UL	n	%	LL	UL
HRV	No	238	27.7	24.8	30.9	8	44.4	21.5	69.2
	Yes	620	72.3	69.1	75.2	10	55.6	30.8	78.5

HRV = Human rotavirus vaccine

N = Total number of subjects in the given category

n(%) = number(percentage)of subjects in the given category

Table 19Adverse events experienced by subjects - by classification of
concomitant vaccination (Total Vaccinated cohort)

						Adverse	events			
				Y	es			Ν	0	
					95%	6 CI			95%	6 CI
Group	Classification	Ν	n	%	LL	UL	n	%	LL	UL
HRV	ANY	858	620	72.3	69.1	75.2	238	27.7	24.8	30.9
	BCG	29	19	65.5	45.7	82.1	10	34.5	17.9	54.3
	DTP	465	336	72.3	67.9	76.3	129	27.7	23.7	32.1
	DTPa	69	59	85.5	75.0	92.8	10	14.5	7.2	25.0
	HBV	155	122	78.7	71.4	84.9	33	21.3	15.1	28.6
	HIB	815	598	73.4	70.2	76.4	217	26.6	23.6	29.8
	IPV	456	329	72.1	67.8	76.2	127	27.9	23.8	32.2
	MeMuRu	1	1	100	2.5	100.0	0	0.0	0.0	97.5
	PCV	2	1	50.0	1.3	98.7	1	50.0	1.3	98.7
	Pn	776	570	73.5	70.2	76.5	206	26.5	23.5	29.8
	RAB	54	45	83.3	70.7	92.1	9	16.7	7.9	29.3

HRV = Human rotavirus vaccine

N = Total number of subjects in the given classification

n(%) = number(percentage)of subjects in the given classification

Table 20 presents the AEs by medical history, concomitant vaccination and concomitant medication for the Total Vaccinated cohort.

- Overall, at least one expected AE was reported for 62.7% of the subjects who had a previous medical history, 66.0% of subjects who received concomitant medication and 58.3% of the subjects who received concomitant vaccination, respectively.
- Irritability was the most frequently reported expected AE reported for 55.1% of the subjects who had previous medical history, 47.3% of subjects who received concomitant medication and 46.2% of the subjects who received concomitant vaccination, respectively.
- Overall, at least one unexpected AE was reported for 43.2% of the subjects who had a previous medical history, 82.9% of the subjects who received concomitant medication and 46.7% of subjects who received concomitant vaccination, respectively.

Second Annual Study Report for 111700 (Rota-070 PMS)

• Cough was the most frequently reported unexpected AE reported for 26.3% of the subjects who had previous medical history, 30.5% of the subjects who received concomitant medication and 23.9% of subjects who received concomitant vaccination, respectively.

Table 20Expected & Unexpected adverse events by medical history,
concomitant vaccination, concomitant medication (Total Vaccinated
cohort)

		Medical	Histor	у	Cond	comitan	t medic	ation	Cond	omitant	t vaccii	nation
Preferred term (code)		es		lo	Y	es	N	lo	Y	es	Ν	lo
	N=	118	N=	758	N=	374	N=	502	N=	858	N	=18
	n	%	n	%	n	%	n	%	n	%	n	%
			Ex	pected a	adverse	events	*					
Constipation (10010774)	0	0.0	5	0.7	5	1.3	0	0.0	5	0.6	0	0.0
Decreased appetite (10061428)	41	34.7	218	28.8	121	32.4	138	27.5	256	29.8	3	16.7
Dermatitis (10012431)	2	1.7	10	1.3	12	3.2	0	0.0	12	1.4	0	0.0
Diarrhoea (10012735)	10	8.5	45	5.9	35	9.4	20	4.0	54	6.3	1	5.6
Irritability (10022998)	65	55.1	340	44.9	177	47.3	228	45.4	396	46.2	9	50.0
Pyrexia (10037660)	28	23.7	110	14.5	61	16.3	77	15.3	136	15.9	2	11.1
Rash (10037844)	0	0.0	2	0.3	1	0.3	1	0.2	2	0.2	0	0.0
Rhinorrhoea (10039101)	1	0.8	5	0.7	6	1.6	0	0.0	6	0.7	0	0.0
Upper respiratory tract infection (10046306)	3	2.5	54	7.1	57	15.2	0	0.0	56	6.5	1	5.6
Vomiting (10047700)	30	25.4	170	22.4	87	23.3	113	22.5	195	22.7	5	27.8
Total	74	62.7	436	57.5	247	66.0	263	52.4	500	58.3	10	55.6
				xpected	advers		ts*					
Acute sinusitis (10001076)	1	0.8	2	0.3	3	0.8	0	0.0	3	0.3	0	0.0
Acute tonsillitis (10001093)	0	0.0	4	0.5	4	1.1	0	0.0	4	0.5	0	0.0
Asthma (10003553)	0	0.0	2	0.3	2	0.5	0	0.0	2	0.2	0	0.0
Atopy (10003645)	0	0.0	6	0.8	6	1.6	0	0.0	6	0.7	0	0.0
Balanoposthitis	0	0.0	1	0.1	1	0.3	0	0.0	1	0.1	0	0.0
(10004078)							_					
Bronchiolitis (10006448)	2	1.7	62	8.2	64	17.1	0	0.0	64	7.5	0	0.0
Bronchitis (10006451)	2	1.7	10	1.3	12	3.2	0	0.0	12	1.4	0	0.0
Cellulitis (10007882)	1	0.8	1	0.1	2	0.5	0	0.0	2	0.2	0	0.0
Colitis (10009887)	0	0.0	2	0.3	2	0.5	0	0.0	2	0.2	0	0.0
Conjunctivitis (10010741)	0	0.0	7	0.9	7	1.9	0	0.0	7	0.8	0	0.0
Conjunctivitis allergic (10010744)	0	0.0	1	0.1	1	0.3	0	0.0	1	0.1	0	0.0
Cough (10011224)	31	26.3	178	23.5	114	30.5	95	18.9	205	23.9	4	22.2
Croup infectious (10011416)	0	0.0	1	0.1	1	0.3	0	0.0	1	0.1	0	0.0
Cystitis (10011781)	0	0.0	1	0.1	1	0.3	0	0.0	1	0.1	0	0.0
Dermatitis atopic (10012438)	2	1.7	32	4.2	34	9.1	0	0.0	34	4.0	0	0.0
Dermatitis contact (10012442)	0	0.0	2	0.3	2	0.5	0	0.0	2	0.2	0	0.0
Dermatitis diaper (10012444)	0	0.0	6	0.8	6	1.6	0	0.0	6	0.7	0	0.0
Dyspepsia (10013946)	1	0.8	2	0.3	3	0.8	0	0.0	3	0.3	0	0.0
Ear infection (10014011)	0	0.0	1	0.1	1	0.3	0	0.0	1	0.1	0	0.0
Eczema (10014184)	0	0.0	2	0.3	2	0.5	0	0.0	2	0.2	0	0.0
Empyema (10014568)	0	0.0	3	0.4	3	0.8	0	0.0	3	0.3	0	0.0
Enteritis infectious (10058839)	0	0.0	1	0.1	1	0.3	0	0.0	1	0.1	0	0.0
Entropion (10061842)	0	0.0	1	0.1	1	0.3	0	0.0	1	0.1	0	0.0
Eye discharge	1	0.8	1	0.1	2	0.5	0	0.0	2	0.2	0	0.0

Rotarix[™] Post-Marketing Surveillance annual report Page 46 *GlaxoSmithKline Korea*

Second Annual Study Report for 111700 (Rota-070 PMS)

		Medical	· · · · · · · · · · · · · · · · · · ·			comitan	I.			comitan	1	
Preferred term (code)		es		lo		es		lo		es		lo
	N=	118	N=	758	N=	374	N=	502	N=	858	N=	=18
	n	%	n	%	n	%	n	%	n	%	n	%
(10015915)												
Fungal infection (10017533)	0	0.0	1	0.1	1	0.3	0	0.0	1	0.1	0	0.0
Gastritis (10017853)	1	0.8	7	0.9	8	2.1	0	0.0	8	0.9	0	0.0
Gastroenteritis (10017888)	3	2.5	21	2.8	24	6.4	0	0.0	24	2.8	0	0.0
Gastroenteritis viral (10017918)	0	0.0	2	0.3	2	0.5	0	0.0	2	0.2	0	0.0
Gastrointestinal disorder (10017944)	2	1.7	24	3.2	26	7.0	0	0.0	26	3.0	0	0.0
Gastrooesophageal reflux disease (10017885)	0	0.0	2	0.3	2	0.5	0	0.0	2	0.2	0	0.0
Hypersensitivity (10020751)	0	0.0	2	0.3	2	0.5	0	0.0	2	0.2	0	0.0
lleus paralytic (10021333)	0	0.0	1	0.1	1	0.3	0	0.0	1	0.1	0	0.0
Influenza (10022000)	0	0.0	1	0.1	1	0.3	0	0.0	1	0.1	0	0.0
Jaundice neonatal (10023138)	0	0.0	1	0.1	1	0.3	0	0.0	1	0.1	0	0.0
Laryngitis (10023874)	0	0.0	1	0.1	1	0.3	0	0.0	1	0.1	0	0.0
Lower respiratory tract infection (10024968)	0	0.0	2	0.3	2	0.5	0	0.0	2	0.2	0	0.0
Milk allergy (10027633)	0	0.0	1	0.1	1	0.3	0	0.0	1	0.1	0	0.0
Nasal congestion (10028735)	1	0.8	2	0.3	3	0.8	0	0.0	3	0.3	0	0.0
Nasopharyngitis (10028810)	9	7.6	70	9.2	79	21.1	0	0.0	78	9.1	1	5.6
Oral candidiasis (10030963)	1	0.8	3	0.4	4	1.1	0	0.0	4	0.5	0	0.0
Otitis externa (10033072)	1	0.8	1	0.1	2	0.5	0	0.0	2	0.2	0	0.0
Otitis media (10033078)	0	0.0	7	0.9	7	1.9	0	0.0	7	0.8	0	0.0
Otitis media acute (10033079)	1	0.8	6	0.8	7	1.9	0	0.0	7	0.8	0	0.0
Pharyngitis (10034835)	0	0.0	10	1.3	10	2.7	0	0.0	10	1.2	0	0.0
Pneumonia (10035664)	0	0.0	3	0.4	3	0.8	0	0.0	3	0.3	0	0.0
Rash (10037844)	0	0.0	1	0.1	1	0.3	0	0.0	1	0.1	0	0.0
Regurgitation (10067171)	1	0.8	0	0.0	1	0.3	0	0.0	1	0.1	0	0.0
Respiratory tract infection (10062352)	0	0.0	2	0.3	2	0.5	0	0.0	2	0.2	0	0.0
Rhinitis (10039083)	0	0.0	8	1.1	8	2.1	0	0.0	8	0.9	0	0.0
Rhinorrhoea (10039101)	0	0.0	1	0.1	1	0.3	0	0.0	1	0.1	0	0.0
Seborrhoeic dermatitis (10039793)	2	1.7	2	0.3	4	1.1	0	0.0	3	0.3	1	5.6
Sepsis (10040047)	0	0.0	1	0.1	1	0.3	0	0.0	1	0.1	0	0.0
Skin lesion (10040882)	0	0.0	1	0.1	1	0.3	0	0.0	1	0.1	0	0.0
Tonsillitis (10044008)	0	0.0	1	0.1	1	0.3	0	0.0	1	0.1	0	0.0
Tremor (10044565)	0	0.0	1	0.1	1	0.3	0	0.0	1	0.1	0	0.0
Tubulointerstitial nephritis (10048302)	0	0.0	1	0.1	1	0.3	0	0.0	1	0.1	0	0.0
Ulcer (10045285)	0	0.0	1	0.1	1	0.3	0	0.0	1	0.1	0	0.0

Rotarix[™] Post-Marketing Surveillance annual report Page 47 GlaxoSmithKline Korea

Second Annual Study Report for 111700 (Rota-070 PMS)

		Medical	Histor	/	Cond	omitan	t medic	ation	Conc	omitant	t vaccir	nation
Preferred term (code)	-	es 118		lo 758	-	es 374	-	lo 502	-	es 858		lo •18
	n			%	n	%	n	%	n	%	n	%
Upper respiratory tract infection (10046306)	4	3.4	20	2.6	24	6.4	0	0.0	24	2.8	0	0.0
Urethritis (10046480)	0	0.0	1	0.1	1	0.3	0	0.0	1	0.1	0	0.0
Urinary tract infection (10046571)	0	0.0	1	0.1	1	0.3	0	0.0	1	0.1	0	0.0
Urticaria (10046735)	0	0.0	4	0.5	4	1.1	0	0.0	4	0.5	0	0.0
Total	51	43.2	354	46.7	310	82.9	95	18.9	401	46.7	4	22.2

N = Number of subjects

n (%) = number (percentage) of subjects with the specified category * The classification of adverse events as expected & unexpected AEs is done by Low level term code mentioned in the cleaning report of this study.

Total = number (percentage) of subjects with at least one AE reported, irrespective of the classification

Second Annual Study Report for 111700 (Rota-070 PMS)

A.6 Adverse event by adverse event duration

Table 21 presents the expected and unexpected AEs by duration for the Total Vaccinated cohort.

Expected AEs:

Post Dose 1 of RotarixTM:

- Of the 349 cases of irritability reported, 102 (29.2%) cases lasted for a day, 89 (25.5%) cases lasted for 2 days, 65 (18.6%) cases lasted for 3 days and 93 (26.6%) cases lasted for 4 to 7 days after vaccination.
- Of the 208 cases of decreased appetite reported, 57 (27.4%) cases lasted for a day, 52 (25.0%) cases lasted for 2 days, 42 (20.2%) cases lasted for 3 days and 57 (27.4%) cases lasted for 4 to 7 days after vaccination.
- Of the 166 cases of vomiting reported, 55 (33.1%) cases lasted for a day, 30 (18.1%) cases lasted for 2 days, 27 (16.3%) cases lasted for 3 days and 54 (32.5%) cases lasted for 4 to 7 days after vaccination.

Post Dose 2 of RotarixTM:

- Of the 139 cases of irritability reported, 45 (32.4%) cases lasted for a day, 47 (33.8%) cases lasted for 2 days, 19 (13.7%) cases lasted for 3 days and 28 (20.1%) cases lasted for 4 to 7 days after vaccination.
- Of the 88 cases of decreased appetite reported, 29 (33.0%) cases lasted for a day, 21 (23.9%) cases lasted for 2 days, 12 (13.6%) cases lasted for 3 days and 26 (29.5%) cases lasted for 4 to 7 days after vaccination.
- Of the 58 cases of vomiting reported, 15 (25.9%) cases lasted for a day, 10 (17.2%) cases lasted for 2 days, 11 (19.0%) cases lasted for 3 days and 22(37.9) cases lasted for 4 to 7 days after vaccination.

Unexpected AEs:

Post Dose 1 of RotarixTM:

- Of the 153 cases of cough reported, 44 (28.8%) cases lasted for a day, 31 (20.3%) cases lasted for 2 days, 25 (16.3%) cases lasted for 3 days, 41 (26.8%) cases lasted for 4 to 7 days after vaccination. Twelve (7.8%) cases of cough lasted for 8 to 15 days after vaccination.
- Of the 39 cases of nasopharyngitis reported, 5 (12.8%) cases lasted for 2 days, 16 (41.0%) cases lasted for 3 days, 13 (33.3%) cases lasted for 4 to 7 days and 4 (10.3%) cases lasted for 8 to 15 days after vaccination. One (2.6%) case of nasopharyngitis reported lasted for more than 30 days after vaccination.
- Of the 45 cases of bronchiolitis reported, 3 (6.7%) cases lasted for 2 days, 12 (26.7%) cases lasted for 3 days, 17 (37.8%) cases lasted for 4 to 7 days, 9

Second Annual Study Report for 111700 (Rota-070 PMS)

(20.0%) cases lasted for 8 to 15 days, 2 (4.4%) cases lasted for 16 to 30 days after vaccination. Two (4.4%) cases of bronchiolitis reported lasted for more than 30 days after vaccination.

Post Dose 2 of RotarixTM:

- Of the 90 cases of cough reported, 19 (21.1%) cases lasted for a day, 20 (22.2%) cases lasted for 2 days, 12 (13.3%) cases lasted for 3 days and 26 (28.9%) cases lasted for 4 to 7 days after vaccination. Thirteen (14.4%) cases of cough lasted for 8 to 15 days after vaccination.
- Of the 60 cases of nasopharyngitis reported, 8 (13.3%) cases lasted for 2 days, 26 (43.3%) cases lasted for 3 days, 23 (38.3%) cases lasted for 4 to 7 days and 2 (3.3%) cases lasted for 8 to 15 days after vaccination. One (1.7%) case of nasopharyngitis lasted for 16 to 30 days after vaccination.
- Of the 33 cases of bronchiolitis reported, 6 (18.2%) cases lasted for 2 days, 12 (36.4%) cases lasted for 3 days and 11 (33.3%) cases lasted for 4 to 7 days after vaccination. Four (12.1%) cases of bronchiolitis lasted for 8 to 15 days after vaccination.

Second Annual Study Report for 111700 (Rota-070 PMS)

Table 21 Expected & Unexpected adverse events by duration (Total Vaccinated cohort)

			DA	Y 0	I	DAY 1	[DAY 2	C	AY 3	D	AY 4-7	DA	Y 8-15	DAY	16-30	DA	Y >30
Preferred term (code)	Dose	Ν	n	%	n	%	n	%	n	n	n	%	n	%	n	%	n	%
						Expected	l adver	se events	by dura	tion*								
Constipation (10010774)	1	3	0	0	0	0	2	66.7	1	33.3	0	0	0	0	0	0	0	0
	2	2	0	0	0	0	0	0	0	0	2	100.0	0	0	0	0	0	0
Decreased appetite (10061428)	1	208	0	0	57	27.4	52	25.0	42	20.2	57	27.4	0	0	0	0	0	0
	2	88	0	0	29	33.0	21	23.9	12	13.6	26	29.5	0	0	0	0	0	0
Dermatitis (10012431)	1	8	0	0	2	25.0	1	12.5	2	25.0	3	37.5	0	0	0	0	0	0
	2	4	0	0	1	25.0	2	50.0	0	0	1	25.0	0	0	0	0	0	0
Diarrhoea (10012735)	1	39	0	0	14	35.9	9	23.1	3	7.7	12	30.8	1	2.6	0	0	0	0
	2	17	0	0	9	52.9	2	11.8	3	17.6	3	17.6	0	0	0	0	0	0
Irritability (10022998)	1	349	0	0	102	29.2	89	25.5	65	18.6	93	26.6	0	0	0	0	0	0
	2	139	0	0	45	32.4	47	33.8	19	13.7	28	20.1	0	0	0	0	0	0
Pyrexia (10037660)	1	115	0	0	64	55.7	30	26.1	10	8.7	11	9.6	0	0	0	0	0	0
	2	35	0	0	13	37.1	14	40.0	3	8.6	5	14.3	0	0	0	0	0	0
Rash (10037844)	1	2	0	0	0	0	1	50.0	1	50.0	0	0	0	0	0	0	0	0
Rhinorrhoea (10039101)	1	3	0	0	0	0	0	0	2	66.7	1	33.3	0	0	0	0	0	0
	2	3	0	0	0	0	0	0	2	66.7	1	33.3	0	0	0	0	0	0
Upper respiratory tract infection (10046306)	1	36	0	0	1	2.8	7	19.4	9	25.0	14	38.9	4	11.1	1	2.8	0	0
	2	29	0	0	0	0	1	3.4	14	48.3	11	37.9	2	6.9	1	3.4	0	0
Vomiting (10047700)	1	166	0	0	55	33.1	30	18.1	27	16.3	54	32.5	0	0	0	0	0	0
	2	58	0	0	15	25.9	10	17.2	11	19.0	22	37.9	0	0	0	0	0	0
		Į.	1			Unexpecte	d adve	erse events	by dur	ation*			1	1				
Acute sinusitis (10001076)	1	2	0	0	0	0	0	0	1	50.0	1	50.0	0	0	0	0	0	0
	2	1	0	0	0	0	1	100.0	0	0	0	0	0	0	0	0	0	0
Acute tonsillitis (10001093)	1	1	0	0	0	0	0	0	1	100.0	0	0	0	0	0	0	0	0
	2	3	0	0	0	0	0	0	1	33.3	1	33.3	1	33.3	0	0	0	0
Asthma (10003553)	1	1	0	0	0	0	0	0	0	0	1	100.0	0	0	0	0	0	0
``````````````````````````````````````	2	1	0	0	0	0	0	0	1	100.0	0	0	0	0	0	0	0	0
Atopy (10003645)	1	3	0	0	1	33.3	1	33.3	0	0	1	33.3	0	0	0	0	0	0
, , ,	2	3	0	0	2	66.7	0	0	0	0	0	0	1	33.3	0	0	0	0
Balanoposthitis (10004078)	2	1	0	0	0	0	0	0	0	0	1	100.0	0	0	0	0	0	0
Bronchiolitis (10006448)	1	45	0	0	0	0	3	6.7	12	26.7	17	37.8	9	20.0	2	4.4	2	4.4

Rotarix™ Post-Marketing Surveillance annual report Page GlaxoSmithKline Korea

			DA	Y 0	0	DAY 1	C	DAY 2	C	DAY 3	D	AY 4-7	DA	Y 8-15	DAY	′ 16-30	D	AY >30
Preferred term (code)	Dose	Ν	n	%	n	%	n	%	n	n	n	%	n	%	n	%	n	%
	2	33	0	0	0	0	6	18.2	12	36.4	11	33.3	4	12.1	0	0	0	0
Bronchitis (10006451)	1	6	0	0	0	0	3	50.0	0	0	1	16.7	2	33.3	0	0	0	0
	2	6	0	0	0	0	0	0	3	50.0	2	33.3	1	16.7	0	0	0	0
Cellulitis (10007882)	1	1	0	0	1	100.0	0	0	0	0	0	0	0	0	0	0	0	0
	2	1	0	0	0	0	0	0	0	0	1	100.0	0	0	0	0	0	0
Colitis (10009887)	1	2	0	0	0	0	1	50.0	0	0	1	50.0	0	0	0	0	0	0
Conjunctivitis (10010741)	1	5	0	0	1	20.0	0	0	1	20.0	2	40.0	0	0	1	20.0	0	0
	2	2	0	0	1	50.0	0	0	0	0	1	50.0	0	0	0	0	0	0
Conjunctivitis allergic (10010744)	1	1	0	0	0	0	0	0	1	100.0	0	0	0	0	0	0	0	0
Cough (10011224)	1	153	0	0	44	28.8	31	20.3	25	16.3	41	26.8	12	7.8	0	0	0	0
	2	90	0	0	19	21.1	20	22.2	12	13.3	26	28.9	13	14.4	0	0	0	0
Croup infectious (10011416)	2	1	0	0	0	0	0	0	0	0	0	0	1	100.0	0	0	0	0
Cystitis (10011781)	2	1	0	0	0	0	0	0	0	0	0	0	1	100.0	0	0	0	0
Dermatitis atopic (10012438)	1	23	0	0	2	8.7	7	30.4	3	13.0	10	43.5	0	0	1	4.3	0	0
	2	14	0	0	0	0	8	57.1	3	21.4	3	21.4	0	0	0	0	0	0
Dermatitis contact (10012442)	2	2	0	0	0	0	0	0	1	50.0	1	50.0	0	0	0	0	0	0
Dermatitis diaper (10012444)	2	6	0	0	2	33.3	1	16.7	2	33.3	1	16.7	0	0	0	0	0	0
Dyspepsia (10013946)	1	1	0	0	0	0	0	0	0	0	1	100.0	0	0	0	0	0	0
	2	2	0	0	0	0	0	0	1	50.0	1	50.0	0	0	0	0	0	0
Ear infection (10014011)	1	1	0	0	0	0	0	0	0	0	1	100.0	0	0	0	0	0	0
Eczema (10014184)	1	2	0	0	1	50.0	1	50.0	0	0	0	0	0	0	0	0	0	0
Empyema (10014568)	1	2	0	0	0	0	1	50.0	1	50.0	0	0	0	0	0	0	0	0
	2	1	0	0	0	0	0	0	1	100.0	0	0	0	0	0	0	0	0
Enteritis infectious (10058839)	2	1	0	0	0	0	1	100.0	0	0	0	0	0	0	0	0	0	0
Entropion (10061842)	2	1	0	0	1	100.0	0	0	0	0	0	0	0	0	0	0	0	0
Eye discharge (10015915)	1	2	0	0	1	50.0	0	0	0	0	1	50.0	0	0	0	0	0	0
Fungal infection (10017533)	2	1	0	0	1	100.0	0	0	0	0	0	0	0	0	0	0	0	0
Gastritis (10017853)	1	6	0	0	0	0	4	66.7	2	33.3	0	0	0	0	0	0	0	0
	2	4	0	0	0	0	0	0	3	75.0	1	25.0	0	0	0	0	0	0
Gastroenteritis (10017888)	1	22	0	0	0	0	8	36.4	1	4.5	9	40.9	1	4.5	2	9.1	1	4.5
	2	7	0	0	0	0	2	28.6	3	42.9	2	28.6	0	0	0	0	0	0
Gastroenteritis viral (10017918)	1	1	0	0	0	0	0	0	0	0	1	100.0	0	0	0	0	0	0
. ,	2	1	0	0	0	0	0	0	1	100.0	0	0	0	0	0	0	0	0
Gastrointestinal disorder	1	19	0	0	0	0	9	47.4	3	15.8	4	21.1	3	15.8	0	0	0	0

Rotarix[™] Post-Marketing Surveillance annual report Page GlaxoSmithKline Korea

			DA	Y 0	[	DAY 1	I	DAY 2	0	DAY 3	D	AY 4-7	DA	Y 8-15	DAY	′ 16-30	D	AY >30
Preferred term (code)	Dose	Ν	n	%	n	%	n	%	n	n	n	%	n	%	n	%	n	%
(10017944)																		
	2	8	0	0	0	0	3	37.5	2	25.0	2	25.0	1	12.5	0	0	0	0
Gastrooesophageal reflux disease (10017885)	1	1	0	0	0	0	0	0	1	100.0	0	0	0	0	0	0	0	0
	2	1	0	0	0	0	1	100.0	0	0	0	0	0	0	0	0	0	0
Hypersensitivity (10020751)	2	2	0	0	0	0	0	0	1	50.0	1	50.0	0	0	0	0	0	0
Ileus paralytic (10021333)	1	1	0	0	0	0	0	0	0	0	0	0	0	0	1	100.0	0	0
Influenza (10022000)	2	1	0	0	0	0	0	0	1	100.0	0	0	0	0	0	0	0	0
Jaundice neonatal (10023138)	2	1	0	0	0	0	1	100.0	0	0	0	0	0	0	0	0	0	0
Laryngitis (10023874)	2	1	0	0	0	0	0	0	0	0	1	100.0	0	0	0	0	0	0
Lower respiratory tract infection (10024968)	1	2	0	0	0	0	1	50.0	1	50.0	0	0	0	0	0	0	0	0
	2	1	0	0	0	0	0	0	1	100.0	0	0	0	0	0	0	0	0
Milk allergy (10027633)	1	1	0	0	0	0	0	0	0	0	1	100.0	0	0	0	0	0	0
Nasal congestion (10028735)	1	3	0	0	0	0	0	0	2	66.7	1	33.3	0	0	0	0	0	0
Nasopharyngitis (10028810)	1	39	0	0	0	0	5	12.8	16	41.0	13	33.3	4	10.3	0	0	1	2.6
	2	60	0	0	0	0	8	13.3	26	43.3	23	38.3	2	3.3	1	1.7	0	0
Oral candidiasis (10030963)	1	4	0	0	0	0	0	0	0	0	2	50.0	2	50.0	0	0	0	0
	2	1	0	0	0	0	0	0	1	100.0	0	0	0	0	0	0	0	0
Otitis externa (10033072)	1	1	0	0	0	0	0	0	1	100.0	0	0	0	0	0	0	0	0
	2	1	0	0	0	0	0	0	0	0	1	100.0	0	0	0	0	0	0
Otitis media (10033078)	1	1	0	0	0	0	0	0	0	0	1	100.0	0	0	0	0	0	0
	2	6	0	0	0	0	1	16.7	2	33.3	2	33.3	1	16.7	0	0	0	0
Otitis media acute (10033079)	1	3	0	0	0	0	0	0	1	33.3	1	33.3	0	0	0	0	1	33.3
	2	5	0	0	0	0	0	0	0	0	0	0	4	80.0	1	20.0	0	0
Pharyngitis (10034835)	1	9	0	0	0	0	1	11.1	4	44.4	4	44.4	0	0	0	0	0	0
	2	4	0	0	0	0	0	0	4	100.0	0	0	0	0	0	0	0	0
Pneumonia (10035664)	1	3	0	0	0	0	0	0	0	0	0	0	3	100.0	0	0	0	0
Rash (10037844)	1	1	0	0	0	0	0	0	0	0	1	100.0	0	0	0	0	0	0
Regurgitation (10067171)	1	1	0	0	0	0	0	0	0	0	1	100.0	0	0	0	0	0	0
Respiratory tract infection (10062352)	1	3	0	0	0	0	2	66.7	1	33.3	0	0	0	0	0	0	0	0
-	2	1	0	0	0	0	0	0	1	100.0	0	0	0	0	0	0	0	0
Rhinitis (10039083)	1	5	0	0	0	0	0	0	2	40.0	1	20.0	1	20.0	0	0	1	20.0

Rotarix[™] Post-Marketing Surveillance annual report Page GlaxoSmithKline Korea

			DA	Y 0	I	DAY 1	Ι	DAY 2	[	DAY 3	D	AY 4-7	DA	Y 8-15	DAY	′ 16-30	D	AY >30
Preferred term (code)	Dose	Ν	n	%	n	%	n	%	n	n	n	%	n	%	n	%	n	%
	2	7	0	0	0	0	0	0	6	85.7	1	14.3	0	0	0	0	0	0
Rhinorrhoea (10039101)	1	1	0	0	0	0	0	0	0	0	1	100.0	0	0	0	0	0	0
Seborrhoeic dermatitis (10039793)	1	3	0	0	1	33.3	0	0	0	0	1	33.3	0	0	1	33.3	0	0
	2	2	0	0	0	0	0	0	1	50.0	1	50.0	0	0	0	0	2	0
Sepsis (10040047)	1	1	0	0	0	0	0	0	0	0	0	0	0	0	1	100.0	1	0
Skin lesion (10040882)	2	1	0	0	1	100.0	0	0	0	0	0	0	0	0	0	0	2	0
Tonsillitis (10044008)	1	1	0	0	0	0	1	100.0	0	0	0	0	0	0	0	0	1	0
· · · ·	2	1	0	0	0	0	1	100.0	0	0	0	0	0	0	0	0	2	0
Tremor (10044565)	2	1	0	0	0	0	0	0	0	0	1	100.0	0	0	0	0	2	0
Tubulointerstitial nephritis (10048302)	2	1	0	0	0	0	0	0	0	0	1	100.0	0	0	0	0	2	0
Ulcer (10045285)	2	1	0	0	0	0	0	0	0	0	1	100.0	0	0	0	0	2	0
Upper respiratory tract infection (10046306)	1	12	0	0	2	16.7	0	0	2	16.7	4	33.3	3	25.0	1	8.3	1	0
	2	13	0	0	1	7.7	1	7.7	2	15.4	9	69.2	0	0	0	0	2	0
Urethritis (10046480)	1	1	0	0	0	0	0	0	1	100.0	0	0	0	0	0	0	1	0
Urinary tract infection (10046571)	1	1	0	0	0	0	0	0	0	0	1	100.0	0	0	0	0	1	0
Urticaria (10046735)	1	2	0	0	0	0	0	0	1	50.0	1	50.0	0	0	0	0	1	0
. ,	2	2	0	0	0	0	0	0	0	0	2	100.0	0	0	0	0	2	0

N = Number of events

n (%) = number (percentage)of events with the specified category * The classification of adverse events as Expected & Unexpected AEs is done by Low level term code mentioned in the cleaning report of this study.

Second Annual Study Report for 111700 (Rota-070 PMS)

## B. Adverse events in special subpopulations

## B.1 Old people (65 years or more)

Not applicable.

## B.2 Infant

Not applicable.

## B.3 Pregnant or nursing mother

Not applicable.

## B.4 Patients with renal impairment

Not applicable.

## B.5 Patients with hepatic impairment

Not applicable.

## C. Factors considered as affecting the manifestation of adverse events

The analysis is not applicable for this time point and will be done for the cumulative report.

## 5.1.5 Classification of adverse events

## A. Severity

Table 22 presents the expected and unexpected AEs by severity for the Total Vaccinated cohort.

## Expected AEs

Post Dose 1 of RotarixTM:

- Of the 349 cases of irritability reported, 220 (63.0%) cases were assessed as mild, 103 (29.5%) cases were assessed as moderate and only 26 (7.4%) cases of irritability were assessed as severe.
- Of the 208 cases of decreased appetite reported, 174 (83.7%) cases were assessed as mild, 31 (14.9%) cases were assessed as moderate and only 3 (1.4%) cases of decreased appetitewere assessed as severe.

Second Annual Study Report for 111700 (Rota-070 PMS)

- Of the 166 cases of vomiting reported, 83 (50.3%) cases were assessed as mild, 42 (25.5%) cases were assessed as moderate and only 40 (24.2%) cases of vomiting were assessed as severe.
- Of the 115 cases of pyrexia reported, 83 (72.2%) cases were assessed as mild, 29 (25.2%) cases were assessed as moderate and only 3 (2.6%) cases of pyrexia were assessed as severe.
- Of the 39 cases of diarrhoea reported, 21 (55.3%) cases were assessed as mild, 14 (36.8%) cases were assessed as moderate and only 3 (7.9%) cases of diarrhoea were assessed as severe.

Post Dose 2 of RotarixTM:

- Of the 139 cases of irritability reported, 95 (68.3%) cases were assessed as mild, 39 (28.1%) cases were assessed as moderate and only 5 (3.6%) cases of irritability were assessed as severe.
- Of the 88 cases of decreased appetite reported, 75 (85.2%) cases were assessed as mild, 12 (13.6%) cases were assessed as moderate and only one (1.1%) case of decreased appetite were assessed as severe.
- Of the 58 cases of vomiting reported, 24 (42.1%) cases were assessed as mild, 17 (29.8%) cases were assessed as moderate and only 16 (28.1%) cases of vomiting were assessed as severe.
- Of the 35 cases of pyrexia reported, 27(77.1%) cases were assessed as mild and 8 (22.9%) cases were assessed as moderate. None of the cases were assessed as severe.
- Of the 17 cases of diarrhoea reported, 11 (64.7%) cases were assessed as mild, 4 (23.5%) cases were assessed as moderate and only 2 (11.8%) cases of diarrhoea were assessed as severe.

Unexpected AEs

Post Dose 1 of RotarixTM:

- Of the 153 cases of cough reported, 132 (86.8%) cases were assessed as mild, 19 (12.4%) cases were assessed as moderate and only one (0.7%) case of cough was assessed as severe.
- Of the 45 cases of bronchiolitis reported, 30 (66.7%) cases were assessed as mild, 14 (31.1%) cases were assessed as moderate and only one (2.2%) case of bronchiolitis was assessed as severe.
- Of the 22 cases of GE reported, 17 (77.3%) cases of GE were assessed as mild, 4 (18.2%) cases of GE were assessed as moderate and only one (4.5%) case of GE was assessed as severe.
- Of the 3 cases of otitis media acute reported, 2 (66.7%) cases were assessed as mild and only one (33.3%) case of AOM was assessed as severe.

Post Dose 2 of RotarixTM:

Second Annual Study Report for 111700 (Rota-070 PMS)

- Of the 90 cases of cough reported, 72 (80.0%) cases were assessed as mild, 17 (18.9%) cases were assessed as moderate and only one (1.1%) case of cough was assessed as severe.
- Of the 33 cases of bronchiolitis reported, 25 (75.8%) cases were assessed as mild and 8 (24.2%) cases were assessed as moderate. None of the cases of bronchiolitis reported post Dose 2 of RotarixTMwere assessed as severe.
- Of the 7 cases of GE reported, 4 (57.1%) cases were assessed as mild, 3 (42.9%) cases were assessed as moderate. None of the cases of GE reported post Dose 2 of RotarixTM were assessed as severe.
- Of the 5 cases of otitis media acute reported, 2 (40.0%) cases were assessed as mild and 3 (60.0%) cases were assessed as moderate. None of the cases of otitis media aute reported post Dose 2 of Rotarix[™] were assessed as severe.

			Μ	lild	Mod	erate	Se	vere
Preferred Term (code)	Dose	N	n	%	n	%	n	%
	Expect	ed adverse ev	ents by	severity*				
Constipation (10010774)	1	3	2	66.7	1	33.3	0	0.0
· · · ·	2	2	2	100	0	0.0	0	0.0
Decreased appetite (10061428)	1	208	174	83.7	31	14.9	3	1.4
· · · ·	2	88	75	85.2	12	13.6	1	1.1
Dermatitis (10012431)	1	8	8	100	0	0.0	0	0.0
· · · ·	2	4	4	100	0	0.0	0	0.0
Diarrhoea (10012735)	1	39	21	55.3	14	36.8	3	7.9
· / /	2	17	11	64.7	4	23.5	2	11.8
Irritability (10022998)	1	349	220	63.0	103	29.5	26	7.4
, ,	2	139	95	68.3	39	28.1	5	3.6
Pyrexia (10037660)	1	115	83	72.2	29	25.2	3	2.6
	2	35	27	77.1	8	22.9	0	0.0
Rash (10037844)	1	2	2	100	0	0.0	0	0.0
Rhinorrhoea (10039101)	1	3	3	100	0	0.0	0	0.0
	2	3	2	66.7	1	33.3	0	0.0
Upper respiratory tract infection (10046306)	1	36	30	83.3	6	16.7	0	0.0
, ,	2	29	24	82.8	5	17.2	0	0.0
Vomiting (10047700)	1	166	83	50.3	42	25.5	40	24.2
. ,	2	58	24	42.1	17	29.8	16	28.1
	Unexpec	ted adverse e	events by	y severity	*			
Acute sinusitis (10001076)	1	2	1	50.0	1	50.0	0	0.0
	2	1	1	100	0	0.0	0	0.0

# Table 22 Expected & Unexpected adverse events by severity (Total Vaccinated cohort)

Rotarix[™] Post-Marketing Surveillance annual report Page 57 GlaxoSmithKline Korea

			Μ	ild	Mod	lerate	Se	vere
Preferred Term (code)	Dose	N	n	%	n	%	n	%
Acute tonsillitis (10001093)	1	1	1	100	0	0.0	0	0.0
· · · ·	2	3	2	66.7	1	33.3	0	0.0
Asthma (10003553)	1	1	0	0.0	1	100	0	0.0
	2	1	1	100	0	0.0	0	0.0
Atopy (10003645)	1	3	3	100	0	0.0	0	0.0
	2	3	3	100	0	0.0	0	0.0
Balanoposthitis (10004078)	2	1	1	100	0	0.0	0	0.0
Bronchiolitis (10006448)	1	45	30	66.7	14	31.1	1	2.2
	2	33	25	75.8	8	24.2	0	0.0
Bronchitis (10006451)	1	6	3	50.0	3	50.0	0	0.0
	2	6	6	100	0	0.0	0	0.0
Cellulitis (10007882)	1	1	1	100	0	0.0	0	0.0
	2	1	1	100	0	0.0	0	0.0
Colitis (10009887)	1	2	1	50.0	1	50.0	0	0.0
Conjunctivitis (10010741)	1	5	5	100	0	0.0	0	0.0
	2	2	2	100	0	0.0	0	0.0
Conjunctivitis allergic (10010744)	1	1	1	100	0	0.0	0	0.0
Cough (10011224)	1	153	132	86.3	19	12.4	1	0.7
0	2	90	72	80.0	17	18.9	1	1.1
Croup infectious (10011416)		1	0	0.0	1	100	0	0.0
Cystitis (10011781)	2	1	0	0.0	1	100	0	0.0
Dermatitis atopic (10012438)	1	23	22	95.7	1	4.3	0	0.0
	2	14	13	92.9	1	7.1	0	0.0
Dermatitis contact (10012442)	2	2	2	100	0	0.0	0	0.0
Dermatitis diaper (10012444)	2	6	6	100	0	0.0	0	0.0
Dyspepsia (10013946)	1	1	1	100	0	0.0	0	0.0
	2	2	2	100	0	0.0	0	0.0
Ear infection (10014011)	1	1	1	100	0	0.0	0	0.0
Eczema (10014184)	1	2	2	100	0	0.0	0	0.0
Empyema (10014568)	1	2	1	50.0	1	50.0	0	0.0
	2	1	1	100	0	0.0	0	0.0
Enteritis infectious (10058839)	2	1	1	100	0	0.0	0	0.0
Entropion (10061842)	2	1	1	100	0	0.0	0	0.0
Eye discharge (10015915)	1	2	2	100	0	0.0	0	0.0
Fungal infection (10017533)	2	1	0	0.0	1	100	0	0.0

Rotarix[™] Post-Marketing Surveillance annual report Page 58 GlaxoSmithKline Korea

			N	lild	Mod	lerate	Se	vere
Preferred Term (code)	Dose	N	n	%	n	%	n	%
Gastritis (10017853)	1	6	3	50.0	3	50.0	0	0.0
	2	4	3	75.0	1	25.0	0	0.0
Gastroenteritis (10017888)	1	22	17	77.3	4	18.2	1	4.5
	2	7	4	57.1	3	42.9	0	0.0
Gastroenteritis viral (10017918)	1	1	0	0.0	1	100	0	0.0
	2	1	0	0.0	1	100	0	0.0
Gastrointestinal disorder (10017944)	1	19	16	84.2	3	15.8	0	0.0
	2	8	7	87.5	1	12.5	0	0.0
Gastrooesophageal reflux disease (10017885)	1	1	1	100	0	0.0	0	0.0
	2	1	1	100	0	0.0	0	0.0
Hypersensitivity (10020751)	2	2	2	100	0	0.0	0	0.0
lleus paralytic (10021333)	1	1	0	0.0	1	100	0	0.0
Influenza (10022000)	2	1	1	100	0	0.0	0	0.0
Jaundice neonatal (10023138)	2	1	0	0.0	1	100	0	0.0
Laryngitis (10023874)	2	1	1	100	0	0.0	0	0.0
Lower respiratory tract infection (10024968)	1	2	0	0.0	2	100	0	0.0
, ,	2	1	0	0.0	1	100	0	0.0
Milk allergy (10027633)	1	1	1	100	0	0.0	0	0.0
Nasal congestion (10028735)	1	3	2	66.7	1	33.3	0	0.0
Nasopharyngitis (10028810)	1	39	35	89.7	4	10.3	0	0.0
	2	60	46	76.7	14	23.3	0	0.0
Oral candidiasis (10030963)	1	4	2	50.0	2	50.0	0	0.0
	2	1	1	100	0	0.0	0	0.0
Otitis externa (10033072)	1	1	1	100	0	0.0	0	0.0
	2	1	1	100	0	0.0	0	0.0
Otitis media (10033078)	1	1	1	100	0	0.0	0	0.0
-	2	6	5	83.3	1	16.7	0	0.0
Otitis media acute (10033079)	1	3	2	66.7	0	0.0	1	33.3
Pharyngitis (10034835)	2 1	5 9	2 7	40.0 77.8	3 2	60.0 22.2	0 0	0.0
	2	4	4	100	0	0.0	0	0.0
Pneumonia (10035664)	1	3	1	33.3	2	66.7	0	0.0

Rotarix[™] Post-Marketing Surveillance annual report Page 59 GlaxoSmithKline Korea

			N	lild	Мос	lerate	Se	vere
Preferred Term (code)	Dose	N	n	%	n	%	n	%
Rash (10037844)	1	1	1	100	0	0.0	0	0.0
Regurgitation (10067171)	1	1	1	100	0	0.0	0	0.0
Respiratory tract infection (10062352)	1	3	0	0.0	3	100	0	0.0
	2	1	0	0.0	1	100	0	0.0
Rhinitis (10039083)	1	5	3	60.0	2	40.0	0	0.0
	2	7	4	57.1	3	42.9	0	0.0
Rhinorrhoea (10039101)	1	1	1	100	0	0.0	0	0.0
Seborrhoeic dermatitis (10039793)	1	3	3	100	0	0.0	0	0.0
	2	2	2	100	0	0.0	0	0.0
Sepsis (10040047)	1	1	1	100	0	0.0	0	0.0
Skin lesion (10040882)	2	1	1	100	0	0.0	0	0.0
Tonsillitis (10044008)	1	1	1	100	0	0.0	0	0.0
	2	1	1	100	0	0.0	0	0.0
Tremor (10044565)	2	1	1	100	0	0.0	0	0.0
Tubulointerstitial nephritis (10048302)	2	1	1	100	0	0.0	0	0.0
Ulcer (10045285)	2	1	1	100	0	0.0	0	0.0
Upper respiratory tract infection (10046306)	1	12	9	75.0	3	25.0	0	0.0
	2	13	12	92.3	1	7.7	0	0.0
Urethritis (10046480)	1	1	1	100	0	0.0	0	0.0
Urinary tract infection (10046571)	1	1	1	100	0	0.0	0	0.0
Urticaria (10046735)	1	2	2	100	0	0.0	0	0.0
	2	2	1	50.0	1	50.0	0	0.0

Second Annual Study Report for 111700 (Rota-070 PMS)

N = Number of events

n (%) = number (percentage) of events with the specified category

* The classification of adverse events as Expected & Unexpected AEs is done by Low level term code mentioned in the cleaning report of this study.

## B. Causal relationship with the survey vaccine

Table 23 presents the expected and unexpected AEs by causality for the Total Vaccinated cohort.

## Expected AEs:

Post Dose 1 of RotarixTM:

Second Annual Study Report for 111700 (Rota-070 PMS)

- Of the 349 cases of irritability reported, one (0.3%) case of irritability was assessed as definitely related, 9 (2.6%) cases as probably related and 30 (8.6%) cases as possibly related to vaccination.
- Of the 208 cases of decreased appetite reported, one (0.5%) case of decreased appetitewas assessed as definitely related, 3 (1.4%) cases as probably related and 14 (6.7%) cases as possibly related to vaccination.
- Of the 166 cases of vomiting reported, three (1.8%) cases of vomiting were assessed as definitely related, 5 (3.0%) cases as probably related and 29 (17.5%) cases as possibly related to vaccination.
- Of the 115 cases of pyrexia reported, one (0.9%) case of pyrexia was assessed as definitely related, 5 (4.3%) cases as probably related and 17 (14.8%) cases as possibly related to vaccination.
- Of the 39 cases of diarrhoea reported, 2 (5.1%) cases of diarrhoea were assessed as definitely related, one (2.6%) case as probably related and 10 (25.6%) cases as possibly related to vaccination.

Post Dose 2 of RotarixTM:

- Of the 139 cases of irritability reported, one (0.7%) case of irritability was assessed as definitely related, 2 (1.4%) cases as probably related and 10 (7.2%) cases as possibly related to vaccination.
- Of the 88 cases of decreased appetite reported, 2 (2.3%) cases of decreased appetite were assessed as probably related and 6 (6.8%) cases as possibly related to vaccination.
- Of the 58 cases of vomiting reported, one (1.7%) case of vomiting was assessed as probably related and 5 (8.6%) cases as possibly related to vaccination.
- Of the 35 cases of pyrexia reported, 6 (17.1%) cases of pyrexia were assessed as possibly related to vaccination.
- Of the 17 cases of diarrhoea reported, 3 (17.6%) cases of diarrhoea were assessed as possibly related to vaccination.

## Unexpected AEs:

Post Dose 1 of RotarixTM:

- Of the 153 cases of cough reported, 4 (2.6%) cases were assessed as possibly related to vaccination and 3 (2.0%) cases of cough were assessed as unknown.
- Of the 22 cases of GE reported one (4.5%) case was assessed as possibly related to vaccination.
- Of the 19 cases of gastrointestinal disorders reported two (10.5%) cases were assessed as possibly related to vaccination.

Post Dose 2 of RotarixTM:

• Of the 90 cases of cough reported, one (1.1%) case was assessed as possibly related to vaccination and 3 (3.3%) cases of cough were assessed as unknown.

Second Annual Study Report for 111700 (Rota-070 PMS)

- Of the 33 cases of bronchiolitis reported, one (3.0%) case of bronchiolitis was assessed as possibly related to vaccination and one (3.0%) case of bronchiolitis was assessed as unknown.
- One (50.0%) case of utricaria was assessed as probably related to vaccination.
- Of the 8 cases of gastrointestinal disorders reported 1 (12.5%) case was assessed as probably related to vaccination.

Table 23	Expected & Unexpected adverse events by causality (Total
	Vaccinated cohort)

			Defir rela	•		bably ated		sibly ated		bably related	Unk	nown
Preferred Term (Code)	Dose	N	n	%	n	%	n	%	n	%	n	%
		Expected	advers	se even	ts by o	causali	ty*					
Constipation (10010774)	1	3	0	0.0	0	0.0	0	0.0	3	100	0	0.0
	2	2	0	0.0	0	0.0	0	0.0	2	100	0	0.0
Decreased appetite (10061428)	1	208	1	0.5	3	1.4	14	6.7	190	91.3	0	0.0
	2	88	0	0.0	2	2.3	6	6.8	80	90.9	0	0.0
Dermatitis (10012431)	1	8	0	0.0	0	0.0	0	0.0	8	100	0	0.0
	2	4	0	0.0	0	0.0	0	0.0	4	100	0	0.0
Diarrhoea (10012735)	1	39	2	5.1	1	2.6	10	25.6	26	66.7	0	0.0
	2	17	0	0.0	0	0.0	3	17.6	14	82.4	0	0.0
Irritability (10022998)	1	349	1	0.3	9	2.6	30	8.6	309	88.5	0	0.0
	2	139	1	0.7	2	1.4	10	7.2	126	90.6	0	0.0
Pyrexia (10037660)	1	115	1	0.9	5	4.3	17	14.8	92	80.0	0	0.0
	2	35	0	0.0	0	0.0	6	17.1	29	82.9	0	0.0
Rash (10037844)	1	2	0	0.0	0	0.0	0	0.0	2	100	0	0.0
Rhinorrhoea (10039101)	1	3	0	0.0	0	0.0	0	0.0	3	100	0	0.0
	2	3	0	0.0	0	0.0	0	0.0	3	100	0	0.0
Upper respiratory tract infection (10046306)	1	36	0	0.0	0	0.0	0	0.0	36	100	0	0.0
	2	29	0	0.0	0	0.0	0	0.0	29	100	0	0.0
Vomiting (10047700)	1	166	3	1.8	5	3.0	29	17.5	127	76.5	2	1.2
	2	58	0	0.0	1	1.7	5	8.6	52	89.7	0	0.0
	U	nexpecte	d adve	rse eve	nts by	causa	lity*					
Acute sinusitis (10001076)	1	2	0	0.0	0	0.0	0	0.0	2	100	0	0.0
	2	1	0	0.0	0	0.0	0	0.0	1	100	0	0.0
Acute tonsillitis (10001093)	1	1	0	0.0	0	0.0	0	0.0	1	100	0	0.0
	2	3	0	0.0	0	0.0	0	0.0	3	100	0	0.0
Asthma (10003553)	1	1	0	0.0	0	0.0	0	0.0	1	100	0	0.0
	2	1	0	0.0	0	0.0	0	0.0	1	100	0	0.0
Atopy (10003645)	1	3	0	0.0	0	0.0	0	0.0	3	100	0	0.0
	2	3	0	0.0	0	0.0	0	0.0	3	100	0	0.0

Rotarix[™] Post-Marketing Surveillance annual report Page 62 GlaxoSmithKline Korea

			Defir rela	•		bably ated		sibly ated		bably elated	Unk	nown
Preferred Term (Code)	Dose	N	n	%	n	%	n	%	n	%	n	%
Balanoposthitis (10004078)	2	1	0	0.0	0	0.0	0	0.0	1	100	0	0.0
Bronchiolitis (10006448)	1	45	0	0.0	0	0.0	0	0.0	45	100	0	0.0
	2	33	0	0.0	0	0.0	1	3.0	31	93.9	1	3.0
Bronchitis (10006451)	1	6	0	0.0	0	0.0	0	0.0	6	100	0	0.0
	2	6	0	0.0	0	0.0	0	0.0	6	100	0	0.0
Cellulitis (10007882)	1	1	0	0.0	0	0.0	0	0.0	1	100	0	0.0
	2	1	0	0.0	0	0.0	0	0.0	1	100	0	0.0
Colitis (10009887)	1	2	0	0.0	0	0.0	0	0.0	2	100	0	0.0
Conjunctivitis (10010741)	1	5	0	0.0	0	0.0	0	0.0	5	100	0	0.0
	2	2	0	0.0	0	0.0	0	0.0	2	100	0	0.0
Conjunctivitis allergic (10010744)	1	1	0	0.0	0	0.0	0	0.0	1	100	0	0.0
Cough (10011224)	1	153	0	0.0	0	0.0	4	2.6	145	94.8	3	2.0
One infections	2	90	0	0.0	0	0.0	1	1.1	86	95.6	3	3.3
Croup infectious (10011416)	2	1	0	0.0	0	0.0	0	0.0	1	100	0	0.0
Cystitis (10011781)	2	1	0	0.0	0	0.0	0	0.0	1	100	0	0.0
Dermatitis atopic (10012438)	1	23	0	0.0	0	0.0	0	0.0	23	100	0	0.0
<b>D</b>	2	14	0	0.0	0	0.0	1	7.1	13	92.9	0	0.0
Dermatitis contact (10012442)	2	2	0	0.0	0	0.0	0	0.0	2	100	0	0.0
Dermatitis diaper (10012444)	2	6	0	0.0	0	0.0	0	0.0	6	100	0	0.0
Dyspepsia (10013946)	1	1	0	0.0	0	0.0	0	0.0	1	100	0	0.0
· · · ·	2	2	0	0.0	0	0.0	0	0.0	2	100	0	0.0
Ear infection (10014011)	1	1	0	0.0	0	0.0	0	0.0	1	100	0	0.0
Eczema (10014184)	1	2	0	0.0	0	0.0	0	0.0	2	100	0	0.0
Empyema (10014568)	1	2	0	0.0	0	0.0	0	0.0	2	100	0	0.0
	2	1	0	0.0	0	0.0	0	0.0	1	100	0	0.0
Enteritis infectious (10058839)	2	1	0	0.0	0	0.0	0	0.0	1	100	0	0.0
Entropion (10061842)	2	1	0	0.0	0	0.0	0	0.0	1	100	0	0.0
Eye discharge (10015915)	1	2	0	0.0	0	0.0	0	0.0	2	100	0	0.0
Fungal infection (10017533)	2	1	0	0.0	0	0.0	0	0.0	1	100	0	0.0
Gastritis (10017853)	1	6	0	0.0	0	0.0	0	0.0	6	100	0	0.0
, /	2	4	0	0.0	0	0.0	0	0.0	4	100	0	0.0
Gastroenteritis (10017888)	1	22	0	0.0	0	0.0	1	4.5	21	95.5	0	0.0
. /	2	7	0	0.0	0	0.0	0	0.0	7	100	0	0.0

			Defir rela	nitely Ited		bably ated		sibly ated		bably elated	Unk	nown
Preferred Term (Code)	Dose	N	n	%	n	%	n	%	n	%	n	%
Gastroenteritis viral (10017918)	1	1	0	0.0	0	0.0	0	0.0	1	100	0	0.0
	2	1	0	0.0	0	0.0	0	0.0	1	100	0	0.0
Gastrointestinal disorder (10017944)	1	19	0	0.0	0	0.0	2	10.5	17	89.5	0	0.0
, , ,	2	8	0	0.0	1	12.5	0	0.0	7	87.5	0	0.0
Gastrooesophageal reflux disease (10017885)	1	1	0	0.0	0	0.0	0	0.0	1	100	0	0.0
	2	1	0	0.0	0	0.0	0	0.0	1	100	0	0.0
Hypersensitivity (10020751)	2	2	0	0.0	0	0.0	1	50.0	1	50.0	0	0.0
lleus paralytic (10021333)	1	1	0	0.0	0	0.0	0	0.0	1	100	0	0.0
Influenza (10022000)	2	1	0	0.0	0	0.0	0	0.0	1	100	0	0.0
Jaundice neonatal (10023138)	2	1	0	0.0	0	0.0	0	0.0	1	100	0	0.0
Laryngitis (10023874)	2	1	0	0.0	0	0.0	0	0.0	1	100	0	0.0
Lower respiratory tract infection (10024968)	1	2	0	0.0	0	0.0	0	0.0	2	100	0	0.0
, ,	2	1	0	0.0	0	0.0	0	0.0	1	100	0	0.0
Milk allergy (10027633)	1	1	0	0.0	0	0.0	0	0.0	1	100	0	0.0
Nasal congestion (10028735)	1	3	0	0.0	0	0.0	0	0.0	3	100	0	0.0
Nasopharyngitis (10028810)	1	39	0	0.0	0	0.0	0	0.0	39	100	0	0.0
	2	60	0	0.0	0	0.0	0	0.0	60	100	0	0.0
Oral candidiasis (10030963)	1	4	0	0.0	0	0.0	0	0.0	4	100	0	0.0
Otitis externa (10033072)	<u>2</u> 1	1	0	0.0	0	0.0	0 0	0.0	1	100 100	0	0.0
	2	1	0	0.0	0	0.0	0	0.0	1	100	0	0.0
Otitis media (10033078)	1	1	0	0.0	0	0.0	0	0.0	1	100	0	0.0
ļ	2	6	0	0.0	0	0.0	1	16.7	5	83.3	0	0.0
Otitis media acute (10033079)	1	3	0	0.0	0	0.0	0	0.0	3	100	0	0.0
	2	5	0	0.0	0	0.0	0	0.0	5	100	0	0.0
Pharyngitis (10034835)	1	9	0	0.0	0	0.0	0	0.0	9	100	0	0.0
	2	4	0	0.0	0	0.0	0	0.0	4	100	0	0.0
Pneumonia (10035664)	1	3	0	0.0	0	0.0	0	0.0	3	100	0	0.0
Rash (10037844) Regurgitation (10067171)	1 1	1	0 0	0.0 0.0	0	0.0 0.0	0 0	0.0 0.0	1	100 100	0 0	0.0 0.0

			Defir rela			bably ated		sibly ated		bably elated	Unk	nown
Preferred Term (Code)	Dose	N	n	%	n	%	n	%	n	%	n	%
Respiratory tract infection (10062352)	1	3	0	0.0	0	0.0	0	0.0	3	100	0	0.0
, ,	2	1	0	0.0	0	0.0	0	0.0	1	100	0	0.0
Rhinitis (10039083)	1	5	0	0.0	0	0.0	0	0.0	5	100	0	0.0
	2	7	0	0.0	0	0.0	0	0.0	7	100	0	0.0
Rhinorrhoea (10039101)	1	1	0	0.0	0	0.0	0	0.0	1	100	0	0.0
Seborrhoeic dermatitis (10039793)	1	3	0	0.0	0	0.0	0	0.0	3	100	0	0.0
	2	2	0	0.0	0	0.0	0	0.0	2	100	0	0.0
Sepsis (10040047)	1	1	0	0.0	0	0.0	0	0.0	1	100	0	0.0
Skin lesion (10040882)	2	1	0	0.0	0	0.0	0	0.0	1	100	0	0.0
Tonsillitis (10044008)	1	1	0	0.0	0	0.0	0	0.0	1	100	0	0.0
	2	1	0	0.0	0	0.0	0	0.0	1	100	0	0.0
Tremor (10044565)	2	1	0	0.0	0	0.0	0	0.0	1	100	0	0.0
Tubulointerstitial nephritis (10048302)		1	0	0.0	0	0.0	0	0.0	1	100	0	0.0
Ulcer (10045285)	2	1	0	0.0	0	0.0	0	0.0	1	100	0	0.0
Upper respiratory tract infection (10046306)	1	12	0	0.0	0	0.0	0	0.0	10	83.3	2	16.7
	2	13	0	0.0	0	0.0	0	0.0	10	76.9	3	23.1
Urethritis (10046480)	1	1	0	0.0	0	0.0	0	0.0	1	100	0	0.0
Urinary tract infection (10046571)	1	1	0	0.0	0	0.0	0	0.0	1	100	0	0.0
Urticaria (10046735)	1	2	0	0.0	0	0.0	0	0.0	2	100	0	0.0
	2	2	0	0.0	1	50.0	0	0.0	1	50.0	0	0.0

Second Annual Study Report for 111700 (Rota-070 PMS)

N = Number of events

n(%) = number (percentage)of events with the specified category

* The classification of adverse events as Expected & Unexpected AEs is done by Low level term code mentioned in the cleaning report of this study.

## C. Results of adverse events

Table 24 presents the expected and unexpected AEs by outcome for the Total Vaccinated cohort.

## Expected AEs

• All the expected AEs had resolved by the end of the study period.

### Unexpected AEs

Of the unexpected AEs reported, one (1.7%) case of nasopharyngitis and one (20.0%) case of otitis media acute were reported and resolved with sequelae.

			Recovered /Resolved		Recovering /Resolving		Not recovered / not resolved			
Preferred Term (Code)	Dose	Ν	n	%	n	%	n	%	n	%
	events by outcome*	T	r	1			T	1	T	T
Constipation (10010774)	1	3	3	100	0	0.0	0	0.0	0	0.0
	2	2	2	100	0	0.0	0	0.0	0	0.0
Dermatitis (10012431)	1	8	8	100	0	0.0	0	0.0	0	0.0
. ,	2	4	4	100	0	0.0	0	0.0	0	0.0
Diarrhoea (10012735)	1	3	3	100	0	0.0	0	0.0	0	0.0
. ,	2	2	2	100	0	0.0	0	0.0	0	0.0
Pyrexia (10037660)	1	1	1	100	0	0.0	0	0.0	0	0.0
	2	2	2	100	0	0.0	0	0.0	0	0.0
Rash (10037844)	1	2	2	100	0	0.0	0	0.0	0	0.0
Rhinorrhoea (10039101)	1	3	3	100	0	0.0	0	0.0	0	0.0
	2	3	3	100	0	0.0	0	0.0	0	0.0
Upper respiratory tract infection (10046306)	1	36	36	100	0	0.0	0	0.0	0	0.0
	2	29	29	100	0	0.0	0	0.0	0	0.0
L	Unexp	ected adv	erse ev	ents by	outcor	ne*				
Acute sinusitis (10001076)	1	2	2	100	0	0.0	0	0.0	0	0.0
	2	1	1	100	0	0.0	0	0.0	0	0.0
Acute tonsillitis (10001093)	1	1	1	100	0	0.0	0	0.0	0	0.0
```	2	3	3	100	0	0.0	0	0.0	0	0.0
Asthma (10003553)	1	1	1	100	0	0.0	0	0.0	0	0.0
· · · · ·	2	1	1	100	0	0.0	0	0.0	0	0.0
Atopy (10003645)	1	3	3	100	0	0.0	0	0.0	0	0.0
,	2	3	3	100	0	0.0	0	0.0	0	0.0
Balanoposthitis (10004078)	2	1	1	100	0	0.0	0	0.0	0	0.0
Bronchiolitis (10006448)	1	45	45	100	0	0.0	0	0.0	0	0.0
· /	2	33	33	100	0	0.0	0	0.0	0	0.0
Bronchitis (10006451)	1	6	6	100	0	0.0	0	0.0	0	0.0
· /	2	6	6	100	0	0.0	0	0.0	0	0.0
Cellulitis (10007882)	1	1	1	100	0	0.0	0	0.0	0	0.0
	2	1	1	100	0	0.0	0	0.0	0	0.0
Colitis (10009887)	1	2	2	100	0	0.0	0	0.0	0	0.0
Conjunctivitis (10010741)	1	5	5	100	0	0.0	0	0.0	0	0.0
	2	2	2	100	0	0.0	0	0.0	0	0.0
Conjunctivitis allergic (10010744)	1	1	1	100	0	0.0	0	0.0	0	0.0

Table 24 Expected & Unexpected adverse events by outcome (Total Vaccinated cohort)

Rotarix[™] Post-Marketing Surveillance annual report Page 66 *GlaxoSmithKline Korea*

	Dose		Recovered /Resolved		Recovering /Resolving		Not recovered / not resolved			
Preferred Term (Code)		N	n	%	n	%	n	%	n	%
Cough (10011224)	1 2	3	3 4	100 100	0	0.0	0	0.0	0	0.0 0.0
Croup infectious (10011416)	2	1	1	100	0	0.0	0	0.0	0	0.0
Cystitis (10011781) Dermatitis atopic (10012438)	2 1	1 23	1 23	100 100	0	0.0 0.0	0	0.0 0.0	0	0.0 0.0
(2	14	14	100	0	0.0	0	0.0	0	0.0
Dermatitis contact (10012442)	2	2	2	100	0	0.0	0	0.0	0	0.0
Dermatitis diaper (10012444)	2	6	6	100	0	0.0	0	0.0	0	0.0
Dyspepsia (10013946)	1	1	1	100	0	0.0	0	0.0	0	0.0
(2	2	2	100	0	0.0	0	0.0	0	0.0
Ear infection (10014011)	1	1	1	100	0	0.0	0	0.0	0	0.0
Eczema (10014184)	1	2	2	100	0	0.0	0	0.0	0	0.0
Empyema (10014568)	1	2	2	100	0	0.0	0	0.0	0	0.0
, ,	2	1	1	100	0	0.0	0	0.0	0	0.0
Enteritis infectious (10058839)	2	1	1	100	0	0.0	0	0.0	0	0.0
Entropion (10061842)	2	1	1	100	0	0.0	0	0.0	0	0.0
Eye discharge (10015915)	1	2	2	100	0	0.0	0	0.0	0	0.0
Fungal infection (10017533)	2	1	1	100	0	0.0	0	0.0	0	0.0
Gastritis (10017853)	1	6	6	100	0	0.0	0	0.0	0	0.0
, ,	2	4	4	100	0	0.0	0	0.0	0	0.0
Gastroenteritis (10017888)	1	22	22	100	0	0.0	0	0.0	0	0.0
	2	7	7	100	0	0.0	0	0.0	0	0.0
Gastroenteritis viral (10017918)	1	1	1	100	0	0.0	0	0.0	0	0.0
-	2	1	1	100	0	0.0	0	0.0	0	0.0
Gastrointestinal disorder (10017944)	1	19	19	100	0	0.0	0	0.0	0	0.0
	2	8	8	100	0	0.0	0	0.0	0	0.0
Gastrooesophageal reflux disease (10017885)	1	1	1	100	0	0.0	0	0.0	0	0.0
	2	1	1	100	0	0.0	0	0.0	0	0.0
Hypersensitivity (10020751)	2	2	2	100	0	0.0	0	0.0	0	0.0
lleus paralytic (10021333)	1	1	1	100	0	0.0	0	0.0	0	0.0
Influenza (10022000)	2	1	1	100	0	0.0	0	0.0	0	0.0

Rotarix™ Post-Marketing Surveillance annual report Page 67 *GlaxoSmithKline Korea*

	Dose		Recovered /Resolved		Recovering /Resolving		Not recovered / not resolved			
Preferred Term (Code)		N	n	%	n	%	n	%	n	%
Jaundice neonatal (10023138)	2	1	1	100	0	0.0	0	0.0	0	0.0
Laryngitis (10023874)	2	1	1	100	0	0.0	0	0.0	0	0.0
Lower respiratory tract infection (10024968)	1	2	2	100	0	0.0	0	0.0	0	0.0
· · · ·	2	1	1	100	0	0.0	0	0.0	0	0.0
Milk allergy (10027633)	1	1	1	100	0	0.0	0	0.0	0	0.0
Nasal congestion (10028735)	1	3	3	100	0	0.0	0	0.0	0	0.0
Nasopharyngitis (10028810)	1	39	39	100	0	0.0	0	0.0	0	0.0
	2	60	59	98.3	0	0.0	0	0.0	1	1.7
Oral candidiasis (10030963)	1	4	4	100	0	0.0	0	0.0	0	0.0
	2	1	1	100	0	0.0	0	0.0	0	0.0
Otitis externa (10033072)	1	1	1	100	0	0.0	0	0.0	0	0.0
	2	1	1	100	0	0.0	0	0.0	0	0.0
Otitis media (10033078)	1	1	1	100	0	0.0	0	0.0	0	0.0
· /	2	6	6	100	0	0.0	0	0.0	0	0.0
Otitis media acute (10033079)	1	3	3	100	0	0.0	0	0.0	0	0.0
(2	5	4	80.0	0	0.0	0	0.0	1	20.0
Pharyngitis (10034835)	1	9	9	100	0	0.0	0	0.0	0	0.0
(,	2	4	4	100	0	0.0	0	0.0	0	0.0
Pneumonia (10035664)	1	3	3	100	0	0.0	0	0.0	0	0.0
Rash (10037844)	1	1	1	100	0	0.0	0	0.0	0	0.0
Regurgitation (10067171)	1	1	1	100	0	0.0	0	0.0	0	0.0
Respiratory tract infection (10062352)	1	3	3	100	0	0.0	0	0.0	0	0.0
	2	1	1	100	0	0.0	0	0.0	0	0.0
Rhinitis (10039083)	1	5	5	100	0	0.0	0	0.0	0	0.0
. /	2	7	7	100	0	0.0	0	0.0	0	0.0
Rhinorrhoea (10039101)	1	1	1	100	0	0.0	0	0.0	0	0.0
Seborrhoeic dermatitis (10039793)	1	3	3	100	0	0.0	0	0.0	0	0.0
	2	2	2	100	0	0.0	0	0.0	0	0.0
Sepsis (10040047)	1	1	1	100	0	0.0	0	0.0	0	0.0
Skin lesion (10040882)	2	1	1	100	0	0.0	0	0.0	0	0.0
Tonsillitis (10044008)	1	1	1	100	0	0.0	0	0.0	0	0.0
	2	1	1	100	0	0.0	0	0.0	0	0.0

Rotarix™ Post-Marketing Surveillance annual report Page 68 *GlaxoSmithKline Korea*

			Recovered /Resolved		Recovering /Resolving		Not recovered / not resolved			
Preferred Term (Code)	Dose	N	n	%	n	%	n	%	n	%
Tremor (10044565)	2	1	1	100	0	0.0	0	0.0	0	0.0
Tubulointerstitial nephritis (10048302)	2	1	1	100	0	0.0	0	0.0	0	0.0
Ulcer (10045285)	2	1	1	100	0	0.0	0	0.0	0	0.0
Upper respiratory tract infection (10046306)	1	12	12	100	0	0.0	0	0.0	0	0.0
· · · ·	2	13	13	100	0	0.0	0	0.0	0	0.0
Urethritis (10046480)	1	1	1	100	0	0.0	0	0.0	0	0.0
Urinary tract infection (10046571)	1	1	1	100	0	0.0	0	0.0	0	0.0
Urticaria (10046735)	1	2	2	100	0	0.0	0	0.0	0	0.0
	2	2	2	100	0	0.0	0	0.0	0	0.0

N = Number of events

n (%) = number (percentage)of events with the specified category * The classification of adverse events as expected & unexpected AEs was done by low level term code mentioned in the cleaning report of this study.

VI. Line Listings of adverse events

6. Line-listing of Adverse Events

Line-listing of adverse drug reactions [Appendix No. 3-1]

Line-listing of serious adverse events, adverse drug reaction in PMS special surveillance and post-marketing clinical trial [Appendix No. 3-2]

Line-listing of adverse events [Appendix No.4]

Table of adverse events [Appendix No. 5]

Individual line-listing [Appendix No.7]: provided separately

Second Annual Study Report for 111700 (Rota-070 PMS)

[Annex 3-1] Line-listing of adverse drug reactions

Incidence of related symptoms during the entire study period.

Time	Before licence	Case report
Target		1 st & 2 nd year
Study institute (A) No of sites	-	35
Subject included in the safety analysis Group(B)	-	876
Subject with observed AE (C) No of subject who report ANY AEs	-	118
Symptom reported as AE(D) No of reported AEs	-	195
Incidence of AE(C/B)	-	13.47%

		# of subjects who experienced the corresponding adverse events (%)[#of events]
		Year 1 & 2
System organ class (code)	Preferred Term (code)	n (%) [n*]
Gastrointestinal disorders (10017947)	Diarrhoea (10012735)	15(1.7)[16]
	Gastrointestinal disorder (10017944)	3(0.3)[3]
	Vomiting (10047700)	44(5.0)[45]
General disorders and administration site conditions (10018065)		47(5.4)[53]
()	Pyrexia (10037660)	27(3.1)[29]
Immune system disorders (10021428)	Hypersensitivity (10020751)	1(0.1)[1]
Infections and infestations (10021881)	Bronchiolitis (10006448)	2(0.2)[2]
· · · · · ·	Gastroenteritis (10017888)	1(0.1)[1]
	Otitis media (10033078)	1(0.1)[1]
	Upper respiratory tract infection (10046306)	5(0.6)[5]
Metabolism and nutrition disorders (10027433)	Decreased appetite (10061428)	26(3.0)[26]
Respiratory, thoracic and mediastinal disorders (10038738)	Cough (10011224)	10(1.1)[11]

		# of subjects who experienced the corresponding adverse events (%)[#of events] Year 1 & 2	
System organ class (code)	Preferred Term (code)	n (%) [n*]	
Skin and subcutaneous tissue disorders (10040785)	Dermatitis atopic (10012438)	1(0.1)[1]	
. , ,	Urticaria (10046735)	1(0.1)[1]	

Second Annual Study Report for 111700 (Rota-070 PMS)

Second Annual Study Report for 111700 (Rota-070 PMS)

[Annex 3-2] Line-listing of serious adverse events, adverse drug reaction in PMS	
and special surveillance and post-marketing clinical trial	

Time	Before licence	Case report
Target		1 st & 2 nd year
Study institute (A) No of sites	-	35
Subject included in the safety analysis Group(B)	-	876
Subject with observed AE (C) No of subject who report ANY AEs	-	124
Symptom reported as AE(D) No of reported AEs	-	206
Incidence of AE(C/B)	-	14.15%

		# of subjects who experienced the corresponding adverse events (%)[#of events]
		Year 1 & 2
System organ class (code)	Preferred Term (code)	n (%) [n*]
Gastrointestinal disorders (10017947)	Diarrhoea (10012735)	15(1.7)[16]
,	Gastrointestinal disorder (10017944)	3(0.3)[3]
	Vomiting (10047700)	44(5.0)[45]
	Ileus paralytic (10021333)	1(0.1)[1]
General disorders and administration site conditions (10018065)		47(5.4)[53]
()	Pyrexia (10037660)	27(3.1)[29]
Immune system disorders (10021428)	Hypersensitivity (10020751)	1(0.1)[1]
Infections and infestations (10021881)	Bronchiolitis (10006448)	6(0.7)[6]
()	Gastroenteritis (10017888)	3(0.3)[3]
	Otitis media (10033078)	1(0.1)[1]
	Otitis media acute (10033079)	2((0.2)[2]
	Upper respiratory tract infection (10046306)	5(0.6)[5]
	Croup infectious (10011416)	1(0.1)[1]
	Sepsis(10040047)	1(0.1)[1]
Metabolism and nutrition disorders	Decreased appetite (10061428)	26(3.0)[26]

		# of subjects who experienced the corresponding adverse events (%)[#of events] Year 1 & 2
System organ class (code)	Preferred Term (code)	n (%) [n*]
(10027433)		
Respiratory, thoracic and mediastinal disorders (10038738)	Cough (10011224)	10(1.1)[11]
Skin and subcutaneous tissue disorders (10040785)	Dermatitis atopic (10012438)	1(0.1)[1]
	Urticaria (10046735)	1(0.1)[1]
other		

Second Annual Study Report for 111700 (Rota-070 PMS)

[Annex4] Line listing of AEs

Incidence of adverse events reported during the entire study period.

Target	Before licence	Case report 1st & 2nd year
Study institute (A) No of sites	-	35
Subject included in the safety analysis Group (B)	-	876
Subject with observed AE (C) No of subject who report ANY AEs	-	630
Symptom reported as AE (D) No of reported AEs	-	2010
Incidence of AE (C/B)	-	71.91%

		# of subjects who experienced the corresponding adverse events (%)[#of events] Year 1 & 2
System organ class (code)	Preferred Term (Code)	n (%) [n*]
Eye disorders (10015919)	Conjunctivitis (10010741)	7(0.8)[7]
	Conjunctivitis allergic (10010744)	1(0.1)[1]
	Entropion (10061842)	1(0.1)[1]
	Eye discharge (10015915)	2(0.2)[2]
Gastrointestinal disorders (10017947)	Colitis (10009887)	2(0.2)[2]
	Constipation (10010774)	5(0.6)[5]
	Diarrhoea (10012735)	55(6.3)[56]
	Dyspepsia (10013946)	3(0.3)[3]
	Gastritis (10017853)	8(0.9)[10]
	Gastrointestinal disorder (10017944)	26(3.0)[27]
	Gastrooesophageal reflux disease (10017885)	2(0.2)[2]
	lleus paralytic (10021333)	1(0.1)[1]
	Regurgitation (10067171)	1(0.1)[1]
	Vomiting (10047700)	200(22.8)[224]
General disorders and administration site conditions (10018065)	Irritability (10022998)	405(46.2)[488]
, , ,	Pyrexia (10037660)	138(15.8)[150]
	Ulcer (10045285)	1(0.1)[1]
Immune system disorders (10021428)	Atopy (10003645)	6(0.7)[6]
	Hypersensitivity (10020751)	2(0.2)[2]

Rotarix[™] Post-Marketing Surveillance annual report Page 76 GlaxoSmithKline Korea

		# of subjects who experienced the corresponding adverse events (%)[#of events] Year 1 & 2
Sustam arman alaga	Droforred Torm (Code)	
System organ class (code)	Preferred Term (Code)	n (%) [n*]
(coue)	Milk allergy (10027633)	1(0.1)[1]
Infections and	Acute sinusitis (10021033)	
infestations (10021881)		3(0.3)[3]
(10021001)	Acute tonsillitis (10001093)	4(0.5)[4]
	Bronchiolitis (10006448)	65(7.4)[79]
	Bronchitis (10006451)	12(1.4)[12]
	Cellulitis (10007882)	
	Croup infectious (10011416)	2(0.2)[2]
		1(0.1)[1]
	Cystitis (10011781)	1(0.1)[1]
	Ear infection (10014011)	1(0.1)[1]
	Empyema (10014568)	3(0.3)[3]
	Enteritis infectious (10058839)	1(0.1)[1]
	Fungal infection (10017533)	1(0.1)[1]
	Gastroenteritis (10017888)	24(2.7)[29]
	Gastroenteritis viral (10017918)	2(0.2)[2]
	Influenza (10022000)	1(0.1)[1]
	Laryngitis (10023874)	1(0.1)[1]
	Lower respiratory tract infection (10024968)	2(0.2)[3]
	Nasopharyngitis (10028810)	79(9.0)[99]
	Oral candidiasis (10030963)	4(0.5)[5]
	Otitis externa (10033072)	2(0.2)[2]
	Otitis media (10033078)	7(0.8)[7]
	Otitis media acute (10033079)	7(0.8)[8]
	Pharyngitis (10034835)	11(1.3)[14]
	Pneumonia (10035664)	3(0.3)[3]
	Respiratory tract infection (10062352)	2(0.2)[4]
	Rhinitis (10039083)	8(0.9)[12]
	Sepsis (10040047)	1(0.1)[1]
	Tonsillitis (10044008)	1(0.1)[2]
	Upper respiratory tract infection (10046306)	80(9.1)[90]
	Urethritis (10046480)	1(0.1)[1]
	Urinary tract infection (10046571)	1(0.1)[1]
Metabolism and nutrition disorders (10027433)	Decreased appetite (10061428)	259(29.6)[296]
Nervous system disorders (10029205)	Tremor (10044565)	1(0.1)[1]
Pregnancy, puerperium and	Jaundice neonatal (10023138)	1(0.1)[1]
perinatal conditions		
(10036585) Renal and urinary	Tubulainteratitial pophritic (10049202)	1(0.1)[1]
	Tubulointerstitial nephritis (10048302)	1(0.1)[1]
disorders (10038359)	Releasesthitic (10004078)	
Reproductive system	Balanoposthitis (10004078)	1(0.1)[1]
and breast disorders		
(10038604)		0/0.0/001
Respiratory, thoracic and mediastinal	Asthma (10003553)	2(0.2)[2]
disorders (10038738)		000/00 000 (0)
	Cough (10011224)	209(23.9)[243]

Rotarix[™] Post-Marketing Surveillance annual report Page 77 GlaxoSmithKline Korea

		# of subjects who experienced the corresponding adverse events (%)[#of events] Year 1 & 2
System organ class (code)	Preferred Term (Code)	n (%) [n*]
	Nasal congestion (10028735)	3(0.3)[3]
	Rhinorrhoea (10039101)	7(0.8)[7]
Skin and	Dermatitis (10012431)	12(1.4)[12]
subcutaneous tissue disorders (10040785)		
	Dermatitis atopic (10012438)	34(3.9)[37]
	Dermatitis contact (10012442)	2(0.2)[2]
	Dermatitis diaper (10012444)	6(0.7)[6]
	Eczema (10014184)	2(0.2)[2]
	Rash (10037844)	3(0.3)[3]
	Seborrhoeic dermatitis (10039793)	4(0.5)[5]
	Skin lesion (10040882)	1(0.1)[1]
	Urticaria (10046735)	4(0.5)[4]
Vista	and out at No DONOLIJOU TIO, and Out is at No DDD	

Note: subjects No. PPD reported ACUTE BRONCHIOLITIS, and Subject No PPD reported ACUTE PHARYNGITIS 31 days after Dose 1. So these two AEs are counted in the above table.

[Annex No.5] Table of adverse event

Country where the drug is marketed	Effective date and additional action date (Approval date)	Marketing date	Product Name	Remarks
Albania	20-Nov-08		Rotarix	Rota-lyophilised
Argentina	27-Dec-05	06-Jan-06	Rotarix	Rota-lyophilised
Aruba	30-Nov-05		Rotarix	Rota-lyophilised
Australia	08-Mar-06	23-May-06	Rotarix	Rota-lyophilised
Austria	21-Feb-06	02-May-06	Rotarix	Rota-lyophilised
Azerbajian	01-Dec-08	01-Mar-09	Rotarix	Rota-lyophilised
Bahrain	12-Jul-05	12-Oct-05	Rotarix	Rota-lyophilised
Bangladesh	28-Dec-06	28-Mar-07	Rotarix	Rota-lyophilised
Belarus	28-Jun-08		Rotarix	Rota-lyophilised
Belgium	21-Feb-06	01-Jun-06	Rotarix	Rota-lyophilised
Benin	15-Jan-07	15-Apr-07	Rotarix	Rota-lyophilised
Bolivia	12-Dec-06		Rotarix	Rota-lyophilised
Brazil	11-Jul-05	01-Aug-05	Rotarix	Rota-lyophilised
Bulgaria	21-Feb-06	21-May-06	Rotarix	Rota-lyophilised
Burkina Faso	13-Sep-06	13-Dec-06	Rotarix	Rota-lyophilised
Cambodia	39682	22-Nov-08	Rotarix	Rota-lyophilised
Cameroon	24-Aug-05	24-Nov-05	Rotarix	Rota-lyophilised
Canada	09-Oct-07	09-Jan-08	Rotarix	Rota-lyophilised
Chile	18-Aug-05	07-Mar-06	Rotarix	Rota-lyophilised
Colombia	09-Aug-05	10-Sep-05	Rotarix	Rota-lyophilised
Congo	23-Aug-05	23-Nov-05	Rotarix	Rota-lyophilised
Costa Rica	03-Nov-06	28-Feb-07	Rotarix	Rota-lyophilised
Croatia	26-Jun-08	26-Sep-08	Rotarix	Rota-lyophilised
Curacao	06-Sep-05		Rotarix	Rota-lyophilised
Cyprus	21-Feb-06	20-Oct-07	Rotarix	Rota-lyophilised
Czech Republic	21-Feb-06	01-Dec-06	Rotarix	Rota-lyophilised
Democratic Republic of Congo	18-Aug-05		Rotarix	Rota-lyophilised
Denmark	21-Feb-06	17-Jul-06	Rotarix	Rota-lyophilised
Dominican Republic	04-Jun-04	16-Feb-06	Rotarix	Rota-lyophilised
Ecuador	21-Oct-05	31-Jan-06	Rotarix	Rota-lyophilised
Egypt	05-Apr-07	30-Jun-07	Rotarix	Rota-lyophilised
El Salvador	31-Aug-05	10-Oct-05	Rotarix	Rota-lyophilised
Estonia	21-Feb-06	11-Sep-06	Rotarix	Rota-lyophilised
Finland	21-Feb-06	15-May-06	Rotarix	Rota-lyophilised

[Annex No. 6] List of license in other countries

Rotarix[™] Post-Marketing Surveillance annual report Page 80 GlaxoSmithKline Korea

France	21-Feb-06	29-May-06	Rotarix	Rota-lyophilised
Gabon	31-Mar-05	01-Jul-05	Rotarix	Rota-lyophilised
Germany	21-Feb-06	28-Apr-06	Rotarix	Rota-lyophilised
Greece	21-Feb-06	16-Nov-06	Rotarix	Rota-lyophilised
Guatemala	06-Jun-05	20-Jul-05	Rotarix	Rota-lyophilised
Guinea	09-Feb-06		Rotarix	Rota-lyophilised
Honduras	31-May-06	31-Aug-06	Rotarix	Rota-lyophilised
Hong Kong	21-Jul-06		Rotarix	Rota-lyophilised
Hungary	21-Feb-06	01-Oct-06	Rotarix	Rota-lyophilised
Iceland	24-Apr-06		Rotarix	Rota-lyophilised
India	21-Feb-08	21-May-08	Rotarix	Rota-lyophilised
Ireland	21-Feb-06	01-Mar-07	Rotarix	Rota-lyophilised
Israel	23-Oct-07	23-Jan-08	Rotarix	Rota-lyophilised
Italy	21-Feb-06	24-Oct-06	Rotarix	Rota-lyophilised
Ivory Coast	21-Dec-06	21-Mar-07	Rotarix	Rota-lyophilised
Jamaica	23-Nov-05	19-Feb-06	Rotarix	Rota-lyophilised
Jordan	05-Mar-07	05-Jun-07	Rotarix	Rota-lyophilised
Kazakhstan	04-Jul-07		Rotarix	Rota-lyophilised
Kenya	13-Jul-05	30-Apr-06	Rotarix	Rota-lyophilised
Kuwait	25-Dec-07	25-Mar-08	Rotarix	Rota-lyophilised
Latvia	21-Feb-06	08-Aug-08	Rotarix	Rota-lyophilised
Lebanon	30-Apr-08	30-Jul-08	Rotarix	Rota-lyophilised
Lithuania	21-Feb-06	13-Jul-06	Rotarix	Rota-lyophilised
Luxembourg	21-Feb-06	21-May-06	Rotarix	Rota-lyophilised
Madagascar	20-Dec-05		Rotarix	Rota-lyophilised
Malawi	18-Apr-05		Rotarix	Rota-lyophilised
Malaysia	23-Mar-06	23-Jun-06	Rotarix	Rota-lyophilised
Mali	26-Jan-06	26-Apr-06	Rotarix	Rota-lyophilised
Malta	21-Feb-06	01-Jul-06	Rotarix	Rota-lyophilised
Mauritania	18-May-06		Rotarix	Rota-lyophilised
Mauritius	26-Apr-05	25-Mar-06	Rotarix	Rota-lyophilised
Mexico	12-Jul-04	20-Dec-04	Rotarix	Rota-lyophilised
Могоссо	16-Aug-06	16-Nov-06	Rotarix	Rota-lyophilised
Myanmar	29-May-07	29-Aug-07	Rotarix	Rota-lyophilised
Namibia	38905	07-Oct-06	Rotarix	Rota-lyophilised
Netherlands	21-Feb-06	29-Jun-06	Rotarix	Rota-lyophilised
New Zealand	21-Dec-06	21-Mar-07	Rotarix	Rota-lyophilised
Nicaragua	24-Apr-06	24-Jul-06	Rotarix	Rota-lyophilised
Niger	17-Jul-07		Rotarix	Rota-lyophilised
Nigeria	31-Jan-06	01-May-06	Rotarix	Rota-lyophilised

Rotarix™ Post-Marketing Surveillance annual report Page 81 *GlaxoSmithKline Korea*

Norway	08-Mar-06	10-Jun-06	Rotarix	Rota-lyophilised
Pakistan	25-Jan-07	25-Apr-07	Rotarix	Rota-lyophilised
			Rotarix	Rota-lyophilised
Panama	22-Dec-05	08-Mar-06	Rotarix	Rota-lyophilised
Paraguay	16-Aug-06	16-Nov-06	Rotarix	Rota-lyophilised
Peru	26-Jul-05	18-Aug-05	Rotarix	Rota-lyophilised
Philippines	01-Sep-05	01-Dec-05	Rotarix	Rota-lyophilised
Poland	21-Feb-06	06-Jul-06		
Portugal	21-Feb-06	29-May-06	Rotarix	Rota-lyophilised
Qatar	24-May-06	30-Nov-06	Rotarix	Rota-lyophilised
RCA	04-Oct-05		Rotarix	Rota-lyophilised
Romania	21-Feb-06	21-May-06	Rotarix	Rota-lyophilised
Saudi Arabia	30-May-06	30-Aug-06	Rotarix	Rota-lyophilised
Senegal	21-Apr-06	21-Jul-06	Rotarix	Rota-lyophilised
Serbia	02-Oct-08		Rotarix	Rota-lyophilised
Singapore	05-Oct-05	20-Oct-05	Rotarix	Rota-lyophilised
Slovakia	21-Feb-06	23-Oct-06	Rotarix	Rota-lyophilised
Slovenia	21-Feb-06	05-Jan-07	Rotarix	Rota-lyophilised
South Africa	07-Jul-06	07-Oct-06	Rotarix	Rota-lyophilised
South Korea	07-Mar-08	Jun-08	Rotarix	Rota-lyophilised
Spain	21-Feb-06	24-Jul-06	Rotarix	Rota-lyophilised
Sri Lanka	26-May-06	26-Aug-06	Rotarix	Rota-lyophilised
Suriname	05-May-05		Rotarix	Rota-lyophilised
Sweden	21-Feb-06	15-Jun-06	Rotarix	Rota-lyophilised
Switzerland	29-Jan-07	30-Apr-07	Rotarix	Rota-lyophilised
Taiwan	31-Aug-06	01-Dec-06	Rotarix	Rota-lyophilised
Thailand	30-Dec-05	31-Mar-06	Rotarix	Rota-lyophilised
Тодо	02-Jun-06	02-Sep-06	Rotarix	Rota-lyophilised
Trinidad and Tobago	05-Jul-05	21-Sep-05	Rotarix	Rota-lyophilised
Tunisia	08-Mar-08	08-Jun-08	Rotarix	Rota-lyophilised
Uganda	14-Aug-09		Rotarix	Rota-lyophilised
UK	21-Feb-06	22-May-06	Rotarix	Rota-lyophilised
United Arab Emirates	28-Nov-05	23-Mar-06	Rotarix	Rota-lyophilised
United States	03-Apr-08	03-Jul-08	Rotarix	Rota-lyophilised
Venezuela	22-Sep-05	21-Jan-06	Rotarix	Rota-lyophilised
Vietnam	28-May-07	29-Jul-07	Rotarix	Rota-lyophilised
WHO	30-Jan-07	30-Apr-07	Rotarix	Rota-lyophilised
Yemen	31-Jul-06	31-Oct-06	Rotarix	Rota-lyophilised
Argentina	02-Feb-09	02-Dec-09	Rotarix	Rota-Liquid
Australia	08-Aug-08	01-Mar-09	Rotarix	Rota-Liquid

Austria	01-Sep-08		Rotarix	Rota-Liquid
Bangladesh	28-Jan-10		Rotarix	Rota-Liquid
Belgium	01-Sep-08		Rotarix	Rota-Liquid
Benin	25-May-09		Rotarix	Rota-Liquid
Bolivia	24-Aug-09	01-Oct-09	Rotarix	Rota-Liquid
Brazil	12-Mar-07	19-Sep-07	Rotarix	Rota-Liquid
Bulgaria	01-Sep-08		Rotarix	Rota-Liquid
Burkina Faso	29-Jul-09		Rotarix	Rota-Liquid
Canada	11-Jan-10		Rotarix	Rota-Liquid
Chile	04-Nov-09	04-Feb-10	Rotarix	Rota-Liquid
Colombia	09-Sep-08	01-Sep-09	Rotarix	Rota-Liquid
Congo	30-Jun-09		Rotarix	Rota-Liquid
Cyprus	01-Sep-08		Rotarix	Rota-Liquid
Czech Republic	01-Sep-08		Rotarix	Rota-Liquid
Democratic Republic of Congo	04-Sep-09		Rotarix	Rota-Liquid
Denmark	01-Sep-08		Rotarix	Rota-Liquid
Dominican Republic	03-Jul-09		Rotarix	Rota-Liquid
Ecuador	20-Nov-09	01-Oct-09	Rotarix	Rota-Liquid
El Salvador	26-Mar-09	01-Oct-09	Rotarix	Rota-Liquid
Estonia	01-Sep-08		Rotarix	Rota-Liquid
Finland	01-Sep-08		Rotarix	Rota-Liquid
France	01-Sep-08		Rotarix	Rota-Liquid
Gabon	39994		Rotarix	Rota-Liquid
Germany	01-Sep-08		Rotarix	Rota-Liquid
Greece	01-Sep-08		Rotarix	Rota-Liquid
Guatemala	22-Apr-09		Rotarix	Rota-Liquid
Honduras	25-May-09	01-Sep-09	Rotarix	Rota-Liquid
Hong Kong	20-May-08	28-Sep-08	Rotarix	Rota-Liquid
Hungary	01-Sep-08		Rotarix	Rota-Liquid
Iceland	39692		Rotarix	Rota-Liquid
Ireland	01-Sep-08		Rotarix	Rota-Liquid
Italy	01-Sep-08		Rotarix	Rota-Liquid
Ivory Coast	05-Nov-09		Rotarix	Rota-Liquid
Kenya	01-Aug-08		Rotarix	Rota-Liquid
Latvia	01-Sep-08		Rotarix	Rota-Liquid
Lithuania	01-Sep-08		Rotarix	Rota-Liquid
Luxembourg	01-Sep-08		Rotarix	Rota-Liquid
Malaysia	19-Feb-09		Rotarix	Rota-Liquid

Mali	09-Nov-09		Rotarix	Rota-Liquid
Malta	01-Sep-08		Rotarix	Rota-Liquid
Mexico	10-Jun-09	10-Sep-09	Rotarix	Rota-Liquid
Moldova	06-Feb-09		Rotarix	Rota-Liquid
Myanmar	14-Dec-09		Rotarix	Rota-Liquid
Netherlands	01-Sep-08		Rotarix	Rota-Liquid
New Zealand	27-Mar-09		Rotarix	Rota-Liquid
Nicaragua	18-Jun-09		Rotarix	Rota-Liquid
Niger	05-Jun-09		Rotarix	Rota-Liquid
Norway	39727		Rotarix	Rota-Liquid
Paraguay	20-Jul-09	01-Oct-09	Rotarix	Rota-Liquid
Peru	29-May-09	29-Aug-09	Rotarix	Rota-Liquid
Philippines	16-Feb-09		Rotarix	Rota-Liquid
Poland	01-Sep-08		Rotarix	Rota-Liquid
Portugal	01-Sep-08	23-Apr-09	Rotarix	Rota-Liquid
RCA	04-Jun-09		Rotarix	Rota-Liquid
Romania	01-Sep-08		Rotarix	Rota-Liquid
Singapore	04-Dec-09		Rotarix	Rota-Liquid
Slovakia	01-Sep-08		Rotarix	Rota-Liquid
Slovenia	01-Sep-08	16-Sep-09	Rotarix	Rota-Liquid
South Africa	05-Mar-09	01-Apr-09	Rotarix	Rota-Liquid
Spain	01-Sep-08	06-May-09	Rotarix	Rota-Liquid
Sweden	01-Sep-08		Rotarix	Rota-Liquid
Switzerland	14-May-09		Rotarix	Rota-Liquid
Taiwan	17-Dec-09		Rotarix	Rota-Liquid
Thailand	26-Jun-09		Rotarix	Rota-Liquid
UK	01-Sep-08		Rotarix	Rota-Liquid
Ukraine	10-Jun-09		Rotarix	Rota-Liquid
Uruguay	17-Nov-09	17-Feb-10	Rotarix	Rota-Liquid
Venezuela	10-Feb-09	01-Sep-09	Rotarix	Rota-Liquid
WHO	12-Mar-09		Rotarix	Rota-Liquid

VII. Considerations of the results and future plan

7. Considerations of the results and future plan

This study report presents the data from the surveillance following the registration of Rotarix[™] in Korea on 07 March 2008. The safety of GSK Biologicals' Rotarix [™] vaccine was to be assessed in subjects aged 6 – 16 weeks, as per the requirement of Korean Food and Drug Administration.

A total of 877 subjects were enrolled in the surveillance study to receive RotarixTM vaccine and the safety data collected for 876 subjects were analysed.

- Irritability was the most frequently reported expected AE during the study period. This is in line with other studies conducted in Asia (Bangladesh (Rota-045 trial) [Zaman, 2009] and Japan (Rota-056 trial) (107625\444563)). Majority of the irritability cases lasted for a day after both doses of the study vaccination. Less than 1% of the irritability cases reported after both doses of the study vaccination were assessed by the investigator to be definitely related to vaccination. The severity of irritability cases decreased from post Dose 1 of the study vaccination to post Dose 2 of the study vaccination and 3.6% of the irritability cases reported post Dose 2 of the study vaccination were assessed as severe).
- Cough was the most frequently reported unexpected AE during the study period. Majority of the cough cases lasted for a day after Dose 1 of the study vaccination and 4 to 7 days after Dose 2 of the study vaccination. None of the cases of cough reported were assessed by the investigator to be definitely related to vaccination. The percentage of cough cases assessed by the investigator to be possibly related to study vaccination was 2.6% post Dose 1 of the study vaccination and 1.1% post Dose 2 of the study vaccination. The percentage of cough cases which were assessed by the investigator to be severe post Dose 1 and Dose 2 of the study vaccination were 0.7% and 1.1%, respectively.
- Irritability, reported for 5.4% of subjects and cough, reported for 1.1% of subjects were also the most frequently reported expected and unexpected ADRs, respectively.
- Of the 118 subjects who had a previous medical history, a total of 85 (72.0%) subjects experienced AEs.
- Overall, at least one expected AE was reported for 62.7% of the subjects who had a previous medical history, 66.0% of subjects who received concomitant medication and 58.3% of the subjects who received concomitant vaccination, respectively. Irritability was the most frequently reported expected AE among subjects who had a previous medical history, subjects who received concomitant medication and subjects who received concomitant medication and subjects who received concomitant vaccination.
- Overall, at least one unexpected AE was reported for 43.2% of the subjects who had a previous medical history, 82.9% of the subjects who received concomitant medication and 46.7% of subjects who received concomitant vaccination, respectively. Cough was the most frequently reported unexpected AE among subjects who had previous medical

Second Annual Study Report for 111700 (Rota-070 PMS)

history, subjects who received concomitant medication and subjects who received concomitant vaccination.

• Eleven SAEs were reported for 6 subjects during the study period. These included sepsis, bronchiolitis, AOM, acute GE, acute bronchiolitis, paralytic ileus and infectious croup. None of the SAEs were considered by the investigator to have a causal relationship to vaccination.

Thus, the results of this surveillance indicate that GSK Biologicals' live attenuated HRV vaccine, RotarixTM is well tolerated and has a good safety profile when administered in Korean infants.

References

Zaman K, Sack DA, Yunus M, et al. Successful co-administration of a human rotavirus and oral poliovirus vaccines in Bangladeshi infants in a 2-dose schedule at 12 and 16 weeks of age. Vaccine. 2009; 27(9):1333-9.

VIII. INVOICE SALES

8. Invoice Sales

Period	Shipping amount (60T)

IX. Data on foreign adverse events

9. Data on foreign adverse events



Sponsor: GlaxoSmithKline Biologicals 9th Floor LS Yongsan Tower building, 191 Hangang-ro-2-ga, Yongsan-gu, Seoul, 140-702, Korea

Product NamesGlaxoSmithKline (GSK) Biologicals' oral live
attenuated human rotavirus (HRV) vaccine, Rotarix™
or Rotarix™ liquid formulation (oral suspension or
prefilled syringe) (Amendment 4: 23 February 2012)

eTrack number and abbreviated title	111700 (Rota-070 PMS)		
Date of protocol	Final: 11 April 2008		
Amendment 1	Final: 09 May 2008		
Amendment 2	Final: 13 October 2008		
Amendment 3	Final: 10 February 2010		
Amendment 4	Final: 23 February 2012		
Title	Safety of GlaxoSmithKline Biologicals' oral live attenuated human rotavirus vaccine, Rotarix TM or <i>RotarixTM liquid formulation (oral suspension or</i> <i>prefilled syringe)</i> when administered according to the prescribing information in Korea. (Amendment 4: 23 February 2012)		
Detailed Title	Open, multi-centric, post-marketing surveillance (PMS) to monitor the safety of GlaxoSmithKline (GSK) Biologicals' oral live attenuated human rotavirus (HRV) vaccine, Rotarix TM or Rotarix TM <i>liquid formulation (oral suspension or prefilled</i> <i>syringe)</i> when administered according to the prescribing information in Korea. (Amendment 4: 23 February 2012)		
Co-ordinating author	PPD Scientific Writer		
Contributing authors	• Bio Medical Director, Korea		
	• PPD Medical Director, Clinical R&D and Medical Affairs, Korea		
	• PPD Senior Manager, GCRD,		
	Rotavirus vaccine		

Continued on the next page

		Amendment
eTrack number and abbreviated title	111700 (Rota-07	0 PMS)
Date of protocol	Final: 11 April 20	008
Amendment 1	Final: 09 May 20	08
Amendment 2	Final: 13 October	r 2008
Amendment 3	Final: 10 Februar	y 2010
Amendment 4	Final: 23 Februar	y 2012
Detailed Title	(PMS) to monitor (GSK) Biological rotavirus (HRV) <i>liquid formulatio</i> <i>syringe)</i> when ad	ric, post-marketing surveillance r the safety of GlaxoSmithKline ls' oral live attenuated human vaccine, Rotarix TM or Rotarix TM on (oral suspension or prefilled ministered according to the mation in Korea. (Amendment 4: 23
	PPD .	Director, GCRD, Rotavirus
	vaccine	
	● PPD	Associate Biometrician, CDOC-B
	● PPD	Manager Biometrics, CDOC-B
	● PPD	Director – GCRD – Biometrics
	• PPD M	ledical Consultant, Korea

- PPD Clinical Research Project Leader, Korea
- PPD Central Study Co-ordinator,
 GCRD
- PPD Senior Manager, Post Marketing Surveillance, Safety
- PPD Clinical Development Manager, GCRD
- PPD Global Study Manager, GCRD
 - PPD Project Leader, Korea

Medical Advisor, Korea

GSK Biologicals' Protocol DS V 12.5

Copyright 2008 the GlaxoSmithKline group of companies. All rights reserved. Unauthorized copying or use of this information is prohibited.

PPD

.

Protocol Amendment 4 Sponsor Signatory Approval

eTrack number and abbreviated title	111700 (Rota-070 PMS)
Amendment 4	Final: 23 February 2012
Detailed Title	Open, multi-centric, post-marketing surveillance (PMS) to monitor the safety of GlaxoSmithKline (GSK) Biologicals' oral live attenuated human rotavirus (HRV) vaccine, Rotarix [™] or Rotarix [™] liquid formulation (oral suspension or prefilled syringe) when administered according to the prescribing information in Korea. (Amendment 4: 23 February 2012)
Sponsor signatory:	Dr. Emilio F. Ledesma, Vice President, Clinical R&D and Medical Affairs, Asia Pacific
Signature:	
Date:	

For internal use only

Protocol Amendment 4 Rationale

Amendment number:	Amendment 4
Rationale/background for	changes:
The protocol has been amer	ided to reflect the two new vaccine presentations that have
been launched in Korea. Th	e current PMS will thus collect safety information from
subjects who have received	either Rotarix TM or Rotarix TM liquid formulation (oral
suspension or prefilled syrir	nge).

Protocol Amendment 4 Investigator Agreement

I agree:

- To assume responsibility for the proper conduct of the study at this site.
- To conduct the study in compliance with this protocol, any mutually agreed future protocol amendments, and with any other study conduct procedures provided by GlaxoSmithKline Biologicals (GSK Biologicals).
- To ensure that all persons assisting me with the study are adequately informed about the GSK Biologicals' RotarixTM and other study-related duties and functions as described in the protocol.
- Not to implement any changes to the protocol without agreement from the sponsor and prior review and written approval from the Institutional Review Board (IRB) or Independent Ethics Committee (IEC) (except where site does not have IRB/IEC according to APPOL and LSOP), except where necessary to eliminate an immediate hazard to the subjects, or where permitted by all applicable regulatory requirements (for example, for administrative aspects of the study).
- That I am thoroughly familiar with the appropriate use of the vaccine, as described in this protocol, and any other information provided by the sponsor, including, but not limited to, the following: the current Investigator's Brochure (IB) or equivalent document, IB supplement (if applicable), prescribing information (in the case of a marketed vaccine).
- That I am aware of, and will comply with, applicable ethical practices and all applicable regulatory requirements.
- That I have been informed that certain regulatory authorities require the sponsor to obtain and supply, as necessary, details about the investigator's ownership interest in the sponsor or the investigational product, and more generally about his/her financial ties with the sponsor. GSK Biologicals will use and disclose the information solely for the purpose of complying with regulatory requirements.

Hence I:

• Agree that GSK Biologicals may disclose any information it has about such ownership interests and financial ties to regulatory authorities.

eTrack number and abbreviated title	111700 (Rota-070 PMS)
Amendment 4	Final: 23 February 2012
Detailed Title	Open, multi-centric, post-marketing surveillance (PMS) to monitor the safety of GlaxoSmithKline (GSK) Biologicals' oral live attenuated human rotavirus (HRV) vaccine, Rotarix [™] or Rotarix [™] <i>liquid formulation (oral suspension or prefilled</i> <i>syringe)</i> when administered according to the prescribing information in Korea. (Amendment 4: 23 February 2012)
Investigator name:	

Investigator signature:

Date:

For internal use only

Synopsis

Detailed Title	Open, multi-centric, post-marketing surveillance (PMS) to monitor the safety of GlaxoSmithKline (GSK) Biologicals' oral live attenuated human rotavirus (HRV) vaccine, Rotarix [™] or Rotarix [™] liquid formulation (oral suspension or prefilled syringe) when administered according to the prescribing information in Korea. (Amendment 4: 23 February 2012)
Indication/PMS population	Prevention of gastroenteritis (GE) caused by rotavirus (RV) (serotype G1P[8], G3P[8], G4P[8], G9P[8]) in infants from the age of 6 weeks.
Rationale	GSK Biologicals' vaccine, Rotarix [™] (lyophilised formulation) was registered in Korea in March 2008. Rotarix [™] liquid formulation (oral suspension) was registered in Korea in January 2011 while Rotarix [™] liquid formulation (prefilled syringe) was registered in December 2011. Following the vaccine registration, safety information on the use of all the Rotarix [™] presentations is required as per the regulations of the Korean Food and Drugs Administration (KFDA) in at least 3000 evaluable Korean infants. (Amendment 4: 23 February 2012)
Objective	To assess the safety of Rotarix TM or Rotarix TM liquid formulation (oral suspension or prefilled syringe) in infants when administered according to the prescribing information in Korea. (Amendment 4: 23 February 2012)
PMS design	• PMS design: Open-label, non-comparative, multi-centre PMS in Korea.
	 Vaccination schedule: Two doses of RotarixTM or RotarixTM liquid formulation (oral suspension or prefilled syringe) will be administered orally as per the prescribing information in Korea.
	 First vaccination will be given to infants from the age of 6 weeks.
	 Second vaccination will be given at least 4 weeks after Dose 1. Administration of Dose 2 is preferably given before the age of 16 weeks.
	Two doses of Rotarix [™] or Rotarix [™] liquid formulation (oral suspension or prefilled syringe) should be given before 24 weeks of age.
	• Control: None.

- Type of PMS: Self-contained.
- Two visits are recommended as follows:

	 Visit 1: RotarixTM or RotarixTM liquid formulation (oral suspension or prefilled syringe) vaccination, subjects will be allowed to receive concomitant vaccinations.
	 Visit 2: RotarixTM or RotarixTM liquid formulation (oral suspension or prefilled syringe) vaccination, subjects will be allowed to receive concomitant vaccinations.
	 Recording of AEs from Day 0 to Day 30 using the diary card after each dose of Rotarix[™] or Rotarix[™] liquid formulation (oral suspension or prefilled syringe).
	• Recording of serious adverse events (SAEs) during the entire PMS period.
	• Duration of the PMS: The intended duration of the PMS, per infant, will be approximately 3 months.
	• Data collection: Standardised hard copy case report form (CRF). (Amendment 4: 23 February 2012)
Number of subjects	As per the KFDA requirements, safety information from at least 3000 evaluable infants are needed <i>for this PMS study</i> . (Amendment 4: 23 February 2012)
Endpoints	 Occurrence of AEs during the 31-day (Day 0 – Day 30) follow-up period after each vaccine dose according to Medical Dictionary for Regulatory Activities (MedDRA) classification.
	• Occurrence of SAEs during the entire PMS period.

TABLE OF CONTENTS

PAGE

SYI	NOPSIS	7	
LIST OF ABBREVIATIONS			
GL	OSSARY OF TERMS	14	
1.	INTRODUCTION 1.1. Background 1.2. Rationale for the Post Marketing Surveillance (PMS)	16	
2.	OBJECTIVE	17	
3.	PMS DESIGN OVERVIEW	18	
4.	PMS COHORT		
5.	 CONDUCT OF PMS. 5.1. Ethics and regulatory considerations	20 20 22 22 22 22 22 24	
6.	INDICATION AND DOSAGE/ADMINISTRATION. 6.1. Rotarix. 6.2. Dosage and administration	26 27 27 27 27 27 27 27 27 27	
7.	HEALTH ECONOMICS	28	
8.	 ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS	28	

		8.2.1.	Disease-related events or outcomes not qualifying as serious adverse events	30
	8.3.	Lack of	efficacy	
	8.4.			
	0.4.	 8.4. Clinical laboratory parameters and other abnormal assessments qualifying as adverse events and serious adverse events 8.5. Time period, frequency, and method of detecting adverse events and serious adverse events 		
	85			
	0.5.			
	8.6.		ng adverse events and serious adverse events	
	0.0.	8.6.1.	Assessment of intensity	
		8.6.2.		
		8.6.3.		
	8.7.		p of adverse events and serious adverse events and	
	0.7.		nent of outcome	35
	8.8.		reporting of serious adverse events to GSK Biologicals	
	0.0.	8.8.1.	Time frames for submitting serious adverse event reports	
		0.0.1.	to GSK Biologicals	36
		8.8.2.	Completion and transmission of serious adverse event	
		0.0.2.	reports to GSK Biologicals	36
	8.9.	Regulato	bry reporting requirements for serious adverse events	
	8.10.	Post-PM	IS adverse events and serious adverse events	
	8.11.		ICY	
	8.12.		nt of adverse events	
9.	SUBJE	ECT COM	IPLETION AND WITHDRAWAL	
	9.1.	Subject	completion	
	9.2.		withdrawal	
		9.2.1.		
		9.2.2.		
10.	DATA	EVALUA	TION: CRITERIA FOR EVALUATION OF OBJECTIVES	39
	10.1.	Endpoin	ts	39
	10.2.		ed sample size	
	10.3.	Cohorts	to be evaluated	
		10.3.1.	Total Vaccinated cohort	
	10.4.	Derived	and transformed data	40
	10.5.		alyses	
		10.5.1.	Analysis of demographics/baseline characteristics	
		10.5.2.		
	10.6.	Planned	interim analysis	41
11.	ADMIN	IISTRATI	VE MATTERS	42
12.	REFE	RENCES		43

LIST OF TABLES

PAGE

Table 1	List of PMS procedures	23
Table 2	Composition of GSK Biologicals' HRV vaccine	26
Table 3	Reporting periods for adverse events and serious adverse events	31
Table 4	Exact two-sided 95% CI for a sample size of 3000 subjects	

LIST OF APPENDICES

PAGE

Appendix A	Administrative Matters	45
Appendix B	Overview of the Recruitment Plan	50
Appendix C	Prescribing Information	51
Appendix D	Amendments and Administrative Changes to the Protocol	52

List of Abbreviations

AE	Adverse event
CCID ₅₀	Median cell culture infective dose (quantity of virus causing infection in 50% of exposed cells)
CI	Confidence Interval
CRF	Case Report Form
GAVI	Global Alliance for Vaccines and Immunisations
GCP	Good Clinical Practice
GE	Gastroenteritis
GSK	GlaxoSmithKline
HRV	Human Rotavirus
ICF	Informed Consent Form
ICH	International Conference on Harmonisation
IEC	Independent Ethics Committee
IRB	Institutional Review Board
KFDA	Korean Food and Drugs Administration
MedDRA	Medical Dictionary for Regulatory Activities
РАТН	Program for Appropriate Technology in Health
PMS	Post Marketing Surveillance
RV	Rotavirus
SAE	Serious Adverse Events
SOP	Standard Operating Procedure
WHO	World Health Organisation

Glossary of Terms

Adverse event:	Any untoward medical occurrence, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
	An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. For marketed medicinal products, this also includes failure to produce expected benefits (i.e. lack of efficacy), abuse or misuse.
Diarrhoea:	Passage of three or more looser than normal stools (loose or watery stools), within a day.
Eligible:	Qualified for enrolment into the PMS based upon strict adherence to inclusion/exclusion criteria.
eTrack:	GSK's clinical trials tracking tool.
Expected adverse event:	The presence/occurrence/intensity of an adverse event that is expected from the infant or an observer during the post-vaccination follow-up period as described in the locally approved prescribing information.
Gastroenteritis:	Diarrhoea with or without vomiting.
Medical Monitor:	An individual medically qualified to assume the responsibilities of the sponsor (GSK Biologicals) especially in regards to the ethics, clinical safety of a PMS and the assessment of adverse events.
Protocol amendment:	ICH defines a protocol amendment as: "A written description of a change(s) to or formal clarification of a protocol." GSK Biologicals further details this to include a change to an approved protocol that affects the safety of subjects, scope of the investigation, PMS design, or scientific integrity of the PMS.
Protocol administrative change:	A protocol administrative change addresses changes to only logistical or administrative aspects of the PMS. N.B. Any change that falls under the definition of a protocol amendment (e.g. a change that affects the safety of subjects, scope of the investigation, PMS design, or scientific integrity of the PMS) MUST be prepared as an amendment to the protocol.

Site Monitor:An individual assigned by the sponsor who is responsible for assuring proper conduct of the PMS at one or more investigational sites.Study Monitor:An individual assigned by the sponsor who is responsible for assuring proper conduct of a PMS.Subject:Term used throughout the protocol to denote an individual whose parents/guardians have been contacted in order to participate in the PMS.Subject number:A unique number identifying a subject, assigned to each subject consenting to participate in the PMS.Unexpected adverse event:Any adverse event that is not reflected in the locally approved prescribing information.Vomiting:One or more episodes of forceful emptying of partially digested stomach contents ≥ 1 hour after feeding within a day.		Amendment 4
for assuring proper conduct of a PMS.Subject:Term used throughout the protocol to denote an individual whose parents/guardians have been contacted in order to participate in the PMS.Subject number:A unique number identifying a subject, assigned to each subject consenting to participate in the PMS.Unexpected adverse event:Any adverse event that is not reflected in the locally approved prescribing information.Vomiting:One or more episodes of forceful emptying of partially digested stomach contents ≥ 1 hour after feeding within a	Site Monitor:	for assuring proper conduct of the PMS at one or more
individual whose parents/guardians have been contacted in order to participate in the PMS.Subject number:A unique number identifying a subject, assigned to each subject consenting to participate in the PMS.Unexpected adverse event:Any adverse event that is not reflected in the locally approved prescribing information.Vomiting:One or more episodes of forceful emptying of partially digested stomach contents ≥ 1 hour after feeding within a	Study Monitor:	
subject consenting to participate in the PMS.Unexpected adverse event:Any adverse event that is not reflected in the locally approved prescribing information.Vomiting:One or more episodes of forceful emptying of partially digested stomach contents ≥ 1 hour after feeding within a	Subject:	individual whose parents/guardians have been contacted
event:approved prescribing information.Vomiting:One or more episodes of forceful emptying of partially digested stomach contents ≥ 1 hour after feeding within a	Subject number:	
digested stomach contents ≥ 1 hour after feeding within a	1	5
	Vomiting:	digested stomach contents ≥ 1 hour after feeding within a

1. INTRODUCTION

Rotavirus (RV) is associated with acute gastroenteritis (GE) in infants and is responsible for approximately half a million deaths in children in developing countries [Glass, 2006; Steele, 2003]. High mortality due to RV is evident in developing countries such as Africa, Latin America and the Asian subcontinent. RV is prevalent in Asia all year around causing about 45% of the diarrhoeal hospitalisations in children less than 5 years of age [Phua, 2006]. Previous studies conducted revealed that RV was responsible for 46% of 4668 hospitalisations among Korean children with acute GE. Also, RV was the most prevalent etiologic agent causing severe diarrhoeal illness among children aged 6-24 months, which accounted for 84% of all cases [Seo, 2000].

The large global health burden due to RV disease in both developed and developing countries prompted the development of RV vaccines since only non-specific symptomatic therapies are available. In fact, in recent years, many international organisations such as World health Organisation (WHO), the Global Alliance for Vaccines and Immunisations (GAVI) and the Children's Vaccine Program at the Program for Appropriate Technology in Health (PATH) have identified RV vaccines as a priority for development. [Fischer, 2007; WHO, 2007; Glass, 2005; Bresse, 2004].

1.1. Background

GSK Biologicals has produced an oral live attenuated human rotavirus (HRV) vaccine [Rotarix[™]] containing the RIX4414 vaccine strain of G1P1A P[8] specificity developed from the parent 89-12 vaccine strain with proven efficacy [Bernstein, 1998; Bernstein, 1999; Bernstein, 2002].

Rotarix[™] has been evaluated in Phase I – III clinical studies in Asia (including Korea), Africa, Europe, Latin America and North America.

Clinical trials conducted with RotarixTM showed that two doses of the vaccine were immunogenic, well tolerated, and effective against RV GE hospitalisations, severe RV GE and any RV GE caused by several circulating strains [Ruiz-Palacios, 2006; Salinas, 2005; Vesikari, 2006]. In a large phase III clinical trial in Latin America, vaccine efficacy against severe RV GE was 84.7% [95% CI: 71.7%; 92.4%] (p-value <0.001) and vaccine efficacy against serotype-specific (G1P[8]) severe RV GE (with a score of \geq 11 on the Vesikari scale) was 90.8% [95% CI: 70.5%; 98.2%]. This study also demonstrated that the vaccine was not associated with an increased risk of intussusception during 31 days after administration of either of the two doses as compared to the placebo. The overall serious adverse event (SAE) profile of the vaccine was similar to the placebo [Ruiz-Palacios, 2006].

A phase III trial was conducted in Korea to assess the reactogenicity and immunogenicity profile of the vaccine. Two doses of the vaccine were shown to be well-tolerated, immunogenic (66.7% [95% CI: 51.6%; 79.6%]) with a good safety profile [Jung Soo, 2007].

In a phase III trial conducted in the European Union, the vaccine efficacy during the first efficacy follow-up period (2 weeks post-dose 2 up to the end of the first RV season) was 95.8% [95%CI: 89.6%; 98.7%] against severe RV GE. Vaccine efficacy was 90.4% [95% CI: 85.1%; 94.1%] against severe RV GE in the combined efficacy period (2 weeks post-dose 2 through the two consecutive RV seasons following vaccinations). For increasing disease severity with Vesikari scores between 11 and 20, vaccine efficacy was increasingly higher, reaching 100% against more severe RV GE (Vesikari score ≥ 17 points) The HRV vaccine was highly protective against any and severe RV GE caused by G1, G3, G4 and G9 strains. Vaccine efficacy against severe RV GE caused by G2 serotype was 85.5% [95% CI: 24.0%; 98.5%] in the combined efficacy period [Vesikari, 2007].

Co-administration of routine childhood vaccines with two doses of Rotarix[™] elicited excellent vaccine take and were well tolerated in studies conducted in United States, Canada, Singapore, Latin America and Europe [Dennehy, 2005; Phua, 2005; Salinas, 2005; Vesikari, 2006]. The lyophilised formulation of Rotarix[™] is currently licensed in over 100 countries worldwide and has been recommended for inclusion in National Immunisation programs in Brazil, Venezuela, Ecuador, Panama, El Salvador, Mexico and Australia.


1.2. Rationale for the Post Marketing Surveillance (PMS)

GSK Biologicals' vaccine, RotarixTM (lyophilised formulation) was registered in Korea in March 2008. RotarixTM liquid formulation (oral suspension) was registered in Korea in January 2011 while RotarixTM liquid formulation (prefilled syringe) was registered in December 2011. Following the vaccine registration, safety information on the use of all the RotarixTM presentations is required as per the regulations of the Korean Food and Drugs Administration (KFDA) in at least 3000 evaluable Korean infants. (Amendment 4: 23 February 2012)

2. OBJECTIVE

To assess the safety of Rotarix[™] or Rotarix[™] liquid formulation (oral suspension or prefilled syringe) in infants when administered according to the prescribing information in Korea. (Amendment 4: 23 February 2012)

Refer to Section 10.1 for definition of the endpoints.



3. PMS DESIGN OVERVIEW

N: Number of subjects planned to be enrolled.

Infants who have received a dose of the vaccine prior to the start of the PMS will have only one visit followed by the phone contact.

PMS conclusion: An infant's parent/guardian who will be contacted to provide details of any AEs experienced by the infant 30 days after the infant receives the last vaccination or an infant for whom diary card transcription into CRF will be been done through phone contact is considered to have completed the PMS.

- PMS design: Open-label, non-comparative, multi-centre PMS in Korea.
- Vaccination schedule: Two doses of Rotarix[™] or Rotarix[™] liquid formulation (oral suspension or prefilled syringe) will be administered orally as per the prescribing information in Korea.
 - First vaccination will be given to infants from the age of 6 weeks.
 - Second vaccination will be given at least 4 weeks after Dose 1. Administration of Dose 2 is preferably given before the age of 16 weeks.

Two doses of Rotarix[™] or Rotarix[™] liquid formulation (oral suspension or prefilled syringe) should be given before 24 weeks of age.

- Control: None.
- Type of PMS: Self-contained.
- Two visits are recommended as follows:
 - Visit 1: Rotarix[™] or Rotarix[™] liquid formulation (oral suspension or prefilled syringe) vaccination, subjects will be allowed to receive concomitant vaccinations.
 - − Visit 2: RotarixTM or RotarixTM liquid formulation (oral suspension or prefilled syringe) vaccination, subjects will be allowed to receive concomitant vaccinations.
- Recording of AEs from Day 0 to Day 30 using diary cards after each dose of RotarixTM or RotarixTM liquid formulation (oral suspension or prefilled syringe).

- Recording of SAEs during the entire PMS period.
- Duration of the PMS: The intended duration of the PMS, per infant, will be approximately 3 months.
- Refer to Appendix B for details of the recruitment plan.
- Data collection: Standardised hard copy case report form (CRF).

(Amendment 4: 23 February 2012)

4. PMS COHORT

4.1. Number of subjects / centres

As per the KFDA requirements, safety information from at least 3000 evaluable infants are needed *for this PMS study*.

Infants will be recruited from the age of 6 weeks in this multi-centre PMS.

Details of recruitment at each centre, including any criteria for termination of enrolment at a particular centre, will be discussed in the recruitment plan, which is summarised in Appendix B (Amendment 4: 23 February 2012)

4.2. Inclusion criteria

Infants who satisfy the following criteria can enter the PMS:

- Infants who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol (e.g. completion of the diary cards) should be enrolled in the PMS.
- A male or female infant from the age of 6 weeks at the time of the first vaccination. (Note: Two doses of the RotarixTM or RotarixTM liquid formulation (oral suspension or prefilled syringe) vaccine should be completed by the age of 24 weeks). (Amendment 4: 23 February 2012)
- Written informed consent obtained from the parent or guardian of the infant.

4.3. Exclusion criteria for enrolment

At the time of PMS entry, the contraindications and precautions of use indicated in the prescribing information should be checked and the infant must not be included in the PMS if there is any contraindication. Any changes in the locally approved Prescribing Information must be implemented immediately.

4.4. Elimination criteria during the PMS

Not applicable.

4.5. Contraindications to subsequent vaccination

Refer to the prescribing information for contraindications. Any changes in the locally approved Prescribing Information must be implemented immediately.

4.6. Warnings and Precautions

Refer to the prescribing information for warnings and precautions. Any changes in the locally approved Prescribing Information must be implemented immediately.

5. CONDUCT OF PMS

5.1. Ethics and regulatory considerations

The PMS will be conducted according to the local rules and regulations of the country (KFDA) and relevant GSK SOPs/Policies and Guidance.

Submission of the protocol and any protocol amendments to regulatory agencies will occur in accordance with local regulatory requirements and relevant GSK SOPs/Policies and Guidance. If needed, this protocol/protocol amendment will be submitted to an Institutional Review Board (IRB).

Independent Ethics Committee/Institutional Review Board (IEC/IRB) approval has to be obtained prior to study start. If the regulatory authority and/or IEC/IRB advise that PMS studies do not need ethical review this must be documented. In any event, submission to an IEC/IRB in all institutions where IEC/IRB are available must be carried out and documented.

5.1.1. Informed consent

In obtaining and documenting informed consent, the investigator should comply with the applicable regulatory requirement(s), and to the applicable ethical principles. Prior to the beginning of the PMS, the investigator should have, if applicable, the IRB written approval/favourable opinion of the written informed consent form and any other written information to be provided to the participating infants' parents/guardians, if applicable.

Freely given informed consent should be obtained from every infants' parents/guardians for the collection of personal and safety information prior to or post vaccination.

Information should be given in both oral and written form whenever possible and as deemed appropriate by the IRB.

An investigator or designate will describe the protocol to potential infants' parents/guardians face to face. The Informed Consent Form may be read to the infants' parents/guardians, but, in any event, the investigator or designate shall give the infants' parents/guardians ample opportunity to inquire about details of the PMS and ask any questions before dating and signing the Informed Consent Form.

While informed consent information can be presented to groups at an initial information session, each infant's parents/guardians must be given the opportunity to individually pose questions to the investigator or designate prior to the infant's parents/ guardians dating and signing the Informed Consent Form.

Informed Consent Form must be in a language fully comprehensible to the prospective infants' parents/guardians. Informed consent shall be documented by the use of a written consent form (when applicable, approved by the IRB) and signed and dated by the parents/guardians and by the person who conducted the informed consent discussion. The signature confirms the consent is based on information that has been understood. All illiterate individuals will have the PMS, the Informed Consent Form explained to them point by point by the interviewer in the presence of an impartial witness. The witness will personally sign and date the consent form.

Each infant's signed informed consent form must be kept on file by the investigator for possible inspection by Regulatory Authorities and/or GSK Biologicals' professional and Regulatory Compliance persons. The parents/guardians should receive a copy of the signed and dated written informed consent form and any other written information provided to the infants' parents/guardians, and should receive copies of any signed and dated consent form updates. Any amendments to the written information will be provided to infants' parents/guardians.

Both the informed consent discussion and the written informed consent form and any other written information to be provided to the infants' parents/guardians should include explanations of the following:

- a. This is a regulatory mandated PMS.
- b. The purpose of the PMS.
- c. The PMS procedures to be followed.
- d. The infant's parents'/guardians' responsibilities.
- e. The reasonably foreseeable risks or inconveniences to the infants.
- f. The reasonable expected benefits.
- g. That the infants' participation in the PMS is voluntary and infants' parents/guardians may refuse to participate or withdraw from the PMS, at any time, without penalty or loss of benefits to which subjects are otherwise entitled.
- h. That the monitor(s), the auditor(s), the IRB, and the regulatory authority(ies) will be granted direct access to the infant's original medical records for verification of PMS procedures and/or data, without violating the confidentiality of infant, to the extent permitted by the applicable laws and regulations and that, by signing a written informed consent, the infant's parents/guardians is authorising such access.
- i. That records identifying infants will be kept confidential and, to the extent permitted by the applicable laws and/or regulations, will not be made publicly available. If the results of the PMS are published, infants' identity will remain confidential.
- j. The approximate number of infants involved in the PMS.

k. The expected duration of a infant's participation in the PMS.

GSK Biologicals will prepare a model Informed Consent Form which will embody all the elements described above. While it is strongly recommended that this model document be followed as closely as possible, the informed consent requirements given in this document are not intended to pre-empt any local regulations which require additional information to be disclosed for informed consent to be legally effective. Clinical judgement, local regulations and requirements should guide the final structure and content of the document.

The investigator has the final responsibility for the final presentation of Informed Consent Form, respecting the mandatory requirements of local regulations. The consent form generated by the investigator with the assistance of the sponsor's representative, must be approved (along with the protocol, and any other necessary documentation) by the IRB (if applicable) and be acceptable to GSK Biologicals.

5.2. General PMS aspects

All concomitant vaccinations according to local practice are allowed during the PMS and administration of these should be documented in the CRF.

5.3. Subject identification

Subject numbers will be assigned sequentially to infants whose parents/guardians have given consent to participate in the PMS, according to the range of subject numbers allocated to each PMS centre.

5.4. Outline of PMS procedures

The outline of PMS procedures is presented in Table 1.

Age	From the a	ge of 6 weeks		
Visit	VISIT 1	Diary Card Return*	VISIT 2§	Diary Card Return*
Timing	Day 0	Day 30 or after	At least 4 weeks after Dose 1	Day 30 or after
Informed consent	٠			
Check inclusion criteria	•			
Check exclusion criteria	•			
Check contraindications	•		•	
Medical history	•			
Physical examination	•		0	
Recording of body temperature	•		•	
Recording of previous Rotarix [™] vaccination	•			
Vaccination	•		•	
Recording of AEs occurring from Day 0 to Day 30 after vaccination, by infants' parents/guardians on diary cards	•	•	•	•
Return of diary cards		•		•
Record any concomitant medication/vaccination	٠	•	•	•
Reporting of Serious Adverse Events	•	•	•	•
PMS Conclusion		۹		•

Table 1List of PMS procedures

• is used to indicate a PMS procedure that requires documentation in the individual CRF.

• is used to indicate a PMS procedure that does not require documentation in the individual CRF.

*Diary card will be returned by parents/guardians of infants on Day 30 or after. If the same is not returned, the investigator will make a phone contact to record all AEs in the medical record and then transcribe the information into the CRF.

§Visit 2 will be omitted only for those infants who have received one dose of *Rotarix*[™] or *Rotarix*[™] *liquid formulation (oral suspension or prefilled syringe)* prior to the start of the PMS and have received the second dose of the vaccine at Visit 1 or if the investigator confirms that the infant will not be vaccinated in the same centre. The infants who have received a dose of the vaccine prior to the start of the PMS will have only one visit followed by the phone contact and the post-Dose 2 data collected will be recorded under the Visit 2 section of the CRF. ¶If infants receive the 2nd dose at Visit 1 or if the investigator confirms that infants will not be vaccinated in the same centre. (Amendment 4: 23 February 2012)

It is the investigator's responsibility to ensure that the intervals between visits/contacts are followed as closely as possible. There should be an interval of at least 4 weeks between two doses. Administration of the second dose is preferably given before the age of 16 weeks and should be completed by the age of 24 weeks.

However, if circumstances dictate other intervals, this will not lead to the exclusion from the analysis. The date of the previous visit serves as the reference date for intervals between study visits.

5.5. Detailed description of visits

Visit 1 (Day 0): RotarixTM or RotarixTM liquid formulation (oral suspension or prefilled syringe) vaccination (Amendment 4: 23 February 2012)

- Written informed consent obtained from parents/guardians of the infant.
- Checking inclusion/exclusion criteria (See sections 4.2 and 4.3).
- Checking of contraindications to vaccination.
- Recording of medical history and physical examination.
- Recording of body temperature (measured by oral/axillary/tympanic route).
- Record previous history of any RotarixTM or RotarixTM liquid formulation (oral suspension or prefilled syringe) vaccine administration (if applicable)
- Vaccination:
 - One dose of Rotarix[™] or Rotarix[™] liquid formulation (oral suspension or prefilled syringe) will be administered orally according to instructions specified in section 6.2.
 - Infants will be allowed to receive concomitant vaccinations.

The vaccinees will be observed closely for at least 30 minutes, with appropriate medical treatment readily available in case of a rare anaphylactic reaction following the administration of vaccines.

• Diary cards will be provided to the parents/guardians of all infants to record information on AEs occurring on the day of Dose 1 and the following 30 days.

The infants' parents/guardians will be instructed to contact the investigator immediately should the infant manifest any signs or symptoms they perceive as serious. The parents/guardians should be instructed to return the completed diary card to the investigator 30 days following Dose 1, at the next contact or by mail.

- Recording of any prior or concomitant medication or vaccination administered in the CRF.
- Reporting of SAEs.

Day 30 (Return of diary cards/Phone Contact)

- Recording of all AEs occurring from Day 0 Day 30 after Dose 1.
- Parents/guardians will be contacted by phone if the investigator does not receive the diary cards.
- The investigator will verify the diary card and transcribe the information into the appropriate sections of the CRF, in English.
- Recording of concomitant medication/vaccination administered in the CRF.

- Recording of SAEs.
- PMS conclusion for infants who have received one dose of the vaccine prior to the start of the PMS and have received the second dose of the vaccine at Visit 1 or if the investigator confirms that the infant will not be administered the second dose at the same centre.

Visit 2: RotarixTM or RotarixTM liquid formulation (oral suspension or prefilled syringe) vaccination (Amendment 4: 23 February 2012)

- Checking of contraindications to vaccination.
- Recording of body temperature (measured by oral/axillary/tympanic route).
- Vaccination:
 - One dose of Rotarix[™] or Rotarix[™] liquid formulation (oral suspension or prefilled syringe) will be administered orally according to instructions specified in section 6.2.
 - Infants will be allowed to receive concomitant vaccinations.

The vaccinees will be observed closely for at least 30 minutes, with appropriate medical treatment readily available in case of a rare anaphylactic reaction following the administration of vaccines.

- Diary cards will be provided to the parents/guardians of all subjects to record information on AEs occurring on the day of Dose 2 and the following 30 days.
- The infants' parents/guardians will be instructed to contact the investigator immediately should the infant manifest any signs or symptoms they perceive as serious. The parents/guardians should be instructed to return the completed diary card to the investigator 30 days following Dose 2, at the next contact or by mail.
- Recording of any concomitant medication or vaccination administered in the CRF.
- Reporting of SAEs.

Day 30 after Visit 2 (Return of diary cards/Phone Contact)

- Recording of all AEs occurring from Day 0 Day 30 after Dose 2.
- Parents/guardians will be contacted by phone if the investigator does not receive the diary cards.
- The investigator will verify the diary card and transcribe the information into the appropriate sections of the CRF, in English.
- Recording of concomitant medication/vaccination administered in the CRF.
- Recording of SAEs.
- PMS conclusion.

5.6. Sample handling and analysis

Not applicable.

6. INDICATION AND DOSAGE/ADMINISTRATION

6.1. Rotarix

RotarixTM or RotarixTM liquid formulation (oral suspension or prefilled syringe) to be used in this PMS has been developed and manufactured by GSK Biologicals. (Amendment 4: 23 February 2012)

The Quality Control Standards and Requirements for the vaccine are described in separate release protocols and the required approvals have been obtained.

Commercial vaccines are assumed to comply with the specifications given in the manufacturer's Summary of Product Characteristics.

Table 2 presents the detailed formulation of the HRV vaccine.

Table 2 Composition of GSK Biologicals' HRV vaccine

Composition	Compound Objective	Ingredient	Reference	Quantity
Glass container	Active substance	Live attenuated human rotavirus (RIX4414 strain)	GSK Monograph	not less than 10 ^{6.0} CCID ₅₀

CCID₅₀: median Cell Culture Infective Dose (quantity of virus causing infection in 50% of exposed cells)

6.2. Dosage and administration

RotarixTM or RotarixTM liquid formulation (oral suspension) or RotarixTM liquid formulation (prefilled syringe) will be administered twice orally as per the prescribing information in Korea.

- First vaccination will be given to infants aged 6 weeks and above.
- Second vaccination will be given at least 4 weeks after Dose 1. Administration of Dose 2 is preferably given before the age of 16 weeks.

Two doses of RotarixTM or RotarixTM liquid formulation (oral suspension or prefilled syringe) should be given before 24 weeks of age.

The vaccinees will be observed closely for at least 30 minutes following the administration of vaccines, with appropriate medical treatment readily available in case of a rare anaphylactic reaction.

Refer to the prescribing information for details on the dosage and administration of the vaccine. (Amendment 4: 23 February 2012)

6.3. Storage

The vaccine must be stored in an airtight container at the defined temperature range (i.e. +2 to +8°C). It should be protected from light.

6.4. Subject number allocation

Target enrolment will be **at least** 3000 evaluable infants. All infants enrolled into the PMS will receive RotarixTM or RotarixTM liquid formulation (oral suspension or prefilled syringe) vaccine in routine clinical practice settings. (Amendment 4: 23 February 2012)

Subject numbers will be allotted in a sequential manner.

6.5. Method of blinding and breaking the blind

Not applicable.

6.6. Replacement of unusable vaccine doses

Not applicable. The vaccine will be purchased by the infant's parent/guardian.

6.7. Packaging

Not applicable.

6.8. Vaccine accountability

Not applicable.

6.9. Concomitant medication/treatment

At each visit/contact, the investigator should question the infant's parents/guardian about any medication(s) taken.

All concomitant medication, with the exception of vitamins and/or dietary supplements, administered at ANY time during the period starting with administration of each dose of RotarixTM or RotarixTM liquid formulation (oral suspension or prefilled syringe) after enrolling into the PMS up to the end of the follow-up period for AEs are to be recorded with generic name of the medication (trade names are allowed for combination drugs, i.e. multi-component drugs), medical indication, total daily dose, route of administration, start and end dates of treatment. (Amendment 4: 23 February 2012)

Any vaccine administered in the period beginning 30 days preceding each dose of RotarixTM or RotarixTM liquid formulation (oral suspension or prefilled syringe) and ending one month (minimum 30 days) after is to be recorded with trade name, route of administration and date(s) of administration. (Amendment 4: 23 February 2012)

A prophylactic medication is a medication administered in the absence of ANY symptom and in anticipation of a reaction to the vaccination (e.g. an anti-pyretic is considered to be prophylactic when it is given in the absence of fever [Oral temperature <37.5°C/Axillary temperature <37.5°C/Tympanic temperature on oral setting <37.5°C] and any other symptom, to prevent fever from occurring). Any concomitant medication administered prophylactically in anticipation of reaction to the vaccination must be recorded in the CRF with generic name of the medication (trade names are allowed for combination drugs only), total daily dose, route of administration, start and end dates of treatment and coded as 'Prophylactic'.

During the period starting with administration of each dose of Rotarix[™] or Rotarix[™] liquid formulation (oral suspension or prefilled syringe) up to the end of the follow-up period for AEs, concomitant medication administered for the treatment of an AE must be recorded in the CRF with generic name of the medication (trade names are allowed for combination drugs only), medical indication (including which AE), total daily dose, route of administration, start and end dates of treatment. Similarly, concomitant medication administered for the treatment of an SAE, at any time, must be recorded on the SAE Report Form. Refer to Section 8.2 for definition of SAE. (Amendment 4: 23 February 2012)

7. HEALTH ECONOMICS

Not applicable.

8. ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS

The investigator is responsible for the detection and documentation of events meeting the criteria and definition of an AE or SAE as provided in this protocol. During the PMS, when there is a safety evaluation, the investigator or site staff will be responsible for detecting AEs and SAEs, as detailed in this section of the protocol.

Each infant's parents/guardians will be instructed to contact the investigator immediately should the infant manifest any signs or symptoms they perceive as serious.

8.1. Definition of an adverse event

An AE is any untoward medical occurrence, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. For marketed medicinal products, this also includes failure to produce expected benefits (i.e. lack of efficacy), abuse or misuse.

Examples of an AE include:

- Significant or unexpected worsening or exacerbation of the condition/indication under the PMS.
- Exacerbation of a chronic or intermittent pre-existing condition including either an increase in frequency and/or intensity of the condition.
- New conditions detected or diagnosed after medicinal product administration even though it may have been present prior to the start of the PMS.
- Signs, symptoms, or the clinical sequelae of a suspected interaction.
- Signs, symptoms, or the clinical sequelae of a suspected overdose of either medicinal product or a concurrent medication (overdose per se should not be reported as an AE/SAE).
- Significant failure of expected pharmacological or biological action.
- Signs, symptoms temporally associated with vaccine administration.

Examples of an AE DO NOT include:

- Medical or surgical procedure (e.g. endoscopy, appendectomy); the condition that leads to the procedure is an AE.
- Situations where an untoward medical occurrence did not occur (social and/or convenience admission to a hospital).
- Anticipated day-to-day fluctuations of pre-existing disease(s) or condition(s) present or detected at the start of the PMS that do not worsen.

Example of events to be recorded in the medical history section of the CRF:

• Pre-existing conditions or signs and/or symptoms present in a subject prior to the start of the PMS (i.e. prior to the first vaccination).

8.2. Definition of a serious adverse event

An SAE is any untoward medical occurrence that:

- a. results in death,
- b. is life-threatening,

NOTE: The term 'life-threatening' in the definition of 'serious' refers to an event in which the subject was at risk of death at the time of the event. It does not refer to an event, which hypothetically might have caused death, if it were more severe.

c. requires hospitalisation or prolongation of existing hospitalisation,

NOTE: In general, hospitalisation signifies that the subject has been detained (usually involving at least an overnight stay) at the hospital or emergency ward for observation and/or treatment that would not have been appropriate in the physician's office or outpatient setting. Complications that occur during hospitalisation are AEs. If a complication prolongs hospitalisation or fulfils any other serious criteria, the event is

serious. When in doubt as to whether "hospitalisation" occurred or was necessary, the AE should be considered serious.

Hospitalisation for elective treatment of a pre-existing condition that did not worsen from baseline is not considered an AE.

d. results in disability/incapacity, or

NOTE: The term disability means a substantial disruption of a person's ability to conduct normal life functions. This definition is not intended to include experiences of relatively minor medical significance such as uncomplicated headache, nausea, vomiting, diarrhoea, influenza, and accidental trauma (e.g. sprained ankle) which may interfere or prevent everyday life functions but do not constitute a substantial disruption.

(Amendment 4: 23 February 2012)

Medical or scientific judgement should be exercised in deciding whether reporting is appropriate in other situations, such as important medical events that may not be immediately life-threatening or result in death or hospitalisation but may jeopardize the subject or may require medical or surgical intervention to prevent one of the other outcomes listed in the above definition. These should also be considered serious. Examples of such events are invasive or malignant cancers, intensive treatment in an emergency room or at home for allergic bronchospasm, blood dyscrasias or convulsions that do not result in hospitalisation.

8.2.1. Disease-related events or outcomes not qualifying as serious adverse events

Not applicable.

8.3. Lack of efficacy

"Lack of efficacy" per se will not be reported as an AE. The signs and symptoms or clinical sequelae resulting from lack of efficacy will be reported if they fulfil the AE or SAE definition (including clarifications).

8.4. Clinical laboratory parameters and other abnormal assessments qualifying as adverse events and serious adverse events

Abnormal laboratory findings (e.g. clinical chemistry, haematology, urinalysis) or other abnormal assessments (e.g. ECGs, X-rays, vital signs etc) that are judged by the investigator to be clinically significant will be recorded as AEs or SAEs if they meet the definition of an AE, as defined in Section 8.1 or SAE, as defined in Section 8.2. Clinically significant abnormal laboratory findings or other abnormal assessments that are detected during the PMS or are present at baseline and significantly worsen following the start of the PMS will be reported as AEs or SAEs.

The investigator should liaise with treating physician (if different from investigator) in all cases where PMS participants are hospitalised with SAE.

The investigator will exercise his or her medical and scientific judgement in deciding whether an abnormal laboratory finding or other abnormal assessment is clinically significant.

8.5. Time period, frequency, and method of detecting adverse events and serious adverse events

All AEs occurring within 31 days (Day 0 - Day 30) following administration of each dose of vaccine received after enrolling into the PMS must be recorded into the Adverse Event form in the infant's CRF, irrespective of intensity or whether or not they are considered vaccination-related.

The standard time period for collecting and recording SAEs will begin at the first receipt of *RotarixTM or RotarixTM liquid formulation (oral suspension or prefilled syringe)* and will end at the last contact for each infant. See Section 8.8 for instructions for reporting and recording SAEs. (Amendment 4: 23 February 2012)

An overview of the protocol-required reporting periods for adverse events and serious adverse events is given in Table 3.

Table 3 Reporting periods for adverse events and serious adverse events

PMS activity	Dose 1 Day 0	30 days post-vacc.	Dose 2 Month 2	30 days post-vacc.
Reporting of AEs				
Reporting of SAEs				

Vacc.: vaccination; Post-vacc.: post-vaccination

The investigator will inquire about the occurrence of AEs/SAEs at every visit/contact during the PMS.

All AEs either observed by the investigator or one of his clinical collaborators or reported by the infant's parent/guardian spontaneously or in response to a direct question will be evaluated by the investigator. AEs not previously documented in the PMS will be recorded in the Adverse Event form within the infant's CRF. The nature of each event, date and time (where appropriate) of onset, outcome, intensity and relationship to vaccination should be established. Details of any corrective treatment should be recorded on the appropriate page of the CRF. Refer to Section 6.9.

As a consistent method of soliciting AEs, the infant's parent/guardian should be asked a non-leading question such as:

"Has your child acted differently or felt different in any way since receiving the vaccine or since the last visit?"

N.B. The investigator should record only those AEs having occurred within the time frame defined above.

AEs already documented in the CRF, i.e. at a previous assessment, and designated as "not recovered/not resolved" or "recovering/resolving" should be reviewed at subsequent visits, as necessary. If these have resolved, the documentation in the CRF should be completed.

When an AE/SAE occurs, it is the responsibility of the investigator to review all documentation (e.g. hospital progress notes, laboratory, and diagnostics reports) relative to the event. The investigator will then record all relevant information regarding an AE/SAE on the CRF or SAE Report Form as applicable. It is not acceptable for the investigator to send photocopies of the infant's medical records to GSK Biologicals in lieu of the appropriate completed AE/SAE pages. However, there may be instances when copies of medical records for certain cases are requested by GSK Biologicals. In this instance, all subject identifiers will be blinded on the copies of the medical records prior to submission to GSK Biologicals.

The investigator will attempt to establish a diagnosis of the event based on signs, symptoms, and/or other clinical information. In such cases, the diagnosis should be documented as the AE/SAE and not the individual signs/symptoms.

8.6. Evaluating adverse events and serious adverse events

8.6.1. Assessment of intensity

The investigator will make an assessment of the maximum intensity that occurred over the duration of the event for all AEs, i.e. (i.e. non-serious adverse events) reported during the PMS. The assessment will be based on the investigator's clinical judgement.

The intensity of each AE recorded in the CRF, as applicable, should be assigned to one of the following categories:

1 (mild)	=	An AE which is easily tolerated by the infant, causing minimal discomfort and not interfering with everyday activities.
2 (moderate)	=	An AE which is sufficiently discomforting to interfere with normal everyday activities.
3 (severe)	=	An AE which prevents normal, everyday activities. (In a young child, such an AE would, for example, prevent attendance at school/kindergarten/a day-care centre and would cause the parents/guardians to seek medical advice).

An AE that is assessed as Grade "3" (severe) should not be confused with a SAE. Grade "3" is a category utilised for rating the intensity of an event. An event is defined as 'serious' when it meets one of the pre-defined outcomes as described in Section 8.2.

8.6.2. Assessment of causality

The investigator is obligated to assess the relationship between Rotarix[™] or Rotarix[™] liquid formulation (oral suspension or prefilled syringe) and the occurrence of each AE/SAE. The investigator will use clinical judgement to determine the relationship. Alternative causes, such as natural history of the underlying diseases, concomitant therapy, other risk factors and the temporal relationship of the event to Rotarix[™] or Rotarix[™] liquid formulation (oral suspension or prefilled syringe) will be considered and investigated. The investigator will also consult the Product Information, for marketed products, in the determination of his/her assessment. (Amendment 4: 23 February 2012)

There may be situations when a SAE has occurred and the investigator has minimal information to include in the initial report to GSK Biologicals. However, it is very important that the investigator always makes an assessment of causality for every event prior to submission of the SAE to GSK Biologicals. The investigator may change his/her opinion of causality in light of follow-up information, amending the SAE information accordingly. The causality assessment is one of the criteria used when determining regulatory reporting requirements.

In case of concomitant administration of multiple vaccines, it may not be possible to determine the causal relationship of general AEs to the individual vaccines administered. The investigator should, therefore, assess whether the AE could be causally related to vaccination rather than to the individual vaccines.

Causality of all AEs should be assessed by the investigator using the following question:

Is there a reasonable possibility that the AE may have been caused by Rotarix[™] or *Rotarix*[™] *liquid formulation (oral suspension or prefilled syringe)*?

Assessment of causality of these AEs will be done to reflect the requirement of KFDA to assess the relationship of the AEs. (Amendment 4: 23 February 2012)

NOTE: The use of the term "drug" here refers to the vaccine.

As per KFDA requirements, causality will be assessed as:

Certain:

• The relationship of the administration and use of the drug is reasonable and it is not able to be explained by other medication, chemical substances or concomitant disease, it shows clinically reasonable response on withdrawal of the drug, the decisive case in the Pharmacological or phenomenological aspect on re-challenge of the drugs if needed.

Probable/Likely:

• The temporal sequence of the administration and use of the drug is appropriate and it does not seem that it is accompanied by other medications, chemical substances or concomitant disease, in the case that shows clinically appropriate response on withdrawal of the drug (no information for re-challenge).

Possible:

• The temporal sequence of the administration and use of the drug is appropriate but it is also able to be explained by other medications, chemical substances or concomitant disease, and information related to withdrawal of the drug is insufficient or vague.

Unlikely:

• It is a transitory case which may not have causality with the administration and use of the drug, it is also able to be explained reasonably by other medications, chemical substances or latent disease.

Conditional/Unclassified:

• In the case that more information is needed for a proper evaluation or additional information is under review.

Unassessible/Unclassifiable:

• In the case that could not be judged due to insufficient or conflicting information and no way to complement or validate.

8.6.3. Medically attended visits

For each AE the infant experiences, the infant's parents/guardians will be asked if they received medical attention defined as hospitalisation, an emergency room visit or a visit to or from medical personnel (medical doctor) for any reason and this information will be recorded in the CRF.

8.7. Follow-up of adverse events and serious adverse events and assessment of outcome

After the initial AE/SAE report, the investigator is required to proactively follow each infant and provide further information to GSK Biologicals on the infant's condition.

All AEs and SAEs documented at a previous visit/contact and designated as not recovered/not resolved or recovering/resolving will be reviewed at subsequent visits/contacts.

Investigators will follow-up infants:

- with SAEs or infants withdrawn from the PMS as a result of an AE, until the event has resolved, subsided, stabilised, disappeared, the event is otherwise explained, or the infant is lost to follow-up;
- or, in the case of other non-serious AEs, until they complete the PMS or they are lost to follow-up.

Clinically significant laboratory abnormalities will be followed up until they have returned to normal, or a satisfactory explanation has been provided. Additional information (including but not limited to laboratory results) relative to the subsequent course of such an abnormality noted for any infant must be made available to the Study Monitor.

GSK Biologicals may request that the investigator perform or arrange for the conduct of supplemental measurements and/or evaluations to elucidate as fully as possible the nature and/or causality of the AE or SAE. The investigator is obliged to assist. If an infant dies during participation in the PMS or during a recognised follow-up period, GSK Biologicals will be provided with a copy of any available post-mortem findings, including histopathology.

New or updated information will be recorded on the originally completed SAE Report Form. All changes on the SAE Report Form should be signed and dated by the investigator. The updated SAE Report Form should be resent to GSK Biologicals within 24 hours of receipt of the follow-up information as outlined in Section 8.8.1.

Outcome of any non-serious AE occurring within 31 days (Day 0 - Day 30) days post-vaccination or any SAE reported during the entire PMS will be assessed as:

- Recovered/resolved
- Not recovered/not resolved
- Recovering/resolving
- Recovered with sequelae/resolved with sequelae
- Fatal (SAEs only)
- Unknown

8.8. Prompt reporting of serious adverse events to GSK Biologicals

8.8.1. Time frames for submitting serious adverse event reports to GSK Biologicals

SAEs will be reported promptly to GSK once the investigator determines that the event meets the protocol definition of an SAE. The investigator or designate will fax the SAE reports to GSK Biologicals' Study Contact for Serious Adverse Event Reporting WITHIN 24 HOURS OF HIS/HER BECOMING AWARE OF THESE EVENTS. Additional or follow-up information relating to the initial SAE report is also to be reported to the GSK Biologicals' Study Contact for Serious Adverse Event Reporting within 24 hours of receipt of such information.


8.8.2. Completion and transmission of serious adverse event reports to GSK Biologicals

Once an investigator becomes aware that a SAE has occurred in an infant, she/he will report the information to GSK within 24 hours as outlined in Section 8.8.1. The SAE Report Form will always be completed as thoroughly as possible with all available details of the event, signed by the investigator (or designee), and forwarded to GSK within the designated time frames. If the investigator does not have all information regarding an SAE, he/she will not wait to receive additional information before notifying GSK of the event and completing the form. The form will be updated when additional information is received and forwarded to GSK WITHIN 24 HOURS as outlined in Section 8.8.1.

The investigator will always provide an assessment of causality at the time of the initial report as described in Section 8.6.2.

Facsimile (Fax) transmission of the SAE Report Form is the preferred method to transmit this information to the Study Contact for Reporting SAEs. In rare circumstances and in the absence of facsimile equipment, notification by telephone is acceptable, with a copy of the SAE Report Form sent by overnight mail. Initial notification via the telephone does not replace the need for the investigator to complete and sign the SAE Report Form within 24 hours as outlined in Section 8.8.1.

In the event of a death determined by the investigator to be related to vaccination, sending of the fax must be accompanied by telephone call to the Study Contact for Reporting SAEs.



8.9. Regulatory reporting requirements for serious adverse events

The investigator will promptly report all SAEs to GSK in accordance with the procedures detailed in Section 8.8. GSK Biologicals has a legal responsibility to promptly notify, as appropriate, both the local regulatory authority and other regulatory agencies about the safety of a product under clinical investigation. Prompt notification of SAEs by the investigator to the Study Contact for Reporting SAEs is essential so that legal obligations and ethical responsibilities towards the safety of other subjects are met.

The investigator, or responsible person according to local requirements, will comply with the applicable local regulatory requirements related to the reporting of SAEs to the IRB/IEC and, if required, to the applicable government authority.

8.10. Post-PMS adverse events and serious adverse events

A post-PMS AE/SAE is defined as any event that occurs outside of the AE/SAE detection period defined in Section 8.5. Investigators are not obligated to actively seek AEs or SAEs in former PMS participants.

However, if the investigator learns of any SAE, including a death, at any time after an infant has been discharged from the PMS, and he/she considers the event reasonably related to RotarixTM or RotarixTM liquid formulation (oral suspension or prefilled syringe), the investigator will promptly notify the Study Contact for Reporting SAEs. (Amendment 4: 23 February 2012)

8.11. Pregnancy

Not applicable.

8.12. Treatment of adverse events

Treatment of any adverse event is at the sole discretion of the investigator and according to current good medical practice. Any medication administered for the treatment of an AE should be recorded in the infant's CRF. Refer to Section 6.9.

9. SUBJECT COMPLETION AND WITHDRAWAL

9.1. Subject completion

An infant who has the 30 day safety contact after the second RotarixTM or RotarixTM liquid formulation (oral suspension or prefilled syringe) vaccination is considered to have completed the PMS. (Amendment 4: 23 February 2012)

9.2. Subject withdrawal

9.2.1. Subject withdrawal from the PMS

A subject qualifies as a 'withdrawal' from the PMS if the second Rotarix[™] or Rotarix[™] liquid formulation (oral suspension or prefilled syringe) vaccination is not given in this PMS or when the 30 day safety contact after the last Rotarix[™] or Rotarix[™] liquid formulation (oral suspension or prefilled syringe) dose does not take place. (Amendment 4: 23 February 2012)

Investigators will make an attempt to contact those subjects who do not return for scheduled visits.

Information relative to the withdrawal will be documented on the PMS Conclusion page of the CRF. The investigator will document whether the decision to withdraw from the PMS was made by the infant's parent or guardian or the investigator and which of the following possible reasons was responsible for withdrawal:

- serious adverse event
- non-serious adverse event
- consent withdrawal, not due to an adverse event
- moved from the PMS area
- lost to follow-up
- other (specify).

9.2.2. Subject withdrawal from Rotarix

A 'withdrawal' from RotarixTM or RotarixTM liquid formulation (oral suspension or prefilled syringe) is any infant who does not receive the second RotarixTM or RotarixTM liquid formulation (oral suspension or prefilled syringe) dose in the PMS. An infant withdrawn from RotarixTM or RotarixTM liquid formulation (oral suspension or prefilled syringe)

syringe) may not necessarily be withdrawn from the PMS as further procedures or follow-up may be performed (safety) if planned in the protocol.

Information relative to premature discontinuation of RotarixTM or RotarixTM liquid formulation (oral suspension or prefilled syringe) will be documented on the Vaccine Administration page of the CRF. The investigator will document whether the decision to discontinue further vaccination was made by the infant's parent or guardian or the investigator and which of the following possible reasons was responsible for withdrawal: (Amendment 4: 23 February 2012)

- serious adverse event,
- non-serious adverse event,
- other (specify).

10. DATA EVALUATION: CRITERIA FOR EVALUATION OF OBJECTIVES

10.1. Endpoints

- Occurrence of AEs during the 31-day (Day 0 Day 30) follow-up period after each vaccine dose according to Medical Dictionary for Regulatory Activities (MedDRA) classification.
- Occurrence of SAEs during the entire PMS period.

10.2. Estimated sample size

According to KFDA regulation requirement, at least 3000 evaluable subjects will be recruited for the PMS.

Table 4 presents the exact two-sided 95% confidence interval for a sample size of 3000subjects. (Amendment 4: 23 February 2012)

Table 4 Exact two-sided 95% CI for a sample size of 3000 subjects

Observed rate expressed as a percentage (number of subjects reporting at least one symptom)	Exact two-sided 95% CI for this observed rate for a sample size of 3000 subjects		
	Lower limit (LL)	Upper limit (UL)	
50(1500)	48.2	51.8	
55(1650)	53.2	56.8	
60(1800)	58.2	61.8	
65(1950)	63.3	66.7	
70(2100)	68.3	71.6	
75(2250)	73.4	76.5	
80 (2400)	78.5	81.4	
85(2550)	83.7	86.3	

10.3. Cohorts to be evaluated

10.3.1. Total Vaccinated cohort

The total vaccinated cohort will include all vaccinated subjects with at least one dose of *RotarixTM or RotarixTM liquid formulation (oral suspension or prefilled syringe)* administration documented: (Amendment 4: 23 February 2012)

• a safety analysis based on the total vaccinated cohort will include all vaccinated subjects.

10.4. Derived and transformed data

Infants who missed reporting symptoms (AEs or concomitant medications) will be treated as infants without symptoms (AEs or concomitant medications, respectively). In case of significant non-compliance of PMS procedures for reporting symptoms, the analysis plan will be reassessed to ensure more accurate reporting of PMS data by further analysis.

10.5. Final analyses

Statistical analyses will be performed as per the GSK standards as well as to reflect the requirements of KFDA.

10.5.1. Analysis of demographics/baseline characteristics

The mean, range and standard deviation of age in weeks at each dose will be calculated. The racial, rotavirus vaccination history and gender composition of the vaccinated subjects will be also presented.

The distribution of subjects enrolled among the PMS centres will be tabulated.

10.5.2. Analysis of safety

For all infants enrolled prior to Amendment 3 dated 10 February 2010, the following statistical analysis will be performed:

The overall incidence, with exact 95% confidence interval (CI), of any adverse events (solicited or unsolicited) during the 8-day solicited follow-up period will be tabulated, for each dose, for overall doses and per subject. The same calculations will be done for any adverse events (solicited or unsolicited); rated as grade "3" and for those assessed as causally related to vaccination.

The incidence, with exact 95% CI, of each individual solicited general symptom, will be calculated, over the solicited follow-up period, after each dose, for all doses and per subject. The same calculations will be done for each individual solicited general symptom rated as grade "3" and for each individual solicited general symptom related to vaccination.

The verbatim reports of unsolicited symptoms will be reviewed by a physician and the signs and symptoms will be coded according to MedDRA. Every verbatim term will be matched with the appropriate Preferred Term. The percentage of subjects with unsolicited symptoms occurring within 31 days with its exact 95% CI will be tabulated by preferred term. Similar tabulation will be done for unsolicited symptoms with relationship to vaccination and for unsolicited adverse events rated as grade 3.

The percentage of subjects who received at least one concomitant medication/vaccination during the 8-day (Day 0 - Day 7) solicited follow-up period will be tabulated by type of medication, with exact 95% CI. Similar tabulations will be done for subjects who receive concomitant medication/vaccination during the entire PMS period.

Serious adverse events and withdrawals due to adverse events reported during the PMS period will be described in detail.

For all subjects enrolled after the Amendment 3 dated 10 February 2010, the following statistical analysis will be performed:

The AEs/SAEs collected will be analysed in the study report according to the expectedness and unexpectedness criteria. Refer to the Glossary of Terms for the definitions of expected AEs and unexpected AEs.

The overall incidence, with exact 95% confidence interval (CI), of any adverse events occurring within 31 days will be tabulated, for each dose, for overall doses and per subject. The same calculations will be done for any adverse events; rated as grade "3" and for all the causality grading mandated by KFDA.

The verbatim reports of AEs will be reviewed by a physician and the signs and symptoms will be coded according to MedDRA. Every verbatim term will be matched with the appropriate Preferred Term. The percentage of subjects with AEs occurring within 31 days with its exact 95% CI will be tabulated by preferred term. Similar tabulation will be done for AEs rated as grade 3 and for all causality grading mandated by KFDA.

The percentage of subjects who received at least one concomitant medication/vaccination during the 30 day follow-up period will be tabulated by type of medication, with exact 95% CI. Similar tabulations will be done for subjects who receive concomitant medication/vaccination during the entire PMS period.

Serious adverse events and withdrawals due to adverse events reported during the PMS period will be described in detail.

In addition, specific statistical analyses (e.g. AEs classified by gender, past medical history, concomitant medication/vaccination etc) will be performed to reflect the KFDA requirements.

10.6. Planned interim analysis

Annual reports will be written for 6 years. The last annual report will be replaced by a comprehensive report. All analyses described above will be performed on cleaned data

41

for each annual report. The analysis, including individual data listings, will be cumulative and based on the cohort for vaccinated subjects for which the PMS conclusion page has been received at GSK before the pre-defined cut-off date. All reports will be sent to the GSK Biologicals' Central Safety and Pharmacovigilance (BCSP).

11. ADMINISTRATIVE MATTERS

To comply with local rules, regulations, relevant GSK SOPs/Policies/Guidance, important administrative obligations relating to investigator responsibilities, monitoring, archiving data, audits, confidentiality and publications must be fulfilled. See Appendix B for details.

12. **REFERENCES**

Bernstein DI, Sack DA, Reisinger K et al. Second year follow-up evaluation of live attenuated human rotavirus vaccine 89-12 in healthy infants. *J Infect Dis.* 2002;186:1487-9.

Bernstein DI, Sack DA, Rothstein E et al. Efficacy of live attenuated human rotavirus vaccine 89-12 in infants. *Lancet*. 1999;354:287-90.

Bernstein DI, Smith VE, Sherwood JR et al. Safety and immunogenicity of a live attenuated human rotavirus 89-12 vaccine. *Vaccine*. 1998;16:381-7.

Bresse JS, Fang ZY, Wang B et al. First Report from the Asian Rotavirus Surveillance Network. *Emerging Infectious Diseases*. 2004; 988-995.

Dennehy PH. A short report on the highlights of world-wide development of RIX4414: A North American experience. Comparative evaluation of safety and immunogenicity of two dosages of an oral live attenuated human rotavirus vaccine (RIX4414) in infants in the United States and Canada. *PID*. 2005; 3780-3781.

Fischer TK, Viboud C, Parashar U, et al. Hospitalizations and Deaths from Diarrhoea and Rotavirus among Children <5 Years of Age in the United States, 1993-2003. *J Infect Dis.* 2007; 195 (8): 1117-25.

Glass R.I, Parashar U.D. The Promise of New Rotavirus Vaccines. NEJM. 2006; 75-77.

Glass RI, Bresee JS, Turcios R et al. Rotavirus Vaccines: Targeting the Developing World. *Journal of Infectious Diseases*. 2005; S160-166.

Jung Soo Kim et al. Immunogenicity and reactogenicity profile of oral, live-attenuated human rotavirus vaccine, RIX4414 (RotarixTM) in Korean infants. Presented at the World Congress of Pediatric Infectious Diseases 15-18-November 2007, Bangkok.

Phua K.B, Quak S.H, Emmanuel S et al. A short report on highlights of worldwide development of RIX4414: A Singaporean experience. *Vaccine*. 2006; 3782-3783.

Phua KB, Quak SH, Lee BW et al. Evaluation of RIX4414, A Live, Attenuated Rotavirus Vaccine, in a Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial Involving 2464 Singaporean Infants. *Journal of Infectious Diseases*. 2005; S6-16.

Ruiz-Palacios GM, Perez-Schael I, Velazquez RF et al. Safety and Efficacy of an Attenuated vaccine against Severe Rotavirus Gastroenteritis. NEJM. 2006; 11-22.

Salinas B, Perez-Schael I, Linhares AC, et al. Evaluation of safety, immunogenicity and efficacy of an attenuated rotavirus vaccine RIX4414: a randomized, placebo-controlled trial in Latin American infants. *Pediatr Infect Dis J.* 2005:807-16.

Seo JK, Sim JG. Overview of rotavirus infections in Korea. *Pediatrics International*. 2000; 406-410.

43

Steele A.D, Peenze I, de Beer M.C et al. Anticipating rotavirus vaccines: epidemiology and surveillance of rotavirus in South Africa. *Vaccine*. 2003; 354-360.

Vesikari T, Karvonen A, Prymula R, et al. Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study. *Lancet*. 2007;370:1757-1763.

Vesikari T, Karvonen A, Puustinen et al. A short report on highlights of world-wide development of RIX4414: An European experience. *Vaccine*. 2006; 3779.

Vesikari T, Prymula R, Schuster V, et al. *Rotarix*[™] (RIX4414), an oral human rotavirus vaccine, is highly immunogenic when co-administered with diphtheria-tetanus-pertussis (DTPa)-combined vaccines in healthy infants from Europe. Presented at the 24th Annual Meeting of the European Society for Pediatric Infectious Diseases (ESPID), Basel, Switzerland, 3-5 May 2006.

Weekly epidemiological record, WHO position paper. August 2007.

Appendix A Administrative Matters

I. Responsibilities of the Investigator

- To ensure that he/she has sufficient time to conduct and complete the PMS and has adequate staff and appropriate facilities and equipment which are available for the duration of the PMS and to ensure that other studies do not divert essential subjects or facilities away from the PMS at hand.
- To prepare and maintain adequate subject source data or raw data designed to record observations, and other data pertinent to the PMS.
- To co-operate with a representative of GSK Biologicals in the monitoring process of the PMS and in resolution of queries about the data.
- To conduct the study in compliance with the protocol any amendment, all applicable regulatory requirements and GSK SOPs/Policies and Guidance.
- To permit drug regulatory agencies and GSK audits.

II. Protocol Amendments and Administrative changes

- No changes to the protocol will be allowed unless discussed in detail with the GSK Biologicals' Clinical Development Manager/Medical Monitor and filed as an amendment/administrative change to this protocol.
- Any amendment/administrative change to the protocol will be adhered to by the participating centre(s) and will apply to all subjects. Written IRB approval of protocol amendments is required prior to implementation, except where the sites do not have IRB.

III. Sponsor's Termination of PMS

GSK Biologicals reserves the right to temporarily suspend or prematurely discontinue this PMS either at a single site or at all sites at any time for reasons including, but not limited to, safety or ethical issues or severe non-compliance. Reasons for suspension or early termination will be documented in the PMS file at GSK Biologicals.

If GSK Biologicals determines that suspension or early termination is needed, GSK Biologicals will discuss this with the Investigator (including the reasons for taking such action). When feasible, GSK Biologicals will provide advance notification to the investigator of the impending action prior to it taking effect.

GSK Biologicals will promptly inform, via written communication, all investigators and/or institutions conducting the PMS, if the PMS is suspended or terminated for safety reasons, and will also inform the regulatory authorities of the suspension or termination of the PMS and the reason(s) for the action. If required by applicable regulations, the investigator must inform the IRB promptly (except where the sites do not have IRB) and provide the reason for the suspension or termination. If the study is prematurely discontinued, all PMS data must be returned to GSK. Financial compensation to investigators and/or institutions will be in accordance with the agreement established between the investigator and/or institutions and GSK.

IV. Case Report Form Instructions

Prior to screening the first potential participant, the investigator will provide the Site Monitor with a list (Site Staff Signature Sheet) showing the name and title, signature and initials of all site staff who have a critical effect on the conduct of the PMS and to whom the investigator has delegated significant PMS related duties such as entering data on the CRFs or changing entries on CRFs. If the authorised individuals should change during the PMS, the investigator is to inform GSK Biologicals GSK Biologicals' representative of the specific change(s).

CRFs (and subject diary cards, if applicable), will be supplied by GSK Biologicals for recording all data. It is the responsibility of the investigator or co-investigator to ensure that data are legible, accurate, adequately recorded and, when entered on paper copy, completely filled in with a black ink fountain or ballpoint pen.

Errors must be corrected by drawing a single line through the incorrect entry and writing in the new value/data positioned as close to the original as possible. The correction must then be initialled and dated (and justified, whenever possible), where necessary, by the authorised individual making the change. The original entry must not be obliterated, overwritten or erased when a correction is made.

When a subject completes a visit, it is anticipated that relevant sections of the CRF will be completed by the investigator (or designated staff as documented in the Site Staff Signature Sheet) as soon as possible after the last data becoming available. Similarly, when a subject completes a PMS, it is anticipated that all relevant CRF pages will be completed promptly after the last data becoming available.

As soon as the subject has completed/withdrawn from the PMS and the CRF is completed, the investigator or medically qualified sub-investigator to whom this task has been delegated will sign the PMS conclusion pages of the CRF to confirm that they have reviewed the data and that the data are complete and accurate. In all cases the investigator remains accountable for the PMS data collected.

An original (top copy) CRF or log sheets must be submitted for all subjects who have undergone protocol specific procedures, whether or not the subject completed the PMS.

While completed CRFs are reviewed by a GSK Biologicals' professional monitor at the site, errors detected by subsequent in-house CRF review may necessitate clarification or correction of errors with documentation and approval by the investigator or appropriately qualified designee as documented on the Site Staff Signature Sheet. In all cases, the investigator remains accountable for the PMS data. Wherever possible the investigator should assist in the clarification or correction of errors detected after PMS finalisation promptly after being brought to the attention of the investigator.

Any questions or comments related to the CRF should be directed to the assigned Site Monitor.

V. Monitoring by GSK Biologicals

To ensure compliance with the protocol, monitoring visits by a professional representative of the sponsor will be scheduled to take place early in the PMS, during the PMS at appropriate intervals and after the last subject has completed the PMS. It is anticipated that monitoring visits will occur at a frequency defined and communicated to the investigator before PMS start.

These visits are for the purpose of confirming that GSK Biologicals' sponsored studies are being conducted in accordance with the ethical principles, the applicable regulatory requirement(s) and relevant GSK SOPs/Policies and Guidance (verifying continuing compliance with the protocol, amendment(s), verifying that the site staff and facilities continue to be adequate to conduct the PMS. Direct access to all PMS-related site and source data/documents is mandatory for the purpose of monitoring review. The monitor will perform a CRF review and a Source Document verification (verifying CRF entries by comparing them with the source data/documents that will be made available by the investigator for this purpose: any data item for which the CRF will serve as the source must be identified, agreed and documented. Data to be recorded directly onto the CRF pages will be specified in writing preferably in the source documentation agreement form that is contained in both the monitor's and investigator's file. The investigator must ensure provision of reasonable time, space and adequate qualified personnel for monitoring visits. Source data verification (SDV) must be conducted using a GSK standard SDV sampling strategy (as defined at the study start in the study specific monitoring guidelines) in which monitors will perform partial SDV for all subjects and full SDV for selected subjects.

VI. Archiving of Data

Following closure of the PMS, the investigator must maintain all site records in a safe and secure location. The records must be maintained to allow easy and timely retrieval, when needed (e.g., audit or inspection), and, whenever feasible, to allow any subsequent review of data in conjunction with assessment of the facility, supporting systems, and staff. Where permitted by applicable laws/regulations or institutional policy, some or all of these records can be maintained in a validated format other than hard copy (e.g. microfiche, scanned, for example); however, caution needs to be exercised before such action is taken. The investigator must assure that all reproductions are legible and are a true and accurate copy of the original, and meet accessibility and retrieval standards, including re-generating a hard copy, if required. Furthermore, the investigator must ensure there is an acceptable back-up of these reproductions and that an acceptable quality control process exists for making these reproductions.

GSK will inform the investigator/ institution of the time period for retaining these records to comply with all applicable regulatory requirements. However, the investigator/ institution should seek the written approval of the sponsor before proceeding with the disposal of these records. The minimum retention time will meet the strictest standard applicable to that site for the study, as dictated by ICH GCP E6 Section 4.9, any

institutional requirements or applicable laws or regulations, or GSK standards/procedures; otherwise, the minimum retention period will default to 3 years.

The investigator/ institution must notify GSK of any changes in the archival arrangements, including, but not limited to, the following: archival at an off-site facility, transfer of ownership of the records in the event the investigator leaves the site.

VII. Audits

For the purpose of compliance with Regulatory Agency Guidelines and relevant GSK SOPs/Policies and Guidance it may be necessary for GSK or a Drug Regulatory Agency to conduct a site audit. This may occur at any time from start to after conclusion of the PMS.

When an investigator signs the protocol, he agrees to permit drug regulatory agencies and GSK audits, providing direct access to source data/ documents. Furthermore, if an investigator refuses an inspection, his data will not be accepted in support of a New Drug Registration and/or Application, Biologics Licensing Application.

Having the highest quality data and studies are essential aspects of vaccine development. GSK has a Regulatory Compliance staff who audit investigational sites. Regulatory Compliance assesses the quality of data with regard to accuracy, adequacy and consistency. In addition, Regulatory Compliance assures that GSK Biologicals' sponsored studies are in accordance with relevant regulatory/guidelines and relevant GSK SOPs/Policies and Guidance are being followed.

GSK Biologicals will gladly help investigators prepare for an inspection.

VIII. Ownership, Confidentiality and Publication

Ownership:

All information provided by GSK and all data and information generated by the site as part of the PMS (other than a subject's medical records) are the sole property of GSK.

All rights, title, and interests in any inventions, know-how or other intellectual or industrial property rights which are conceived or reduced to practice by site staff during the course of or as a result of the PMS are the sole property of GSK, and are hereby assigned to GSK.

If a written contract for the conduct of the PMS which includes ownership provisions inconsistent with this statement is executed between GSK and the site, that contract's ownership provisions shall apply rather than this statement.

Confidentiality:

Documented evidence that a potential investigator is aware and agrees to the confidential nature of the information related to the PMS must be obtained by means of a confidentiality agreement.

48

All information provided by GSK and all data and information generated by the site as part of the PMS (other than a subject's medical records) will be kept confidential by the investigator and other site staff. This information and data will not be used by the investigator or other site personnel for any purpose other than conducting the PMS. These restrictions do not apply to: (1) information which becomes publicly available through no fault of the investigator or site staff; (2) information which it is necessary to disclose in confidence to an IRB solely for the evaluation of the PMS; (3) information which it is necessary to disclose in order to provide appropriate medical care to a subject; or (4) PMS results which may be published as described in the next paragraph. If a written contract for the conduct of the PMS which includes confidentiality provisions inconsistent with this statement is executed, that contract's confidentiality provisions shall apply rather than this statement.

Publication:

For multicentre studies, the first publication or disclosure of results shall be a complete, joint multicentre publication or disclosure coordinated by GSK. Thereafter, any secondary publications will reference the original publication(s).

Prior to submitting for publication, presentation, use for instructional purposes, or otherwise disclosing the results generated by the site (collectively, a "Publication"), the investigator shall provide GSK with a copy of the proposed Publication and allow GSK a period to review the proposed Publication (at least 21 (twenty-one) days [or at least 15 (fifteen) working days for abstracts/posters/presentations]. Proposed Publications shall not include either GSK confidential information other than the results or personal data on any subject, such as name or initials.

At GSK's request, the submission or other disclosure of a proposed Publication will be delayed a sufficient time to allow GSK to seek patent or similar protection of any inventions, know-how or other intellectual or industrial property rights disclosed in the proposed Publication.

If a written contract for the conduct of the PMS, which includes publication provisions inconsistent with this statement is executed, that contract's publication provisions shall apply rather than this statement.

Appendix B Overview of the Recruitment Plan

- The PMS will be conducted at multiple centres in Korea.
- Infants aged 6 weeks or above at the time of first vaccination will be enrolled in this PMS.
- Infants recruited by investigators will be given the vaccination as a part of their normal practice.
- Target enrolment will be at least 3000 evaluable infants.
- The PMS is required to be conducted in at least one hospital (with IRB oversight) in order for PMS to be conducted in private clinics (with no IRB).
- The recruitment will be monitored by the study monitor.

Appendix C Prescribing Information

Refer to locally approved prescribing information.

Appendix D Amendments and Administrative Changes to the Protocol

GlaxoSmithKline Biologicals						
Clinical Research & Development						
	Protocol Amendment					
eTrack number and abbreviated title	111700 (Rota-070 PMS)					
Title	Reactogenicity and safety of GlaxoSmithKline (GSK) Biologicals' oral live attenuated human rotavirus (HRV) vaccine, Rotarix TM when administered according to the prescribing information in Korea.					
Detailed Title:	Open, multi-centric, post-marketing surveillance (PMS) to monitor the reactogenicity and safety of GlaxoSmithKline (GSK) Biologicals' oral live attenuated human rotavirus (HRV) vaccine, Rotarix [™] when administered according to the prescribing information in Korea.					
Amendment number:	Amendment 1					
Amendment date:	09 May 2008					
Co-ordinating author:	PPD Scientific Writer					
Rationale/background for	r changes:					
The protocol was amended to comply with the Korean Food and Drug Administration (KFDA) requirements.						
Amended text has been in	cluded in <i>bold italics</i> in the following section(s):					
Section 8.6.2 Assessment of causality						

Section 8.6.2 Assessment of causality

- 1. Definitely related:
 - There is evidence of exposure to the vaccine of the drug.
 - The temporal sequence of the AE onset relative to administration of the vaccine *drug* is reasonable
 - AE is more likely explained by the vaccine *drug* than by another cause
 - The AE is subsiding or disappearing on withdrawal of the drug
 - Rechallenge (if feasible) is positive.
 - The AE shows a pattern consistent with previous knowledge of the vaccine *drug* or the vaccine *drug* class.
- 2. Probably related:
 - There is evidence of exposure to the vaccine of the drug.
 - The temporal sequence of the AE onset relative to administration of the vaccine *drug* is reasonable
 - AE is more likely explained by the vaccine *drug* than by another cause
 - The AE is subsiding or disappearing on withdrawal of the drug
- 3. Possibly related:
 - There is evidence of exposure to the vaccine of the drug.
 - The temporal sequence of the AE onset relative to administration of the vaccine *drug* is reasonable
 - The AE could have been due to another equally likely cause
 - The AE is subsiding or disappearing on withdrawal of the drug (if performed)
- 4. Unlikely to be *Probably not* related:
 - There is no evidence of exposure of the drug
 - There is another more likely cause of the AE
 - The AE is not disappearing even on withdrawal of the drug (if performed) or ambiguous
- 5. Unknown

CI	inical Research	n & Development				
CI		mendment				
eTrack number and	eTrack number and 111700 (Rota-070 PMS)					
abbreviated title						
Title	Biologicals' or vaccine, Rotar	y and safety of GlaxoSmithKline (GSK) ral live attenuated human rotavirus (HRV) ix [™] when administered according to the formation in Korea.				
Detailed Title:	to monitor the GlaxoSmithKl human rotavir	entric, post-marketing surveillance (PMS) reactogenicity and safety of line (GSK) Biologicals' oral live attenuated us (HRV) vaccine, Rotarix TM when according to the prescribing information in				
Amendment number:	Amendment 2					
Amendment date:	13 October 20	08				
Co-ordinating author:	PPD Scientific Writer					

Rationale/background for changes:

The protocol was amended to modify the timelines for the interim analysis thereby replacing bi-annual reports with annual reports. In addition, the protocol amendment investigator agreement page has been included in the protocol.

Section 10.6 Planned interim analysis

Bi-annual reports will be written for the first two years and Annual reports will be written for the remaining 4 6 years. A comprehensive report will be written at the end of 6 years. The last annual report will be replaced by a comprehensive report. All analyses described above will be performed on cleaned data for each bi-annual/annual report. The analysis, including individual data listings, will be cumulative and based on the cohort for vaccinated subjects for which the PMS conclusion page has been received at GSK before the pre-defined cut-off date. All reports will be sent to the GSK Biologicals' Central Safety and Pharmacovigilance (BCSP).

Protocol Amendment Investigator Agreement

I agree:

- To assume responsibility for the proper conduct of the study at this site.
- To conduct the study in compliance with this protocol, any mutually agreed future protocol amendments, and with any other study conduct procedures provided by GlaxoSmithKline Biologicals (GSK Biologicals).
- To ensure that all persons assisting me with the study are adequately informed about the GSK Biologicals' RotarixTM and other study-related duties and functions as described in the protocol.
- Not to implement any changes to the protocol without agreement from the sponsor and prior review and written approval from the Institutional Review Board (IRB) or Independent Ethics Committee (IEC) (except where site does not have IRB/IEC according to APPOL and LSOP), except where necessary to eliminate an immediate hazard to the subjects, or where permitted by all applicable regulatory requirements (for example, for administrative aspects of the study).
- That I am thoroughly familiar with the appropriate use of the vaccine, as described in this protocol, and any other information provided by the sponsor, including, but not limited to, the following: the current Investigator's Brochure (IB) or equivalent document, IB supplement (if applicable), prescribing information (in the case of a marketed vaccine).
- That I am aware of, and will comply with, "Good Clinical Practice" (GCP) and all applicable regulatory requirements.

GlaxoSmithKline Biologicals

		ol Amendment
eTrack number and abbreviated title	111700 (F	Rota-070 PMS)
Title	attenuated when adm	GlaxoSmithKline (GSK) Biologicals' oral live I human rotavirus (HRV) vaccine, Rotarix [™] ninistered according to the prescribing on in Korea. (Amendment 3: 10 February
Detailed Title:	to monitor Biological vaccine, R	Iti-centric, post-marketing surveillance (PMS) r the safety of GlaxoSmithKline (GSK) ls' oral live attenuated human rotavirus (HRV) Rotarix [™] when administered according to the g information in Korea. (Amendment 3: 10 2010)
Amendment number:	Amendme	ent 3
Amendment date:	10 Februa	ry 2010
Co-ordinating author:	PPD	Scientific Writer

The protocol has been amended to reflect the changes made to the guidelines for Korean New Drug Re-examination by the Korean Food and Drug Administration (KFDA). The current PMS will be conducted as per the local regulatory requirements. Additionally, the protocol reflects the changes in study personnel including the sponsor signatory of the study. The prescribing information has been removed from the protocol.

The changes have been reflected in all applicable sections across the document.

CONFIDENTIAL

Amended text has been indicated by *bold italics*.

Contributing Authors:

- PPD Bio Medical Director, Korea
- PPD Clinical Development Manager, GCRD
- PPD Global Study Manager, GCRD
- PPD Project Leader, Korea
- PPD Medical Advisor, Korea

Protocol Amendment Sponsor Signatory Approval:

PPD

Vice President and Director, Clinical R & D and Medical Affairs, Asia-Pacific, Australasia and China/Hong Kong

Dr. PPD

Vice President, Clinical R&D and Medical Affairs, Asia Pacific

Title Page: Sponsor:

4th-Floor, Yeonsei Severance Building 84-11, Namdaemoon-Ro 5-ga, JungGu, Seoul, 100-753, Korea

9th Floor LS Yongsan Tower building, 191 Hangang-ro-2-ga, Yongsan-gu, Seoul, 140-702, Korea

Title:

Reactogenicity and *S*afety of GlaxoSmithKline (GSK) Biologicals' oral live attenuated human rotavirus (HRV) vaccine, Rotarix[™] when administered according to the prescribing information in Korea.

Detailed Title:

Open, multi-centric, post-marketing surveillance (PMS) to monitor the reactogenicity and safety of GlaxoSmithKline (GSK) Biologicals' oral live attenuated human rotavirus (HRV) vaccine, Rotarix[™] when administered according to the prescribing information in Korea.

Section 1.2 Rationale for the Post Marketing Surveillance:

GSK Biologicals' vaccine, RotarixTM was registered in Korea in March 2008, following which, the present PMS will collect reactogenicity and safety data on the use of RotarixTM in at least 3000 Korean infants as per the regulations of the Korean Food and Drugs Administration (KFDA). safety information on the use of RotarixTM in at least 3000 Korean infants is required as per the regulations of the Korean Food and Drugs Administration (KFDA).


Section 2. Objectives:

To assess the reactogenicity and safety of RotarixTM in infants when administered according to the prescribing information in Korea.

Section 3. PMS Design Overview:

Sequential						
allocation of						
subject						
numbers						
				0.01		
ļļ		HRV vaccin	le(N = 300)	00)		
<u> </u>				*		
T	T	T	T		- T	
Visit 1	1	I	Visit 2	I	I	
Day (Day 7	Day 30		Day 7	Day 30	
	1 Return of Dia		Dose 2			
	card	Reporting	10000	Diary card		
		of AEs		C. C	of AEs	
		(Phone			(Phone	
		contact)			contact)	

Approximately 500 subjects will be enrolled every year for 6 years.



N: Number of subjects planned to be enrolled.

Infants who have received a dose of the vaccine prior to the start of the PMS will have only one visit followed by the phone contact.

PMS conclusion: An infant's parent/guardian who will be contacted to provide details of any AEs experienced by the infant 30 days after the infant receives the last vaccination or an infant for whom diary card transcription into CRF will be been done through phone contact is considered to have completed the PMS.

- All infants will be followed-up for reactogenicity and safety.
- Recording of solicited AEs such as fever, fussiness/irritability, diarrhoea, vomiting, loss of appetite and cough/runny nose from Day 0 to Day 7 after each dose of RotarixTM.
- Active *R*ecording of unsolicited AEs from Day 0 to Day 7 30 using the diary cards after each dose of RotarixTM. Passive recording of unsolicited symptoms from Day 8 up to Day 30 after each dose of RotarixTM by phone contact.

Section 4.1 Number of subjects/centres:

A total of at least 3000 evaluable infants (approximately 500 per year) will be enrolled.

As per the KFDA requirements, safety information from a total of 3000 evaluable infants are needed and approximately 500 infants per year will be enrolled.

Section 4.3 Exclusion Criteria for enrolment:

At the time of PMS entry, the contraindications and precautions of use indicated in the prescribing information should be checked and the infant must not be included in the PMS if there is any contraindication. (Refer to Prescribing Information in Appendix C).

Section 4.5 Contraindications to subsequent vaccination:

Refer to the prescribing information for contraindications. *Any changes in the locally approved Prescribing Information must be implemented immediately.*

Section 4.6 Warnings and Precautions:

Refer to the prescribing information for contraindications. *Any changes in the locally approved Prescribing Information must be implemented immediately.*

Section 5.1 Ethics and regulatory considerations:

The PMS will be conducted according to Good Clinical Practice (GCP), the Declaration of Helsinki, the local rules and regulations of the country (KFDA) and relevant GSK SOPs/Policies and Guidance.

Submission of the protocol and any protocol amendments to regulatory agencies will occur in accordance with local regulatory requirements *and relevant GSK SOPs/Policies and Guidance*. If needed, this protocol/*protocol amendment* will be submitted to *an* Institutional Review Board (IRB).

Independent Ethics Committee/Institutional Review Board (IEC/IRB) approval has to be obtained prior to study start. If the regulatory authority and/or IEC/IRB advise that PMS studies do not need ethical review this must be documented. In any event, submission to an IEC/IRB in all institutions where IEC/IRB are available must be carried out and documented.

Section 5.1.1 Informed consent:

In obtaining and documenting informed consent, the investigator should comply with the applicable regulatory requirement(s) and should adhere to GCP and to the ethical principles that have their origin in the Declaration of Helsinki.

Freely given informed consent should be obtained from every infants' parents/guardians prior to PMS participation for the collection of personal and safety information prior to or post vaccination).

An investigator or designate will describe the protocol to potential subjects' infants' parents/guardians face to face. The Informed Consent Form may be read to the subjects' infants' parents/guardians, but, in any event, the investigator or designate shall give the subjects' infants' parents/guardians ample opportunity to inquire about details of the PMS and ask any questions before dating and signing the Informed Consent Form.

Both the informed consent discussion and the written informed consent form and any other written information to be provided to the infants' parents/guardians should include explanations of the following:

j. The approximate number of subjects *infants* involved in the PMS.

k. The expected duration of a subject's infant's participation in the PMS.

Age	From	n the age of 6	i weeks			
Visit	VISIT 1	Diary Card Return*	Reporting Diary Card Return*		Diary Card Return*	Reporting Diary Card Return*
Timing	Day 0	Day 7 or after	Day 30 or after	At least 4 weeks after Dose 1	Day 7 or after	Day 30 or after
Informed consent	•					
Check inclusion criteria	•					
Check exclusion criteria	•					
Check contraindications	•			•		
Medical history	•					
Physical examination	•			0		
Pre-vaccination Recording of body temperature	•			•		
Recording of previous Rotarix™ vaccination	٠					
Vaccination	•			٠		
Daily post-vaccination recording of solicited symptoms within 8 days (Days 0 – Day 7) by subjects' parents/guardians on diary cards	•	•		•	•	
Recording of unsolicited symptoms AEs occurring within 8 days (Day 0 – 7) post-vaccination from Day 0 to Day 30 after vaccination, by subjects infants' parents/guardians on diary cards	•	•	•	•	•	•
Passive reporting of unsolicited symptoms occurring from Day 8 up to Day 30 after vaccination			•			•
Return of diary cards		•	•		•	•
Record any concomitant medication/vaccination	•	•	•	•	•	•
Reporting of Serious Adverse Events	•	•	•	•	٠	•
Reporting of Serious Adverse Events	•	•	•	•	•	1

Section 5.4 Outline of PMS Procedures:

• is used to indicate a PMS procedure that requires documentation in the individual CRF.

o is used to indicate a PMS procedure that does not require documentation in the individual CRF.

*Diary card will be returned by parents/guardians of infants on Day 7 **30** or after. If the same is not returned, the investigator will make a phone contact to record all AEs in the medical record and then transcribe the information into the CRF.

§Visit 2 will be omitted only for those infants who have received one dose of *Rotarix* prior to the start of the PMS and have received the second dose of the vaccine at Visit 1 or if the investigator confirms that the infant will not be vaccinated in the same centre. The infants who have received a dose of the vaccine prior to the start of the PMS will have only one visit followed by the phone contact and the post-Dose 2 data collected will be recorded under the Visit 2 section of the CRF.

¶If infants receive the 2nd dose at Visit 1 or if the investigator confirms that infants will not be vaccinated in the same centre.

Section 5.5 Detailed description of visits:

Visit 1 (Day 0): Rotarix[™] vaccination:

- Checking of contraindications to vaccination (See Appendix C).
- Diary cards will be provided to the parents/guardians of all infants to record information on solicited symptoms (fever, irritability/fussiness, diarrhoea, vomiting, loss of appetite and cough/runny nose) and unsolicited symptoms *AEs* occurring on the day of Dose 1 and the following *30* days.
- The parents/guardians should be instructed to return the completed diary card to the investigator 7-30 days following Dose 1, at the next contact or by mail.

Day 7 (Return of diary cards/Phone contact)

- Recording of solicited symptoms (fever, irritability/fussiness, diarrhoea, vomiting, loss of appetite and cough/runny nose) and unsolicited symptoms occurring from Day 0 – Day 7 after Dose 1.
- Diary cards will be filled out by the parents/guardians of all infants and will be returned to the investigator 7 days following Dose 1, at the next contact or by mail. Parents/guardians will be contacted by phone if the investigator does not receive the diary card.
- Recording of concomitant medication/vaccination administered in the CRF.
- Recording of SAEs.
- The investigator will verify the diary card and transcribe the information into the appropriate sections of the CRF, in English.

Day 30 (Passive Reporting Return of diary cards/Phone Contact)

- Passive reporting of unsolicited AEs occurring from Day 8 up to Day 30 after Dose 1 by phone contact.
- Recording of all AEs occurring from Day 0 Day 30 after Dose 1.
- Parents/guardians will be contacted by phone if the investigator does not receive the diary cards.
- The investigator will verify the diary card and transcribe the information into the appropriate sections of the CRF, in English.

Visit 2: *Rotarix* vaccination

- Checking of contraindications to vaccination (See Appendix C).
- Diary cards will be provided to the parents/guardians of all subjects to record information on solicited symptoms (fever, irritability/fussiness, diarrhoea, vomiting, loss of appetite and cough/runny nose) and unsolicited symptoms *AEs* occurring on the day of Dose 2 and the following 7 30 days.
- The parents/guardians should be instructed to return the completed diary card to the investigator 7 30 days following Dose 2, at the next contact or by mail.

Day 7 after Visit 2(Return of diary cards/Phone contact)

- Recording of solicited symptoms (fever, irritability/fussiness, diarrhoea, vomiting, loss of appetite and cough/runny nose) and unsolicited symptoms occurring from Day 0 – Day 7 after Dose 2.
- Diary cards will be filled out by the parents/guardians of all infants and will be returned to the investigator 7 days following Dose 2, at the next contact or by mail. Parents/guardians will be contacted by phone if the investigator does not receive the diary card.
- Recording of concomitant medication/vaccination administered in the CRF.
- Recording of SAEs.
- The investigator will verify the diary card and transcribe the information into the appropriate sections of the CRF, in English

Day 30 after Visit 2 (Passive Reporting Return of diary cards/Phone Contact)

- Passive reporting of unsolicited AEs occurring from Day 8 up to Day 30 after Dose 2 by phone contact.
- Recording of all AEs occurring from Day 0 Day 30 after Dose 2.
- Parents/guardians will be contacted by phone if the investigator does not receive the diary cards.
- The investigator will verify the diary card and transcribe the information into the appropriate sections of the CRF, in English.

Section 6.2 Dosage and administration:

Refer to the prescribing information in Appendix C for details on the dosage and administration of the vaccine.

Section 6.4 Subject number allocation

Target enrolment will be at least 3000 evaluable subjects infants (approximately 500 subjects per year). All infants enrolled into the PMS will receive RotarixTM vaccine in routine clinical practice settings.

Section 6.5 Method of blinding and breaking the blind

This is an open-label PMS wherein all infants will receive two doses of Rotarix[™]. Not applicable.

Section 6.9 Concomitant medication/treatment:

All concomitant medication, with the exception of vitamins and/or dietary supplements, administered at ANY time during the period starting with administration of each dose of *Rotarix RotarixTM after enrolling into the PMS* up to the end of the follow-up period for unsolicited AEs are to be recorded with generic name of the medication (trade names are allowed for combination drugs, i.e. multi-component drugs), medical indication, total daily dose, route of administration, start and end dates of treatment.

Any vaccine administered in the period beginning 30 days preceding each dose of *Rotarix Rotarix*TM and ending one month (minimum 30 days) after is to be recorded with trade name, route of administration and date(s) of administration.

During the period starting with administration of each dose of *Rotarix Rotarix*[™] up to the end of the follow-up period for unsolicited AEs, concomitant medication administered for the treatment of an AE must be recorded in the CRF with generic name of the medication (trade names are allowed for combination drugs only), medical indication (including which AE), total daily dose, route of administered for the treatment of an SAE, at any time, must be recorded on the SAE Report Form.

Section 8.1 Definition of an adverse event:

N.B. AEs to be recorded as endpoints (solicited events) are described in Section 8.5.1. All other AEs will be recorded as UNSOLICITED AES.

Solicited adverse events

Solicited adverse events will be evaluated within the 8-day (Day 0 – Day 7) follow-up period after each vaccine dose. Diary cards will be provided to the parents/guardians of the subject by the sponsor to record the symptoms observed.

Solicited general AEs

Table 4 specifies the AEs solicited during this PMS.

Table 4 Solicited general adverse events



N.B. Temperature will be recorded in the evening. Should additional temperature measurements be performed at other times of day, the highest temperature will be recorded.

Section 8.5 Time period, frequency, and method of detecting adverse events and serious adverse events

All AEs occurring within 31 days (Day 0 - Day 30) following administration of each dose of vaccine *received after enrolling into the PMS* must be recorded into the Adverse Event form in the infant's CRF, irrespective of intensity or whether or not they are considered vaccination-related.

The standard time period for collecting and recording SAEs will begin at the first receipt of Rotarix *Rotarix*TM and will end at the last contact for each infant.

Section 8.6.1 Assessment of intensity

Intensity of the following AEs will be assessed as described in Table 5.

Tabla 5	Intonsity see	los for solio	itad symptoms
Table 5	munsity sea	ites for some	iteu symptoms

Adverse Event	Intensity grade	Parameter
Fever*	•	Record temperature in °C
Irritability/Fussiness	θ	Behaviour as usual
	1	Crying more than usual/ no effect on normal activity
	2	Crying more than usual/ interferes with normal activity
	3	Crying that cannot be comforted/ prevents normal activity
Diarrhoea¶		Record the number of looser than normal stools /day
Vomiting§		Record the number of vomiting episodes/day
Loss of appetite 0		Appetite as usual
	1	Eating less than usual/ no effect on normal activity
	2	Eating less than usual/ interferes with normal activity
	3	Not eating at all
Cough/runny nose	θ	Normal
	1	Cough/runny nose which is easily tolerated
	2	Cough/runny nose which interferes with daily activity
	3	Cough/runny nose which prevents daily activity

*Fever is defined as: axillary temperature ≥37.5°C/oral temperature ≥37.5°C/tympanic temperature on oral setting ≥37.5°C.

¶Diarrhoea is defined as passage of three or more looser than normal stools within a day.

§Vomiting is defined as one or more episodes of forceful emptying of partially digested stomach contents ≥ 1 hour after feeding within a day.

The maximum intensity of diarrhoea, vomiting and fever occurring during the solicited 8-day (Day 0 — Day 7) follow-up period will be scored at GSK Biologicals as shown in Table 6.

Table 6 Intensity scales used at GSK Biologicals for diarrhoea, vomiting and fever reported during the solicited follow-up period

Adverse Event	Intensity grade	Parameter
Diarrhoea	0	Normal (0 - 2 looser than normal stools/day)
	4	3 looser than normal stools/day
	2	4 - 5 looser than normal stools/day
	3	≥ 6 looser than normal stools/day
Vomiting	θ	Normal (no emesis)
-	1	1 episode of vomiting/day
	2	2 episodes of vomiting/day
	3	≥ 3 episodes of vomiting/day
Fever	θ	tympanic temperature/axillary temperature/oral temperature < 37.5 °C
	4	tympanic temperature/axillary temperature/oral temperature $\ge 37.5 - \le 38.0^{\circ}$ C
	2	tympanic temperature/axillary temperature/oral temperature > $38.0 - \le 39.0^{\circ}$ C
	3	tympanic temperature/axillary temperature/oral temperature > 39.0°C
*Fever is defined as	s: axillary temperatu	re ≥37.5°C/oral temperature ≥37.5°C/tympanic temperature on oral setting

*Fever is defined as: axillary temperature ≥37.5°C/oral temperature ≥37.5°C/tympanic temperature on oral setting ≥37.5°C.

Section 8.6.1 Assessment of Intensity

The investigator will make an assessment of the maximum intensity that occurred over the duration of the event for all other AEs, i.e. unsolicited symptoms, including SAEs *(i.e. non-serious adverse events)* reported during the PMS.

The intensity of each AE and SAE recorded in the CRF or SAE Report Form, as applicable, should be assigned to one of the following categories:

1 (mild)	=	An AE which is easily tolerated by the infant, causing minimal discomfort and not interfering with everyday activities.
2 (moderate)	=	An AE which is sufficiently discomforting to interfere with normal everyday activities.
3 (severe)	=	An AE which prevents normal, everyday activities. (In a young child, such an AE would, for example, prevent attendance at school/kindergarten/a day-care centre and would cause the parents/guardians to seek medical advice).
n AE that is as	sesse	d as Grade "3" (severe) should not be confused with a SAE.

An AE that is assessed as Grade "3" (severe) should not be confused with a SAE. Grade "3" is a category utilised for rating the intensity of an event.; and both AEs and SAEs can be assessed as Grade "3". An event is defined as 'serious' when it meets one of the pre-defined outcomes as described in Section 8.2.

Section 8.6.2 Assessment of causality

The investigator will also consult the Investigator Brochure and/or Product Information, for marketed products, in the determination of his/her assessment.

As per KFDA requirements, causality will be assessed as:

1. Definitely related:

- There is evidence of exposure of the drug.
- The temporal sequence of the AE onset relative to administration of the drug is reasonable
- AE is more likely explained by the drug than by another cause
- The AE is subsiding or disappearing on withdrawal of the drug
- Rechallenge (if feasible) is positive.
- The AE shows a pattern consistent with previous knowledge of the drug or the drug class.

2. Probably related:

There is evidence of exposure of the drug.

- The temporal sequence of the AE onset relative to administration of the drug is reasonable
- AE is more likely explained by the drug than by another cause
- The AE is subsiding or disappearing on withdrawal of the drug

3. Possibly related:

- The temporal sequence of the AE onset relative to administration of the drug is reasonable
- The AE could have been due to another equally likely cause
- 4. Probably not related:
 - There is no evidence of exposure of the drug
 - There is another more likely cause of the AE
 - The AE is not disappearing even on withdrawal of the drug (if performed) or ambiguous
- 5. Unknown

NOTE: The use of the term "drug" here refers to the vaccine.

As per KFDA requirements, causality will be assessed as:

- 1. Certain:
 - The relationship of the administration and use of the drug is reasonable and it is not able to be explained by other medication, chemical substances or concomitant disease, it shows clinically reasonable response on withdrawal of the drug, the decisive case in the pharmacological or phenomenological aspect on re-challenge of the drugs if needed.
- 2. Probable/Likely:
 - The temporal sequence of the administration and use of the drug is appropriate and it does not seem that it is accompanied by other medications, chemical substances or concomitant disease, in the case that shows clinically appropriate response on withdrawal of the drug (no information for re-challenge).
- 3. Possible:
 - The temporal sequence of the administration and use of the drug is appropriate but it is also able to be explained by other medications, chemical substances or concomitant disease, and information related to withdrawal of the drug is insufficient or vague.
- 4. Unlikely:
 - It is a transitory case which may not have causality with the administration and use of the drug, it is also able to be explained reasonably by other medications, chemical substances or latent disease.
- 5. Conditional/Unclassified:
 - In the case that more information is needed for a proper evaluation or additional information is under review.
- 6. Unassessible/Unclassifiable:
 - In the case that could not be judged due to insufficient or conflicting information and no way to complement or validate.

Section 8.6.3 Medically attended visits

For each solicited and unsolicited symptom *AE* the infant experiences, the infant's parents/guardians will be asked if they received medical attention defined as hospitalisation, an emergency room visit or a visit to or from medical personnel (medical doctor) for any reason and this information will be recorded in the CRF.

Section 8.7 Follow-up of adverse events and serious adverse events and assessment of outcome

Outcome of any non-serious AE occurring within 31 days (Day 0 - Day 30) days post-vaccination (i.e. unsolicited AE) or any SAE reported during the entire PMS will be assessed as:

- Recovered/resolved
- Not recovered/not resolved
- Recovering/resolving
- Recovered with sequelae/resolved with sequelae
- Fatal (SAEs only)
- Unknown

Section 8.8.2. Completion and transmission of serious adverse event reports to GSK Biologicals

Study Contact for Reporting SAEs				
Refer to the Spon	sor Information Sheet			
	Back-up Study Conta	et for Reporting SAEs		
GSK Biologicals	Clinical Safety Physic	sian and a state of the state		
Tel: PPD				
Fax: PPD	- or -PPD			
Mobile phones fo	r 7/7 day availability:			
PPD	(Head Safety Evaluation	ation and Risk Management		
-Paediatric)		č		
Back-up mobile phone contact:				
PPD				
PPD				
24/24 hour and 7/7 day availability				

CONFIDENTIAL

Amenament 4				
Study Contact for Reporting SAEs				
Refer to the Sponsor Information Sheet				
Back-up Study Contact for Reporting SAEs				
GSK Biologicals Clinical Safety and Pharmacovigilance				
Fax: PPD or PPD				
24/24 hour and 7/7 day availability				
Section 8.10 Post-PMS adverse events and serious adverse events				
However, if the investigator learns of any SAE, including a death, at any time after an infant has been discharged from the PMS, and he/she considers the event reasonably related to <i>Rotarix-Rotarix</i> TM , the investigator will promptly notify the Study Contact for Reporting SAEs.				
Section 9.1 Subject completion				
An infant who has the 30 day safety contact for passive reporting after the second Rotarix [™] vaccination is considered to have completed the PMS.				
Section 9.2.1 Subject withdrawal from the PMS				
A subject qualifies as a 'withdrawal' from the PMS if the second Rotarix TM vaccination is not given in this PMS or when the 30 day safety contact for passive reporting after the last Rotarix TM dose does not take place.				
Section 10.1 Endpoints				
 Occurrence of solicited AEs during the 8-day (Day 0 – Day 7) follow-up after each vaccine dose. 				
 Occurrence of unsolicited AEs during the 31-day (Day 0 – Day 30) follow-up period after each vaccine dose according to Medical Dictionary for Regulatory Activities (MedDRA) classification. 				
Section 10.3.1 Total Vaccinated Cohort				
The total vaccinated cohort will include all vaccinated subjects with at least one dose of Rotarix Rotarix [™] administration documented				
Section 10.4 Derived and transformed data				
Infants who missed reporting symptoms (solicited/unsolicited AEs or concomitant medications) will be treated as withdrawals infants without symptoms (solicited/unsolicited AEs or concomitant medications, respectively).				

Section 10.5 Final analyses

Statistical analyses will be performed as per the GSK standards as well as to reflect the requirements of KFDA.

Section 10.5.2 Analysis of safety

For all infants enrolled prior to Amendment 3 dated 10 February 2010, the following statistical analysis will be performed:

For all subjects enrolled after the Amendment 3 dated 10 February 2010, the following statistical analysis will be performed:

The AEs/SAEs collected will be analysed in the study report according to the expectedness and unexpectedness criteria. Refer to the Glossary of Terms for the definitions of expected AEs and unexpected AEs.

The overall incidence, with exact 95% confidence interval (CI), of any adverse events occurring within 31 days will be tabulated, for each dose, for overall doses and per subject. The same calculations will be done for any adverse events; rated as grade "3" and for all the causality grading mandated by KFDA.

The verbatim reports of AEs will be reviewed by a physician and the signs and symptoms will be coded according to MedDRA. Every verbatim term will be matched with the appropriate Preferred Term. The percentage of subjects with AEs occurring within 31 days with its exact 95% CI will be tabulated by preferred term. Similar tabulation will be done for AEs rated as grade 3 and for all causality grading mandated by KFDA.

The percentage of subjects who received at least one concomitant medication/vaccination during the 30 day follow-up period will be tabulated by type of medication, with exact 95% CI. Similar tabulations will be done for subjects who receive concomitant medication/vaccination during the entire PMS period.

Serious adverse events and withdrawals due to adverse events reported during the PMS period will be described in detail.

In addition, specific statistical analyses (e.g. AEs classified by gender, past medical history, concomitant medication/vaccination etc) will be performed to reflect the KFDA requirements.

Section 11 Administrative Matters

To comply with Good Clinical Practice, local rules, regulations, relevant GSK SOPs/Policies/Guidance, important administrative obligations relating to investigator responsibilities, monitoring, archiving data, audits, confidentiality and publications must be fulfilled.

Appendix A Administrative Matters

Responsibilities of the Investigator

• To conduct the study in compliance with the protocol any amendment, and "Good Clinical Practice" (GCP) and all applicable regulatory requirements *and GSK SOPs/Policies and Guidance.*

Monitoring by GSK Biologicals

• These visits are for the purpose of confirming that GSK Biologicals' sponsored studies are being conducted in accordance with the ethical principles that have their origins in the Declaration of Helsinki and that are consistent with Good Clinical practice (GCP), the applicable regulatory requirement(s) and relevant GSK SOPs/Policies and Guidance (verifying continuing compliance with the protocol, amendment(s), verifying that the site staff and facilities continue to be adequate to conduct the PMS.

Audits

- For the purpose of compliance with Good Clinical Practice, Regulatory Agency Guidelines and relevant GSK SOPs/Policies and Guidance it may be necessary for GSK or a Drug Regulatory Agency to conduct a site audit.
- In addition, Regulatory Compliance assures that GSK Biologicals' sponsored studies are in accordance with GCP and that relevant *regulatory*/guidelines and relevant GSK SOPs/Policies and Guidance are being followed

Appendix B Overview of Recruitment Plan:

- Target enrolment will be at least 3000 evaluable subjects *infants* (approximately 500 subjects per year)
- The PMS is required to be conducted in at least one hospital (with IRB oversight) in order for PMS to be conducted in private clinics (with no IRB).

Appendix C Prescribing Information

Refer to locally approved prescribing information. (The prescribing information has been deleted from the protocol).

GlaxoSmithKline Biologicals

Clinical Research & Development		
	Protocol Am	endment 4
eTrack study number	eTrack study number 111700 (Rota-070 PMS)	
and Abbreviated Title		
Amendment number:	Amendment 4	
Amendment date:	23 February 20	12
Co-ordinating author:	PPD	Project Manager - Scientific Writing,
	Manpower Bus	iness Solutions for GSK Biologicals.

Rationale/background for changes:

The protocol has been amended to reflect the two new vaccine presentations that have been launched in Korea. The current PMS will thus collect safety information from subjects who have received either RotarixTM or RotarixTM liquid formulation (oral suspension or prefilled syringe).

The changes have been reflected in all applicable sections across the document. **Amended text has been indicated by** *bold italics*.

Title Page:

GlaxoSmithKline (GSK) Biologicals' oral live attenuated human rotavirus (HRV) vaccine, RotarixTM or RotarixTM liquid formulation (oral suspension or prefilled syringe)

Title:

Safety of GlaxoSmithKline (GSK) Biologicals' oral live attenuated human rotavirus (HRV)-vaccine, RotarixTM or RotarixTM liquid formulation (oral suspension or prefilled syringe) when administered according to the prescribing information in Korea.

Detailed Title:

Open, multi-centric, post-marketing surveillance (PMS) to monitor the safety of GlaxoSmithKline (GSK) Biologicals' oral live attenuated human rotavirus (HRV) vaccine, RotarixTM or RotarixTM liquid formulation (oral suspension or prefilled syringe) when administered according to the prescribing information in Korea.

Section 1.2 Rationale:

GSK Biologicals' vaccine, RotarixTM (lyophilised formulation) was registered in Korea in March 2008. RotarixTM liquid formulation (oral suspension) was registered in Korea in January 2011 while RotarixTM liquid formulation (prefilled syringe) was registered in December 2011. Following the vaccine registration, safety information on the use of all the RotarixTM presentations is required as per the regulations of the Korean Food and Drugs Administration (KFDA) in at least 3000 evaluable Korean infants.

Section 2 Objective:

To assess the safety of RotarixTM or RotarixTM liquid formulation (oral suspension or *prefilled syringe*) in infants when administered according to the prescribing information in Korea.

Section 3 PMS Design:

• Vaccination schedule: Two doses of RotarixTM or RotarixTM liquid formulation (oral suspension or prefilled syringe) will be administered orally as per the prescribing information in Korea.

Two doses of Rotarix[™] or Rotarix[™] liquid formulation (oral suspension or prefilled syringe) should be given before 24 weeks of age.

- Two visits are recommended as follows:
 - Visit 1: RotarixTM or RotarixTM liquid formulation (oral suspension or prefilled syringe) vaccination, subjects will be allowed to receive concomitant vaccinations.
 - Visit 2: RotarixTM or RotarixTM liquid formulation (oral suspension or prefilled syringe) vaccination, subjects will be allowed to receive concomitant vaccinations.
- Recording of AEs from Day 0 to Day 30 using the diary card after each dose of RotarixTM or RotarixTM liquid formulation (oral suspension or prefilled syringe).

Section 4.1 Number of Subjects:

As per the KFDA requirements, safety information from at least 3000 evaluable infants are needed *for this PMS study*.

Section 4.2 Inclusion Criteria:

A male or female infant from the age of 6 weeks at the time of the first vaccination. (Note: Two doses of the RotarixTM or RotarixTM liquid formulation (oral suspension or prefilled syringe) vaccine should be completed by the age of 24 weeks).

Footnote for Table 1 List of PMS procedures:

§Visit 2 will be omitted only for those infants who have received one dose of Rotarix[™] or Rotarix[™] liquid formulation (oral suspension or prefilled syringe) prior to the start of the PMS and have received the second dose of the vaccine at Visit 1 or if the investigator confirms that the infant will not be vaccinated in the same centre.

Section 5.5 Detailed description of visits:

Visit 1 (Day 0): Rotarix[™] or Rotarix[™] liquid formulation (oral suspension or prefilled syringe) vaccination

- Record previous history of any RotarixTM or RotarixTM liquid formulation (oral suspension or prefilled syringe) vaccine administration (if applicable)
- Vaccination:
 - One dose of RotarixTM or RotarixTM liquid formulation (oral suspension or prefilled syringe) will be administered orally according to instructions specified in section 6.2.

Visit 2: RotarixTM or RotarixTM liquid formulation (oral suspension or prefilled syringe) vaccination

- Vaccination:
 - One dose of RotarixTM or RotarixTM liquid formulation (oral suspension or prefilled syringe) will be administered orally according to instructions specified in section 6.2.

Section 6 Indication and Dosage/Administration

Rotarix[™] or Rotarix[™] liquid formulation (oral suspension or prefilled syringe) to be used in this PMS has been developed and manufactured by GSK Biologicals.

Section 6.2 Dosage and administration

RotarixTM or RotarixTM liquid formulation (oral suspension) or RotarixTM liquid formulation (prefilled syringe) will be administered twice orally as per the prescribing information in Korea.

Two doses of Rotarix[™] or Rotarix[™] liquid formulation (oral suspension or prefilled syringe) should be given before 24 weeks of age.

Section 6.4 Subject number allocation

Target enrolment will be at least 3000 evaluable infants. All infants enrolled into the PMS will receive Rotarix[™] or Rotarix[™] liquid formulation (oral suspension or prefilled syringe) vaccine in routine clinical practice settings.

Section 6.9 Concomitant medication/treatment

All concomitant medication, with the exception of vitamins and/or dietary supplements, administered at ANY time during the period starting with administration of each dose of RotarixTM or RotarixTM liquid formulation (oral suspension or prefilled syringe) after enrolling into the PMS up to the end of the follow-up period for AEs are to be recorded with generic name of the medication (trade names are allowed for combination drugs, i.e. multi-component drugs), medical indication, total daily dose, route of administration, start and end dates of treatment.

Any vaccine administered in the period beginning 30 days preceding each dose of RotarixTM *or RotarixTM liquid formulation (oral suspension or prefilled syringe)* and ending one month (minimum 30 days) after is to be recorded with trade name, route of administration and date(s) of administration.

During the period starting with administration of each dose of RotarixTM or RotarixTM liquid formulation (oral suspension or prefilled syringe) up to the end of the followup period for AEs, concomitant medication administered for the treatment of an AE must be recorded in the CRF with generic name of the medication (trade names are allowed for combination drugs only), medical indication (including which AE), total daily dose, route of administration, start and end dates of treatment.

Section 8.2 Definition of a serious adverse event

• Is a congenital anomaly/birth defect in the off spring of a subject.

Section 8.5 Time period, frequency and method of detecting adverse events and serious adverse events

The standard time period for collecting and recording SAEs will begin at the first receipt of *RotarixTM or RotarixTM liquid formulation (oral suspension or prefilled syringe)* and will end at the last contact for each infant.

Section 8.6.2 Assessment of causality

The investigator is obligated to assess the relationship between RotarixTM or RotarixTM liquid formulation (oral suspension or prefilled syringe) and the occurrence of each AE/SAE. The investigator will use clinical judgement to determine the relationship. Alternative causes, such as natural history of the underlying diseases, concomitant therapy, other risk factors and the temporal relationship of the event to RotarixTM or RotarixTM liquid formulation (oral suspension or prefilled syringe) will be considered and investigated. The investigator will also consult the Product Information, for marketed products, in the determination of his/her assessment.

Causality of all AEs should be assessed by the investigator using the following question:

Is there a reasonable possibility that the AE may have been caused by Rotarix[™] or *Rotarix*[™] *liquid formulation (oral suspension or prefilled syringe)*?

Section 8.10 Post PMS adverse events and serious adverse events

However, if the investigator learns of any SAE, including a death, at any time after an infant has been discharged from the PMS, and he/she considers the event reasonably related to RotarixTM or RotarixTM liquid formulation (oral suspension or prefilled syringe), the investigator will promptly notify the Study Contact for Reporting SAEs.

Section 9.1 Subject completion

An infant who has the 30 day safety contact after the second RotarixTM or RotarixTM liquid formulation (oral suspension or prefilled syringe) vaccination is considered to have completed the PMS.

Section 9.2.1 Subject withdrawal from the PMS

A subject qualifies as a 'withdrawal' from the PMS if the second RotarixTM or RotarixTM liquid formulation (oral suspension or prefilled syringe) vaccination is not given in this PMS or when the 30 day safety contact after the last RotarixTM or RotarixTM liquid formulation (oral suspension or prefilled syringe) dose does not take place.

Section 9.2.2 Subject withdrawal from Rotarix

A 'withdrawal' from Rotarix[™] or Rotarix[™] liquid formulation (oral suspension or prefilled syringe) is any infant who does not receive the second Rotarix[™] or Rotarix[™] liquid formulation (oral suspension or prefilled syringe) dose in the PMS. An infant withdrawn from Rotarix[™] or Rotarix[™] liquid formulation (oral suspension or prefilled syringe) may not necessarily be withdrawn from the PMS as further procedures or follow-up may be performed (safety) if planned in the protocol.

Information relative to premature discontinuation of Rotarix[™] or Rotarix[™] liquid *formulation (oral suspension or prefilled syringe)* will be documented on the Vaccine Administration page of the CRF.

Section 10.2 Estimated sample size

According to KFDA regulation requirement, at least 3000 evaluable subjects (approximately 500 subjects per year for a period of 6 consecutive years) will be recruited for the PMS.

Table 4 and Table 5 presents the exact two-sided 95% confidence interval for a sample size of 500 (3000) subjects.

Exact two-sided 95% CI for a sample size of 500 subjects

Observed rate expressed as a percentage (number of subjects reporting at least one symptom)	Exact two-sided 95% CI for this observed rate for a sample size of 500 subjects	
	Lower limit (LL)	Upper limit (UL)
50(250)	45.5	54.5
55(275)	50.5	59.4
60(300)	55.6	64.3
65(325)	60.6	69.2
70(350)	65.8	74.0
75(375)	71.0	78.7
80(400)	76.2	83.4
85(425)	81.6	<u>88.0</u>

Section 10.3.1 Total Vaccinated Cohort

The total vaccinated cohort will include all vaccinated subjects with at least one dose of *RotarixTM or RotarixTM liquid formulation (oral suspension or prefilled syringe)* administration documented.

gsk					
GlaxoSmithk	line				
Study I	Repo	rting and A	analysis P	lan Approv	al
Title:	Open, multi-centric, post-marketing surveillance (PMS) to monitor the reactogenicity and safety of GlaxoSmithKline (GSK) Biologicals. oral live attenuated human rotavirus (HRV) vaccine, Rotarix. When administered according to the prescribing information in Korea				
eTrack study number	1117	/00			
eTrack abbreviated title	Rota	-070 PMS			
Scope:	All d	lata pertaining	g to the abo	ve study	
Date:	19-Ja	an-2009			
Co-ordinating author:	PPD				
Other author(s):	PPD				
Approved by:					
Director, Global Clinica					
Research and Developm		Name		Signature	dd-mmm-yyyy
		PPD		Bigliature	dd illillir yyyy
Clinical Development Manager					
		Name		Signature	dd-mmm-yyyy
		PPD			
Project Statistician		Nome		Cionataria	
		Name PPD		Signature	dd-mmm-yyyy
Franchise Statistician		Name		Signature	dd-mmm-yyyy
		PPD			

TABLE OF CONTENTS

PAGE

1.	LIST	OF AMENDMENTS TO THE RAP	9
2.	INTRO	DDUCTION	9
3.	DATA 3.1. 3.2. 3.3. 3.4. 3.5. 3.6. 3.7. 3.8. 3.9.	EVALUATION: CRITERIA FOR EVALUATION OF OBJECTIVES Endpoints Study cohorts to be evaluated Total Vaccinated cohort Derived and transformed data Data presentation description Group description Final analyses Methodology for computing CI Conduct of analyses 3.8.1. Sequence of analyses 3.8.2. Statistical considerations for interim analyses Statistical methods	
4.	CHAN	IGE FROM PROTOCOL	11
5.	ANNE 5.1. 5.2. 5.3.	X 1: INDIVIDUAL LISTINGS AND TEMPLATE OF TABLES Individual listings List of tables 5.2.1. For Demographics & baseline characteristics Analysis: 5.2.2. For Reactogenicity Analysis: 5.2.3. KFDA specific listings 5.2.4. KFDA specific tables Template of tables	12 13 13 14 16 17
6.		X 2: CRITERIA FOR ELIMINATING SUBJECTS FROM STAT YSES	57

LIST OF TABLES AND FIGURES

PAGE

Table D 1	Number of subjects enrolled into the study as well as the number of subjects excluded with reasons for exclusion.	19
Table D 2	Number of subjects by center (Total vaccinated cohort)	19
Table D 3	Number of subjects at each visit and list of withdrawn subjects (Total vaccinated cohort)	19
Table D 4	Number of subjects entered, completed and withdrawn with reason for withdrawal (Total vaccinated cohort)	20
Table D 5	Minimum and maximum activity dates (Total vaccinated cohort)	20
Table D 6	Summary of demographic characteristics (Total vaccinated cohort)	21
Table D 7	Summary of Previous rotavirus vaccination history (Total vaccinated cohort)	22
Table R 1	Number and percentage of subjects who received vaccine dose(s) (Total vaccinated cohort)	23
Table R 2	Compliance in returning symptom sheets (Total Vaccinated Cohort)	23
Table R 3	Percentage of doses and of subjects reporting symptoms (solicited or unsolicited) during the 8-day (Days 0-7) solicited follow-up period (Total vaccinated cohort)	24
Table R 4	Percentage of doses and of subjects reporting grade 3 symptoms (solicited or unsolicited) during the 8-day (Days 0-7) solicited follow-up period (Total vaccinated cohort)	24
Table R 5	Percentage of doses and of subjects reporting symptoms assessed as related to vaccination (solicited or unsolicited) during the 8 day (Days 0-7) solicited follow-up period (Total vaccinated cohort)	24
Table R 6	Percentage of subjects reporting each solicited general symptom including those graded 3 in intensity and those assessed as related to vaccination during the 8-day (Days 0-7) solicited follow-up period, for each dose (Total vaccinated cohort)	25

Table R 7	Percentage of doses and subjects reporting each solicited general symptom including those graded 2 or 3 in intensity and those assessed as related to vaccination during the 8-day (Days 0-7) solicited follow-up period, for all doses and per subject (Total vaccinated cohort)	27
Table R 8	Percentage of subjects reporting the occurrence of unsolicited symptoms classified by MedDRA Primary System Organ Class and Preferred Term within the 31-day (Days 0-30) post-vaccination period (Total vaccinated cohort)	29
Table R 9	Percentage of doses with unsolicited symptoms classified by MedDRA Primary System Organ Class and Preferred Term within the 31-day (Days 0-30) post-vaccination period (Total vaccinated cohort)	30
Table R 10	Percentage of subjects reporting the occurrence of grade 3 unsolicited symptoms classified by MedDRA Primary System Organ Class and Preferred Term within the 31-day (Days 0-30) post-vaccination period (Total vaccinated cohort)	30
Table R 11	Percentage of doses with grade 3 unsolicited symptoms classified by MedDRA Primary System Organ Class and Preferred Term within the 31-day (Days 0-30) post-vaccination period (Total vaccinated cohort)	30
Table R 12	Percentage of subjects reporting the occurrence of unsolicited symptoms classified by MedDRA Primary System Organ Class and Preferred Term that are causally related to vaccination, within the 31-day (Days 0-30) post-vaccination period (Total vaccinated cohort)	30
Table R 13	Percentage of doses with unsolicited symptoms classified by MedDRA Primary System Organ Class and Preferred Term that are causally related to vaccination, within the 31-day (Days 0-30) post-vaccination period (Total vaccinated cohort)	31
Table R 14	Percentage of subjects reporting the occurrence of unsolicited symptoms leading to drop out during the study period (Total vaccinated cohort)	31
Table R 15	Percentage of doses with unsolicited symptoms leading to drop out during the study period (Total vaccinated cohort)	31
Table R 16	Listing of SAEs	31
Table R 17	Number and percentage of doses and of subjects who took at least one concomitant medication from Day 0 to Day 7 after vaccination by type (Total vaccinated cohort)	32

Table R 18	least o	er and percentage of doses and of subjects who took at one concomitant medication during the entire study period se and overall (Total vaccinated cohort)	32
Table CTRS	1	Demography for CTRS	44
Table CTRS	during	Number (%) of subjects with solicited general symptom the 8-day (Days 0-7) post-vaccination period (Total nated Cohort)	45
Table CTRS		Number (%) of subjects with adverse events (Total nated cohort)	47
Table CTRS		Number (%) of subjects with serious adverse events (Total nated cohort)	47

Table KFDA 1	Summary of post marketing surveillance	33
Table KFDA 2	Table of Subjects	34
Table KFDA 3	Line-listing of AE	35
	Line-Listing of Adverse Events with a causal relationship to accination.	36
Table KFDA 5	Line-listing AEs from clinical trial and spontaneous report	37
Table KFDA 6	Line-listing of reported SAE and unexpected ADR	38
Table KFDA 7	Contents of SAE and unexpected ADR	39
Table KFDA 8	Line-listing of SAE and unexpected ADR	40
Table KFDA 9	Individual Line-listing for All Subjects	42
Table KFDA 10	Demographic data - by gender	48
Table KFDA 11	Pre-exist medical history – by gender	48
Table KFDA 12	pre-exist medical history - by classification	49
Table KFDA 13	Pre-rotavirus vaccination history	49
Table KFDA 14	Administration of concomitant medication – by gender	49
Table KFDA 15	Administration of concomitant medication – by classification	50
Table KFDA 16	Administration of concomitant vaccination –	50
Table KFDA 17	Administration of study vaccination – by gender	50
Table KFDA 18 r	Summary of serious adverse events, adverse drug eactions	51
Table KFDA 19	Serious adverse events, adverse drug reactions	51
Table KFDA 20	Adverse events, adverse drug reactions	51
	Adverse events (Solicited and Unsolicited) experienced by subjects during the entire study period; stratified by gender (Total vaccinated cohort)	52

Table KFDA 2	Adverse events (Solicited and Unsolicited) experienced by subjects during the entire study period; stratified by age (Total vaccinated cohort)	52
Table KFDA 2	Adverse events (Solicited and Unsolicited) experienced by subjects at any time during the study; stratified by concomitant medication (Total vaccinated cohort)	52
Table KFDA 2	Adverse events (Solicited and Unsolicited) experienced by subjects at any time during the study; stratified by concomitant vaccination (Total vaccinated cohort)	52
Table KFDA 2	5 Adverse events experienced by subjects at any time during the study; stratified by past medical history status (Total vaccinated cohort)	53
Table KFDA 2	6 Adverse events by medical history – by gender & classification	53
Table KFDA 2	Adverse events by concomitant medication – by classification	53
Table KFDA 2	8 Adverse events by concomitant vaccinations – by Classification	54
Table KFDA 2	9 Adverse events by medical history, Concomitant vaccination, concomitant medication	54
Table KFDA 3	0 Adverse events by duration	55
Table KFDA 3	Adverse events by severity	55
Table KFDA 3	2 Adverse events by causality	56
Table KFDA 3	3 Adverse events by outcome	56

LIST OF ABBREVIATIONS

AE	Adverse event
CI	Confidence Interval
CRF	Case Report Form
GSK	GlaxoSmithKline
MedDRA	Medical Dictionary for Regulatory Activities
NA.	Not Applicable
GE	Gastroenteritis
SAE	Serious Adverse Event
HRV	Human rotavirus
LL	Lower limit
UL	Upper limit
SD	Standard deviation

1. LIST OF AMENDMENTS TO THE RAP

Date	Description
19 Jan 2009	First version

2. INTRODUCTION

This document summarizes the planned statistical analyses (Sections 3 & 4) based on the study features as per protocol amendment 2 dated 13Oct2008. The changes in the analyses as compared to the protocol/amendment 2 are provided in section 4. The list of tables/listings to be produced in the statistical report is available in section 5.

3. DATA EVALUATION: CRITERIA FOR EVALUATION OF OBJECTIVES

3.1. Endpoints

- Occurrence of solicited AEs during the 8-day (Day 0 Day 7) follow-up after each vaccine dose.
- Occurrence of unsolicited AEs during the 31-day (Day 0 Day 30) follow-up period after each vaccine dose according to Medical Dictionary for Regulatory Activities (MedDRA) classification.
- Occurrence of SAEs during the entire PMS period..

3.2. Study cohorts to be evaluated

Total Vaccinated cohort

The total vaccinated cohort will include all vaccinated subjects with at least one dose of Rotarix administration documented:

• a safety analysis based on the total vaccinated cohort will include all vaccinated subjects.

The list of applicable elimination codes for each cohort can be found in the study specific form FORM-BIO-WWCD-9004-05 Elim code specifications.

Cohort	Elimination codes	Eli Type
Total vaccinated cohort	1030	MA

3.3. Derived and transformed data

Infants who missed reporting symptoms (solicited/unsolicited or concomitant medications) will be treated as subjects without symptoms (solicited/unsolicited or concomitant medications, respectively). In case of significant non-compliance of PMS procedures for reporting symptoms, the analysis plan will be reassessed to ensure more accurate reporting of PMS data by further analysis.

3.4. Data presentation description

The following decimal description will be used for the demography, reactogenicity/Safety.

Display Table	Parameters	Number of decimal digits
All summaries	% of count, including LL & UL of CI	1
Demographic characteristics	Mean, median age	1
Demographic characteristics	SD (age)	2

3.5. Group description

The following group will be used for the statistical analyses.

Study	Group order in tables	Group label in tables
Rota_070	1	HRV

3.6. Final analyses

As per protocol.

3.7. Methodology for computing Cl

All CI will be 2 sided 95% CI.

• The exact 95% CIs for proportion within a group will be calculated from Proc StatXact 7.0 assuming independence between doses.

3.8. Conduct of analyses

3.8.1. Sequence of analyses

NA

3.8.2. Statistical considerations for interim analyses

As per protocol

3.9. Statistical methods

As per protocol

4. CHANGE FROM PROTOCOL

- **Derived and Transformed Data**: Infants who missed reporting symptoms (solicited/unsolicited or concomitant medications) will be treated as subjects without symptoms (solicited/unsolicited or concomitant medications, respectively).
- A combined year1 & 2 analyses will be performed for this time point.
- KFDA Specific tables and Listings are mentioned in RAP

5. ANNEX 1: INDIVIDUAL LISTINGS AND TEMPLATE OF TABLES

5.1. Individual listings

Appendix Table I.A - Elimination codes Appendix Table I.B - Demography Appendix Table I.Ci - Dates of birth, Informed consent, Vaccination and Contact Appendix Table I.Cii - Reason for visit not done Appendix Table I.G - Vaccination procedure Appendix Table I.H - Previous History of Rotavirus Vaccination Appendix Table I.I - Reason for not administration of vaccine Appendix Table II.B - Solicited general symptoms Appendix Table II.Ci - Unsolicited adverse events Appendix Table II.Di - Concomitant medications Appendix Table II.Dii - Concomitant vaccinations Appendix Table II.Dii - Study Conclusion

5.2. List of tables

5.2.1. For Demographics & baseline characteristics Analysis:

TABLE # in reference of section 5.3	Table Title	Analysis year 1 & year 2	Масго
Table D 1	Number of subjects enrolled into the study as well as the number of subjects excluded with reasons for exclusion.	CR	%ELIMLIST
Table D 2	Number of subjects by center (Total vaccinated cohort)	CR	%CENTER
Table D 3	Number of subjects at each visit and list of withdrawn subjects (Total vaccinated cohort)	ST	%DROPOUT
Table D 4	Number of subjects entered, completed and withdrawn with reason for withdrawal (Total vaccinated cohort)	CR	%DROP_SUM
Table D 5	Minimum and maximum activity dates (Total vaccinated cohort)	WT	%DATE
Table D 6	Summary of demographic characteristics (Total vaccinated cohort)	CR	%DEMOGRA
Table D 7	Summary of Previous rotavirus vaccination history (Total vaccinated cohort)	CR	%FREQ_DIS
Table CTRS 1	Demography for CTRS	CTRS	%CTR_DEMOG

CR = Within the clinical report

ST = As a supplementary table or figure WT = As a working or CTRS table or figure

5.2.2. For Reactogenicity Analysis:

TABLE # in reference of section 5.3	Table Title	Analysis year 1 & year 2	Macro
Table R 1	Number and percentage of subjects who received vaccine dose(s) (Total vaccinated cohort)	CR	%EXPO
Table R 2	Compliance in returning symptom sheets (Total Vaccinated Cohort)	ST	%COMPLI
Table R 3	Percentage of doses and of subjects reporting symptoms (solicited or unsolicited) during the 8-day (Days 0-7) solicited follow-up period (Total vaccinated cohort)	CR	%LOCGEN
Table R 4	Percentage of doses and of subjects reporting grade 3 symptoms (solicited or unsolicited) during the 8-day (Days 0-7) solicited follow-up period (Total vaccinated cohort)	CR	%LOCGEN
Table R 5	Percentage of doses and of subjects reporting symptoms assessed as related to vaccination (solicited or unsolicited) during the 8 day (Days 0-7) solicited follow-up period (Total vaccinated cohort)	CR	%LOCGEN
Table R 6	Percentage of subjects reporting each solicited general symptom including those graded 3 in intensity and those assessed as related to vaccination during the 8-day (Days 0-7) solicited follow-up period, for each dose (Total vaccinated cohort)	CR	%FREQ
Table R 7	Percentage of doses and subjects reporting each solicited general symptom including those graded 2 or 3 in intensity and those assessed as related to vaccination during the 8-day (Days 0-7) solicited follow-up period, for all doses and per subject (Total vaccinated cohort)	ST	%FREQ
Table R 8	Percentage of subjects reporting the occurrence of unsolicited symptoms classified by MedDRA Primary System Organ Class and Preferred Term within the 31- day (Days 0-30) post-vaccination period (Total vaccinated cohort)	CR	%UNSOL
Table R 9	Percentage of doses with unsolicited symptoms classified by MedDRA Primary System Organ Class and Preferred Term within the 31-day (Days 0-30) post-vaccination period (Total vaccinated cohort)	ST	%UNSOL
Table R 10	Percentage of subjects reporting the occurrence of grade 3 unsolicited symptoms classified by MedDRA Primary System Organ Class and Preferred Term	CR	%UNSOL

TABLE # in reference of section 5.3	Table Title	Analysis year 1 & year 2	Macro
	within the 31-day (Days 0-30) post-vaccination period		
Table D 11	(Total vaccinated cohort)	OT	
Table R 11	Percentage of doses with grade 3 unsolicited symptoms classified by MedDRA Primary System Organ Class and Preferred Term within the 31-day (Days 0-30) post-vaccination period (Total vaccinated cohort)	ST	%UNSOL
Table R 12	Percentage of subjects reporting the occurrence of unsolicited symptoms classified by MedDRA Primary System Organ Class and Preferred Term that are causally related to vaccination, within the 31-day (Days 0-30) post-vaccination period (Total vaccinated cohort)	CR	%UNSOL
Table R 13	Percentage of doses with unsolicited symptoms classified by MedDRA Primary System Organ Class and Preferred Term that are causally related to vaccination, within the 31-day (Days 0-30) post- vaccination period (Total vaccinated cohort)	ST	%UNSOL
Table R 14	Percentage of subjects reporting the occurrence of unsolicited symptoms leading to drop out during the study period (Total vaccinated cohort)	ST	%UNSOL
Table R 15	Percentage of doses with unsolicited symptoms leading to drop out during the study period (Total vaccinated cohort)	ST	%UNSOL
Table R 16	Listing of SAEs	ST	%SAE
Table R 17	Number and percentage of doses and of subjects who took at least one concomitant medication from Day 0 to Day 7 after vaccination by type (Total vaccinated cohort)	CR	%CMED_INC
Table R 18	Number and percentage of doses and of subjects who took at least one concomitant medication during the entire study period by dose and overall (Total vaccinated cohort)	ST	%CMED_INC
Table CTRS 2	Number (%) of subjects with solicited general symptom during the 8-day (Days 0-7) post-vaccination period (Total Vaccinated Cohort)	CTRS	%FREQ
Table CTRS 3	Number (%) of subjects with adverse events (Total vaccinated cohort)	CTRS	%CTR_AE
Table CTRS	Number (%) of subjects with serious adverse events (Total vaccinated cohort)	CTRS	%CTR_SAE
CR = Within the		1	1

CR = Within the clinical report

ST = As a supplementary table or figure

WT = As a working table or figure

5.2.3. KFDA specific listings

TABLE # in reference of section 5.3	Title		
Table KFDA 1	Summary of post marketing surveillance		
Table KFDA 2	Table of Subjects		
Table KFDA 3	Line-listing of AE		
Table KFDA 4	Line-Listing of Adverse Events with a causal relationship to vaccination.		
Table KFDA 5	Line-listing AEs from clinical trial and spontaneous report		
Table KFDA 6	Line-listing of reported SAE and unexpected ADR		
Table KFDA 7	Contents of SAE and unexpected ADR		
Table KFDA 8	Table KFDA 8Line-listing of SAE andunexpected ADR		
Table KFDA 9	Individual Line-listing for All Subjects		

5.2.4. KFDA specific tables

TABLE # in reference of section 5.3	Title
Table KFDA 10	Demographic data - by gender
Table KFDA 11	Pre-exist medical history – by gender
Table KFDA 12	pre-exist medical history - by classification
Table KFDA 13	Pre-rotavirus vaccination history
Table KFDA 14	Administration of concomitant medication – by gender
Table KFDA 15	Administration of concomitant medication – by classification
Table KFDA 16	Administration of concomitant vaccination
Table KFDA 17	Administration of study vaccination – by gender
Table KFDA 18	Summary of serious adverse events, adverse drug reactions
Table KFDA 19	Serious adverse events, adverse drug reactions
Table KFDA 20	Adverse events, adverse drug reactions
Table KFDA 21	Adverse events (Solicited and Unsolicited)
	experienced by subjects during the entire study period; stratified by age (Total vaccinated cohort)
Table KFDA 22	Adverse events (Solicited and Unsolicited) experienced by subjects during the entire study period; stratified by age (Total vaccinated cohort)
Table KFDA 23	Adverse events (Solicited and Unsolicited) experienced by subjects at any time during the study; stratified by concomitant medication (Total vaccinated cohort)
Table KFDA 24	Adverse events (Solicited and Unsolicited) experienced by subjects at any time during the study; stratified by concomitant vaccination (Total vaccinated cohort)
Table KFDA 25	Adverse events experienced by subjects at any time during the study; stratified by past medical history status (Total vaccinated cohort)
Table KFDA 26	Adverse events by medical history – by gender & classification
Table KFDA 27	Adverse events by concomitant medication – by classification
Table KFDA 28	Adverse events by concomitant vaccinations – by Classification
Table KFDA 29	Adverse events by medical history, Concomitant vaccination, concomitant medication

Table KFDA 30	Adverse events by duration
Table KFDA 31	Adverse events by severity
Table KFDA 32	Adverse events by causality
Table KFDA 33	Adverse events by outcome

• Tables KFDA 5,6,8 will be generated by LOC

5.3. Template of tables

The following tables/figures provide lay-out tables for the statistical analyses

Table D 1Number of subjects enrolled into the study as well as the number of
subjects excluded with reasons for exclusion.

	HRV		
Title	n	S	%
Total enrolled cohort	XXX		
Study vaccine dose not administered AT ALL but subject number allocated (code 1030)	XX	XX	
Total vaccinated cohort	XXX		XXX

n= number of subjects eliminated under the respective code

s= number of subjects with the elimination code assigned

Table D 2 Number of subjects by center (Total vaccinated cohort)

Center		HRV		
	n	%		
PPD				
All				

- n = number of subjects included in the group for a given center or for all centers.

- All = sum of all subjects in the group (sum of all center).

- % = n/All*100

- Center = GSK assigned center number.

Table D 3Number of subjects at each visit and list of withdrawn subjects
(Total vaccinated cohort)

Visit	N	Withdrawn Subject	Reasons for withdraw
Visit1			
Visit2			

N = number of subjects in the vaccine group

Table D 4Number of subjects entered, completed and withdrawn with reason
for withdrawal (Total vaccinated cohort)

	HRV
Number of subjects enrolled	
Number of subjects completed	
Number of subjects withdrawn	
Reasons for withdraw:	
Serious Adverse Event	
Non-serious adverse event	
Protocol violation	
Consent withdrawal (not due to an adverse event)	
Migrated/moved from study area	
Lost to follow-up (subjects with incomplete vaccination course)	
Lost to follow-up (subjects with complete vaccination course)	
Others	
Free Bart and a set of a filler to the second set of the set of the	

Enrolled = number of subjects who were enrolled in the study

Completed = number of subjects who completed the study

withdrawn = number of subjects who did not come to concluding visit

Table D 5 Minimum and maximum activity dates (Total vaccinated cohort)

Activity	Description of the Activity	Minimum	Maximum
number		date	date
10	Visit 1		
20	Visit 2		

Table D 6	Summary of demographic characteristics (Total vaccinated cohort)

	Parameters or	HRV N= XXX		
Characteristics	Categories	Value or n	%	
Age(W) at Dose 1 of HRV *	Mean			
	SD			
	Median			
	Minimum			
	Maximum			
Age(W) at Dose 2 of HRV	Mean			
	SD			
	Median			
	Minimum			
	Maximum			
Gender	Female			
	Male			
Race	Korean			
	Other			

N = total number of subjects

n = number of subjects in a given category Value = value of the considered parameter

% = n / Number of subjects with available results x 100

SD= standard deviation

Age(W)= age expressed in Weeks

* = For those subjects who received the first dose of HRV outside the PMS study, age at dose 1 is computed considering the approximate date of vaccination coded in the CRF.

Table D 7Summary of Previous rotavirus vaccination history (Total
vaccinated cohort)

		HRV N= XX	
Characteristics	Parameters or Categories	n	%
Did the subject receive HRV vaccine prior to the PMS study?	Yes		
	No		

N = Total number of subjects

n = number of subjects with HRV vaccination prior to start of this study

% = n / Number of subjects with available results x 10

Yes: Subjects with a dose of HRV prior to start of the PMS study

No: Subjects who received both the doses in this PMS study

Table R 1Number and percentage of subjects who received vaccine dose(s)
(Total vaccinated cohort)

Total number of doses received	HRV (N = XXX)		
	n	%	
1			
2			
Any			

N = number of subjects in the considered cohort

n/% = number/percentage of subjects receiving the specified total number of doses

Any = number and percentage of subjects receiving at least one dose

Table R 2 Compliance in returning symptom sheets (Total Vaccinated Cohort)

Number of Doses	Group	Doses NOT according to protocol	Number of general SS	Compliance % General SS
1	HRV			
2	HRV			

SS = Symptom sheets used for the collection of general solicited AEs

Compliance % = (number of subjects returning a symptom sheet (SS)/number of doses) x 100

Table R 3Percentage of doses and of subjects reporting symptoms (solicited
or unsolicited) during the 8-day (Days 0-7) solicited follow-up period
(Total vaccinated cohort)

		Any symptom						
			95% CI					
	Group	N	n	%	LL	UL		
Dose 1	HRV							
Dose 2	HRV							
Overall/dose	HRV							
Overall/subject	HRV							

For each dose and overall/subject:

N= number of subjects with at least one administered dose

n/%= number/percentage of subjects presenting at least one type of symptom

For overall/dose:

N= number of administered doses

n/%= number/percentage of doses followed by at least one type of symptom

95% CI = exact 95% confidence interval, LL = Lower Limit, UL = Upper Limit

Table R 4Percentage of doses and of subjects reporting grade 3 symptoms
(solicited or unsolicited) during the 8-day (Days 0-7) solicited follow-
up period (Total vaccinated cohort)

See template for **Table R 3**

Table R 5Percentage of doses and of subjects reporting symptoms assessed
as related to vaccination (solicited or unsolicited) during the 8 day
(Days 0-7) solicited follow-up period (Total vaccinated cohort)

See template for **Table R 3**

Table R 6Percentage of subjects reporting each solicited general symptom
including those graded 3 in intensity and those assessed as related
to vaccination during the 8-day (Days 0-7) solicited follow-up period,
for each dose (Total vaccinated cohort)

				HRV		
0				A /	95 % (
Symptom	Туре	N Dose 1	n	%	LL	UL
Cough /Runny nose	All	Dose i				
	Grade 3					
	Related					
Diarrhoea	All					
	Grade 3					
	Related					
Fever/(Axillary) (°C)	All					
	Grade 3					
	Related					
Irritability	All					
	Grade 3					
	Related					
Loss of appetite	All					
	Grade 3					
	Related					
Vomiting	All					
	Grade 3					
	Related					
		Dose 2				
Cough /Runny nose	All					
	Grade 3					
	Related					
Diarrhoea	All					
	Grade 3					
	Related					
Fever/(Axillary) (°C)	All					
	Grade 3					
	Related					
Irritability	All					
	Grade 3					
	Related					
Loss of appetite	All					
	Grade 3					
	Related					
Vomiting	All					
	Grade 3					
	Related					

For each dose:

N= number of subjects with at least one administered dose n/%= number/percentage of subjects reporting at least once the symptom

Table R 7Percentage of doses and subjects reporting each solicited general
symptom including those graded 2 or 3 in intensity and those
assessed as related to vaccination during the 8-day (Days 0-7)
solicited follow-up period, for all doses and per subject (Total
vaccinated cohort)

					HRV		
				1		95 % (
Symptom	Туре		N	n	%	LL	UL
Cough /Runny nose	All	Overall/sub	ject				
cough /Runny nose	Grade 3						
	Related						
Diarrhoea	All						
Diaitiioea	Grade 3						
	Related						
Fever/(Axillary) (°C)	All						
	Grade 3						
	Related						
Irritability	All						
intaointy	Grade 3						
	Related						
Loss of appetite	All						
	Grade 3						
	Related						
Vomiting	All						
vointing	Grade 3						
	Related						
	Related	Overall/do	60				
Cough /Runny nose	All	Overall/do	30				
	Grade 3						
	Related						
Diarrhoea	All						
	Grade 3						
	Related						
Fever/(Axillary) (°C)	All						
	Grade 3						
	Related						
Irritability	All						
•	Grade 3						
	Related						
Loss of appetite	All						
	Grade 3						
	Related						
Vomiting	All						
	Grade 3						
	Related						

Overall/subject:

N= number of subjects with at least one administered dose n/%= number/percentage of subjects reporting at least once the symptom

For Overall/dose:

N= number of administered doses

n/%= number/percentage of doses followed by at least one type of symptom

Table R 8Percentage of subjects reporting the occurrence of unsolicited
symptoms classified by MedDRA Primary System Organ Class and
Preferred Term within the 31-day (Days 0-30) post-vaccination period
(Total vaccinated cohort)

Primary System Organ Class (CODE)	Preferred Term (CODE)			HRV	
	. ,	n	%	95% CI	
				LL	UL
At least one symptom	Any				
Blood and lymphatic system disorders (10005329)	Anaemia (10002034)				
Autonomic nervous (420)	Mouth dry (0218)				
Body as a whole	Allergy (1058)				
general (1810)	Chest pain (0718)				
	Fever (0725)				
	Influenza-like symptoms (1222)				
	Injury (9001)				
	Pain (0730)				

At least one symptom = At least one symptom experienced regardless of the System Organ Class

N = Number of subjects having received at least one dose

n/% = Number / percentage of subjects reporting at least once a specified symptom within 31 days after vaccination day 0 to day 30

95% CI = Exact 95% confidence interval

Table R 9Percentage of doses with unsolicited symptoms classified by
MedDRA Primary System Organ Class and Preferred Term within the
31-day (Days 0-30) post-vaccination period (Total vaccinated cohort)

			(HRV N=xxx)	
			•		95% CI
Primary System Organ Class (CODE)	Preferred Term (CODE)	n	%	LL	UL
At least one symptom					
Blood and lymphatic system disorders (10005329)	Anaemia (10002034)				
	Iron deficiency anaemia (10022972)				
	Lymphadenitis (10025188)				
Ear and labyrinth disorders (10013993)	Hearing impaired (10019245)				
	Otorrhoea (10033101)				
Eye disorders (10015919)	Conjunctivitis (10010741)				
	Eye swelling (10015967)				
General disorders and administration site conditions (10018065)	Cyst (10011732)				
· · ·	Developmental delay (10012559)				

At least one symptom = at least one symptom experienced (regardless of the MedDRA Preferred Term)

N = number of administered doses

n/% = number/percentage of doses with the symptom

95% CI= exact 95% confidence interval; LL = Lower Limit, UL = Upper Limit

Table R 10Percentage of subjects reporting the occurrence of grade 3
unsolicited symptoms classified by MedDRA Primary System Organ
Class and Preferred Term within the 31-day (Days 0-30) post-
vaccination period (Total vaccinated cohort)

See template for **Table R 8**

Table R 11Percentage of doses with grade 3 unsolicited symptoms classified
by MedDRA Primary System Organ Class and Preferred Term within
the 31-day (Days 0-30) post-vaccination period (Total vaccinated
cohort)

See template for **Table R 9**

Table R 12Percentage of subjects reporting the occurrence of unsolicited
symptoms classified by MedDRA Primary System Organ Class and
Preferred Term that are causally related to vaccination, within the
31-day (Days 0-30) post-vaccination period (Total vaccinated cohort)

See template for **Table R 8**

Table R 13Percentage of doses with unsolicited symptoms classified by
MedDRA Primary System Organ Class and Preferred Term that are
causally related to vaccination, within the 31-day (Days 0-30) post-
vaccination period (Total vaccinated cohort)

See template for **Table R 9**

Table R 14Percentage of subjects reporting the occurrence of unsolicited
symptoms leading to drop out during the study period (Total
vaccinated cohort)

See template for **Table R 8**

Table R 15Percentage of doses with unsolicited symptoms leading to drop out
during the study period (Total vaccinated cohort)

See template for Table R 9

Table R 16Listing of SAEs

Group		Case Id	Age (Week)	Sex	Preferred term	MA type	Day of onset	Causality	Outcome
HRV									
	<u> </u>								
$\Lambda a_0 (wook) = $				<u> </u>					

Age (week) = Age (week) at SAE onset

Table R 17Number and percentage of doses and of subjects who took at least
one concomitant medication from Day 0 to Day 7 after vaccination
by type (Total vaccinated cohort)

			HRV		
				95% CI	
	N	n	%	LL	UL
Dose 1		•		•	
Any	Ххх	Xxx	Ххх	Ххх	Xxx
Any antipyretic	Xxx	Xxx	Ххх	Ххх	Xxx
Prophylactic antipyretic	Ххх	Ххх	Ххх	Ххх	Ххх
Any antibiotic	Ххх	Ххх	Ххх	Ххх	Xxx
Dose 2	•	•	•	•	•
Any	Xxx	Ххх	Ххх	Ххх	Xxx
Any antipyretic	Ххх	Ххх	Ххх	Ххх	Xxx
Prophylactic antipyretic	Ххх	Xxx	Ххх	Ххх	Ххх
Any antibiotic	Ххх	Xxx	Xxx	Ххх	Ххх
Overall/dose	·				
Any	Ххх	Xxx	Ххх	Ххх	Ххх
Any antipyretic	Ххх	Xxx	Ххх	Ххх	Ххх
Prophylactic antipyretic	Ххх	Ххх	Ххх	Ххх	Xxx
Any antibiotic	Ххх	Xxx	Ххх	Ххх	Ххх
Overall/subject	•	•	•	•	•
Any	Ххх	Xxx	Ххх	Xxx	Xxx
Any antipyretic	Ххх	Ххх	Ххх	Ххх	Xxx
Prophylactic antipyretic	Ххх	Xxx	Ххх	Ххх	Ххх
Any antibiotic	Xxx	Xxx	Ххх	Xxx	Xxx

For each dose and overall/subject:

N= number of subjects with at least one administered dose

n/%= number/percentage of subjects who started to take the specified concomitant medication at least once during the mentioned period

For overall/dose:

N= number of administered doses

n/%= number/percentage of doses after which the specified concomitant medication was started at least once during the mentioned period

95% CI = exact 95% confidence interval, LL = Lower Limit, UL = Upper Limit

Table R 18Number and percentage of doses and of subjects who took at least
one concomitant medication during the entire study period by dose
and overall (Total vaccinated cohort)

See template for Table R 17

Table KFDA 1 Summary of post marketing surveillance

	Su	mmary of post m	narketing surveillance
General post marketing surveillance	Performance status (number of sites, number of subjects, etc) and future surveillance plan or reason for unexecution		
		Size of the population	Results
Surveillance on special patients	Surveillance on children (<18 years old)	212	Unsolicited symptoms were reported by 85 subjects within the 31-day post-vaccination period. Grade 3 unsolicited symptoms within the 31-day post- vaccination period was reported by 1 subject. Within the 7-day post-vaccination period, 34 subjects reported unsolicited symptoms.
	Surveillance on pregnant women	0	No relevant data/No relevant subjects.
	Surveillance on renal impairment patients	0	No relevant data/No relevant subjects.
	Surveillance on liver impairment patients	0	No relevant data/No relevant subjects.
	Surveillance on other special patients	0	No relevant data/No relevant subjects.

Table KFDA 2 Table of Subjects




Table KFDA 3 Line-listing of AE

Incidence of adverse events (solicited and unsolicited) reported during the entire study period

fore ence 1 st year - -	2 nd year	3 rd year	Case report 4 th year	5 th year	6 th year	Total
-	2 nd year	3 rd year	4 th year	5 th year	6 th year	Total
-						
-						
-						
-						
-						

Adverse experience	# of subjects	# of subjects who experienced Adverse events (solicited and unsolicited) (%), [#of events]										
Period	1st	2nd	3rd	4th	5th	6th	accumulated					
ENDOCRINE DISORDERS	0 (0.0) [0]			3 (0.9) [3]	0 (0.0) [0]	0 (0.0) [0]	3 (0.3) [3]					
GROWTH HORMONE DEFICIENCY	0 (0.0) [0]			1 (0.3) [1]	0 (0.0) [0]	0 (0.0) [0]	1 (0.1) [1]					
HYPOTHYROIDISM	0 (0.0) [0]			1 (0.3) [1]	0 (0.0) [0]	0 (0.0) [0]	1 (0.1) [1]					

* Classification of symptom reported as AEs according to SOC.

Table KFDA 4 Line-Listing of Adverse Events with a causal relationship to vaccination.

Incidence of related symptoms (solicited and unsolicited) during the entire study period

Line-listing of AE Time Before Case report														
Before licence	Case report													
	1 st year	2 nd year	3 rd year	4 th year	5 th year	6 th year	Total							
-	8	-	-	22	9	8	47							
-	75	-	-	340	300	160	875							
-	4	-	-	14	78	59	155							
-	4	-	-	33	138	138	313							
-	5.3%	-	-	4.1%	26%	36.9%	17.7%							
	licence - - -	licence 1 st year - 8 - 75 - 75 - 4 - 4	Before licence Ist year 2 nd year 1 st year 2 nd year 2 nd year - 8 - - 75 - - 4 - - 4 -	Before licence Ist year 2 nd year 3 rd year 1 st year 2 nd year 3 rd year - - 8 - - - - 75 - - - - 4 - - - - 4 - - -	Before licence Case report 1 st year 2 nd year 3 rd year 4 th year - 8 - - 22 - 75 - 340 - 4 - 14 - 4 - 33	Before licence Case report 1 st year 2 nd year 3 rd year 4 th year 5 th year - 8 - - 22 9 - 75 - - 340 300 - 4 - - 14 78 - 4 - - 33 138	Before licence Case report 1 st year 2 nd year 3 rd year 4 th year 5 th year 6 th year - 8 - - 22 9 8 - 75 - - 340 300 160 - 4 - - 14 78 59 - 4 - - 33 138 138							

Adverse experience	# of subjects who experienced Adverse events (solicited and unsolicited) (%), [#of events]											
Period	1st	2nd	3rd	4th	5th	6 th	Accumulated					
ENDOCRINE DISORDERS	0 (0.0) [0]			0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]					
GROWTH HORMONE DEFICIENCY	0 (0.0) [0]			0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]					
HYPOTHYROIDISM	0 (0.0) [0]			0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]					
PRECOCIOUS PUBERTY	0 (0.0) [0]			0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]					

Table KFDA 5 Line-listing AEs from clinical trial and spontaneous report

Li	Line-listing AEs from clinical trial and spontaneous report												
AEs				AEs									
	1 st year	2 nd year	3 rd year	4 th year	5 th year	MR	comment						
-	-	-	-	-	0		-						

Table KFDA 6 Line-listing of reported SAE and unexpected ADR

This table should include all SAEs and unexpected (which is not listed on the local prescribing information) ADR.

	Line-listing of reported SAE and unexpected ADR												
SAE·ADR	Reported cases (%)												
	1 st year	2 nd year	3 rd year	4 th year	5 th year	MR	comment						
Kawasaki' disease	-	-	-	-	1								
Injection site pruritis	-	-	-	-	2								
Arthralgia	-	-	-	-	1								
Shipping amount													

Table KFDA 7 Contents of SAE and unexpected ADR

Details of KFDA specific Listings: Annex 6 (by each subject information)

			Con	tents	of SAF	Cand unex	specto	ed ADR	2		
No.		AE	gender	Age in	Subject initial	ID or Patient No.	Date of	Severity	Causal r	elationship	Remark
	Body system organ	Specific terminology		weeks			onset		Doctor	Company	
PPD	Systemic	Kawasaki's disease	М	67	-	PPD	30- 10- 2006	1	Y	-	Recovered
		Injection site pruritis	F	260	-	-	29- 10- 2006	1	Y	-	
	Knee	Arthralgia	F	284	-	-	02- 11- 2006	1	Y	-	
		Injection site pruritis	М	480	-	-	31- 10- 2006	2	Y	-	

Table KFDA 8 Line-listing of SAE and unexpected ADR

Detailed description of KFDA specific Listings: Annex 6 and 7 based on CRF contents

		Serious	adv	vers	se ev	vents	s, and une	expected a	adverse dr	ug reaction s	umma	ry table ¹	
Survey patients Name (initial)	Male? female	Age(year)	no	or art o.		-	batient outpa		pregnancy: no	history of AE: no	s?ADRs	major case history such as predisposition etc	number ⁵
PPD	male	2 years	PPD	ł	PPD			lospitar .	occupation:				
							Usage		None reason for use underline the			yes	
product manufa		generic na		S ² ? O	route	daily dose	initiation		original disease and put complication in parenthesis		<u>K</u> /	AWASAKI Di	<u>sease</u>
										dd/mmm/yyyy ⁴	advers treatm th		Whether the precaution for use were reflected o not etc.
Fluari (GS biologi	SK	Influenz vaccine		S	IM	0.25 mL	25/10/02006	25/10/02006	Flu prevention	PPD	Or recove This sub erythma palms, so injection conjunct and infec were exa subject v hospitalii 03/NOV 05/NOV 05/NOV O5/NOV Prescript Sofenac Pseudoep Polybutin Aspirin, Cernevit Becompl Furtman Primene IV Globu 500mg/1 Bepantho UNI-C 1 Augment 7:1, SD i 500mg, Aminoph 100mg, I See detai	zation from /2006 to /2006. ion was inj, Miya-BM, obedrein HCL, ne Syr, Tylenol syr, inj, nexa 2mL/A, 10mL/V, 10% 100mL, iline 0mL/B, en 30mg, 0g/20mL/V, tin Duo Syr nj (1:4) pack wyilline Prospan syr.	None applicable
	0	ther treatm	ent ·	: no			rea	dministration	n : no	results(dd/mi	mm/yyyy) 05/N	OV/2006

Subject PPDhad fever of PPD visited 1 on 1/NOV/2006. Eryth severe edema with pair observed on palms, sol BCG injection site. Dia was KAWASAKI dise prescription was aspiri details on individual da doctor in charge listing) But symptom of charge improve, so subject wa hospitalization from 03/NOV/2006 to 05/NOV/2006 deep desquamation was occr the tips of fingers and the Doctor evaluated causa vaccine was unknown.	ospital ma and s and gnosis se and . (see ta dn't popinion of the reporting organization rrred on bes.	This SAE occurred day 5 after vaccination. And It was difficult to say there is no relationship obviously. Therefore company evaluated causality was yes.	treatment and future	Occurrence of this SAE will be observed through spontaneous report and PSUR.
---	--	--	----------------------------	---

Table KFDA 9 Individual Line-listing for All Subjects

1)

Line-listing of subjects (background of subjects)

Subject No.	Name of center	Resident Registration Number	Gender	Age (months)	Weight (Kg)	Height (Cm)
PPD			Female	31	6.4	60
			male	17	6.1	61
			male	8	6.5	62
			male	8	5.1	56

2)

Line-listing of subjects (medical history)

Subject No.	Name of center	Diagnosis	Past/ Current
PPD		pneumonia	past
			current
			current

3)

Line-listing of subjects (vaccine administration)

Subject No.	Name of center	Indication	Dose	Date of vaccine administration	Route	Sit	te	Administrated according to protocol?
PPD		Prevent Varicella	3	17-Jul-07	IM	thigh	Left	Yes

4)

	Line-listing of subjects (solicited adverse events)							
Subject	Name	AE	Dose	Intensity				

No.	of center			Day0	Day1	Day2	Day3	Day4	Day5	Day6
PPD		drowsiness	2	0	1	0	0	0	0	0
		irritation	1	0	1	0	0	0	0	0
		loss of appetite	1	1	1	1	1	1	0	0

5)

Line-listing of subjects (unsolicited adverse events)

Subject No.	Name of center	AE	Causality/Relationship to investigational products According to KFDA standards	Start date	End date	Outcome
PPD		Dermatitis	Probably not related	30-Jul-07	31-Jul-07	recovered

6)

Line-listing of subjects (concomitant medication)

Subject No.	Name of center	Dose	Trade/Generic name	Medical indication	Total daily dose	Route	Start date	End date	medication is Ongoing? (Yes/No)
PPD		1							
		1							
		1							

7)

Line-listing of subjects (concomitant vaccination)

Subject No.	Name of center	Trade/Generic name	Administration date	Route

Table CTRS 1 Demography for CTRS

Number of subjects	HRV
Planned, N	
N (Total Vaccinated Cohort)	
Completed, n (%)	
Total Number Subjects Withdrawn, n (%)	
Withdrawn due to Adverse Events, n (%)	
Withdrawn for other reasons, n (%)	
Demographics	HRV
N (Total Vaccinated Cohort)	
Females:Males	
Mean Age, weeks (SD)	
White/caucasian, n (%)	

Table CTRS2Number (%) of subjects with solicited general symptom
during the 8-day (Days 0-7) post-vaccination period (Total
Vaccinated Cohort)

			HRV			
					95 %	
Symptom	Туре	<u>N</u>	n	%	LL	UL
Couch /Punny noso	All	Dose 1				
Cough /Runny nose	Grade 3					
	Related					
Diamhaaa						
Diarrhoea	All					
	Grade 3					
	Related					
Fever/(Axillary) (°C)	All					
	Grade 3					
	Related					
Irritability	All					
	Grade 3					
-	Related					
Loss of appetite	All					
	Grade 3					
	Related					
Vomiting	All					
	Grade 3					
	Related					
		Dose 2				
Cough /Runny nose	All					
	Grade 3					
	Related					
Diarrhoea	All					
	Grade 3					
	Related					
Fever/(Axillary) (°C)	All					
	Grade 3					
	Related					
Irritability	All					
	Grade 3					
	Related					
Loss of appetite	All					
	Grade 3					
	Related					
Vomiting	All					
	Grade 3					
	Related					
		Across doses	I	I		I
Cough /Runny nose	All					
	Grade 3					

				HRV		
					95 % (
Symptom	Туре	N	n	%	LL	UL
	Related					
Diarrhoea	All					
	Grade 3					
	Related					
Fever/(Axillary) (°C)	All					
	Grade 3					
	Related					
Irritability	All					
	Grade 3					
	Related					
Loss of appetite	All					
	Grade 3					
	Related					
Vomiting	All					
	Grade 3					
	Related					

N = number of subjects with at least one administered dose

n/% = number/percentage of subjects reporting a specified symptom 95%CI, LL and UL = Exact 95% confidence interval, lower and upper limit

Any = all reports of the specified symptom irrespective of intensity grade and relationship to vaccination

Table CTRS 3 Number (%) of subjects with adverse events (Total vaccinated cohort)

Most frequent adverse events -	HRV
On-Therapy (occuring within day 0-30 following vaccination)	N = XXX
Subjects with any AE(s), n(%)	
Rhinitis	
Nervousness	
Fever	
upper resp tract infection	
Conjunctivitis	
Coughing	
otitis media	
Gastroesophageal reflux	
Flatulence	
Fatigue	
abdominal pain	
crying abnormal	
tooth ache	4 (2.3)

Table CTRS 4 Number (%) of subjects with serious adverse events (Total vaccinated cohort)

All SAEs	HRV N = XXX
Subjects with any SAE(s), n(%) [n related]	
Appetite increased	
Asthma	
Bronchitis	
Crying abnormal	
Eczema	
Fever	
Gastroenteritis	
infection bacterial	
infection viral	
Injury	
Laryngitis	
Meningitis	
otitis media	
Pneumonia	
Seborrhea	
Somnolence	
upper resp tract infection	
All fatal SAEs	HRV N = XXX
Subjects with any SAE(s), n(%) [n related]	

Table KFDA 10

Demographic data - by gender/race

		Male N=	Female N=	Total N=
Age (Weeks)	Mean			
	Range			
	SD			

		Male N=	Female N=	Total N=
Race	Korean			
	Non-Korean			

Table KFDA 11

Pre-exist medical history – by gender

		Male N =		Female N =		Total N =		
		n	%	n	%	n	%	
Medical	Yes							
History	No							
	Total							
BLOOD	Yes							
AND	No							
LYMPHATIC SYSTEM	Total							
CARDIAC	Yes							
	No							
	Total							

N= Number of subjects in each group(Male/Female)

n(%) = number(percentage) of subjects with the specified category(Yes/No)

Table KFDA 12 pre-exist medical history - by classification

	Diagnosis or Sign				959	% CI
Past Medical History	Symptom	Ν	n	%	LL	UL
BLOOD AND LYMPHATIC SYSTEM	ÁNÉMIA					
	NEUTROPENIA					
	SEPSIS					
	SEPSIS NEWBORN					
CARDIAC	ASD. TR.					
	ATRIAL SEPTAL DEFECT					
	PUL. HTN					
	TRICUSPID REGURGITATION					

N= Number of subjects with the specified medical history

n(%) = number(percentage) of subjects with the specified category of diagnosis or symptom

95%CI = 95% confidence interval; LL, UL = lower and upper confidence limits

Table KFDA 13

Pre-rotavirus vaccination history

		Male N=		Female N=		Total N=	
		n	%	n	%	n	%
Rotavirus vaccination	Yes						
	No						

N= Number of subjects in each group(Male/Female)

n(%) = number(percentage) of subjects with the specified category(Yes/No)

Table KFDA 14

Administration of concomitant medication - by gender

		Male N=		Female N=		Total N=	
		n	%	n	%	n	%
Administration of concomitant medication	Yes						
	No						
	Total						

N= Number of subjects in each group(Male/Female)

n(%) = number(percentage) of subjects with the specified category(Yes/No)

Table KFDA 15 Administration of concomitant medication – by classification

			95% CI		
Classification	Ν	n	%	LL	UL
Any					
Any antipyretic					
Prophylactic antipyretic					
Any antibiotic					

N= Number of subjects

n(%) = number(percentage) of subjects with the specified classification

95%CI = 95% confidence interval; LL, UL = lower and upper confidence limits

Table KFDA 16

Administration of concomitant vaccination

			N
		n	%
Administration of concomitant vaccination	Yes		
vaccination	No		
	Total		

N= Number of subjects)

n(%) = number(percentage) of subjects with the specified category(Yes/No)

Table KFDA 17

Administration of study vaccination – by gender

			ale =		nale =	Total N=		
		n	%	n	%	n	%	
Administration of study vaccination	Dose1							
-	Dose 2							
	Total							

N= Number of subjects in each group(Male/Female)

n(%) = number(percentage) of subjects with the specified category(Yes/No)

Table KFDA 18 Summary of serious adverse events, adverse drug reactions

	Preferred			S	AE			Serious ADR						
Primary System Organ Class	Term (Code					95% CI						95% CI		
Primary System Organ Class (Code)	-	Ν	n	n*	%	LL	UL	Ν	n	n*	%	LL	UL	

N= Number of subjects

n(%) = number(percentage) of subjects with the specified category; 95%CI = 95% confidence interval; LL, UL = lower and upper confidence limits

n* = number of symptoms of the specified category

Table KFDA 19 Serious adverse events, adverse drug reactions

Event	Start date	End date	Severity	Causality	Outcome	Change on medication

Table KFDA 20 Adverse events, adverse drug reactions

Expected (solicited) adverse events and adverse drug reactions

			A	LΕ			ADR							
					959	% CI					95%	6 CI		
Events	Ν	n	n*	%	LL	UL	Ν	n	n*	%	LL	UL		
Fever														
Fussiness/irritabiliy														
Diarrhoea														
vomitting														
Loss of appetite														
Cough/Runny nose														

N= Number of subjects

n(%) = number(percentage) of subjects with the specified category; 95%CI = 95% confidence interval; LL, UL = lower and upper confidence limits

n* = number of symptoms of the specified category

Unexpected (unsolicited) adverse events and adverse drug reactions

	Preferred			Α	E			ADR						
Primary System Organ Class	Term (Code					95	% CI					95%	6 CI	
Primary System Organ Class (Code)		Ν	n	n*	%	LL	UL	Ν	n	n*	%	LL	UL	

N= Number of subjects

n(%) = number(percentage) of subjects with the specified category; 95%CI = 95% confidence interval; LL, UL = lower and upper confidence limits

n* = number of symptoms of the specified category

Table KFDA 21Adverse events (Solicited and Unsolicited) experienced by
subjects during the entire study period; stratified by gender (Total
vaccinated cohort)

Factor	Category			Subje	d or unsolici	or unsolicited)						
		Ν			Yes				No			
					95	% CI			95	% CI		
			n	%	LL	UL	N	%	LL	UL		
Gender	Male											
1	Female											

N=Number of subjects in the given category n/%= number/percentage of subjects in the given category

Table KFDA 22Adverse events (Solicited and Unsolicited) experienced by
subjects during the entire study period; stratified by age (Total
vaccinated cohort)

See template for Table KFDA 12

Table KFDA 23Adverse events (Solicited and Unsolicited) experienced by
subjects at any time during the study; stratified by concomitant
medication (Total vaccinated cohort)

See template for Table KFDA 12

Table KFDA 24Adverse events (Solicited and Unsolicited) experienced by
subjects at any time during the study; stratified by concomitant
vaccination (Total vaccinated cohort)

See template for Table KFDA 12

Table KFDA 25Adverse events experienced by subjects at any time during
the study; stratified by past medical history status (Total vaccinated
cohort)

See template for Table KFDA 12

Table KFDA 26Adverse events by medical history – by gender &
classification

		Ma N			nale I=		otal =
Past Medical History	Adverse events	n	%	n	%	n	%
BLOOD AND LYMPHATIC SYSTEM							
CARDIAC							

N= Number of subjects in each group(Male/Female)

n(%) = number(percentage) of subjects with the specified category(Adverse events)

Table KFDA 27 Adverse events by concomitant medication – by classification

	N	Adverse events									
		Yes		Ν	lo	Total					
Classification		n	%	n	%	n	%				
Any											
Any antipyretic											
Prophylactic antipyretic											
Any antibiotic											

N= Number of subjects

n(%) = number(percentage) of subjects with the specified Classification

Table KFDA 28	Adverse events by concomitant vaccinations – by
Class	ification

Classification	Ma N			nale N=	Total N=			
	n %		n	%	n	%		
Any								
BCG								
DTPA								

N= Number of subjects in each group(Male/Female)

n(%) = number(percentage) of subjects with the specified Classification

Table KFDA 29 Adverse events by medical history, Concomitant vaccination, concomitant medication

		N	ledical	Histo	ry		Conco Medic			Concomitant vaccination			
		Y	Yes		No		Yes		lo	Yes		N	lo
	Ν	n	%	n	%	n	%	n	%	n	%	n	%
Expected (Solicited) Advers	se eve	nts											
Fever													
Loss of appetite													
Total (Expected adverse events)													
Unexpected (unsolicited) A	dverse	even	ts										
· · · ·													
Total (Unexpected adverse events)													

N= Number of subjects in each group(Male/Female)

n(%) = number(percentage) of subjects with the specified Classification

Table KFDA 30 Adverse events by duration

		Da	iy 0	Da	Days 1		Days 2		Days 3		Days 4-7		/s 8- 5	Days 16- 30		Days >30	
	Ν	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%
Expected	(solic	ited) a	dvers	e eve	nts									•			
Total																	
Unexpect	ed(un	solicit	ed) ad	verse	event	s											
Total																	

N= Number of subjects in each group(Male/Female)

n(%) = number(percentage) of subjects with the specified Classification

Table KFDA 31

Adverse events by severity

	N	Mild		Mod	erate	Severe		
		n	%	n	%	n	%	
	•		Dos	se1				
Expected (S	olicited) advers	se events						
Total								
Unexpected	(Unsolicited) a	dverse events						
-								
Total								
	-		Dos	e 2				
Expected (S	olicited) advers	se events						
Total								
Unexpected	(Unsolicited) a	dverse events						
Total								

N= Number of subjects in each group(Male/Female)

n(%) = number(percentage) of subjects with the specified Classification

Table KFDA 32 Adverse events by causality

	Ν	Cer	rtain	Probab	le/Likely	Pos	sible	Unli	kely	Conditiona	al/Unclassified
		n	%	n	%	n	%	n	%	n	%
						Dose1					
Expecte	d (Solic	ited) ad	verse ev	/ents							
Total											
Unexpe	cted (Ur	nsolicite	d) adve	rse events							
Total											
					[Dose 2					
Expecte	d (Solic	ited) ad	verse ev	/ents							
Total											
Unexpe	cted (Ur	nsolicite	d) adve	rse events	•	•		•		•	
Total											

N= Number of subjects in each group(Male/Female)

n(%) = number(percentage) of subjects with the specified Classification

Table KFDA 33 Adverse events by outcome

	N	Recovered/Resolved		Not recovered/Not resolved		Recovering/resolving		Recovered with sequelae/resolved with sequelae		unknown	
		n	%	n	%	n	%	n	%	n	%
						Dose1					
Expec	ted (S	Solicited) ad	lverse event	S							
Total											
Unexp	ected	d (Unsolicite	ed) adverse (events			•				
		•									
Total											
						Dose 2			11		
Expec	ted (S	Solicited) ac	lverse event	s							
•	l `	/									
Total											
	ected	d (Unsolicite	ed) adverse e	events	I	1	I	I	I I		
- P		,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	,								
Total											
	-	aff a she in a fa is	n oach aroun			1	1		. I		

N= Number of subjects in each group(Male/Female)

n(%) = number(percentage) of subjects with the specified Classification

6. ANNEX 2: CRITERIA FOR ELIMINATING SUBJECTS FROM STAT ANALYSES

Provided as a separate document

gsk GlaxoSmith	Kline					
S	tatist	tical A	nalysis	s Plan A	pproval	
Protocol Title:	Open, multi-centric, post-marketing surveillance (PMS) to monitor the safety of GlaxoSmithKline (GSK) Biologicals' oral live attenuated human rotavirus (HRV) vaccine, Rotarix [™] or Rotarix [™] liquid formulation (oral suspension or prefilled syringe) when administered according to the prescribing information in Korea.					
eTrack study number	1117	700				
eTrack abbreviated title	(Rot	a-070 P	PMS)			
Protocol version/date	Ame	endmen	t 4: 23 F	ebruary 2	012	
Scope:	All	lata per	taining t	to the above	ve study	
Version:	Ame	endmen	t 2			
Date:	18-E	Dec-201	3			
Co-ordinating author:	PPD					
Other author(s):						
Approved by:	•					
Lead Clinical Developm Combination Vaccines a		PPD				
Rotavirus Vaccines	Name			Signature	dd-mmm-yyyy	
Project Statistician		PPD				
		Name			Signature	dd-mmm-yyyy
Lead Statistician		PPD				
		Name			Signature	dd-mmm-yyyy

TABLE OF CONTENTS


PAGE

1.	DOCUMENT HISTORY
2.	STUDY DESIGN
3.	OBJECTIVES
4.	ENDPOINTS
5.	STUDY POPULATION
6.	STATISTICAL METHODS56.1.1.Analysis of demographics/baseline characteristics56.1.2.Analysis of safety5
7.	STATISTICAL CALCULATIONS.67.1. Derived and transformed data.67.2. Data presentation description.67.3. Group description.77.4. Methodology for computing CI7
8.	CONDUCT OF ANALYSES78.1.Sequence of analyses78.2.8.2.Statistical considerations for interim analyses7
9.	CHANGES FROM PLANNED ANALYSES7
10.	REFERENCES
11.	ABBREVIATIONS

Date	Version	Description
12-Dec-2011	First Version	First approved version
15-Feb-2013	Amendment 1	 Amendment of the SAP is done to consistent with the Protocol Amendment 4: 23 February 2012 Planned analysis Changed in the section 6.1.2 and Section 9 as All the planned analysis will be performed on the basis of WHOART and not based on MedDRA.
18-Dec-2013	Amendment 2	• Planned analysis Changed in the section 6.1.2

1. DOCUMENT HISTORY

2. STUDY DESIGN



N: Number of subjects planned to be enrolled.

Infants who have received a dose of the vaccine prior to the start of the PMS will have only one visit followed by the phone contact.

PMS conclusion: An infant's parent/guardian who will be contacted to provide details of any AEs experienced by the infant 30 days after the infant receives the last vaccination or an infant for whom diary card transcription into CRF will be been done through phone contact is considered to have completed the PMS.

- PMS design: Open-label, non-comparative, multi-centre PMS in Korea.
- Vaccination schedule: Two doses of RotarixTM or RotarixTM liquid formulation (oral suspension or prefilled syringe) will be administered orally as per the prescribing information in Korea.
 - First vaccination will be given to infants from the age of 6 weeks.
 - Second vaccination will be given at least 4 weeks after Dose 1. Administration of Dose 2 is preferably given before the age of 16 weeks.

Two doses of RotarixTM or RotarixTM liquid formulation (oral suspension or prefilled syringe) should be given before 24 weeks of age.

- Control: None.
- Type of PMS: Self-contained.
- Two visits are recommended as follows:
 - Visit 1: RotarixTM or RotarixTM liquid formulation (oral suspension or prefilled syringe) vaccination, subjects will be allowed to receive concomitant vaccinations.
 - Visit 2: Rotarix[™] or Rotarix[™] liquid formulation (oral suspension or prefilled syringe) vaccination, subjects will be allowed to receive concomitant vaccinations.
- Recording of AEs from Day 0 to Day 30 using diary cards after each dose of RotarixTM or RotarixTM liquid formulation (oral suspension or prefilled syringe).
- Recording of SAEs during the entire PMS period.
- Duration of the PMS: The intended duration of the PMS, per infant, will be approximately 3 months.
- Refer to Appendix B for details of the recruitment plan.
- Data collection: Standardised hard copy case report form (CRF).

3. OBJECTIVES

To assess the safety of Rotarix[™] or Rotarix[™] liquid formulation (oral suspension or prefilled syringe) in infants when administered according to the prescribing information in Korea.

Refer to Section 4 for definition of the endpoints.

4. ENDPOINTS

- Occurrence of AEs during the 31-day (Day 0 Day 30) follow-up period after each vaccine dose according to Medical Dictionary for Regulatory Activities (MedDRA) classification.
- Occurrence of SAEs during the entire PMS period.

5. STUDY POPULATION

5.1.1. Total Vaccinated cohort

The total vaccinated cohort will include all vaccinated subjects with at least one dose of RotarixTM or RotarixTM liquid formulation (oral suspension or prefilled syringe) administration documented:

• A safety analysis based on the total vaccinated cohort will include all vaccinated subjects.

Cohort	Elimination codes	Eli Type
Total vaccinated cohort	1030	MA

6. STATISTICAL METHODS

Statistical analyses will be performed as per the requirements *for the* KFDA *submission*.

6.1.1. Analysis of demographics/baseline characteristics

The mean, range and standard deviation of age in weeks at each dose will be calculated. The racial, rotavirus vaccination history and gender composition of the vaccinated subjects will be also presented.

The distribution of subjects enrolled among the PMS centres will be tabulated.

6.1.2. Analysis of safety

The verbatim reports of AEs will be reviewed by a physician and the signs and symptoms will be coded according to WHOART. Every verbatim term will be matched with the appropriate Preferred Term. As per regulatory requirement, all the planned analysis *of*

AE after the SAP Amendment 1 dated 15 February 2013 will be performed on the basis of WHOART and not based on MedDRA.

The analysis of safety will be performed according to expectedness (see Abbreviations). Expectedness will be derived from the *WHOART* PT classification. The list of primary PT associated to expected adverse events will be reviewed before each database freeze for analysis.

The number and percentage of subjects with AEs occurring within 31 days with its exact 95% CI will be tabulated by preferred term. Similar tabulations will be done for the number and percentage of subjects with SAEs during the study period.

Number and percentage of expected adverse events and adverse drug reactions along with the exact 95% CI will be tabulated. Number and percentage of expected AEs and ADRs by SOC and PT will be tabulated.

Number and percentage of unexpected adverse events and adverse drug reactions along with the exact 95% CI will be tabulated. Number and percentage of unexpected AEs and ADRs by SOC and PT will be tabulated.

Serious adverse events reported during the study period will also be summarized.

The percentage of subjects who received at least one concomitant medication/vaccination will be tabulated by type of medication, with exact 95% CI. Similar tabulations will be done for subjects who receive concomitant medication/vaccination during the entire PMS period.

Summary of Adverse events by duration, severity, causality and outcome will be performed to reflect the KFDA requirements.

In addition, specific statistical analyses (e.g. AEs classified by gender, past medical history, concomitant medication/vaccination etc) will be performed to reflect the KFDA requirements

7. STATISTICAL CALCULATIONS

7.1. Derived and transformed data

Infants who missed reporting symptoms (AEs or concomitant medications) will be treated as infants without symptoms (AEs or concomitant medications, respectively). In case of significant non-compliance of PMS procedures for reporting symptoms, the analysis plan will be reassessed to ensure more accurate reporting of PMS data by further analysis.

7.2. Data presentation description

The following decimal description will be used for the demography, reactogenicity/Safety.

Display Table	Parameters	Number of decimal digits
All summaries	% of count, including LL & UL of CI	1
Demographic characteristics	Mean, median age	1
Demographic characteristics	SD (age)	2

7.3. Group description

The following group will be used for the statistical analyses.

Study	Group order in tables	Group label in tables
Rota_070	1	HRV

7.4. Methodology for computing Cl

All CI will be 2 sided 95% CI.

• The exact 95% CIs for proportion within a group will be based on the method by Clopper

Refer to Section 10 for references.

8. CONDUCT OF ANALYSES

8.1. Sequence of analyses

Description	Analysis ID (SDD sub-folder)	TFL short title
Analysis year 3 & year 4	ANALYSIS_E1_01	For year 3,4,5
Analysis year 5	ANALYSIS_E1_03	For year 3,4,5
Analysis year 6	ANALYSIS_E1_04	Comprehensive report

8.2. Statistical considerations for interim analyses

Annual reports will be written for 6 years. The last annual report will be replaced by a comprehensive report. All analyses described above will be performed on cleaned data for each annual report. The analysis, including individual data listings, will be cumulative and based on the cohort for vaccinated subjects for which the PMS conclusion page has been received at GSK before the pre-defined cut-off date. All reports will be sent to the GSK Biologicals' Central Safety and Pharmacovigilance (BCSP).

9. CHANGES FROM PLANNED ANALYSES

• The verbatim reports of AEs will be reviewed by a physician and the signs and symptoms will be coded according to WHOART. Every verbatim term will be matched with the appropriate Preferred Term. As per regulatory requirement, all the planned analysis after the SAP Amendment 1 dated 15 February 2013 will be performed on the basis of WHOART and not based on MedDRA.

- Number and percentage of expected adverse events and adverse drug reactions along with the exact 95% CI will be tabulated. Number and percentage of expected AEs and ADRs by SOC and PT will be tabulated.
- Number and percentage of unexpected adverse events and adverse drug reactions along with the exact 95% CI will be tabulated. Number and percentage of unexpected AEs and ADRs by SOC and PT will be tabulated.
- Summary of Adverse events by duration, severity, causality and outcome will be performed.

10. **REFERENCES**

• Clopper CJ, Pearson ES. The use of confidence or fiducial limits illustrated in the case of binomial. Biometrika. 1934;26:404-413.

11. ABBREVIATIONS

	Adverse event
AE	Adverse event
CI	Confidence Interval
CRF	Case Report Form
GSK	GlaxoSmithKline
MedDRA	Medical Dictionary for Regulatory Activities
SAE	Serious Adverse Event
HRV	Human rotavirus
LL	Lower limit
UL	Upper limit
SD	Standard deviation
PMS	Post Marketing Surveillance
RV	Rotavirus
KFDA	Korean Food and Drugs Administration
WHOART	WHO Adverse Reaction Terminology
Expected	The presence/occurrence/intensity of an adverse event that is expected from
adverse event	the infant or an observer during the post-vaccination follow-up period as
	described in the locally approved prescribing information
Unexpected	Any adverse event that is not reflected in the locally approved prescribing
adverse event	information

gsk GlaxoSmithKline	Rota-070 (111700)	Center No. : [_ <u> _</u>	Subject No.:			
		ROTARI	X (F	Rota	-070) PMS CR	<u>ه هم</u> ۲		1
INFORMED C	ONSEN	T I certify that Informed Consent ha	ns been ob	twined pric	or to any study procedure			<u> _</u>
DEMOGRAPI	HICS			•		DD MN		
Date of Birth:		Race:	delis	t 1	CACE_ 108344	Gender: [M] Male		
DD MMM 1	MMY -	[99][]Non-Korean, specif	y:		For GSK	[F] Female		
ELIGIBILITY	CHECK -	Do not enter the subject in	to the st	udy if h	e/she failed any inclusion or	exclusion criteria bel	ow	
INCLUSION C	all the entry of RITERIA	xiteria?: LJYes [] No	→ If No,	tick (√)	all boxes corresponding to v y with the requirements of the proto	iolation of any inclus	ion/exclusion c	
[2] A male or femal	e aged 6 weeks d consent obtains		vaccinatio	n. (Note:	Two doses of the Rotarix™ vaccine			
[4] At the time of Pi if there is any	MS entry, the col contraindication	atraindications and precautions o	fuse India	cated in t	he prescribing information should be formation must be implemented imm	e checked and the infant	must not be includ	jed in the Pi
GENERAL ME	EDICAL H	HISTORY / PHYSI	CAL	EXA	MINATION	neclately.		
Are you aware of any	pre-existing a	conditions, signs or sympto lagnosis and tick ($$) appro-	ms nras	ent nrin	v to the start of the study?			
MedDRA System O		Diagnosis		Current	Mad DDA Custom Or	Disease		
					Class [10] Eye	Diagnosis	Pas	st / Curren
[1] Skin and subcuta tissue	ineous		-10					
For GSK			-		For GSK			
[2] Musculoskeletal	and							0
connective tissue				D	[11] Ear and labyrinth			
For GSK [3] Cardiac	1				For GSK	·······	·•····	
	-				[12] Endocrine			
For GSK]							
4] Vascular	1				For GSK [13] Metabolism and			
	ľ				nutrition			0
or GSK	L				For GSK			
5] Respiratory, thora nediastinal	acic and		10	C	[14] Blood and	······································		Ċ)
			0		lymphatic system		0	Ľ
or GSK 6) Gastrointestinal	10 <u>12201</u> 1	<u>Anglandan series</u>			For GSK			
•	-		10		[15] Immune system (Incl allergies,			
or GSK	e est terrer,	n en sen en sen sen sen sen sen sen sen		<u></u>	autoimmune disorders) For GSK		<u> </u>	
7] Hepatobillary				CI	[16] Infections and			
			10	D	infestations			
or GSK					For GSK			
8] Renal and urinary					[17] Neoplasms benign, malignant and			[]
-					UNSPECIFIED (Including cysts and polyps)		D	
or GSK 3] Nervous system			+		For GSK			
of mervous system					[18] Surgical and medical procedures			
				707			0	
					[99] Other			
or GSK					For GSK		I	
REVIOUS RO	TAVIRU	S VACCINATION	HIST	ORY				
rade/Generic Na	ime	ation previously to Rotaviru	187 🔲 N	o []Ui			te of vaccin	nation YYY)
·····]	For GS	SK	and the second sec		
		and a state of the		For GS				
		· · · · · ·			»^			

1/6

gsk					ota-07	-		Cente	r No		Subject No :	Visit	4		
		HETO	ATION		11170	<u>)</u>		1 1	· · · · ·			41911	1		
Date if different from			AHOP		_!!! DD	MMM	<u>ا</u>) ار ۲۲	<u>_ </u>	ן Pr דוי	e-vaccination temper	rature : °C px(es) → [A] ⊒ Axillary [0] ⊒ :(Same 1979	**************************************		
Vaccine Adn	ninist	ration	Pleas	e tick	(v) the	most		Route	Has	the study vaccine been	administered according to th	e protoc	iol?		
appropriate b ⊡Rotarix™	ox(es □1) " Dose		A CC P Dose	rod	. DO	SE	Oral	□Yes						
☐Not admir	Not administered>Please complete below ^(*) □No → Please comment:														
^(*) Why not administered? □ [AEX] Non-Serious adverse event → Please complete the Serious Adverse Event form and specify SAE No. [AEX] Non-Serious adverse event → Complete the Non-serious Adverse Event section and specify AE No.															
Please tick (V) major reason for administration					ase spe ade the						/For GSI /Guardians	<u><</u>			
SOLICITED	ADV	ERSE	EVEN	NTS- (GENE	RALS	SYMP	TOM	3*						
Has the subject											an a		· · · · · · · · · · · · · · · · · · ·		
[N] No [Y]]Yes,	Please tick	: (v) No/Y	es for eac	h symptor	n. Il Yes i	s ticked, d	omplete a	- Compression of the local division of the l	[U] Information no	otavailable [NA]∐No va		dministered		
OFNEDA									Öng oing	Date of last day of	Causality / Relationship to investigational		a dl 11.		
GENERAL SYMPTOMS	Day 0	Day 1	Day 2	Day 3	Day 4	Day 5	Day 6	Day 7	after	symptoms	products		edically ided visit?		
				i i			-		day 7?	(DDMMM YYYY)	According to KFDA	1			
Temperature									1						
(FE)								•			[1] Definitely related				
⊡Yes→°C									DNo DYes		[2] Probably related [3] Possibly related	DNc Yes	HO/ER/MD		
DAxillary				-				-	Þ		[4] Probably not related [5] Unknown				
☐Oral ☐Tympanic	not taken	not teken	not taken	not taken	not taken	not taken	not taken	not taken							
Irritability/Fu							laken		<u> </u>		[1] Definitely related	+			
ssiness (IR) ⊡No									DNo		[2] Probably related				
⊡Yes →									⊡Yes i→		[3] Possibly related	⊡Yes →	HO/ER/MD		
Intensity											[5] Unknown				
Diarrhoea (DA)		•									[1] Definitely related				
DNo									DNo DYes		[2] Probably related	DN0			
□Yes → number of									⇒		[3] Possibly related [4] Probably not related	⊡Yes →	HO/ER/MD		
loose stools											(5) Unknown				
Vomiting										1		1			
(VO)									DN0		[1] Definitely related [2] Probably related				
□Yes →									⊡Yes H		[3] Possibly related [4] Probably not related	⊡Yes →	HOIERIMO		
number of vomits										· · · · · · · · · · · · · · · · · · ·	[6][Unknown				
Loss of										· · ·	[1] Definitely related				
appetite (LO)									DNo DYes		[2] Probably related [3] Possibly related		1 7 1		
□Yes →))		[4] Probably not related	⊡Yes →	HO/ER/MD		
Intensity											[5]DUnknown				
Cough/runny nose (CO)					ĺ						[1] Definitely related [2] Definitely related				
⊡No ⊡Yes →									⊡Yes	t the same same same	[3] Possibly related [4] Probably not related	□Yes			
Intensity									[7	HO/ER/MD		
* If any of these								nsity:		Fever		D : Hosp	italization		
serious, please o report to GSK Bi 24 hours.							n See	12/3 AE:del	inition	Axillary, Oral & Tympa 37.5°C			gency Room al Personnel		
UNSOLICIT	ED A	DVER	SE EV	/ENT											
Has the subject	experi	enced a	nv seri		ion-seri	เดมร แก	solicited	adver	Se eve	nts within 31 days of f	ollow up of post-vaccination	2			
]Yes, f	ill in the									Information not available		A] 🗌 No		
TELEPHON	E CO	NTAC	T.		······										
Day 8-30 after v			•						ľ	DD MMM Y	` YYY				
Has safety infor			No, ple	ase cor	nplete a	above th	ne date	attemp	t of las	t phone contact.	n – n – n National Antonia - Antonia - Antonia Antonia Antonia Antonia Antonia Antonia Antonia Antonia Antonia -				
been obtained 7										t above.					
									_						

		(1	ota-07) ו	11		1 1				e of Visit 2: 1	_ _ 	
Did the subject	1000	UUY			TION	f subje	ct rece	ived 2"	dose	on visit1, skip to th	e study conclusion p	g.	
Visit? Yes the one most appro	□No-) priate re	Please ti ason	2 rc* (V)		K) Non-Sa H) Other	rious adv please sp	verse eve ecify (e.g.	nt ->Com	piete the withdray	Non-serious Adverse Eve al. protocol violation)	form and specify SAE No. It section and specify AE No.	or sol	iciled AE code
VACCINE A Date if different from	DMII n visit da	NISTR	OITA	N		MMM			P	re-vaccination temp	[P] Parents/Guardi erature : []	°C	
Vaccine Adn box(es)				e tick (√) the m	iost app	propriat		ute H	as the study vaccine b	box(es) → [A] ∰Axillary een administered accord	OLE Oral ing to the	[T]EE:Tympanic protocol?
Not admir				mnlata	balow	(*)		Or]Yes]No → Please comm	ent [.]		
^(*) Why not adn Please tick (√) reason for non administration	ninister	ed? ijor	ISAE IAEX IOTH] Serious] Non-Se f) Other, j	adverse rious adv	event -) erse aven cily (e.g.:	t →Comp consent v	olete the N withdrawa	e Seriou Ion-serio	Adverse Event form and	specify No.		ode
SOLICITED	ADV	ERSE	EVE	NTS-	GENE	RALS	SYMP	TOMS	3*				
Has the subject	t exper	ienced	any of	the follo	wing sig	ans/sym	notoms	durina	the so	icited period? [U]된 Information :	not available [NA]	 No vaccir	10
GENERAL SYMPTOMS	Day 0	Day 1	Day 2	Day 3	Day 4	Day 5	Day 6	Day 7	Onge ing after day 77	Date of last day	Causality / Relationship to investigational products According to KFDA	Medic	ally attended visit?
Temperature (FE) □No □Yes-→°C □Axillary □Oral □Tympanic	D not takso	not taken		not taken	 not taken	not			⊡No ⊡Yes →		[1][]Definitely related [2][Probably related [3][Probably related [4][Probably not related [5][]Unknown	⊡No ⊡Yes->	II HO/ER/MD
rritability/Fu ssiness (IR) ⊐No ⊐Yes → ntensity						taken	laken		□No □Yes →		[1]]]Definitely related [2]]Probably related [3]]Probably related [4]]Probably not related [6]] Unknown	⊡No ⊡Yes->	L_L_I HO/ER/MD
Diarrhoea DA) DNo DYes → eumber of pose stools									□No □Yes →		[1] Definitely related [2] Probably related [3] Probably related [4] Probably not related [5] Unknown	⊡No ⊡Yes→	L_ _ HO/FR/MD
/omiting VO) ⊒No ⊒Yes → umber of omits)	⊡No ⊡Yes →		[1] Definitely related [2] Probably related [3] Possibly related [4] Probably not related [5] Unknown	□Na □Yes->	I_I_I HOÆR/MD
oss of ppetite (LO) INo IYes → Itensity								L L	⊐No ⊐Yeş →		[1]L:Definitely related [2] Probably related [3] Probably related [4] Probably not related [5] Unknown	⊡No ⊡Yes→	I_I_I HO/ER/MD
ough/runny ose (CO) INo IYes → Itensity									⊐No ⊐Yes →		(1)[]Definitely related (2)[]Probably rolated (3)[Possibly related (4)[Probably not related (5)[]Unknown	⊡No ⊡Yes→	LLI HO/ER/MD
If any of these a erious, please co port to GSK Bio 4 hours.	mplete	and su	bmit a S	erious A	dverse	Event	Inter 0/1/2 See		nition	Fever: Axillary, Oral & Tympanic ≥ 37.5°C	Attended Visit ER :	: Hospitali: Emergen Medical P	cy Room
INSOLICITE	DAD	VERS	SE EV	ENT						I	i	.	
as the subject e l][]No [Y][] accine adminis	res, fill	nced and in the	ny seria Non-Se	us or n rious A	on-seric dverse l	ous unsi Event s	olicited ection (advers or SAE	e even Repo⊓	ts within 31 days of f as necessary* [U]	pliow up of post-vaccina information not avai	ation? fable	[NA][] No
ELEPHONE ay 8-30 after va			「 「						l				
es safety inform en obtained?	ation		lo, plea 'es, plea	se com ase con	plete at nplete ti	ove the	e date a of cont	attempt act abo	of last	phone contact.			

3/6

Esk GlazoSmithkline	Rota-070 (111700)	Center No.:	_I Subject No.: I_I_I	I_I_I Non serious a	adverse event 1
NON SERIOUS ADV	ERSE EVENT (Please report a	Il serious adverse events only on Ser	rious Adverse Event (SAE) Reports)		
	vents occurred within one month (mininates complete the following table		ding those recorded on the Solicited Ac	dverse Events pages?	
AE no.	1	2	3	4	5
Description			· · · · · · · · · · · · · · · · · · ·		
ForGSK					
Date Started	DD MMM YYYY	DD MMM YYYY during immediate post-vaccination	DD MMM YYYY durine mmediate post-vaccination	DD MMM YYYY	DD MMM YYYY
	period(30 minutes)	period(30 minutes)	period(30 minutes)	period(30 minutes)	period(30 minutes)
Date Stopped					
Maximum Intensity	[1] Mild [2] Moderate [3] Severe	[1] Mild [2] Moderate [3] Severe			
Causality/Relationship to invo	estigational products: is there a rease				
Áccd to KFDA standards	[1] Definitely related [2] Probably related [3] Probably nelated [4] Probably not related [5] Unknown	[1] Definitely related [2] Probably related [3] Possibly related [4] Probably not related [5] Unknown	[1] Definitely related [2] Probably related [3] Possibly related [4] Probably not related [5] Unknown	[1] Definitely related [2] Probably related [3] Posbably not related [4] Probably not related [5] Unknown	[1] Definitely related [2] Probably related [3] Possibly related [4] Probably not related [5] Unknown
Outcome	[1] Recovered / Resolved [2] Recovering / resolving [3] Not recovered/ not resolved [4] Recovered with sequelae /Resolved with sequelae	[1] Recovered / Resolved [2] Recovering / resolving [3] Not recovered/ not resolved [4] Recovered with sequelae /Resolved with sequelae	[1] Recovered / Resolved [2] Recovering / resolving [3] Not recovered/ not resolved [4] Recovered with sequelae /Resolved with sequelae	 [1] Recovered / Resolved [2] Recovering / resolving [3] Not recovered/ not resolved [4] Recovered with sequelae /Resolved with sequelae 	[1] Recovered / Resolved [2] Recovering / resolving [3] Not recovered/ not resolved [4] Recovered with sequelae /Resolved with sequelae
Medically attended visit Refer to protocol for definition. If yes, specify type: HO: Hospitalisation ER: Emergency Room -MD: Medical Personnel	[N] □ No [Y] □ Yes → type: ii (HO/ER/MD)	[N] □ No [Y] □ Yes → type: İ_İ_İ (HO/ER/MD)	[N] □ No [Y] □ Yes → type: └_ └_ └ (HO/ER/MD)	[N] □ No [Y] □ Yes → type: l_i_i (HO/ER/MD)	[N] □ No [M] □ Yes → type: l_l_l (HO/ER/MD)

gsk GlaxoSmithKline	Rota-070 (111700)	Center No.: 1	Subject No.:	_1_1_1_1 Non Se	rious Adverse Event 2
NON SERIOUS AD	VERSE EVENT (Continue	e from Non Serious Adv			
AE no.	6	7	8	9	10
Description					
For GSK					
Date Started	DD MMM YYYY D during immediate post-vaccination period(30 minutes)	DD MMM YYYY U during immediate post-vaccination period(30 minutes)	DD MMM YYYY during immediate post-vaccination period(30 minutes)	DD MMM YYYY dung mmediate post-vaccination period(30 minutes)	DD MMM YYYY during immediate post-vaccination period(30 minutes)
Date Stopped					
Maximum Intensity	[1] Mild [2] Moderate [3] Severe	[1] Mild [2] Moderate [3] Severe	[1] Mild [2] Moderate [3] Severe	[1] Mild [2] Moderate [3] Severe	[1] Mild [2] Moderate [3] Severe
Causality/Relationship to inv	estigational products: Is there a reas	onable possibility that the AE may hav	e been caused by the investigational p	product?	
Accd to KFDA standards	[1] Definitely related [2] Probably related [3] Possibly related [4] Probably not related [5] Unknown	[1] Definitely related [2] Probably related [3] Possibly related [4] Probably not related [5] Unknown	 [1] Definitely related [2] Probably related [3] Possibly related [4] Probably not related [5] Unknown 	[1] Definitely related [2] Probably related [3] Possibly related [4] Probably not related [5] Unknown	[1] Definitely related [2] Probably related [3] Possibly related [4] Probably not related [5] Unknown
Outcome	[1] Recovered / Resolved [2] Recovering / resolving [3] Not recovered / not resolved [4] Recovered with sequelae /Resolved with sequelae ////////////////////////////////////	[1] Recovered / Resolved [2] Recovering / resolving [3] Not recovered/ not resolved [4] Recovered with sequelae /Resolved with sequelae	[1] Recovered / Resolved [2] Recovering / resolving [3] Not recovered/ not resolved [4] Recovered with sequelae /Resolved with sequelae	[1] Recovered / Resolved [2] Recovering / resolving [3] Not recovered / not resolved [4] Recovered with sequelae /Resolved with sequelae	[1]_Recovered / Resolved [2]_Recovering / resolving [3]_Not recovered/ not resolved [4]_Recovered with sequelae /Resolved with sequelae
Medically attended visit					
Reter to protocol for definition, if yes, specify type: HO : Hospitaïsation ER : Emergency Room MD : Medicai Personnel	[N]	[N]	[N]⊡ No [Y]⊡ Yes → type: II (HO/ER/MD)	[N] □ No [M] □ Yes → type: I_I_I (HO/ER/MD)	[N]

Page _____of ____

ۍ

20

gsk,	łaxoSmithKki	ne				Rota (1117							: []		Subje	ct No.:			_1	м	edication 1
CONC	OMITA	NT I	MED	ICA	TIO	N													19 ¹ 1		
Concon	nitant me	dicatio	on adr	ninis	lered	for t	he tre	atm	ent	ring 3 [.] of an A	l day AE or	s afte SAE	within the f	ollow-up p	eriod for ad	verse e	te the table l vents must b col in section	e reco			
Trade/G	Generic I	neric Name Medical Indication Tick box if it is used as Prophyla			Medical Indication Tick box if it is used as Prophylactic				Total daily dose	Route*	т	(DD	and end dat MMM YYYY entinuing at end o)			ls drugs used for treating AE?				
For GS			· · · · · · · ·			GSH									Start: _ End: _		<u> </u>		; (🗆 Yes 🗆 No
101 03	<u> </u>				- POI	<u></u>	` <u>`</u>								Start: End:				_ _		🗆 Yes 🗆 No
For GS	K				For	GSH	ς -								Start:			'' _			🛙 Yes 🗆 No
For GS	K				For	GSH	(End: _	_!!!_	 	!! 			
For GS	ĸ				For	GSK	(End:			' !!			C Yes C No
For GS	ĸ				For	GSK	(· · ·					Start: End:	_!!_!	_ ! 	_ _ _ _		ב	🗆 Yes 🗔 No
For GS			<u>.</u>		For	GSK									Start: End:		_!?!!	_ _ _ _			🗆 Yes 🗆 No
	n														Start: [] End: []	1					🗆 Yes 🗆 No
For GS	K				For	GSK	(<u>.</u>	<u>.</u>			·		Start: [_]	!!!_		!! 			Yes 🗆 No
For GS	ĸ				For	GSK	(End: Start:						
For GSI	ĸ			· · · · ·	For	GSK	(]					<u>[]</u>			End:						🖸 Yes 🗖 No
For GSI	ĸ				For	GSK	.								Start: End:	!!!_ !!!_		 		ב	🗘 Yes 🗆 No
For GSI	ĸ		·····		For	GSK	(Start: End: (†_	_11 _11	_ _	 		ב	🗆 Yes 🗆 No
For GSI					For	GSK			·····						Start: _ End: _		_iii	 	1 1	5	🗆 Yeş 🖾 No
	<u>.</u>				FOF	<u></u>			·····			D			Start:]_ End:]			 			🗆 Yes 🗆 No
For GSI	K				For	GSK	<u>(</u>								Start:	 	_'' ''	' _	' _		🛙 Yes 🗆 No
For GSI	ĸ				For	GSM	(_			End: I Start: I I	_!!L 					
For GSI	<u>n nàn được</u>					GSK			-		e . 12			<u> </u>							🗆 Yes 🖾 No
	ation Rou	1						· · · · · ·		1		10	I takan al-	1	Intender -1	In.		1	10	Т.	
EXT	External Unknown	ID PE	Intradi Paren		- P		halation		M N	Intramu		IR SC	Intraarticular Subcutaneed	1T 15 SL	Intrathecal	IV D	Intravenous	PR	Rectal		VA Vaginal

5/6

esk ClaxoSmithKkm	Rota-07	-		erNo:		Sut	oject No	:	_!!		ļ	CONCOMIT	ANT VACCINATION
CONCOM	TANT VACC	INATI	ON	l pister en la compañía de la									
Has any vaccine	other than the stud lease record conco	y vaccine mitant vac	(s) been ad ccination wi	lministered ith trade na	during 3 me and/	30 da for gr	iys prior ar oneric nam	id pos ie, rou	it vacci	nation? vaccine	ad	ministration date	· · · · · · · · · · · · · · · · · · ·
Trade/Gene Name	ric Route*	1	ministrat DD MMM \		Tr	ade	/Generi	c Na	me	Rout	te*		istration date MMM YYYY)
					1								
For GSK					For (3SK			4		•	•	
					1					•			
or GSK			· · · · · ·		For C	SSK				· · · · ·	••••	1	
an a survey and a survey of a		1 1 11	1 1 11				••						
or GSK]				For C	SSK			ļ			<u> </u>	
<u></u>		$\frac{1}{1}$		<u> </u>	1				<u> </u>			1 1 1 1	
For GSK		L`.			For G	SK							
			1 I I I	·				· .	T			1	······
For GSK													
					For G	SK			r				\
		<u> </u>											
or GSK	<u> </u>		**		For G	SK.	1						
Route. Nease Use codes	define de la	IN	lotranasal	TD Trans		ID	Intradermal		Intramu	scular S	L	Sublingual UNK	Unknown
	NCLUSION	<u> H</u>	hitslation	IV Intrav	enous	PO	Onii	SC	Subcuta	naous P	E	Parenteral OTH	Other
	perience any Serio	us Advers	e Event du	ring the stu	idy peric	od?	•						
No Ye	$s \rightarrow If$ yes, specify the three the three three terms in the term in the term in the term is the term in the term in the term is the term in the term in the term is the term in the term in the term is the term in the term in the term is the term in the term in the term is the term in the term in the term is the term in the term in the term is the term in the term in the term is the term in term in term in term is the term in term in term is the term in term in term is the term in	total numi	per of SAEs	<u>s.: _ _</u>								an de Falle - and de seu e se el secondo de la deservación y seguipar	· · · · · · · · · · · · · · · · · · ·
[] [SAE] Se	rious adverse even	t → Pleas	e complete	Major real and submit	it SAE n	epor	drawal (tic Land spec	k 1 bo ify SA	ix only) E No.				
🔲 [AEX] No	n-Serious adverse	event → I	Please com	plete Non-	serious	Adve	rse Event	sectio	on & sp	ecify AE	No	or solic	ited AE code [
	stocol violation, plea												
	onsent withdrawal, i	not due to	an advers	e event									
🔲 [MIG] Mig	rated / moved from	the study	/ area										
[] [LFU] Los	t to follow-up												
🔲 [OTH] Otl	ner, please specify.					,	For GSK						
	decision? [1] 🗌 In						_, u, u u u						,
Date of Last Co	ntact: 1_1												
Was the subject	t in good condition a	at date of	last contac	t? 🗌 Yes	No.	o, →	please giv	e deta	ails with	nin the A	٩dv	erse Events sec	stion
NVESTIGA	TOR'S SIGN	ATUR	E:										
iowledge, comple	e reviewed the data ate and accurate, as	s of the da	ate below	e i onn ior h	na suoj	eut. /	ni iniorma	uon ei	ntered	oy myse	eit c	n my colleagues	is, to the best of m
vestigator's sig	nature:			Date	: L_L	III	 	<u> </u>					
rinted Investigal	ors' name:				DD	м	мм	ŶŶŶŶ	/				
For CEK											•		Pert - pert - and
For GSK Na	me of CRA:					Reci	eipt Date:					<u> </u>	

CRF version 12.5 – 10JUN2008 (Amendment 1)

.

6/6

GlaxoSmithKline	(11	1700)	Genter	No.:		Subjec	t No.:	!!! 	JAE K	eport Form
			PMS	: SAE	Report Form		Initial 🗆 F	ollow-up (times)
Notification Date: 1_1	MNM YYYY	L_I			GSK Receipt					
Patient Details										· · · · · · · · · · · · · · · · · · ·
Center No: I_I_I_			Source	from :	Hospitalization	🗌 Ou	I-patient 🔲 EF	AE. N	1A_TYI	PE.CODE
Subject No: _ _ _			Gender	·: 🗋 N	1ale 🗍 Female	Date of	Birth:			MA -
Medical history includ	ing drug allerg	ic history:								
Medication: (Please	record all me	dication adm	inister	ed. and	check on the s	uspecte	d medication	<u>.</u>	<u>.</u>	
Brand Name/Generic		r	Frequ		Start Date		End Da		· · ·	Used
Name	Manufacturer	Daily dose	ency	Route	DD MMM		DD MMM		Indication	previously
								1111		☐ Yes ☐ No
										Yes
·····		· · · · · · · · · · · · · · · · · · ·								🗌 No
1										Ves
										TYes
			ļ					<u>_ _ _ </u>		No
			1						1	
								1111		Yes
Information of Serio	us Adverse Ev	vent								No No
Information of Serio Onset Date (DD/MMM/Y	AE. AE	vent SRDA	F	End D	1_1_11_1	A	<u></u>	DAT		No
	AE. AE	vent SRDA	F 7 7		ate (DD/MMM/YY)	m:1_1	E. A.E EK	DAT	□ Ong E. () N (7)	No
Onset Date (DD/MMM/Y Maximum Intensity:	AE, AE YYY):1_1_1 DD]Mild []Moo	SRDA MMM YY				m:1_1	E. A.E EK	DAT	□ Ong E. <i>ON 6</i> 7	No
Onset Date (DD/MMM/Y Maximum Intensity: [Possible cause of SAE o	AE. AE YYY): 1_11 DD] Mild [] Moo ther than PMS p	derate Sr sroduct:	evere	□ NA	ate (DD/MMM/YY) AE, AE, I	M:LI	E. AE - EK 	DAT	□ Ong E · () N (7)	No
Onset Date (DD/MMM/Y Maximum Intensity: Possible cause of SAE o] Medical condition(s)	AE, AE VYY): 1_1_1 DD Mild [] Moc ther than PMS p [] Concomitant	derate Sroduct: medication	evere	NA related t	ate (DD/MMM/YY) AE. AE. To to study participatic		E. A.E EK	DAF 1	⊡ Ong E. <i>() N (</i> 9	No
Onset Date (DD/MMM/Y Maximum Intensity: Possible cause of SAE o Medical condition(s) Description of SAE (Plea	AE, AE DD DD Mild [] Moc ther than PMS p [] Concomitant ise provide a full	derate Sr medication description of	evere	NA related t	ate (DD/MMM/YY) AE. AE. To to study participatic		E. A.E EK	DAF 1	□Ong E· <i>ON′</i> 9	No
Onset Date (DD/MMM/Y Maximum Intensity: Possible cause of SAE o Medical condition(s) Description of SAE (Plea	AE, AE VYY): 1_1_1 DD Mild [] Moc ther than PMS p [] Concomitant	derate Sr medication description of	evere	NA related t	ate (DD/MMM/YY) AE. AE. To to study participatic		E. A.E EK	DAF 1	⊡ Ong E · () N (9)	No
Onset Date (DD/MMM/Y Maximum Intensity: Possible cause of SAE o Medical condition(s) Description of SAE (Plea	AE, AE DD DD Mild [] Moc ther than PMS p [] Concomitant ise provide a full	derate Sr medication description of	evere	NA related t	ate (DD/MMM/YY) AE. AE. To to study participatic		E. A.E EK	DAF 1	⊡ Ong E. <i>(</i>) № /ქ	No
Onset Date (DD/MMM/Y Maximum Intensity: [Possible cause of SAE o [] Medical condition(s) Description of SAE (Plea A	AE, AE DD DD Mild [] Moc ther than PMS p [] Concomitant ise provide a full	derate Sr medication description of	evere	NA related t	ate (DD/MMM/YY) AE. AE. To to study participatic		E. A.E EK	DAF 1	E.ON 9	No
Onset Date (DD/MMM/Y Maximum Intensity: Possible cause of SAE o Medical condition(s) Description of SAE (Plea	AE, AF DD DD Mild Moc other than PMS p Concomitant ise provide a full E. AE - D	derate Stroduct: medication description of	evere	NA related f	ate (DD/MMM/YY) AE. AE. To to study participatic		E. A.E EK	DAF 1	⊡ Ong E. () N (9)	No
Onset Date (DD/MMM/Y Maximum Intensity: Possible cause of SAE o [] Medical condition(s) ⁻ Description of SAE (Plea Action of SAE (Plea Action taken with stud [] None] Medication	AE, AFE DD DD Mild ☐Moc ither than PMS p ☐ Concomitant ise provide a full E. AE - D y medication a withdrawn ☐A	SEDA MMM V derate Si roduct: medication d description of DESC is a result of t deministration c	evere] Activity SAE, pat he SAE	NA related t ient state	AE (DD/MMM/YY) AE AE To so study participatic us and treatment d age Route (An NTEP on O etails): Change	E. A.E. EK	DAT 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	E.ONG	No
Onset Date (DD/MMM/Y Maximum Intensity: Possible cause of SAE o [] Medical condition(s) ⁻ Description of SAE (Plea Action of SAE (Plea Action taken with stud [] None] Medication	AE, AFE DD DD Mild ☐Moc ither than PMS p ☐ Concomitant ise provide a full E. AE - D y medication a withdrawn ☐A	SEDA MMM V derate Si roduct: medication d description of DESC is a result of t deministration c	evere] Activity SAE, pat he SAE	NA related t ient state	AE (DD/MMM/YY) AE AE To so study participatic us and treatment d age Route (An NTEP on O etails): Change	E. A.E. EK	DAT 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	E.ONG	No
Onset Date (DD/MMM/Y Maximum Intensity: Possible cause of SAE o [] Medical condition(s) Description of SAE (Plea Action & Outcome Action taken with stud [] None [] Medication Outcome : [] Natural UT COME [] Unknow	AE, AFE DD DD Mild Mild Concomitant ise provide a full E. AE - D y medication a withdrawn □A Recovery	SEDA MMM YV derate Si product: medication description of DESC s a result of t description c days from c days from c	evore] Activity SAE, pat the SAE thange onset day ONST	NA related f ient state	AE (DD/MMM/YY) AE AE In to study participatic us and treatment d age Route [] Not Recovered	Ai (Y): I_I D NTEN on 0 etails): Change [] Rec	to other medical	ion)	E.ONG	poing OING
Onset Date (DD/MMM/Y Maximum Intensity: Possible cause of SAE o [] Medical condition(s) ⁻ Description of SAE (Plea Action & Outcome Action taken with stud] NoneMedication Outcome :Natural DUT COMEUnknow SAE category :Re	AE, AE DD DD Mild [] Moc ither than PMS p [] Concomitant ise provide a full E. AE _ D y medication a withdrawn A Recovery m [] Recovery soulds in death	SEDA MMM YO derate S product: medication description of ESC s a result of t deministration c days from c Life threate	he SAE, pat	NA related f ient state (Dosa (NU Results	ate (DD/MMM/YY) <u>AE</u> , <u>AE</u> , <u>I</u> to study participation us and treatment d us and treatment d <u>age Route []</u> Not Recovered W in disability/incapa	Ai (Y): N TE i onO etails): Change Rec CityO	to other medical covered with con	ion)	E.ONG trnent	poing OING
Onset Date (DD/MMM/Y Maximum Intensity: Possible cause of SAE o [] Medical condition(s) ⁻ Description of SAE (Plea Action & Outcome Action & Outcome Action taken with stud [] NoneMedication Outcome :Natural DUT COMEUnknow SAE category :Re 11700Ho	AE, AE DD DD Mild []Moc ther than PMS p [] Concomitant ise provide a full E. AE - D y medication a withdrawn [] A Recovery m [] Recover sults in death spitalization or p	SEDA MMM YO derate S roduct: medication description of DESC s a result of t deministration c days from c Ang Life threate rolongation of t	Activity SAE, pat he SAE thange onset day ONST ning	In NA related f ient state (IDoss (IDoss (IZ) Results sation	AE (DD/MMM/YY) AE AE I o study participation to study participation us and treatment of age Route [] Not Recovered W in disability/incapa From [_] I I] DD MM	Ai (Y) : [_] p NTEI on [] O etails): Change [] Rec city [] (ther (Specify):	ion)	E. () N. (9)	In No In No In No In No In No In No In No In No In No In No
Onset Date (DD/MMM/Y Maximum Intensity: Possible cause of SAE o [] Medical condition(s) ⁻ Description of SAE (Plea Action & Outcome Action & Outcome Action taken with stud [] NoneMedication Outcome :Natural DUT COMEUnknow SAE category :Re 11700Ho	AE, AE DD DD Mild []Moc ther than PMS p [] Concomitant ise provide a full E. AE - D y medication a withdrawn [] A Recovery m [] Recover sults in death spitalization or p	SEDA MMM YO derate S roduct: medication description of DESC s a result of t deministration c days from c Ang Life threate rolongation of t	Activity SAE, pat he SAE thange onset day ONST ning	In NA related f ient state (IDoss (IDoss (IZ) Results sation	AE (DD/MMM/YY) AE AE I o study participation to study participation us and treatment of age Route [] Not Recovered W in disability/incapa From [_] I I] DD MM	Ai (Y) : [_] p NTEI on [] O etails): Change [] Rec city [] (ther (Specify):	ion)	E. () N. (9)	In No In No
Onset Date (DD/MMM/Y Maximum Intensity: Possible cause of SAE o [] Medical condition(s) ⁻ Description of SAE (Plea Action & Outcome Action & Outcome Action taken with stud [] NoneMedication Outcome :Natural DUT COMEUnknow SAE category :Re 11700Ho	AE, AE DD DD Mild []Moc ther than PMS p [] Concomitant ise provide a full E. AE - D y medication a withdrawn [] A Recovery m [] Recover sults in death spitalization or p	SEDA MMM YO derate S roduct: medication description of DESC s a result of t deministration c days from c Ang Life threate rolongation of t	Activity SAE, pat he SAE thange onset day ONST ning	In NA related f ient state (IDoss (IDoss (IZ) Results sation	AE (DD/MMM/YY) AE AE I o study participation to study participation us and treatment of age Route [] Not Recovered W in disability/incapa From [_] I I] DD MM	Ai (Y) : [_] p NTEI on [] O etails): Change [] Rec city [] (ther (Specify):	ion)	E. () N. (9)	In No In No
Onset Date (DD/MMM/Y Maximum Intensity: Possible cause of SAE o [] Medical condition(s) ⁻ Description of SAE (Plea Action & Outcome Action & Outcome Action taken with stud [] NoneMedication Outcome :Natural OUTCOMEUnknow SAE category :Re 11700Ho	AE, AE DD DD Mild []Moc ther than PMS p [] Concomitant ise provide a full E. AE - D y medication a withdrawn [] A Recovery m [] Recover sults in death spitalization or p	SEDA MMM YO derate S roduct: medication description of DESC s a result of t deministration c days from c Ang Life threate rolongation of t	Activity SAE, pat he SAE thange onset day ONST ning	In NA related f ient state (IDoss (IDoss (IZ) Results sation	AE (DD/MMM/YY) AE AE I o study participation to study participation us and treatment of age Route [] Not Recovered W in disability/incapa From [_] I I] DD MM	Ai (Y) : [_] p NTEI on [] O etails): Change [] Rec city [] (ther (Specify):	ion)	E. () N. (9)	In No In No
Onset Date (DD/MMM/Y Maximum Intensity: Possible cause of SAE o [] Medical condition(s) ⁻ Description of SAE (Plea Action & Outcome Action taken with stud] NoneMedication Outcome :Natural DUT COMEUnknow SAE category :Re 111700Ho Was AE recurred whe Relationship to study re Other comment:	AE, AE DD DD Mild []Moc ther than PMS p [] Concomitant ise provide a full E. AE - D y medication a withdrawn [] A Recovery m [] Recover sults in death spitalization or p	SEDA MMM YO derate S roduct: medication description of DESC s a result of t deministration c days from c Ang Life threate rolongation of t	Activity SAE, pat he SAE thange onset day ONST ning	In NA related f ient state (IDoss (IDoss (IZ) Results sation	AE (DD/MMM/YY) AE AE I o study participation to study participation us and treatment of age Route [] Not Recovered W in disability/incapa From [_] I I] DD MM	Ai (Y) : [_] p NTEI on [] O etails): Change [] Rec city [] (ther (Specify):	ion)	E. () N. (9)	In No In No
Onset Date (DD/MMM/Y Maximum Intensity: Possible cause of SAE o [] Medical condition(s) ⁻ Description of SAE (Plea Action & Outcome Action taken with stud [] None [] Medication Outcome : [] Natural Was Ac recurred whe Relationship to study r Other comment: Reporter	AE, AE DD DD Mild []Moc ther than PMS p [] Concomitant ise provide a full E. AE - D y medication a withdrawn [] A Recovery m [] Recover sults in death spitalization or p	SEDA MMM YO derate S roduct: medication description of DESC s a result of t deministration c days from c Ang Life threate rolongation of t	Activity SAE, pat he SAE thange onset day ONST ning	In NA related f ient state (IDoss (IDoss (IZ) Results sation	ate (DD/MMM/YYY AE. AE. 77 to study participatic us and treatment d age Route [] Not Recovered W in disability/incapa From DD MMM es No 1 iy related Pos	Ai (Y): I P P NTEI Drin O etails): Change Change Change Change Change No recha YY No recha Sibly rela	ther (Specify):	ion)	E. () N. (9)	In No In No
Onset Date (DD/MMM/Y Maximum Intensity: Possible cause of SAE o [] Medical condition(s) ⁻ Description of SAE (Plea Action & Outcome Action taken with stud] NoneMedication Outcome :Natural DUT COMEUnknow SAE category :Re 111700Ho Was AE recurred whe Relationship to study re Other comment:	AE, AE DD DD Mild []Moc ther than PMS p [] Concomitant ise provide a full E. AE - D y medication a withdrawn [] A Recovery m [] Recover sults in death spitalization or p	SEDA MMM YO derate S roduct: medication description of DESC s a result of t deministration c days from c Ang Life threate rolongation of t	Activity SAE, pat he SAE thange onset day ONST ning	In NA related f ient state (IDoss (IDoss (IZ) Results sation	AE (DD/MMM/YY) AE AE I o study participation to study participation us and treatment of age Route [] Not Recovered W in disability/incapa From [_] I I] DD MM	Ai (Y): I P P NTEI Drin O etails): Change Change Change Change Change No recha YY No recha Sibly rela	ther (Specify):	ion)	E. () N. (9)	In No In No In No In No In No In No In No In No In No In No

Der Chit and a constant of all and a constant of all and a constant of all and a constant of all and a constant of all and a constant of all and a constant of all and a constant of all and a constant of all and a constant of all and a constant of all and a constant of

Esk GlaxoSn	nithKline			Rota-070 (111700)		Cen	ter No).: l <u></u> ll	_	Subj	ect No.	: 		м	edicat	on 2
MEDICAT	ION (Contin	ue fr	om Medi	catio	n 1)										
Trade/Gene	гіс Narr	e				dication as Prophylaci	ic.	Total daily dose	Route*	Т	(DD	and end da MMM YYY continuing at end	n		156	frugs d for ng AE
For GSK			F	or GSK		· · · · ·				· -		I I I I I	`		C Ye	5 🗆 N
For GSK			F	or GSK											D Ye	s 🖸 N
For GSK	· · · ·		F	or GSK			- 0								🗆 Ye	s 🗆 N
For GSK			F	or GSK			- []								🗆 Ye	s 🗆 N
For GSK			Ē	or GSK			_ 0								🗆 Ye	s 🗆 No
For GSK			F	or GSK											🗆 Ye:	5 🗆 N
For GSK			F	or GSK			- 🗆					!			🗆 Yei	; 🗆 N
For GSK	• <u>•</u> ••••••		F	or GSK		•••	- 0			1		ii		D	🗆 Ye:	5 🗆 N
For GSK			F	or GSK		1				Start: End:			.! 		□ Yes	; 🗆 N
For GSK			Fe	or GSK			- 0			Start: End:				0	🗆 Yet	; 🗆 N
For GSK		· · · · · · · · · · · · · · · · · · ·	Fr	or GSK		· · · ·					•				🗆 Yeş	
For GSK			Fc	or GSK	1				-						🗆 Yes	: 🗂 No
for GSK	·		Fc	or GSK		. ·				Start: End:				D	🗆 Yes	
or GSK			Fc	or GSK						Start: End:			I		🗆 Yes	
or GSK	an a succession and a succession		Fa	or GSK						Start: _					🗆 Yes	
Medication I	Route, P	lease Us			odes.		<u> </u>			l						
XT Externa	1	Intraderm	T	IH Inhatation		Intramuscul	ar IR	Intraarticuler	IT	Intrathecal	IV	Intravenous	PR Rec	tat	VA	Vagina
NK Unknov	m PE	Parentera		PO Oral	IN	Intranasal	SC		1	Sublingual	TD	Transdermal	TO Top		отн	Other

Page _____of____

WRITTEN INFORMED CONSENT FORM

Title: Safety of GlaxoSmithKline (GSK) Biologicals' oral live attenuated human rotavirus (HRV) vaccine, RotarixTM or RotarixTM liquid formulation (oral suspension or prefilled syringe) when administered according to the prescribing information in Korea.

This post-marketing surveillance was requested by the Korean Food and Drug Administration. This surveillance is an observational process which doesn't affect routine medical practice. The human rotavirus vaccine (referred to as *Rotarix or Rotarix liquid formulation (oral suspension or prefilled syringe)*) has been recently registered in Korea and *at least* 3000 subjects will take part in this surveillance. The purpose of this surveillance is to evaluate the safety (in terms of occurrence of any adverse event or serious adverse events) of the Korean infants aged 6 weeks and above at the time of the first dose of vaccination.

You are kindly requested to let your child/ward participate in this surveillance.

Please take time to read the following information carefully and discuss it if you wish with friends, relatives and your personal doctor and if you decided to let your child/ward to participate, please sign this consent form.

1. Safety Data Collection Procedure

If you decide to let your child/ward to participate, you will be requested to record any symptoms occurring between the day of the vaccine dose and the following 30 days in the diary card that will be given to you by the study doctor. You will need to return the completed diary card 30 days after your child/ward receives the vaccination. You will also be requested to promptly report to the doctor any occurrence of unexpected or serious adverse events after your child/ward receives the vaccine. The duration of the study will be approximately 3 months.

2. Voluntary Participation and Subjects Right to End Participation

Your child's/ward's participation in this surveillance is voluntary. You may refuse to let your child/ward to take part in this surveillance, or once in the surveillance you may decide to discontinue participation at any time. You must inform your study doctor if you decide to do this. Your decision not to let your child/ward to take part in the surveillance or to stop participating in the surveillance will not affect your child's/ward's current or future medical care, or any benefits to which your child/ward may otherwise be entitled.

3. Confidentiality and Data Privacy

If you decide to let your child/ward participate in the surveillance, the study doctor and staff will collect medical and personal information about your child/ward as part of doing the surveillance. GSK staff who sees this information at the site will keep it confidential.

The study site will also transfer to GSK some of the information it collects, in a coded form. The information transferred will not include your child's/ward's name, initials, address, or other direct identifiers. It will be assigned a code number that only the site can connect back to your child's/ward's name.

GSK Biologicals will keep the information and the results collected about your child/ward in this surveillance. Your child/ward's name and address are not included in the information kept by GSK Biologicals - only your doctor will keep this information.

By agreeing to take part in this surveillance, you will be allowing certain persons to see the information about your child/ward (including personal and other information) held by the study doctor. Your child's/ward's information will be looked at to confirm that it is correct and that it is related to your child/ward. This will be done by selected people working for GSK and the government regulatory authorities. These persons are required to maintain the confidentiality of your child's/ward's information. GSK Biologicals has told your doctor to keep the information about your child/ward in a secure place. GSK Biologicals will comply with internal procedures to protect personal and other information even in countries where data privacy laws are less strict than in Europe/US.

4. Foreseeable Risks or Inconvenience

Over 131, 000 infants have been enrolled in studies with GSK Biologicals' HRV vaccine (*Rotarix*). During these studies, over 53, 000 infants have received at least one dose of the vaccine.

As with any vaccine, unexpected illnesses (called serious adverse experiences), including allergic reactions to the vaccine, (itchy skin rash, shortness of breath and swelling of the face or tongue) may occur. Medical equipment necessary to treat any serious reactions to the study vaccine will be available at the site.

The following undesirable event has been observed to be common: (this may occur with up to 1 in 10 doses): diarrhoea.

The following undesirable events have been observed to be uncommon (these may occur with up to 1 in 100 doses): flatulence (gas), abdominal pain and dermatitis.

In rare cases (1 in 1000 doses of the vaccine) blood in stools has been observed.

GSK has identified the presence of material from PCV-1, a virus to which people are commonly exposed, in its Human Rotavirus Vaccine. There is no evidence that PCV-1 can infect humans or is harmful to humans. Based on these considerations and the extensive safety database available, the benefit/risk profile of GSK Biologicals' HRV vaccine has not changed and remains favourable.

5. Expected benefits

Infants who receive the *Rotarix* or *Rotarix liquid formulation (oral suspension or prefilled syringe)* vaccine may have the benefit of being protected against rotavirus disease.

Consent statement

Title: Safety of GlaxoSmithKline (GSK) Biologicals' oral live attenuated human rotavirus (HRV) vaccine, RotarixTM or RotarixTM liquid formulation (oral suspension or *prefilled syringe*) when administered according to the prescribing information in Korea.

I confirm that I have understood the statements in the informed consent form and have had the opportunity to ask questions about this surveillance. Therefore I agree to let my child/ward take part in this surveillance. I will receive the full copy of the informed consent form referred to above, including this signed statement with my signature below.

Participant's Name:

Name of Parent/Guardian:	
Signature of Parent/Guardian:	Date:
Study Doctor's Name:	Date:
Signature of Person conducting Consent:	

TO PPD

Signature of principal or coordinating investigator

GlaxoSmithKline Biologicals

Global Clinical Research and Development

Investigator Approval Page

Please note that by signing this page, you take responsibility for the content of the clinical study report, including appendices

STUDY TITLE: Open, multi-centric, post-marketing surveillance (PMS) to monitor the reactogenicity and safety of GlaxoSmithKline (GSK) Biologicals' oral live attenuated human rotavirus (HRV) vaccine, RotarixTM when administered according to the prescribing information in Korea.

Study: 111700 (Rota-070 PMS)

Development Phase: PMS

I have read this report and confirm that to the best of my knowledge it accurately describes the conduct and results of the study.

Name of Investigator:

SON MOON SHIN

Affiliation /investigational centre:

Signature of Investigator:

Date:

For internal use only
{cars_md5_line_0
{cars_md5_line_l
{cars_md5_line_2
(oars_mdS_line_3
{cars_md5_line_4
(cars_md5_linc_5
{cars_md5_line_6
{cars_md5_line_7
(cars_md5_line_8
{cars_md5_line_9
(cars_md5_line_10
{cars_md5_line_11
[cars_md5_line_12
{cnrs_md5_line_13
(cars_md5_line_14
{cars_md5_line_15
{cara_md5_line_16
(cars_md5_line_17
{cnrs_md5_line_18
{cars_md5_line_19
(cars_md5_line_20
(cars_md5_line_21
(cars_md5_line_22
{cars_md5_line_23
(cars_md5_line_24

22-APR-2010

Cheil general hospital & women's healthcare center

May 6, 2010

1

GlaxoSmithKline Biologicals Global Clinical Research and Development

Sponsor Signatory Approval Page

Please note that by signing this page, you take responsibility for the content of the clinical study report, including appendices

STUDY TITLE: Open, multi-centric, post-marketing surveillance (PMS) to monitor the reactogenicity and safety of GlaxoSmithKline (GSK) Biologicals' oral live attenuated human rotavirus (HRV) vaccine, Rotarix[™] when administered according to the prescribing information in Korea.

Study: 111700 (Rota-070 PMS)

Development Phase: PMS

I have read this report and confirm that to the best of my knowledge it accurately describes the conduct and results of the study.

Name of Sponsor Signatory:	Dr. Emilio Ledesma
Title of Sponsor Signatory:	Vice-President and Director Clinical R&D and Medical Affairs Asia Pacific.
	PPD
Signature:	
Date:	5 May 2010

For internal use only
{cars_md5_line_0
{cars_md5_line_1
{cars_md5_line_2
{cars_md5_line_3
{cars_md5_line_4
{cars_md5_line_5
{cars_md5_line_6
{cars md5 line 7
{cars md5 line 8
{cars_md5_line_9
{cars_md5_line_10
{cars md5 line 11
{cars md5 line 12
{cars md5 line 13
{cars md5 line 14
{cars md5 line 15
{cars md5 line 16
{cars md5 line 17
{cars md5 line 18
{cars_md5_line_18 {cars_md5_line_19
{cars_md5_line_20
{cars_md5_line_21
{cars_md5_line_22

{cars_md5_line_23 {cars_md5_line_24 {cars_md5_line_25

} }